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Abstract 
 
In the first part of the thesis the work towards a new generation of liposomal drug delivery 
systems for anticancer agents is described. The drug delivery system takes advantage of the 
elevated level of secretory phospholipase A2 (sPLA2) IIA in many tumors and the 
enhanced permeability and retention (EPR) effect. The liposomes consists of sPLA2 IIA 
sensitive phospholipids having anticancer drugs covalently attached to the sn-2 position of 
the glycerol backbone in the phospholipids, hence drug leakage is avoided from the carrier 
system.  
 
Various known anticancer agents, like chlorambucil, all-trans retinoic acid, α-tocopheryl 
succinate and calcitriol were examined for their ability to be incorporated into the 
investigated drug delivery system and syntheses of the phospholipid prodrugs are 
described. 
 
The majority of the phospholipid prodrugs were able to form particles with diameters close 
to 100 nm upon extrusion at 20 °C indicating that unilamellar vesicles are formed. When 
subjected to sPLA2 the phospholipid prodrugs were converted into cytotoxic lysolipids and 
along with the released anticancer drug a chemotherapeutic cocktail is formed. 
Cytotoxicity studies in several cancer lines revealed that upon sPLA2 triggering the 
formulated phospholipid prodrugs displayed IC50 values in range from 3–36 µM and 
complete cell death was observed when higher drug concentrations were applied. 
Promising for the drug delivery system the majority of the phospholipid prodrugs remain 
non-toxic in the absence of the enzyme meaning the prodrugs will not damage healthy 
tissue during the transport in the body.  
 
In the second part of the thesis the synthetic studies towards a library of small natural-
product-like molecules are described. The collection of molecules was synthesized via a 
diversity oriented synthesis (DOS) based strategy using a limited number of reaction types. 
Upon coupling of unsaturated building blocks ring closing metathesis cascades were used 
to “reprogram” the molecular scaffold and highly diverse structures were obtained. In total 
20 novel compounds with a broad structural diversity were prepared in 5 or 6 synthetic 
steps.        
 
 
  
IV 
 
Resumé 
 
I den første del af afhandlingen beskrives arbejdet med en ny generation af liposomal drug 
delivery systemer til brug for cytotoksiske stoffer. Drug delivery systemet udnytter 
forhøjede koncentrationer af secerneret phospholipase A2 (sPLA2) IIA i kræft svulster og at 
cancervæv er mere porøst end raskt væv, hvorved nanopartikler som liposomer kan 
diffundere ind i kræftvæv men ikke ind i raskt væv. Liposomerne består af sPLA2 IIA 
sensitive phospholipider hvori det cytotoksiske stof kovalent er bundet til sn-2 positionen 
af glycerol enheden i phospholipiderne således at udsivning fra liposomerne undgås.  
 
Adskillige kendte anticancer stoffer, som chlorambucil, retinsyre, α-tocopheryl succinat og 
calcitriol blev testet for deres evne til at indgå i det undersøgte drug delivery system og 
syntesen af phospholipid prodrugsene beskrives. 
 
Hovedparten af de fremstillede phospholipid prodrugs var i stand til efter ekstrudering ved 
20 °C at danne partikler med diametere omkring 100 nm, hvilket indikerer dannelsen af 
liposomer. I stedeværelse af sPLA2 omdannes phospholipid prodrugsene til cytotoksiske 
lysolipider og sammen med det frigjorte anticancer stof dannes en cocktail af 
kemoterapeutiske stoffer. Evnen til at frembringe celledød blev undersøgt i forskellige 
kræftceller og i stedeværelse af sPLA2 viste phospholipid prodrugsene IC50 værdier mellem 
3–36 µM og fuldstændig celledød blev opnået ved anvendelse af højere koncentrationer. 
Lovende for drug delivery systemet, så var hovedparten af phosphilipid prodrugsene ikke i 
stand til at frembringe celledød i fravær af enzymet hvorved prodrugsene ikke vil skade 
raskt væv under transporten i kroppen. 
 
I den anden del af afhandlingen beskrives de syntetiske studier mod fremstillingen af et 
bibliotek af naturstof-lignende molekyler. Samlingen af molekyler blev syntetiseret ved en 
DOS (Diversity Oriented Synthesis) baseret syntesestrategi ved anvendelse af få 
reaktionstyper. Simple byggeblokke blev sammensat og ved hjælp af ringluknings 
metatese kaskader blev det molekylære skellet af de kombinerede byggeblokke 
omstruktureret og strukturer med en høj diversitet blev opnået. I alt blev 20 nye stoffer 
med en bred struktural forskellighed fremstillet i 5 eller 6 syntese trin.  
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1. Introduction to Liposomal Drug Delivery 
 
Cancer remains one of the most frequent and devastating diseases and the number of cases 
continue to grow. 1,2 As illustrated in Figure 1 for the Nordic countries the numbers of 
death caused by cancer (the mortality) and the number of new cases of cancer (the 
incidence) have increased during the last 50 years. Althoug the mortality tends to decline3 
there is continuous need for new and better cancer therapies.  
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Figure 1. Graphical representation of the number of death (mortality) caused by cancer and the number of
new cases of cancer (incidence) in the last 50 years in the Nordic countries, Finland, Sweden, Norway,
Denmark, Iceland and the Faroe Islands. Data adapted from Nordcan.4 
 
Many potent anticancer drugs have been discovered and developed however their in vivo 
application suffer from inefficient drug delivery to tumors leading to severe side effects on 
healthy organs. Hence there is a need for drug delivery systems which selectively can 
deliver chemotherapeutic agents to cancerous tissue thus minimizing side effects and 
increasing the therapeutic window of the administrated drug affording better antitumor 
efficiency and patient compliance.   
 
In the beginning of the twentieth century Paul Ehrlich, a German immunologist and a 
pioneer in medicinal chemistry envisioned the perfect drug as a “magic bullet” that 
automatically targets and selectively kills the diseased cells without damaging healthy 
tissue.5 Liposomes have been proclaimed as a likely candidate to fulfill Paul Ehrlich vision 
and ever since the discovery of liposomes by Alec Bangham6,7 in the beginning of the 
1960th many efforts have gone into making liposomes applicable as drug carriers.8  
Liposomal Drug Delivery 
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This thesis describes work towards a new generation of liposomal drug delivery systems 
with potential in cancer treatment aiming to bring Paul Erhlich vision of a “magic bullet” 
one step closer. In the following section a brief introduction to phospholipids and 
liposomes is given followed by an overview of the state of the art in liposomal drug 
delivery.  
 
1.1 Phospholipids and Liposomes 
Phospholipids are among the most abundant biomolecules in nature and the major 
component in biological membranes. Two main classes of phospholipids exist depending 
on whether they contain a glycerol or a sphingosyl backbone,9 for the work described in 
this thesis only glycerophospholipids have interest and the general skeleton of 
glycerophospholipids (Figure 2) consists of two chains of fatty acids which via ester bonds 
are connected to a glycerol backbone with a polar phosphate headgroup, like 
phosphatidylcholine (PC) (Figure 2). In addition to PC, headgroups like phosphatidylserine 
(PS), phosphatidylethanolamine (PE) and phosphatidylglycerol (PG) are present in natural 
occurring phospholipids.9  Likewise numerous fatty acids have been isolated and identified 
from natural sources including both fully saturated, like palmitic acid and unsaturated, such 
as oleic acid.9  
 
The dominant nomenclature for phospholipids is the sn-nomenclature (stereospecific 
numbering) proposed by Hirshmann. 10  The sn-nomenclature rely on a stereospecific 
numbering of the the carbon atoms in the glycerol backbone and the atoms are numbered 
the sn-1, sn-2 and sn-3 position without consideration for the substituents (see Figure 2 and 
the Abbreviation list for further description of the sn-nomenclature). 
 
 
Figure 2. Example of a phospholipid, 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC). The skeleton consists of two chains of fatty 
acid esters and a glycerol backbone with a polar phosphate headgroup.  
 
In the beginning of the 1960th Bangham and co-workers6,7 observed that upon dispersion of 
phospholipids in water a spontaneous aggregation into spherical vesicles occur due to the 
formation of phospholipid bilayers. Bilayers (Figure 3) are formed because of the 
amphiphilic character of phospholipids, the hydrophobic tails come together and form an 
inner layer shielded from water while the polar headgroups hydrated by water provide a 
thin shell as the outer layers.11 What Bangham observed was formation of multilamellar 
vesicles (MLVs), which are lipid bilayers structured in an onion-like fashion (see Figure 3) 
and with an average diameter above 500 nm.6,7 MLVs can be converted into unilamellar 
vesicles (UVs) by e.g. sonication11,12 or extrusion11,13 giving particles with diameters close 
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to 100 nm (see Figure 3). Solutions of MLVs are milky and unclear while UVs provide 
clear and transparent solutions. By definition liposomes can be seen both as MLVs and 
UVs but for cancer therapy the smaller UVs are of most interest (vide infra).14 
 
Aqueous phospholipid solutions display a series of temperature dependent reversible phase 
transitions, which are important for the properties and behavior of liposomes.15 The phase 
transition temperatures can be demonstrated by obtaining a differential scanning 
calorimetry (DSC) scan. From the DSC scan of MLVs of 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC, Figure 4) it is evident that the bilayers undergo a transformation 
from an ordered solid phase to a more disordered ripple phase (pre-transition temperature) 
and then into a fluid phase (main phase transition temperature, Tm). The phase transition 
temperatures depend on the ability of the to phospholipids to create well ordered and dence 
bilayers and phospholipids having two saturated fatty acids in the sn-1 and sn-2 position 
have high Tm’s , (Tm of DPPC is 41 °C)16 whereas phospholipids having unsaturated fatty 
acids have lower Tm’s , (Tm of POPC is –20 °C).17 The physical state of the bilayers affect 
the permeability, stability and flexibility of the liposomes, hence extrusion of MLVs of 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) through a 100 nm filter needs to be 
performed above the Tm of DSPC at 55 °C,17 as it is impossible below the Tm due to the 
stiffness of the bilayers. 
 
  
 
Figure 3. Illustration of phospholipid bilayers in a multilamellar vesicle (top left) and 
phospholipid bilayer in a unilamellar vesicle (top right). Cryo-electro microscopy 
pictures of a multilamellar vesicle (bottom left) and unilamellar vesicles (bottom right). 
Data from Mouritsen.15  
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Figure 4. DCS scan of MLVs of DPPC. The small peak separating the solid and 
the ripples phase corresponds to the pre-transition temperature and the large peak 
separating the ripple and fluid phase corresponds to Tm. Data from Mouritsen.15  
 
1.2 Liposomes in Drug Delivery 
A decade after the discovery of liposomes Gregoridis et al.18 suggested that liposomes 
could have potential as drug carriers due to their ability to encapsulate compounds either in 
the aqueous interior of the vesicles or in the lipophilic membrane. Initially the use of 
liposomes was hampered by a poor stability in serum due to interaction with plasma 
proteins like lipoproteins but that was circumvented by using phospholipids with a high Tm 
like DPPC in co-formulation with cholesterol (conventional liposomes).14 However three 
major obstacles were still to be overcomed in order for liposomes to be a successful drug 
carrier in cancer therapy, a rapid clearance from the blood stream, a low drug accumulation 
in the tumors (targeting) and an uncontrolled drug release from the carrier.8  
 
For a long time the application of liposomes suffered from a fast clearance from the blood 
stream, it was observed that when conventional liposomes were injected intravenously they 
rapidly were recognized and removed by the reticuloendothelial system (RES) hence 
leading to an accumulation in the liver and spleen followed by a clearance from the body 
by macrophages.14,8 Unless you are targeting a disease in these organs, this is not desirable, 
but a major step forward was the introduction of liposomes coated with the synthetic 
polymer polyethylene glycol (PEG).19,20,21 It was shown that pegylated liposomes have a 
significant longer half-life in the blood stream than conventional liposomes. The reason for 
this is that the attachment of PEG provides a hydrated environment around the liposomes 
and together with the steric barrier the recognition and clearance by the RES is reduced. 
Initial studies by Blume et al.19 revealed that addition of a pegylated conjugate of 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG) to DSPC increased the half-
life in the blood stream in mice from 0.5 h for pure DSPC to 8.5 h for the 9:1 mixture of 
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DSPC and DSPE-PEG (see Figure 5). For other systems of pegylated liposomes half lives 
up to 72 h in humans are reported.22   
Figure 5. Liposome level in the blood stream as a function 
of time after intraveneous administration in mice. Tritium-
labelled liposomes of DSPC (●) and 9:1 DSPC:DSPE-PEG 
(■). Figure adapted from Blume et al.19  
 
Due to the enhanced permeability and retention (EPR) effect long circulating liposomes 
tend to accumulate in tumors. The EPR effect, first introduced by Maeda and co-
workers,23,24 is a consequence of the leaky vasculature found in tumor tissue and the lack 
of an effective lymphatic drainage system. The junctions between cells in tumors vary 
from 100-800 nm which allows penetration of drug carriers like liposomes.25 In contrast, 
the gaps between cells in healthy tissue are less than 6 nm meaning liposomes cannot enter 
here (see Figure 6).25  
 
Figure 6. Illustration of passive targeting of long circulating liposomes (o) into 
tumors. Due to larger junctions between endothelium cells in tumor tissue compared 
to healthy tissue nanoparticles, such as liposomes, can diffuse into tumors but not 
into healthy tissue.  
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However the endothelium gaps in organs like the kidney (40-60 nm), liver and spleen 
(<150 nm)25 are bigger by which nanoparticles also penetrate into these organs, but due to 
the pegylation the clearance of liposomes by macrophages are delayed and thus the 
liposomes can to some extent pass in and out from the liver and spleen without being 
cleared from the body while they stay in the tumors due to the unefficient lymphatic 
drainage system.22  
 
Data from Unezaki et al.26 illustrate how pegylated liposomes take advantage of the EPR 
effect (Table 1). Unezaki et al. showed that intravenous administration of doxorubicin 
encapsulated in pegylated liposomes into tumor-bearing mice provided a significant higher 
accumulation in tumors than when doxorubicin encapsulated in conventional liposomes or 
free doxorubicin were administrated (Table 1). Furthermore, as a consequence of the 
pegylation the circulation time in the blood stream was improved, whereas the degree of 
accumulation into organs, like the liver and heart was similar to what observed for 
conventional liposomes.  
 
Table 1. Amount of doxorubicin presented as tissue AUCa values after intravenous injection of free 
doxorubicin and doxorubicin encapsulated in conventional and pegylated liposomes into tumor-bearing 
mice at a dose of 5 mg doxorubicin per kg. Data adapted from Unezaki et al.26 
 
Formulation 
Tissue AUC (h·µg/g) 
Blood Liver Heart Lung Spleen Kidney Tumor 
Doxorubicin 1 169 63 106 178 146 18 
Doxorubicin in conventional liposomesb 343 341 41 68 366 72 50 
Doxorubicin in pegylated liposomesc 810 309 42 91 320 132 170 
aAUC = area under the concentration-time curve, calculated for 1–24 h after injection and giving as 
h·µg/g. bThe conventional liposomes consist of DSPC/cholesterol 1:1. cThe pegylated liposomes consist 
of DSPC-PEG/DSPC/cholesterol 6:47:47.  
 
The use of passive targeting and hence the EPR effect is limited and cannot be applied to 
target all forms of cancers. Thus efforts have been directed towards the development of 
active approaches for drug targeting. This can be done by specific modification of the drug 
carrier system with agents or ligands having affinity for recognizing and/or interacting with 
specific cells, tissues or organs in the body. The approach has been explored targeting 
various receptors and antigens on cell membranes and an example is targeting of the folate 
receptor.27,28,29 The folate receptor is over-expressed in many cancer cells with epithelial 
origin and the receptor has been targeted with liposomes conjugated to folic acid. Folic 
acid and thereby also the drug-containing liposomes are taken up by the cells via receptor 
mediated endocytosis (see Figure 7 for the folic acid phospholipid conjugate studied by 
Gabizon et al.28). Another successful approach is conjugation of antibodies to liposomes 
and hence binding to specific surface proteins30 and in recent years, several in vivo studies 
have demonstrated the potential of using antibody-coated liposomes to increase drug 
accumulation in tumors. In a study by Park et al., 31  doxorubicin-loaded liposomes 
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conjugated to antibodies showed significantly increased antitumor efficacy against breast 
cancer xenografts in mice as compared with non-coated liposomes of identical 
composition. Moreover other in vivo studies have demonstrated the potential of using 
antibody-coated liposomes in delivering anticancer drugs to colon and prostate tumors in 
mice.32 
 
 
Figure 7. Structure of the folic acid phospholipid conjugate studied by Gabizon et al.28 for 
active targeting. Folic acid (red) is conjugated via a PEG (blue) chain to DSPE (green).  
 
Having various strategies that can deliver drug-containing liposomes to tumors the next 
obstacle to overcome is drug release. i  As discussed above an optimal drug delivery 
formulation should be able to retain and stabilize the carried drug during blood circulation 
and effectively deliver the drug to the target tissue. Therefore utilization of site specific 
release mechanisms are advantageous and several have been investigated,8  e.g. pH,33,34 
light,35,36 and heat sensitive liposomes.37,38 Another appealing type of release mechanism 
rely on enzymatic triggering. By taking advantage of elevated levels of specific enzymes in 
diseased tissue site specific triggering is possible.8, 39 , 40  One of the studied release 
mechanisms takes advantage of elastase and its ubiquitous involvement in inflammatory 
and tumorigenic conditions. Elastases ability to recognize simple peptide sequences allows 
for a short peptide attachment to the headgroup of phospholipids. Meers and co-workers 
have worked with attachments of first N-acetyl-Ala-Ala (N-Ac-AA)41 to the headgroup of 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and later on with the more 
elastase sensitive sequence of MeO-succinyl-Ala-Ala-Pro-Val (MeO-suc-AAPV).42 Due to 
the small headgroup DOPE itself cannot form stable membrane bilayers at physiological 
pH, however small modifications of the headgroup, like mono-methylation alters the 
properties and stable liposomes can be formulated.41,43 Meers and co-workers have shown 
that conjugation of DOPE to the elestase sensitive peptide chain MeO-suc-AAPV creates 
phospholipids (MeO-suc-AAPV-DOPE) that can form liposomes but upon subjection to 
elastase the liposomes collapse as a consequence of formation of fusogenic DOPE lipids 
and the encapsulated molecules are released (see Figure 8).42 
 
                                                 
i A release mechanism is involved in some active targeting strategies. 
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Figure 8. Illustration of the liposome-forming MeO-suc-AAPV-DOPE phospholipid that upon 
subjection to elastase are hydrolyzed to non-liposome-forming DOPE lipids under release of the 
peptide chain (MeO-suc-AAPV) resulting in an overall collapse of the drug-containing liposomes.42  
 
Another approach described by Davis et al.44 utilize that the membrane-bound form of 
alkaline phosphatase is over-expressed in some tumor tissue45 and they have managed to 
design alkaline phosphatase sensitive liposomes.44 By mixing DOPE and the cholesterol 
phosphate derivative shown in Figure 9 stable liposomes were obtained but in the presence 
of alkaline phosphatase the liposomes collapse as a consequence of the enzyme-mediated 
cleavage of the phosphate. Furthermore, enzymes like matrix metalloproteinases46 and 
secretory phospholipase A2 (sPLA2)47,48 have been explored as a site specific trigger in 
liposomal drug delivery and particular sPLA2 offers an interesting opportunity for enzyme 
triggered drug release. Therefore, the enzyme and sPLA2 dependent drug delivery systems 
will be described in further details in the next sections as this form the basis for the work 
described in the rest of this thesis.   
 
Figure 9. Alkaline phosphatase sensitive cholesterol derivative.44  
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1.3 Secretory Phospholipase A2 and its Utilization as a Site Specific Trigger 
The phospholipase A2 superfamily consists of a broad range of enzymes defined by their 
ability to catalyze the hydrolysis of the ester bond at the sn-2 position in phospholipids 
yielding fatty acid and lysolipids (see Figure 10).49,50 The family of extracelluar sPLA2 
enzymes (IB, IIA, IIC, IID, IIE, IIF, III, V, X and XIIA) are small proteins (14-19 kDa) 
which require Ca2+ for enzymatic activity49,50 and the group I, II V and X sPLA2’s are 
closely related and share a common mechanism for the hydrolysis.49 
 
 
Figure 10. Schematic illustration of the mechanism for the sPLA2 catalyzed hydrolysis of phospholipids 
yielding fatty acids and lysolipids. Key protein residues are drawn in blue, the substrate in red, the 
calcium ion and the water molecule both in brown. R1 and R2 represents aliphatic chains. Adapted from 
Scott et al.51 
 
A prerequisite for hydrolysis is formation of a stable Michaelis-Menten complex between 
the phospholipid substrate and the enzyme. Coordination from Ca2+ to both the 
phospholipid substrate and the protein residues Gly29 and Asp48 is crucial for the 
stabilization and keeps the substrate and enzyme together (Figure 10).51 The ester cleavage 
proceeds through activation and positioning of a water molecule by hydrogen bonding to 
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His47 assisted by Asp91 (Figure 10A). After abstraction of a hydrogen from the incoming 
water molecule a nucleophilic attack on the carbonyl in the sn-2 position occurs forming 
the intermediate (Figure 10B), regeneration of the carbonyl releases the lysolipid and the 
carboxylic acid by which the catalytic cycle is completed and the enzyme is ready for 
another substrate (Figure 10).51 
 
The subtype of the enzyme family, sPLA2 IIA has been suggested as a therapeutic target 
for site specific triggering47,52 due to its over-expression in several human cancer tissues 
(Table 2)53,54 including breast, stomach, colorectal, pancreatic, prostate and liver cancer.  
 
Table 2. Concentration of sPLA2 II in effusions from patients 
with various cancers.a Data from Abe et al.53 
 sPLA2 II concentration (ng/mL) 
Cancer Mean ± SD Range 
Breast 40 ± 19 12–67 
Stomach 51 ± 50 10–188 
Pancreas 56 ± 38 31-131 
Liver 36b 26–45 
aHealthy tissue <10 ng/mL. bOnly two measurements. 
 
Interestingly, the catalytic activity of sPLA2 is higher towards aggregated phospholipids 
such as liposomes and micelles than towards lipid monomers – a phenomenon known as 
interfacial activation.55 Also the physical state of the phospholipids alter the activity and 
whereas it has been demonstrated that snake (Agkistrodon piscivorus piscivorus) venom 
sPLA2 has maximum enzyme activity at the Tm, human sPLA2 IIA increase its activity 
with the temperature until 50 °C after which the enzyme is completely inactive as a 
consequence of denaturation.56 Likewise, the various subtypes of sPLA2 have different 
substrate affinity and whereas the human sPLA2 IIA subtype acts on negatively charged 
substrates57,58,59 subtypes like sPLA2 V and X hydrolyze both negatively charged and 
zwitterionic lipids.59 In the design of liposomal drug delivery systems utilizing the elevated 
levels of sPLA2 IIA in tumors it is therefore important to construct liposomes with a 
negatively charged surface. However it has been reported that intravenous administration 
of negatively charged liposomes may induce complement activation60  but that can be 
suppressed by mixing with neutral phospholipids. In continuation of this, studies have 
shown that neutral phospholipids, like PC lipids in mixtures with PG lipids also are 
hydrolyzed by human sPLA2 IIA.56,61 Furthermore, enzymatic studies have shown that 
sPLA2 activity is retained on pegylated liposomes which are important for the construction 
of liposomal drug carriers having a long circulation time in the blood stream.47,62  
 
The natural substrates for sPLA2 are 1,2-diacyl-sn-glycerophospholipids like POPC 
(Figure 2) but the enzyme has a much broader substrate scope and is able to hydrolyze a 
variety of phospholipids, like phospholipids with a sn-1-ether moiety,63,64 sn-2-thioesters65 
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and lipids with alkyl substituents at the sn-1 position66 (see Figure 11). However the 
enzyme is very sensitive to the stereochemistry of the glycerol backbone and only 
phospholipids having an L-glycerol backbone are substrates for sPLA2. Indeed D-
glycerophospholipids have been exploited as competitive inhibitors.67 
 
Figure 11. Small selection of the variety of synthetic phospholipids sPLA2 is able to hydrolyze. 
 
By taking advantage of the elevated levels of sPLA2 IIA in tumors and the EPR effect 
liposomal drug delivery systems consisting of sPLA2 sensitive phospholipids (see Figure 
12) have been developed.48,63 The enzyme sensitive liposomes are constructed of sn-1-
ether phospholipids having saturated aliphatic chains in the sn-1 and sn-2 position.63,64 
Upon sPLA2 activation the phospholipids are converted into fatty acids and sn-1-ether 
lysolipids which are highly cytotoxic compounds and also known as anticancer ether 
lipids.64,68  
 
                                          
 
Figure 12. Schematic overview of the strategy for using sPLA2 degradable liposomes in cancer treatment. 
The sn-1-ether phospholipid prodrugs are formulated as liposomes encapsulating anticancer drugs. Because 
of the EPR effect, the liposomes will accumulate in cancer tissue and sPLA2, which is up-regulated in 
tumors, will degrade the drug containing liposomes, releasing the encapsulated drugs which together with the 
cytotoxic lysolipids and the fatty acids attack the cancer cells. 
 
The prodrug strategy masks the anticancer ether lipid and minimizes the hemolytic effect 
often seen for anticancer ether lipids in vivo.69,70 In vitro studies with the sPLA2 sensitive 
liposomes have shown that the enzyme need to be present in order to induce significant 
Cancer tissue 
▪ Porous structure  
▪ Elevated levels of sPLA2
Drug release  
mediated by sPLA2
Cancer cell  
Pegylated drug containing 
sPLA2 degradable liposomes 
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cell death, showing the potential of the phospholipid prodrug strategy.63,64 The sPLA2 
degradable liposomes are also capable of encapsulating hydrophilic drugs like cis-platin 
and doxorubicin and formulated with pegylated phospholipids long circulating liposomes 
have been created.8 Therefore in overall the enzyme activation releases two anticancer 
drugs selectively in the cancer tissue. In vivo studies of the drug delivery system have 
demonstrated that growth inhibition of sPLA2 expressing tumor cells were significant 
better when the drug (cis-platin or doxorubicin) was encapsulated into the enzyme 
sensitive liposomes, compared to when the drugs were administrated alone and the 
formulation was also superior to the commercial available formulation of doxorubicin, 
Doxil®.8 
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1.4 New Generation of Enzyme Sensitive Phospholipids 
Although liposomes are capable of delivering drugs to tumors a major problem in 
liposomal drug delivery is leakage of the encapsulated drugs. That can be lowered by 
addition of cholesterol to the liposomal formulation, but for drug delivery strategies relying 
on site specific drug release via sPLA2 activation it is desirable to avoid or minimize the 
addition of cholesterol, as cholesterol harms the enzyme activity and studies have revealed 
that liposomes having >20% cholesterol are non-degradable by sPLA2.8 An uncontrolled 
drug leakage can be prevented by covalent attachment of anticancer drugs to phospholipids 
creating prodrugs that upon triggering, e.g. by sPLA2 release the attached drugs. This 
strategy makes it possible to use empty liposomes hence avoiding drug leakage from the 
interior and ideally the liposomes become non-toxic during circulation in the blood stream. 
An example on such a phospholipid prodrug is empty liposomes of the sn-1-ether 
phospholipids illustrated in Figure 12, which are prodrugs of anticancer ether lipids. More 
recently incorporation of capsaicin into sPLA2 sensitive phospholipids has been achieved 
and upon sPLA2 mediated hydrolysis capsaicin was released after cyclization (see Figure 
13).71  
 
 
Figure 13. Release of capsaicin from phospholipid prodrug upon 
cyclization mediated by sPLA2.71 
 
The liposomal drug delivery system studied in this work relies on covalent incorporation of 
anticancer drugs directly to the sn-2 position of sn-1-ether phospholipids. Hydrolysis of the 
ester-bond at the sn-2 position by sPLA2 will convert the phospholipid prodrugs into two 
cytotoxic agents, the sn-1-ether lysolipid and the anticancer drug (see Figure 14 for an 
overview of the principle). Lysolipids are known to achieve their cytotoxic activity through 
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multiple mechanisms,69 one involves membrane perturbation by which the lysolipids are 
likely to enhance the cellular uptake of the other anticancer drug causing a synergistic 
effect between two drugs. Previously, it has been demonstrated that lysolipids and fatty 
acids enhance membrane permeability.72 
 
Interestingly cytotoxicity studies have shown that the stereochemistry of the PG headgroup 
has an impact on the activity of sn-1-ether lysolipids and the (S)-isomer displayed 
significantly higher cytotoxicity than the corresponding (R)-isomer which is why the PG 
lipids are designed to have the (S)-configuration.68 
 
Figure 14. Schematic overview of the investigated drug delivery concept. The phospholipid prodrugs are 
formulated as liposomes. Because of the EPR effect, the liposomes will accumulate in cancer tissue and 
sPLA2, which is up-regulated in tumors, will hydrolyze the prodrugs, releasing two anticancer agents.  
 
It is crucial for the prodrug strategy that suitable drug candidates are available. Since the 
incorporated drug will be part of the lipophilic membrane, a hydrophobic nature is an 
obvious requirement and, furthermore, a carboxylic acid moiety is needed for the 
attachment of the drug to the phospholipid backbone. A number of candidates have been 
identified such as chlorambucil,73 , 74  all-trans retinoic acid (ATRA),75 , 76 , α-tocopheryl 
succinate77,78 a derivative of vitamin E and prostaglandins like 15-deoxy-Δ12,14-PGJ279 (see  
Figure 15).  
 
Incorporation of structures like chlorambucil into the phospholipid bilayer contrasts the 
(predominantly) saturated aliphatic chains in liposome forming phospholipids like in 
DPPC. In the initial screening for a suitable drug candidate it was therefore interesting to 
study the ability of the phospholipid prodrugs to form liposomes, furthermore, it was 
crucial that the ester-bond at the sn-2 position was hydrolyzed by sPLA2 hence converting 
the prodrugs into cytotoxic agents. As a final initial screening parameter it was important 
that the prodrugs were non-toxic in the absence of sPLA2. The anticancer drugs shown in  
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Figure 15 have together with calcitriol (Chapter 7) been examined for their ability to be 
incorporated into the liposomal drug delivery system illustrated in Figure 14.   
 
 
 
Figure 15. Suitable drug candidates for incorporation into the investigated drug delivery system. 
 
A major part of the work carried out involves synthesis of phospholipids having either a 
PC or PG headgroup, why the coming section provides a brief overview of the most 
modern ways of making PC and PG lipids.   
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2. Phospholipid Synthesis – An Overview 
 
In the following synthesis of phospholipids will be reviewed. Focus will be on mixed-acid 
1,2-diacyl-sn-glycerophospholipids and 1-O-alkyl-2-acyl-sn-glycerophospho-lipids having 
either a PC or PG headgroup. Two general approaches are used for the synthesis of 
phospholipids having different aliphatic chains at the sn-1 and sn-2 position (see Figure 
16).  
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Figure 16. Retrosynthesis of 1,2-diacyl-sn-glycerophospholipids and 1-O-akyl-2-acyl-sn-
glycerophospholipids. 
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One strategy relies on installation of the aliphatic chains and then attachment of the 
phosphate headgroup (1st strategy in Figure 16) whereas in the second strategy the aliphatic 
chain at the sn-1 position and the phosphate headgroup at the sn-3 position are installed 
first and then acylation of the hydroxyl at the sn-2 position is achieved at a later stage (2nd 
strategy in Figure 16). 
 
Acyl-migration in unprotected glycerol derivatives is a major challenge in synthesizing 
phospholipids.80 The migrations are promoted by both base and acid meaning that the 
synthetic transformations have to be performed under mild conditions. Furthermore, as 
described in section 1.1 many fatty acids are unsaturated which must be considered when 
planning the synthesis.  
 
The commercially available compounds 1,2-isopropylidene-sn-glycerol and 2,3-
isopropylidene-sn-glycerol serve as the most applied starting materials for the synthesis of 
1,2-O-diacyl-glycerophospholipids. 1,2-Isopropylidene-sn-glycerol is made from D-
mannitol81,82 whereas 2,3-isopropylidene-sn-glycerol can be made from L-erythrulose,83 L -
serine82 or L-ascorbic acid.84 In addition to 2,3-isopropylidene-sn-glycerol, glycidols like 
(R)-glycidyl tosylate are used in the synthesis of sn-1-ether phospholipids. Glycidols can 
be made in high enantiomeric purity by asymmetric epoxidation of allyl alcohols.85    
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2.1 Synthesis of 1,2-Diacyl-sn-glycerophospholipids 
Starting from 2,3-isopropylidene-sn-glycerol acylation of the sn-1 position has been 
performed using either carbodiimide mediated chemistry or via reaction with acid 
chlorides (Table 3). The removal of the isopropylidene protecting group without acyl-
migration has been achieved under mild acidic conditions using acidic exchange resins, 
like Amberlyst-H+ (entry 3 in Table 3), however long reaction times (>24 h) have been 
necessary in order to obtain good yields. Furthermore, hydroxyl coordinating reagents like 
B(OH)3 in MeNO2 or trifluoroacetic acid (TFA) in B(OEt)3 has been efficient in the 
desired deprotection as well (entry 1 and 2 in Table 3). 
 
Table 3. Synthesis of 1-acyl-sn-glycerol from 2,3-isopropylidene-sn-glycerol. 
 
 
 
Entry R1COOH Reaction conditions 
186 6-heptynoic acid (a) Ethyl-(3-dimethylaminopropyl)-carbodiimide 
hydro chloride (EDCI), 4-dimethylaminopyridine 
(DMAP), CH2Cl2 (97%); (b) B(OH)3, MeNO2 (84%). 
287 Stearic acid (a) Stearoyl chloride, Et3N, DMAP, CH2Cl2; (b) TFA, 
CF3CH2OH, B(OEt)3 (74%) 
388 Stearic acid (a) EDCI, DMAP, CH2Cl2 (84%);  
(b) Amberlyst-H+, MeOH (75%). 
489 Linoleic acid (a) EDCI, DMAP, THF; (b) Dowex 50W, MeOHa 
aYield not reported. 
 
Starting from 1,2-isopropylidene-sn-glycerol, protection of the sn-3 position is the first 
step. Various acid stabile protecting groups have been applied in the synthesis of 3-O-
protected-sn-glycerols (Table 4) and among the used protecting groups are p-
methoxybenzyl (PMB), tert-butyldiphenylsilyl (TBDPS), benzyl (Bn) and tosyl (Ts). The 
protecting groups are introduced under basic conditions and the following isopropylidene 
deprotection is achieved using acid catalysis, and having no ester-functionality acyl-
migration is not an issue and strong acids are used, giving short reaction times and 
excellent yields (Table 4). In addition tetrahydropyranyl (THP, entry 3 in Table 4) is also 
successfully applied in this type of glycerol functionalization.  
  
Liposomal Drug Delivery 
24 
 
Table 4. Synthesis of 3-O-protected-sn-glycerols from 1,2-isopropylidene-sn-glycerol. 
 
 
 
Entry Pg Reaction conditions 
190 PMB (a) PMBCl, KH, Bu4NI, THF; (b) TsOH, MeOH (98%). 
291,92 PMB (a) PMBCl, NaH, DMF (90%); (b) AcOH, MeOH (99%). 
393 THP (a) 3,4-dihydropyran (DHP), pyridine p-toluenesulfonate 
(PPTS), CH2Cl2 (92%); (b) Bi(OTf)3, THF/H2O 4:1 (76%). 
494 TBDPS (a) TBDPSCl, imidazole, THF; (b) HCl, H2O, EtOH (97%). 
595 Bn (a) NaH, BnCl, DMSO (55%); (b) AcOH, H2O (95%). 
696 Ts (a) TsCl, Pyridine (91%); (b) HCl, H2O, acetone (100%).  
 
The 1-acyl-sn-glycerols (from Table 3) are by using appropriate protecting groups 
converted into 1,2-diacyl-sn-glycerols (Table 5). It is crucial that both the protecting of the 
sn-3 position and the final deprotection (step c in Table 5) can be achieved under 
conditions which avoid racemization. Dimethoxytrityl (DMT) has been used by Neff et 
al.86 however the group is so acid labile that chromatography through silica must be done 
with care or with addition of base to the eluent like Neff et al.86 have done. Hence the 
removal can be done under mild conditions and using B(OH)3 in MeNO2 the desired 1,2-
diacyl-sn-glycerol is achieved (entry 1 in Table 5). Gaffney et al.87 have used the 9-(9-
phenyl)xanthenyl (pixyl or Px) protecting group, prepared by mixing the glycerol 
derivative and PxOH in AcOH followed by evaporation in vacuo. Deprotection was done 
by treatment with a dilute solution of Cl2CHCOOH and pyrrole in CH2Cl2, which was 
tolerated by the unsaturated arachidonoyl moiety in the sn-2 position (entry 3 in Table 5). 
Silyl protecting groups like tert-butyldimethylsilyl (TBDMS) was ruled out by Dodd et 
al.97 as an applicable protecting group for glycerols due to acyl-migration upon treatment 
with fluorine sources like HF or tetrabutylammonium fluoride (TBAF). However Burgos et 
al. 98  have shown that applying the rather unusual deprotection conditions, N-
bromosuccinimide (NBS) in DMSO and THF99 migration was avoided and the 1,2-diacyl-
sn-glycerol was obtained and the enantiomeric purity was verified by Mosher ester 
analysis100 (entry 2 in Table 5). Recently Stamatov et al.101 have developed a two step 
procedure for the deprotection of silyl protected glycerols, in which the silyl ether (such as 
triisopropylsilyl, TIPS) is converted into the trichloroacetate via treatment with Et3N·3HF 
and trichloroacetic anhydride at 80 °C, then the trichloroacetate is hydrolyzed by pyridine 
in MeOH and THF affording the 1,2-diacyl-sn-glycerols (entry 5 and 6 in Table 5). A 
drawback in this method is the reaction temperature at 80 °C required for the 
trichloroacetate formation which limit the substrate scope, however an oleoyl moiety in 
both the sn-1 and sn-2 position has resist the conditions. Examination of other unsaturated 
fatty acids remains.  
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Table 5. Synthesis of 1,2-diacyl-sn-glycerols from 1-acyl-sn-glycerols. 
 
 
 
Entry R1COOH Pg R2COOH Reaction conditions 
186 6-Heptynoic acid DMT Myristic acid (a) DMTCl, DMAP, pyridine (94%); 
(b) myristic acid, EDCI, DMAP, 
CH2Cl2 (92%); (c) B(OH)3, MeNO2 
(81%). 
298 Stearic acid TBDMS Stearic acid (a) TBDMSCl, imidazole, THF; (b) 
C17H35COCl, pyridine (77%); NBS, 
DMSO, THF. 
387 Stearic acid Px Arachidonic acid (a) PxOH, AcOH (72%); (b) 
arachidonic acid, 2,6-Cl2C6H3COCl, 
1-methylimidazole, CH2Cl2; (c) 
Cl2CHCOOH, pyrrole, CH2Cl2 
(90%). 
488 Stearic acid DMT Arachidonic acid (a) DMTCl, pyridine (96%); (b) 
arachidonic acid, DCC, DMAP, 
CH2Cl2 (100%); (c) TFA, pyrrole 
(72%). 
5101 Oleic acid TBDMS Acetic acid (a) TBDMSCl, imidazole, THF 
(85%); (b) AcCl, pyridine (94%); (c) 
(i) Et3N·3HF, (CCl3CO)2O; (ii) 
pyridine, MeOH, THF (93%). 
6101 Oleic acid TIPS Oleic acid (a) TIPSCl, imidazole, THF (80%); 
(b) oleoyl chloride, pyridine (93%); 
(c) (i) Et3N·3HF, (CCl3CO)2O (ii) 
pyridine, MeOH, THF (92%). 
 
Monoacylation of 3-O-protected-glycerols (from Table 4) have been achieved in moderate 
to good yields using a Steglich esterification102 (Table 6). Applying the coupling reagents 
in excess double-acylation has also been obtained (entry 2 in Table 6). Likewise 
attachment of the second fatty acid to the sn-2 position (step b in Table 6) have been 
achieved using the Steglich coupling or via reaction with acid chlorides. When double 
bonds are absent the benzyl protected strategy has been used and Martin et al.103 have 
removed the benzyl ether by hydrogenolysis to obtain pure 1,2-diacyl-sn-glycerols (entry 3 
in Table 6). The PMB-group has efficiently been removed by 2,3-dichloro-5,6-dicyano-
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1,4-benzoquinone (DDQ) in moist CH2Cl2 allowing a carboxybenzyl (Cbz) group to be 
present (entry 4 in Table 6).92  
 
Table 6. Synthesis of 1,2-diacyl-sn-glycerols from 3-O-protected-sn-glycerols. 
 
 
 
Entry Pg R1COOH R2COOH Reaction conditions 
1104 PMB Stearic acid Eicosanoic 
acid 
(a) Stearic acid, dicyclohexylcarbodiimide 
(DCC), DMAP, CH2Cl2 (63%); (b) Eicosanoic 
acid, DCC, DMAP, CH2Cl2 (82%); (c) DDQ, 
H2O, CH2Cl2 (88%). 
293 THP Palmitic acid Palmitic acid (a+b) Palmitic acid, DCC, DMAP, CHCl3 
(79%); (c) 0.15 M HCl, CHCl3, MeOH (93%). 
3103 Bn Palmitic acid Propanoic acid (a) Palmitic acid, DCC, DMAP, CHCl3 (69%); 
(b) Propionoic acid, DCC, DMAP, CHCl3 
(96%); (c) H2, Pd/C, EtOH, AcOH (99%). 
492 PMB CbzNH(CH2)11CO2H Palmitic acid (a) CbzNH(CH2)11COOH, DCC, DMAP, 
CH2Cl2 (89%); (b) Palmitoyl chloride, 
pyridine, DMAP, CH2Cl2 (70%); (c) DDQ, 
H2O, CH2Cl2 (91%). 
 
When it is desirable to install the ester at the sn-2 position at a later stage, e.g. after 
attachments of the phosphate headgroup, 1-acyl-2-O-protected-sn-glycerols are needed and 
although this is not the most applied strategy for synthesis of phospholipids examples are 
reported. Starting from a 1-acyl-sn-glycerol Bibak et al.105 (Table 7) have used a protecting 
group strategy which initiate with a (9-fluorenylmethyl) carbamate (Fmoc) protection of 
the sn-3 position followed by a THP protection of the sn-2 position. Subsequent removal of 
Fmoc with piperidine in CH2Cl2 gave the 1-acyl-2-O-protected-sn-glycerol.  
 
Table 7. Synthesis of 1-acyl-2-O-protected-sn-glycerols from 1-acyl-sn-glycerols. 
 
 
 
Entry R1COOH Pg1 Pg2 Reaction conditions 
1105 Palmitic acid Fmoc THP (a) FmocCl, DMAP, CHCl3 (58%); (b) DHP, PPTS, 
CH2Cl2 (86%); (c) Piperidine, CH2Cl2 (87%). 
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1-Acyl-2-O-protected-sn-glycerols have also been obtained from 3-O-protected-sn-
glycerols (Table 8). Like described earlier selective acylations of the sn-1 position have 
been achieved using the Steglich coupling.102 Having the sn-3 position PMB-protected 
Martin et al.103 were successful with benzyloxy methyl (BOM) protection of the sn-2 
position and liberation of the sn-3 position was mediated by DDQ in moist CH2Cl2 (entry 1 
in Table 8). Starting from 3-O-tosyl-sn-glycerol Rosseto et al.106 have used a strategy in 
which the sn-2 position was THP protected and the tosylate was then converted into the 
corresponding methoxyacetate and after some optimization it was found that tert-
butylamine in MeOH and CHCl3 was capable to selective hydrolyze the methoxyacetate 
over the ester at the sn-1 position (entry 2 in Table 8).   
 
Table 8. Synthesis of 1-acyl-2-O-protected-sn-glycerols from 3-O-protected-sn-glycerols. 
 
. 
Entry Pg1 R1COOH Pg2 Reaction conditions 
191,103 PMB Palmitic acid BOM (a) Palmitic acid, DCC, DMAP, CH2Cl2 (54%); (b) 
BOMCl, DIPEA, CH2Cl2 (94%); (c) DDQ, H2O, CH2Cl2 
(88%). 
2106 Ts Palmitic acid THP (a) Palmitic acid, DCC, DMAP, CH2Cl2 (72%); (b) 3,4-
dihydropyran, PPTS, CH2Cl2 (95%); (c) (i) CH3OCH2COO- 
Et4N+, MeCN (ii) tBuNH2, MeOH, CHCl3 (80%). 
 
After installation of a phosphate headgroup (see section 2.3 and 2.4) on 1-acyl-2-O-
protected-sn-glycerols (Table 9) removal of the protecting group at the sn-2 position has to 
be done under conditions in which acyl-migration is prevented, and using either a Bn or 
BOM protection, palladium catalyzed hydrogenolysis has been capable of doing that (entry 
1, 3 and 4 in Table 9). Using slightly acidic conditions Hajdu and co-workers105,106 have 
been able to remove a THP group without migration (entry 2 in Table 9). Acylation of the 
liberated sn-2 position has been done using various acylation methods, such as the Steglich 
coupling102 (entry 1 in Table 9) and various carboxylic acid has been attached like the 
unsaturated docosahexaenoic acid (entry 1 in Table 9). In general good yields are reported 
for esterification on PC lysolipids (like in entry 1 and 2 in Table 9 and Table 14) however 
Shizuka et al.91 report that no conversion was observed when acylation of 1-palmitoyl-2-
lyso-sn-glycero-3-phosphocholine with ent-15-epi-F2t-isoprostanoic acid was attempted 
using various coupling methods. But when the PC headgroup was protected as (2-
chloroethyl) methyl phosphate the desired acylation occurred (entry 3 in Table 9).          
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Table 9. Synthesis of 1,2-diacyl-sn-glycerophospholipids from 1-acyl-2-O-protected-sn-glycerols. 
 
 
 
Entry R1COOH Pg R3 a R2COOH Reaction conditions 
1107 Stearic acid Bn PC Docosahexaenoic 
acidb 
(a) H2, Pd(OH)2/C, MeOH, H2O; (b) 
docosahexaenoic acid, DCC, DMAP, CHCl3 
(62%). 
2105,106 Palmitic acid  THP PC Palmitic acid (a) 0.15 M HCl, dioxane, H2O; (b) p-
nitrophenyl palmitate, DMAP, CHCl3 
(62%).  
391 Palmitic acid BOM PCc ent-15-epi-F2t-
isoprostanoic acid 
(a) H2, Pd/C, THF, H2O (99%); (b) EDCI, 
DMAP, CH2Cl2 (54%). 
4108 Dodecanoic 
acid 
Bn PGd Oleic acid (a) H2, Pd/C, EtOAc, MeOH (100%); (b) 
oleic acid, EDCI, DMAP, CH2Cl2 (85%). 
aPhosphate headgroup, see section 2.3 and 2.4 for synthesis. bcis-4,7,10,13,16,19-docosahexaenoic acid. 
cProtected as (2-chloroethyl) methyl phosphate. dProtected, see section 2.4. 
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2.2 Synthesis of 1-O-Alkyl-2-acyl-sn-glycerophospholipids 
In the following synthesis of 1-O-alkyl-2-acyl-sn-glycerophospholipids initiated from 2,3-
isopropylidene-sn-glycerol or (R)-glycidyl tosylate are reviewed. Starting from 2,3-
isopropylidene-sn-glycerol conversion into 1-O-alkyl-sn-glycerols have been accessed by 
alkylation of the sn-1 position using a Williamson ether synthesis109 followed by acid 
catalyzed acetal hydrolysis (Table 10).  
 
Table 10. Synthesis of 1-O-alkyl-sn-glycerol from 2,3-isopropylidene-sn-glycerol. 
 
 
 
Entry R1OH Reaction conditions 
1110 Hexadecanol (a) C16H33I, NaH, DMF, THF; (b) TFA/H2O 9:1 (55%)a. 
2111 Hexadecanol (a) C16H33OMs, NaH, benzene (80%); (b) HCl, THF (78%). 
386 10-Undecynol (a) 10-Undecynyl bromide, NaH, DMF (55%); (b) AcOH, H2O (99%). 
aYield over two step 
 
Like for 1,2-diacyl-sn-glycerols (see Table 5) synthesis of 1-O-alkyl-2-acyl-sn-glycerols 
are achieved by using appropriate protection of the sn-3 position (Table 11). However 1-O-
alkyl-2-acyl-sn-glycerols does not have the same tendency to undergo acyl-migration as 
1,2-diacyl-sn-glycerols and Yashunsky et al.110 have removed a triethylsilyl (TES) group 
with Et3N·3HF in MeCN and CH2Cl2 (entry 1 and 2 in Table 11). While TBDPS have been 
removed by TBAF in the presence of imidazole (entry 3 in Table 11), in the absence of 
imidazole substantial acyl-migration took place.90 The two step procedure developed by 
Stamatov et al.101 for the deprotection of silyl ethers in 1,2-diacyl-sn-glycerols were also 
capable of removing TBDMS without acyl-migration in 1-O-alkyl-2-acyl-sn-glycerols 
(entry 4 in Table 11). Furthermore, DMT protection of the sn-3 position has been 
successful (entry 5 in Table 11). 
  
Liposomal Drug Delivery 
30 
 
Table 11. Synthesis of 1-O-alkyl-2-acyl-sn-glycerols from 1-O-alkyl-sn-glycerols. 
 
 
 
Entry R1OH Pg R2COOH Reaction conditions 
1110 Hexadecanol TES Oleic acid (a) TESCl, pyridine, CH2Cl2; (b) Oleoyl 
chloride, Et3N, DMAP, pyridine; (c) 
Et3N·3HF, MeCN, CH2Cl2 (58%)c.  
2110 Hexadecanol TES Linoleic acid (a) TESCl, pyridine, CH2Cl2; (b) 
Linoleoyl chloride, Et3N, DMAP, 
pyridine; (c) Et3N·3HF, MeCN, CH2Cl2 
(58%)a.  
390,112 (Z)-1-Octadecenol TBDPS Palmitic acid (a) TBDPSCl, imidazole, DMF (90%); 
(b) (C15H31CO)2O, DMAP, CHCl3 (98%); 
(c) TBAF, imidazole, THF (>74%). 
4101 Hexadecanol TBDMS AcOH (a) TBDMSCl, imidazole, THF (85%); 
(b) AcCl, pyridine, CH2Cl2 (95%); (c) (i) 
Et3N·3HF, (CCl3CO)2O (ii) pyridine, 
MeOH, THF (92%). 
586 10-Undecynol DMT Myristic acid (a) DMTCl, DMAP, pyridine (94%); (b) 
Myristic acid, EDCI, DMAP, CH2Cl2 
(99%); (c) B(OH)3, MeNO2 (81%). 
aYield over three steps. 
 
Another convenient route used for the introduction of the sn-1-ether functionality is Lewis 
acid catalyzed epoxide opening of glycidols like (R)-glycidyl tosylate with alcohols (Table 
12). Guivisdalsky et al.114 discovered that BF3·OEt2 mediated the desired epoxide opening 
with excellent regioselectivity and high enantiomeric excess, whereas other Lewis acid like 
Ti(OiPr)4 and SnCl4 gave much lower conversion. Furthermore, Guivisdalsky et al.114 
demonstrated that while epoxide opening of (R)-glycidyl tosylate with hexadecanol 
exclusively gave the sn-1-ether, epoxide opening of the corresponding TBDPS glycidol 
resulted in a 9:1 ratio between the desired sn-1-ether and the undesired sn-2-ether. Hence 
Andresen et al.68 have synthesized a collection of different sn-1-ether phsopholipids from 
(R)-glycidyl tosylate. Having the sn-1-ether functionality introduced synthesis of 1-O-
alkyl-2-O-protected-sn-glycerols has been achieved using either a Bn or THP protection of 
the sn-2 position. Bn protection has been performed under both basic conditions (entry 1 in 
Table 12) and acidic conditions using benzyl trichloroacetimidate (entry 2 in Table 12). 
Removal of the tosyl group has been achieved by converting the tosylate into the acetate, 
which then either has been reduced with LiAlH4 (entry 1 in Table 12) or hydrolyzed (entry 
3 in Table 12). Applying NaNO2 Andresen et al.68 have obtained the alcohol in one step 
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from the tosylate (entry 2 in Table 12) albeit the overall yield was lower than using the two 
step procedure.  
 
Table 12. Synthesis of 1-O-alkyl-2-O-protected-sn-glycerols from (R)-glycidyl tosylate. 
 
 
 
Entry R1OH Pg Reaction conditions 
1113,114 Hexadecanol Bn (a) C16H33OH, BF3·OEt2, CHCl3 (80%); (b) BnOTf, 
2,6-di-tert-butyl-4-methylpyridine, CH2Cl2 (96%); 
(c) (i) CsOAc, DMF, DMSO (ii) LiAlH4, Et2O 
(92%). 
268 Octadecanol Bn (a) C18H37OH, BF3·OEt2, CH2Cl2 (91%); (b) 
BnOC(NH)CCl3, TfOH, dioxane (96%); (c) NaNO2, 
DMF (72%). 
3115 CH3OCO(CH2)4CH2OH THP (a) CH3OCO(CH2)4CH2OH, BF3·OEt2, CH2Cl2 
(89%); (b) DHP, PPTS, CH2Cl2 (69%); (c) (i) 
Et4NOAc, MeCN (ii) K2CO3, MeOH (68%). 
 
Ohno et al.111 have also managed to synthesize a 1-O-alkyl-2-O-protected-sn-glycerol from 
1-O-alkyl-sn-glycerol. The sn-3 position was selectively protected with a trityl (Tr) group, 
followed by benzylation of the sn-2 position after which the trityl group was removed 
again via treatment with acid (Table 13). 
 
Table 13. Synthesis of 1-O-alkyl-2-O-protected-sn-glycerols from 1-O-alkyl-sn-glycerols. 
 
 
 
Entry R1OH Pg1 Pg2 Reaction conditions 
1111 Hexadecanol Tr Bn (a) TrCl, DMAP, pyridine (92%); (b) KH, 
BnCl, benzene (100%); (c) TsOH·H2O, MeOH 
(92%). 
 
Synthesis of 1-O-alkyl-2-acyl-sn-glycerophospholipids from 1-O-alkyl-2-O-protected-sn-
glycerols has been performed in very much the same way as synthesis of 1,2-diacyl-sn-
glycerophospholipids from 1-acyl-2-O-protected-sn-glycerols (see Table 9). Benzyl 
protection of the sn-2 position has been used by Guivisdalsky et al.113 and hydrogenolysis 
under palladium catalysis gave the lysolipids (entry 1-3 in Table 14). Having a vinyl-ether 
in the sn-1 position Shin et al.112 have used a TBDMS protection of the sn-2 position and in 
the presence of imidazole the deprotection was achieved with TBAF in THF (entry 4 in 
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Table 14). Interestingly, the following acylation of the sn-2 position has only been reported 
via reaction with anhydrides (entry 1,2 and 4 in Table 14) albeit in good yields.   
 
Table 14. Synthesis of 1-O-alkyl-2-acyl-sn-glycerophospholipids from 1-O-alkyl-2-O-protected-sn-
glycerols. 
 
 
 
Entry R1OH Pg R3 a R2COOH Reaction conditions 
1113 Hexadecanol Bn PC Palmitic acid (a) H2, Pd(OH)2/C, MeOH, H2O (100%); 
(b) (C15H31CO)2O, DMAP, CHCl3 (98%) 
268,111 Octadecanol Bn PC AcOH (a) H2, Pd/C, MeOH (>77%); (b) Ac2O, 
pyridine (93%).  
368 Octadecanol Bn PGb  (a) H2, Pd/C, MeOH (>67%). 
4112 (Z)-1-Hexadecenol TBDMS PC Palmitic acid (a) TBAF, imidazole, THF (98%); (b) 
(C15 H31CO)2O, DMAP, CH2Cl2 (53%). 
aPhosphate headgroup. bProtected, see section 2.4. 
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2.3 Synthesis of Phosphatidylcholine (PC) Headgroup 
Installation of the PC headgroup has been done by different procedures116 however two 
procedures are mainly used and they are shown in Scheme 1 and further reaction details 
are giving in Table 15. The first procedure (entry 1 in Table 15 and Scheme 1) is a one pot 
procedure in which the glycerol are reacted with phosphorus oxychloride, then one 
equivalent of choline tosylate is added and the in situ generated dichlorophosphate undergo 
substitution with choline and addition of H2O fulfill the synthesis. The procedure is very 
sensitive to moisture while inconsistent yields have been reported.64 In the second 
procedure (entry 2 in Table 15 and Scheme 1) the glycerol is reacted with ethylene 
chlorophosphate in the first step and after purification the final step is ring opening of the 
glycerol-ethylenephosphate-conjugate with Me3N, which is done at 65 °C in a pressure 
bottle to avoid evaporation of Me3N and with reaction times above 24 h. Compared to the 
first procedure this is rather harsh conditions and furthermore, Me3N is not convenient to 
handle due to the low boiling point at 3-4 °C.117 But this chemistry is less sensitive to 
moisture and furthermore, the ethylenephosphate-intermidiate can be isolated while 
deprotection and functionalization of the sn-2 position can be done prior to the final 
conversion into the PC lipid, like reported in entry 3 in Table 9. For further procedures to 
PC lipids see the review by Paltauf and Hermetter.116  
 
Scheme 1. Synthetic routes to the PC headgroup. ROH represent a glycerol-derivative 
 
 
Table 15. Synthesis of the PC headgroup – reaction details (see Scheme 1). 
Entry Reaction conditions Yielda 
168,113,118 (i) POCl3, Et3N, CH2Cl2; (ii) choline tosylate, 
pyridine; (iii) H2O. 
75% 
268,106,105,112 (i) ethylene chlorophosphate, Et3N, benzene; (ii) 
Me3N, MeCN, 65 °C (pressure bottle, 24 h). 
60% 
aRepresentative value 
 
  
Liposomal Drug Delivery 
34 
 
2.4 Synthesis of Phosphatidylglycerol (PG) Headgroup 
Although that synthesis of PG lipids are less common than synthesis of PC lipids various 
procedures have been developed116 and three of the mainly used are presented in Scheme 2 
and Table 16. In the first procedure (entry 1 in Table 16 and Scheme 2) the glycerol is 
subjected to methyl dichlorophosphate and 2,2,6,6-tetramethyl piperidine (TMP) and 
followed by addition of 2,3-isopropylidene-sn-glycerol the protected PG lipid is obtained 
and if desirable it can be isolated by column chromatography. Due to the protections of the 
glycerol and the phosphate, modifications elsewhere in the molecule can be done, like 
observed in entry 4 in Table 9.108 Hydrolysis of the methyl phosphate ester has been 
achieved via treatment with Me3N in MeCN and iPrOH while the glycerol has been 
liberated under slightly acidic conditions, however long reaction times (>14 h) are needed 
for both conversions.  
The two other procedures (entry 2 and 3 in Table 16 and Scheme 2) involve tetrazole 
mediated phosphoramidite couplings followed by oxidation of the phosphite to the 
phosphate with peroxides, such as tBuOOH. All three procedures lead to the formation of 
the same protected phosphate, and in addition to the Me3N mediated hydrolysis (entry 2 
and 3 in Table 16), the methyl phosphate ester has also been cleaved with NaI in 2-
butanone (entry 3 in Table 16). The overall yields for the three routes are comparable.  
 
Scheme 2. Synthetic routes to the PG headgroup. ROH represent a glycerol-derivative.  
 
 
Table 16. Synthesis of the PG headgroup – reaction details (see Scheme 2). 
Entry Reaction conditions Yield 
168 (i) MeOPOCl2, TMP, toluene; (ii) 2,3-isopropylidene-sn-glycerol, TMP; (iii) Me3N, 
MeCN, iPrOH; (iv) HCl, MeOH, CH2Cl2.   
61% 
268 (i) (iPr)2NPClOMe, TMP, CH2Cl2; (ii) 5-phenyltetrazole, 2,3-isopropylidene-sn-
glycerol; (iii) tBuOOH; (iv) Me3N, MeCN, iPrOH; (v) HCl, MeOH, CH2Cl2. 
67% 
3108 (i) ((iPr)2N)2POMe, tetrazole, CH2Cl2; (ii) 2,3-isopropylidene-sn-glycerol, tetrazole; 
(iii) mCPBA; (iv) NaI, 2-butanone; (v) TFA, MeOH, CH2Cl2.  
55% 
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3. Chlorambucil Phospholipid Prodrugs 
 
3.1 Introduction 
To demonstrate proof-of-principle chlorambucil was selected for incorporation into the 
investigated liposomal drug delivery system. Chlorambucil is a chemotherapeutic agent of 
the mustard gas type119 and it was originally synthesized by Everett et al. in 1953.73 It is 
used clinically for the treatment of lymphocytic leukemia120 typically in combination with 
other drugs. Chlorambucil is orally administrated (Leukeran®), but undergoes rapid 
metabolism, and as a result the stability in aqueous environments is low and chlorambucil 
has an elimination half-life of 1.5 h.121,122,123 The prodrug formulation could remedy this, 
since this system will shield chlorambucil from degradation through the incorporation in 
the lipophilic part of the liposomal membrane and deliver it directly to the tumor, 
decreasing metabolism compared to the oral administration route. To investigate the effect 
of sn-1 ether chain length and headgroup charge on enzymatic activity, prodrugs 1 and 2 
(Figure 17) were prepared with both C16 and C18 ether chains and a PC and PG headgroup, 
respectively. 
 
 
Figure 17. The four target chlorambucil sn-1-ether phospholipid prodrugs. Prodrugs 
1a and 1b have a PC headgroup with a C16 and a C18 ether chain respectively. Target 
compounds 2a and 2b have the negatively charged PG headgroup. 
 
3.2 Synthesis of Chlorambucil Phospholipid Prodrugs 
The synthesis of sn-1-ether phospholipids have, as described in section 2.2, been accessed 
via different routes, starting from 2,3-isopropylidene-sn-glycerol (see Table 10) or (R)-
glycidyl tosylate (see Table 12). (R)-Glycidyl tosylate ((–)-3) served as the starting 
material in this work and the aliphatic ether chain was introduced by ring-opening of the 
epoxide under Lewis acid catalysis,114 resulting in yields of 89% and 97% for 4a and 4b, 
respectively (Scheme 3). The PMB group was chosen for protection of the secondary 
alcohol and introduced by using para-methoxybenzyl trichloroacetimidate (PMBTCA) 
with La(OTf)3 catalysis.124,125 The resulting tosylate was converted into the acetate with 
CsOAc in a 9:1 mixture of DMSO and DMF and the ester was hydrolyzed with NaOMe in 
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MeOH at 40 °C yielding the primary alcohols 5a and 5b in overall yields of 70% and 78% 
respectively over 3 steps (Scheme 3). It was essential to carry out the hydrolysis at elevated 
temperature in order to obtain homogeneous reaction mixtures and achieve full conversion 
in the transformations. Inspired by Andresen et al.68 a direct conversion of the tosylates to 
the alcohols 5a and 5b using NaNO2 in DMSO was attempted and yields up to 94% over 
two steps (including the PMB-protection) were achieved, but the result was not 
reproducible and inconsistent yields from 60% to 94% were obtained. The corresponding 
carboxylic acid was observed as the major by-product in the experiments giving low yields 
and since there is precedence for oxidation of alcohols in aqueous environments in the 
presence of HNO2 and oxygen126,127 it is likely that the oxidation occurred during the 
aqueous workup. It was attempted to circumvent the undesired oxidation by applying a 
basic workup, but that did not improve the yield of the desired alcohol.  
 
Scheme 3. Synthesis of phospholipid precursor 5a and 5b.a  
 
 
 
aReagents: (a) C16H33OH or C18H37OH, BF3·OEt2, CH2Cl2; (b) (i) PMBTCA, La(OTf)3, toluene; (ii) 
CsOAc, DMSO, DMF; (iii) NaOMe, MeOH; (c) (i) PMBTCA, La(OTf)3, toluene; (ii) NaNO2, DMSO. 
 
The PC headgroup was attached to the primary alcohols 5a and 5b by reaction with 
phosphorus oxychloride and Et3N, followed by addition of choline tosylate, pyridine and 
finally H2O (Scheme 4 and compare with Table 15). Excess choline tosylate was removed 
on an MB-3 ion-exchange column and after purification by column chromatography the 
PMB-group was removed by hydrogenolysis mediated by Pd/C in a quantitative yield, but 
disappointingly upon scaleup a slow conversion was observed. Instead DDQ in an 18:1 
mixture of CH2Cl2 and H2O, 128  was attempted and these conditions resulted in full 
conversion within 3 h and with satisfactory isolated yields of 6 (Scheme 4). The final 
attachment of chlorambucil to the phospholipid backbone was achieved via a Steglich 
esterification102 with DCC and a catalytic amount of DMAP. When the acylation of 6a was 
performed in ethanol-free chloroform at 20 °C or CH2Cl2 in the temperature range from 
0 °C to reflux no incorporation of chlorambucil was observed, but when the conditions 
were changed to reflux in 1,2-dichloroethane the acylation occurred in a 75% yield, albeit 
only after adding 5 equivalents of chlorambucil and DCC in portions over 31 h. The 
acylation of 6b led to an isolated yield of 76% in refluxing chloroform and that was not 
improved by using 1,2-dichlorethane as the solvent. Changing the coupling reagents to 
EDCI and DMAP129 did not improve the conversion of the 6. In continuation of this 
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Shizuka et al.91 report that acylation of compounds like 6 was not achievable in their hands 
whereas fine yields have been obtained by others (see Table 9 and Table 14).   
 
Scheme 4. Synthesis of chlorambucil phospholipid prodrugs 1.a 
 
 
 
aReagents: (a) (i) POCl3, Et3N, CH2Cl2; (ii) choline tosylate, pyridine; (iii) H2O; (iv) H2, Pd/C, EtOAc, 
MeOH or DDQ, CH2Cl2, H2O; (b) chlorambucil, DCC, DMAP, CHCl3 or 1,2-dichloroethane. 
 
3.3 Biophysical Characterization and Enzyme Activity 
The chlorambucil phospholipid prodrugs (1 and 2 ii) were formulated as liposomes by 
extrusion in 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid (HEPES) buffer using 
the dry lipid film technique.130 The phospholipid solutions were analyzed by dynamic light 
scattering (DLS) in order to investigate the particle size and the DLS analysis revealed that 
1 and 2 form particles in the liposome size region (Table 17) and with a low polydispersity, 
indicating formation of unilaminar vesicles. The thermodynamic phase behavior was 
investigated by DSC but no phase transition was observed in the tested temperature range 
(20–70 °C) illustrating that the phospholipid bilayers are in a fluid state at 20 °C. 
Furthermore, the prodrugs were not able to encapsulate calcein. Presumably, these 
observations are a consequence of the incorporation of chlorambucil which prevents well 
ordered chain packing.    
 
Table 17. DLS analysis of chlorambucil phospholipid 
prodrugs. 
Compound Particle size 
 Diameter (nm) PdIa 
1a 124 0.12 
1b 125 0.22 
2a 104 0.08 
2b 113 0.05 
aPdI = polydispersity index 
 
The ability of sPLA2 to degrade the chlorambucil phospholipid prodrugs 1 and 2 were 
studied by treating the liposome solutions with snake (Agkistrodon piscivorus piscivorus) 
venom sPLA2 at 37 °C. Snake venom sPLA2 is a convenient model enzyme, since it is not 
                                                 
ii The synthesis of phospholipid 2 was performed by colleague Dr. Mikkel S. Christensen.135 
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sensitive to the charge of the surface, unlike human sPLA2 IIA, but shows the same 
substrate specificity.61,56,131 In order to investigate the enzymatic activity on a molecular 
level matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-
TOF MS) and HPLC were applied. MALDI-TOF MS has recently been exploited as a very 
fast and sensitive technique for detection of phospholipids132,133,134 and it was decided to 
study the enzyme activity with this method in order to verify that the phospholipid 
prodrugs were consumed and the anticancer drugs released. For the measurements 2,5-
dihydroxybenzoic acid (DHB) and CF3COONa in methanol containing 1,2-dipalmitoyl-sn-
glycero-3-phosphoglycerol (DPPG) as an internal standard was used as the matrix, which 
did not interfere with the regions of interest in the MS spectra. The disappearance over 
time of the prodrugs signals (M+H+ and M+Na+) in the MS spectra in Figure 18 shows that 
snake (Agkistrodon piscivorus piscivorus) venom sPLA2 hydrolyze the prodrugs 1a and 2a 
and the emergence of the lysolipid signals (M+H+ and M+Na+) verify the release of the 
expected lysolipids. From the spectra it is also possible to get information about the 
conversion rate, and whereas 2a is almost fully consumed after 2 h, 1a needs more than 24 
h for full digestion by sPLA2. The MALDI-TOF MS analysis of 1b and 2b revealed that 
full degradation is obtained in 2–6 h (Table 18). These results were verified by HPLC 
(Figure 19 and Table 18).  
 
 
Figure 18. MALDI-TOF MS monitoring of snake (Agkistrodon piscivorus piscivorus) venom sPLA2
activity on chlorambucil phospholipid prodrug 1a (top) and 2a (bottom). The spectra demonstrate that the 
prodrugs (right) are consumed and the lysolipids (left) are released. 
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Figure 19. HPLC chromatogram for the snake (Agkistrodon piscivorus piscivorus) venom sPLA2 
experiment on chlorambucil phospholipid prodrug 1a showing the amount of prodrug (left) and lysolipid 
6a (right) before the addition of the enzyme and after 2, 4, 6 and 24 h.  
 
Table 18. Activity of snake (Agkistrodon piscivorus piscivorus) venom and human sPLA2 
IIA on prodrugs 1 and 2, monitored by MALDI-TOF MS and HPLC.a  
Substrate Full Hydrolysis by sPLA2 within 48 h 
Snake venom sPLA2 Human sPLA2 IIA 
MALDI-TOF MS HPLC MALDI-TOF MS 
1a + + – 
1b + + nd 
2a + + nd 
2b + + + 
aSee Pedersen et al.135 for all MS spectra and HPLC chromatograms. nd = not determined.  
 
To further elucidate the scope of the drug delivery system, the activity of human sPLA2 
IIA on the liposome solutions of 1a and 2b was investigated. As expected and evident from 
the MS spectra in Figure 20 the human enzyme is sensitive to the surface charged and only 
2b with the negatively charged PG headgroup was hydrolyzed while 1a having a neutral 
headgroup was not degraded. Neither HPLC nor MALDI-TOF MS was capable of 
detecting the released chlorambucil, but that was not surprising given the low stability of 
free chlorambucil in an aqueous environment.121 Chatterji et al. report 15 min as the half-
life of chlorambucil in a buffer like the HEPES buffer at 37 °C.122 Subjection of the 
chlorambucil phospholipid prodrugs to the reaction conditions for 48 h but in absence of 
the enzyme revealed that the prodrugs remain intact. No significant degradation of the 
prodrugs (Figure 20) or hydrolysis of the chloroethyl groups of chlorambucil was detected 
by MALDI-TOF MS, proving that the liposomal formulation enhances the stability by 
having the chlorambucil moiety in the lipophilic membrane and thereby shield it from the 
aqueous environment. These findings were further supported by the 4-(4-nitrobenzyl)-
pyridine alkylating assay (Figure 21),136,137,138 which showed that alkylation occurred when 
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liposomes of 1b and 2b were subjected to sPLA2, whereas no alkylating activity of 1b and 
2b was detected in the absence of sPLA2 (Figure 21).iii 
 
Figure 20. MALDI-TOF MS monitoring of human sPLA2 IIA activity on 1a (left) and 2b (right). The
spectra demonstrate that the negatively charged phospholipid 2b is hydrolyzed by the humane enzyme
whereas the neutral phospholipid 1a is not. 
 
 
Figure 21. UV spectra (left) from alkylation of prodrug 2b (red linie) and prodrug 2b + sPLA2 (blue linie) 
determined by the 4-(4-nitrobenzyl)-pyridine alkylating assay. A strong absorption at 560 nm illustrates 
alkylating activity. Concept behind the 4-(4-nitrobenzyl)-pyridine alkylating assay (right). The blue pigment 
has high UV absorbans at 560 nm. RX = alkylating agent 
 
3.4 Cytotoxicity 
To demonstrate the sPLA2 dependent cytotoxicity of the chlorambucil phospholipid 
prodrugs, the activity of 1b against HT-29 colon and MT-3 breast cancer cells for 24 h and 
2b against the same two cell lines in addition to ES-2 ovarian cancer cells was investigated 
(Table 19). None of these cells secrete sPLA2, which is an advantage in these studies as it 
enables to control the presence or absence of the enzyme in each experiment. Without 
                                                 
iii  Control experiments demonstrated that no absorption at 560 nm was observed for 4-(4-nitrobenzyl)-
pyridine, HEPES buffer, HEPES buffer + sPLA2 or chlorambucil, whereas the combination 4-(4-
nitrobenzyl)-pyridine and chlorambucil gave a highly colored solution with a strong absorption at 560 nm. 
See also Pedersen et al.135 
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addition of snake (Agkistrodon piscivorus piscivorus) venom sPLA2, 1b and 2b were not 
able to induce significant cell death demonstrating that in absence of the enzyme the 
prodrugs are not cytotoxic, which is crucial for the prodrug strategy. In the presence of the 
enzyme, 1b and 2b become cytotoxic and IC50 values in the range from 8–36 µM were 
obtained, illustrating that the cytotoxicity arise from a sPLA2 triggered breakdown of the 
prodrugs into cytotoxic lysolipids and chlorambucil. However the IC50 values for lysolipid 
6b and chlorambucil show that the effect of the incorporated chlorambucil is minor than 
the effect of the lysolipid. It is hard to see the effect of chlorambucil for 1b in HT-29 and 
MT-3 cells and for 2b in MT-3 cells, whereas the IC50 values for 2b in HT-29 and ES-2 
cells are below those of chlorambucil and lysolipid 6b indicating that a co-operative effect 
of the compounds released may occur here. When the cells were treated only with snake 
(Agkistrodon piscivorus piscivorus) venom sPLA2 no effect on cell viability was observed.  
 
Table 19. IC50 values (M) of chlorambucil, lysolipid (6b) and the prodrugs 1b 
and 2b in the presence and absence of sPLA2.a 
Compound 
HT-29 
IC50 (M) 
MT-3 
IC50 (M) 
ES-2 
IC50 (M) 
Chlorambucil 70   10 95  21 34  3 
1b > 200 > 200  nd 
2b > 200 > 200 97  2 
1b + sPLA2 32  2 36  4 nd 
2b + sPLA2 10  1 36  4 8  0.5 
6b 18  5 35  1 30  1  
sPLA2 -b -b -b 
aCytotoxicity was measured using the MTT assay as cell viability 48 h after 
incubation with the indicated substances for 24 h and showed by mean  SD (n = 
3); nd = not determined; snake (Agkistrodon piscivorus piscivorus) venom sPLA2 
was added to a final concentration of 5 nM. bNo change in cell viability was 
observed after 24 h. 
 
3.5 Conclusion 
Synthesis of prodrug 1 was achieved and the synthetic route allows for an easy 
incorporation of other drugs since the drug is attached in the last synthetic step. Prodrug 1 
and 2 were able to form particles in the liposome size region indicating formation of 
unilamellar vesicles, which demonstrate that incorporation of a bulky and partly 
hydrophilic substituent, like chlorambucil, to the sn-2-position maintain the ability of 
phospholipids to form bilayers. Gratifyingly, the chlorambucil prodrugs 1 and 2 were 
consumed by sPLA2, the enzyme activity was investigated with HPLC and MALDI-TOF 
MS, which proven to be an easy and reliable method for analyzing enzymatic activity. The 
cytotoxicity studies demonstrated that in the absence of the enzyme no significant cell 
death occurred but upon sPLA2 activation the prodrugs are converted into cytotoxic 
components, chlorambucil and lysolipids. Furthermore, it was demonstrated that this 
liposomal drug delivery system shields the chlorambucil moiety from the aqueous 
Liposomal Drug Delivery 
42 
 
environment and enhance the stability. Taken together, the results obtained from this work 
was very promising for the overall scope of the investigated drug delivery system, although 
the effect from chlorambucil in the tested cell line was not significant compared to the 
cytotoxicity of the lysolipids.     
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4. Liposomal Formulation of Retinoids Designed for Enzyme Triggered 
Release 
 
4.1 Introduction 
Retinoids,139 such as ATRA (Figure 22), are known for their broad and diverse biological 
functions and various strategies have been explored to make retinoids applicable as 
drugs.140 One of the biological functions of ATRA is its anticancer activity towards a broad 
range of cancer types, like breast, prostate and colon cancer.75,76 For example, orally 
administrated ATRA is used clinically in the treatment of leukaemia.141,142 However, the 
oral administration route is restricted by a relative low bioavailability 143  and a fast 
clearance from the blood stream,144 and thus alternative ways of administrating ATRA 
would be beneficial. Intravenous administration is hampered by the low water solubility of 
ATRA but this can be circumvented by formulating ATRA in liposome based drug 
delivery systems.145 , 146 , 147 , 148  Unfortunately, the liposomal formulation strategies have 
often been plagued by problems with leakage, which have led to an uncontrolled release of 
ATRA from the carrier system. Furthermore, ATRA is sensitive to acid and light139 thus a 
liposomal formulation could be beneficial and the presence of a carboxylic acid moiety 
allows incorporation into the investigated drug delivery system. The target ATRA 
phospholipid prodrugs are illustrated in Figure 22. 
 
Figure 22. Structure of ATRA and the target ATRA phospholipids prodrug 7 and 8.  
 
4.2 Synthesis of ATRA Phospholipid Prodrugs 
With lysolipid 6a in hand (from Scheme 4) the synthesis of phospholipid 7 was attempted 
by acylation of 6a with ATRA. The reaction was investigated applying the same conditions 
as used in the synthesis of 1, and as observed under the incorporation of chlorambucil it 
was necessary to use an excess of ATRA and the coupling reagents in order to get a decent 
conversion of 6a (Scheme 5). However, 1H NMR analysis of the isolated material revealed 
that two isomers was formed, corresponding to esters of ATRA ((13E)-retinoic acid) and 
(13Z)-retinoic acid. The isomers was distinguished in 1H NMR by the signal for the proton 
alpha to the carbonyl in the retinoids which resonate at 5.8 ppm for the (13E)-isomer and at 
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5.6 ppm for the (13Z)-isomer and determined by 1H NMR the (13E)/(13Z) isomer ratio was 
3:1. When Keck acylation conditions129 in refluxing 1,2-dichloroethane was attempted 
neither the yield nor the ratio between the two isomers was improved.  
 
Scheme 5. Acylation of lysolipid 6a with ATRA using DCC and DMAP gave a mixture of two 
inseparable retinoid isomers. a 
 
 
a Reagents: (a) ATRA, DCC, DMAP, CHCl3. 
 
The disappointing outcome of the acylation with ATRA motivated an examination of the 
carbodiimide mediated isomerisation. Extensive studies iv  of acylation on hexadecanol 
revealed that the isomerisation only occurs when DMAP and a proton source are present, 
while a significant lower degree of isomersation was observed when either DMAP or a 
proton source was absent.149 The proposed isomerization mechanism150 is illustrated in 
Figure 23. 
 
 
Figure 23. Proposed mechanism for the isomerization of ATRA mediated by carbodiimide activation. 
                                                 
iv The studies were carried out by colleague Dr. Mikkel S. Christensen, see Christensen et al.149  
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The observed isomerization occurred when the carboxylic acid in ATRA was activated in 
the carbodiimide mediated esterification. To circumvent this, an acylation method in which 
the alcohol is activated was examined. Therefore the Mitsunobu reaction151 was explored 
and studies on hexadecanol revealed that the acylation occurs without isomerization and 
the ATRA ester was isolated in a high yield.149 Applying the Mitsunubu conditions, initial 
studies on lysolipid 6a showed a very low conversion into the ATRA ester, wherefore it 
was decided to incorporate ATRA at an earlier stage in the synthesis and a revised 
synthetic strategy was initiated from (S)-glycidyl tosylate ((+)-3). Ring opening of the 
epoxide (+)-3 under Lewis acid catalysis with hexadecanol gave the desired ether and 
removal of the tosylate applying the two-step procedure also used in the synthesis of 5 
(Scheme 3) gave the diol 9 (Scheme 6). Selective TBDMS-protection of the primary 
alcohol to give 10 was achieved in a good yield and 10 was then esterified with ATRA 
using Mitsunubu conditions applying diisopropyl azodicarboxylate (DIAD) and PPh3 in 
THF. Coelution of DIAD and the product precluded isolation hence the ATRA ester was 
deprotected immediately. Desilylation with TBAF and imidazole in THF90 led to acyl 
migration from the sn-2 to the sn-3 position, but that was circumvented by the use of 
aqueous HF in MeCN, and the desired alcohol 11 was isolated in 35 % yield over the two 
steps (Scheme 6). Installation of the PC headgroup was achieved in the same way as under 
the synthesis of 6 (Scheme 4). The somewhat low yield on 40%, which also was observed 
during the synthesis of 6, is presumably related to the use of the water sensitive POCl3 and 
the hydroscopic choline tosylate.  
 
Scheme 6. Synthesis of ATRA phospholipid prodrug 7 using a revised synthetic strategy. a 
 
(+)-3
OTs
O a
65%
C16H33O OH
OH
9
b
89%
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OH
10
c
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C16H33O OH
O
O
R
d
40%
C16H33O O
O
P
O
O
NMe3
O
O
R
7: RCOOH = ATRA  
 
a Reagents: (a) (i) C16H33OH, BF3·OEt2, CH2Cl2; (ii) CsOAc, DMSO, DMF; (iii) NaOMe, MeOH; (b) 
TBDMSCl, Et3N, DMAP, DMF, CH2Cl2; (c) (i) ATRA, DIAD, PPh3, THF; (ii) HF, H2O, MeCN; (d) 
(i) POCl3, Et3N, CH2Cl2; (ii) choline tosylate, pyridine; (iii) H2O.  
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4.3 Enzymatic Activity 
In order to study sPLA2 activity the phospholipid prodrugs 7 and 8v were formulated as 
liposomes in HEPES buffer and particles with an average diameter close to 100 nm was 
formed. The liposome solutions were incubated with snake (Agkistrodon piscivorus 
piscivorus or Naja mossambica mossambica) venom sPLA2 at 37 °C for 48 h however 
MALDI-TOF MS analysis of the liposome solutions revealed that no hydrolysis had 
occurred (Figure 24). Fawzy et al.152 and Hope et al.153 have demonstrated two decades 
ago that ATRA is an inhibitor of sPLA2 and therefore the hydrolysis of DPPG in the 
presence of ATRA was investigated. Snake (Naja mossambica mossambica) venom sPLA2 
was subjected to solutions of DPPG and 0, 0.1 or 1 eq. ATRA. Complete hydrolysis of 
DPPG was observed within 24 h in all three experiments,vi by which it can be ruled out 
that the lack of hydrolysis is a consequence of sPLA2 inhibition. The lack of hydrolysis 
must therefore be related to the structure of ATRA, the rigidity of the molecule and the 
presence of a methyl substituent in close vicinity to the carboxylic acid contrast with 
naturally occurring fatty acids, that are predominantly saturated and flexible molecules 
without branching. Furthermore, Bonsen et al. have demonstrated that compounds like 2-
methylhexanoic acid and 3,3-dimethylbutanoic acid are not released from the sn-2 position 
by sPLA2,67 illustrating that substituents in close proximity to the sn-2 position hamper the 
enzyme activity.           
 
 
Figure 24. MALDI-TOF MS monitoring of snake (Naja mossambica 
mossambica) venom activity on ATRA phospholipid prodrug 8.   
 
4.4 Molecular Dynamics Simulations of Enzymatic Activity 
To get a better understanding of why substrates like 8 is not hydrolyzed by sPLA2, 
molecular dynamics (MD) simulations were performed of the Michaelis-Menten complex 
of 8 in the active site of sPLA2 (denoted as sPLA2–8). The enzymatic activity of sPLA2 on 
phospholipids depends on several factors, including binding of the enzyme to the 
membrane surface, membrane properties, formation of the Michaelis-Menten complex, 
etc.154 In this MD study only the stability of the Michaelis-Menten complex is investigated 
and it is then assumped that if a stable Michaelis-Menten complex is observed during the 
                                                 
v The synthesis of ATRA phospholipid prodrug 8 was performed by colleague Dr. Mikkel S. Christensen.149 
vi See Christensen et al.149 for further details. 
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simulations and water molecules enter the active site then hydrolysis is expected to occur. 
Previous work has demonstrated good correlation between experimental results and MD 
simulations.66,131 Five simulations of 13 ns of the sPLA2–8 complex were obtained and the 
stability of the simulations was checked by computing the time evolution of the root mean 
square deviation (RMSD) of the C atoms with respect to the protein structure obtained 
after minimization. Stable RMSD data were obtained with a constant value between 1–1.5 
Å (Figure 25, left), which is in agreement with earlier obtained results.66,131 
 
 
Figure 25. RMSDs of Cα atoms with respect to the initial protein structure of sPLA2 as a function of 
simulation time (left). Representation of the active site in sPLA2 with hydrogen bonds and ionic interactions 
indicated with dashed bonds (right). Key protein residues are drawn in blue, the substrate in red, the calcium 
ion and the water molecule both in brown. The two gray circles indicate the H–S region, where the overlap in 
dark grey represents the water count region. Labels are shown in black and atom types indicated in 
parentheses refer to the Protein Data Bank nomenclature. 
 
A schematic representation of the catalytic mechanism is shown in Figure 25 indicating 
that the calcium ion (co-factor) is coordinated to the Asp48 carboxylate groups (atoms: 
OD1 and OD2), the Gly29 carbonyl (O), the carbonyl (O22) in the substrate (S) and the 
phosphate (O4) in S. Atom types given in parentheses refer to the Protein Data Bank 
nomenclature. Furthermore, the catalytic residue, His47, is stabilized by Asp91, which 
forms hydrogen bonds with Tyr51 and Tyr66. The water molecule acting as the 
nucleophile enters the region between His47ND1 and SC21. This region will be referred to as 
the H–S region (Figure 25). The stability of the Michaelis-Menten complex for sPLA2–8 
was investigated by monitoring the following distances during the simulations: Ca2+–
Gly29O, Ca2+–Asp48OD1, Ca2+–Asp48OD2, Ca2+–SO4, Ca2+–SO22, SO22–Gly29NH, His47HE2–
Asp91OD1, His47ND1–SC21, Asp91OD2–Tyr66OH and Asp91OD1–Tyr51OH. The time evolution 
of these distances is given in Table 20. 
 
The key distance analysis revealed that many of distances remain constant for the sPLA2–8 
complex, e.g. the Ca2+–SO4 distance (see Figure 26) and with values comparable to sPLA2–
DPPG (Table 20). However three of the distances (His47ND1–SC21, SO22–Gly29NH and 
Ca2+–SO22) were significantly longer than observed in the sPLA2–DPPG complex, 
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demonstrating that 8 do not fit perfectly into the active site of the enzyme. From the 
distance versus time plots in Figure 26 it is evident that the carbonyl (SO22) in the ATRA 
moiety of 8 changes its position constantly and never finds a stable position in the enzyme 
pocket. This observation is verified by snapshots (Figure 26) from the simulations, which 
reveal that the ATRA moiety rotates almost 180° during the simulation, causing distortion 
in the desired Michaelis-Menten complex, by which the conclusion from the key distance 
analysis is that no hydrolysis is expected to occur.   
 
Table 20. Monitored key distances between selected atoms that are 
involved in stabilization of the Michaelis-Menten complex, compare 
with Figure 25. The reported data are the mean distances ± SD in Å.   
Distances 
 
Compound 
8 DPPGa 
Asp91OD1–Tyr51OH 1.8 ± 0.3 3.1 ± 0.3 
Asp91OD2–Tyr66OH  1.7 ± 0.1 2.7 ± 0.1 
His47HE2–Asp91OD1 1.8 ± 0.1 1.9 ± 0.3 
His47ND1–SC21 6.0 ± 0.4 4.5 ± 0.4 
Ca2+–Asp48OD1 2.2 ± 0.1 2.2 ± 0.2 
Ca2+–Asp48OD2 2.2 ± 0.1 2.2 ± 0.1 
Ca2+–Gly29O  2.4 ± 0.2 2.4 ± 0.2 
SO22–Gly29NH  3.5 ± 0.6 2.7 ± 0.5 
Ca2+–SO22 4.8 ± 0.6 2.4 ± 0.2 
Ca2+–SO4 2.1 ± 0.1 2.1 ± 0.1 
a Data from Linderoth et al.66 
 
Entrance of water into the active site is another crucial factor for enzyme activity, and 
previous studies have showed a good correlation between experimentally obtained sPLA2 
activity and detection of water molecules in the H–S region within 3.5 Å of His47ND1 and 
SC21 in MD simulations for phospholipids in which the key distances are constant.66,131 The 
number of water molecules in the H–S region within 3.5 Å, 4.5 Å and 5.5 Å were counted 
and normalized to the number of water molecules at 6 Å (Table 21). The relative water 
count at 3.5 Å for sPLA2–8 is significantly lower than that of sPLA2–DPPG, contributing 
to the hypothesis that hydrolysis of 8 by the enzyme is highly disfavoured. But it is also 
evident from Table 21 that some water molecules enter the active site, and in order to rule 
out that hydrolysis can occur when that happens the Ca2+–SO22 distance were measured, 
and it was found that every time water was within the H–S region the Ca2+–SO22 distance 
never become shorter than 4.4 Å which is 2 Å longer than observed in the sPLA2– DPPG 
complex. In Figure 27 a snapshot from the simulation is shown in which water is within 
3.5 Å of His47ND1 and SC21 but key distances, like Ca2+–SO22 are longer than tolerated in 
order to obtain hydrolysis. Therefore, the conclusion from the MD simulations is that the 
key distance analysis showed that 8 has an imperfect positioning in sPLA2 and the water 
count analysis displayed that the number of water molecules reaching the active site is low 
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and therefore it is expected that no hydrolysis will occur which is in agreement with the 
experimental observations.  
 
 
Figure 26. Distance versus time plots for SO22–Gly29NH (top right) and Ca2+–SO4 (top left). Snapshot from 
the beginning of the simulation (bottom left), in which the β-methyl group in the ATRA moiety points 
“left” and snapshot from the end of the simulation (bottom right) in which the same β-methyl points “right”. 
 
 
Table 21. Relative water counts as a function of the distance from both 
His47ND1 and SC21 (the H–S region).a 
Compound Relative water 
count at 3.5 Å 
Relative water 
count at 4.5 Å 
Relative water 
count at 5.5 Å 
8 0.001 0.3 1.0 
DPPG66  0.1 0.4 0.7 
a Normalized to the water count at 6 Å.  
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Figure 27. Snapshot from the simulation of sPLA2–8, in which 
H2O is within 3.5 Å of His47ND1 and SC21 but the Ca2+–SO22 
distance is 4.66 Å which is significantly longer than observed in 
substrates for sPLA2, like DPPG. Furthermore, the distances for 
His47ND1–SC21 (4.18 Å) and Ca2+–Gly29O (2.60 Å) are included.    
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4.5 Revised Prodrug Strategy for Liposomal Delivery of Retinoids 
The efforts towards sPLA2 sensitive phospholipids which can release retinoids like ATRA 
was not successful, however knowing that some esters and amides of ATRA retain their 
anticancer activity155,156,157,158 it was decided to incorporate an aliphatic C6-linker between 
ATRA and the phospholipid backbone (see Figure 29). MD simulations of 13 in the active 
site of sPLA2 showed that incorporation of the aliphatic C6-linker creates sufficient 
flexibility to obtain a stable Michaelis-Menten complex and the amount of water entering 
the catalytic site was similar to what was observed for the sPLA2–DPPG complex and thus 
it is expected that the hydrolysis of 13 will occur.vii One major drawback in applying 
ATRA as a drug is its nonselective activation of retinoic acid receptor (RAR) subtypes 
(RARs, α, β, γ), retinoic X receptor subtypes (RXRs, α, β, γ) and/or the subtype RAR 
isoforms, α1, α2, β1–β5, γ1 and γ2.75, 159  The lack of selectivity is believed to be 
responsible for the severe side effects that have been observed during chronic 
administration of ATRA159 and therefore there is much interest in discovering more 
selective RAR agonists.160,161 Targeting of RARβ2 has been found to have a suppressive 
effect on human tumors,162 and recently 4-(4-octylphenyl)-benzoic acid (12, Figure 28) 
was identified as a selective RARβ2 agonist.163,164,165 The lipophilicity of 12 makes it is a 
good candidate for incorporation into the investigated liposomal drug delivery system. 
However, since Bonsen et al. have demonstrated that benzoic acid is not released from the 
sn-2-position by sPLA267 direct attachment of 12 to the phospholipids was ruled out. 
Instead, it was decided to investigate how attachment of an aliphatic C6-linker would 
influence the cytotoxicity of 12 and the sPLA2 activity towards the corresponding prodrug. 
 
Figure 28. Structure of the selective RARβ2 agonist 12.  
 
At this stage of the project it was decide to focus on PG lipids and furthermore, it became 
interesting in addition to sn-1-ether phospholipids to investigate sn-1-ester phospholipids 
and so the prodrugs was designed to contain either an sn-1-ester or an sn-1-ether 
functionality (Figure 29). Upon activation of sPLA2, the prodrugs will be converted into 
the free drug and lysolipids (Figure 29) and while sn-1-ether lysolipids have good 
metabolic stability and are cytotoxic against many cell lines,68,69 sn-1-ester lysolipids are 
rapidly metabolized (by e.g. lysophospholipases) and have been dismissed as suitable 
lysolipid drug candidates.69 Information about the cytotoxicity of sn-1-ester lysolipids is 
limited and covers only lysophosphatidylcholine lipids,166,167,168 however these lipids have 
                                                 
vii The MD simulations of sPLA2–14 were performed by collaborator Dr. Arun K. Subramanian, see Pedersen 
et al.174 
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shown to be slightly better substrates for sPLA2 than sn-1-ether lipids,131 and therefore it 
was decided to synthesize both types of prodrugs in order to study their relative hydrolysis 
rate and cytotoxicity. 
 
 
Figure 29. Schematic overview of the revised drug delivery strategy for liposomal delivery of retinoids. The
sPLA2 degradable phospholipid prodrugs are designed to have an aliphatic C6-linker incorporated between
the drug, R'COOH (ATRA and 12) and the phospholipid backbone. 
 
4.6 Synthesis of Retinoid Esters 
The linker moiety tert-butyl 6-hydroxyhexanoate (22), which was synthesized in one step 
from 6-caprolactone (21, Scheme 7), was coupled with ATRA by a Mitsunobu reaction151 
(Scheme 7). The following tert-butyl deprotection led to degradation of the ATRA 
skeleton under acidic conditions (5% TFA or ZnBr2 169 in CH2Cl2 or HF in refluxing 
MeCN), but using 2,6-lutidine and TMSOTf in CH2Cl2 170  the carboxylic acid 9 was 
afforded in a good yield (Scheme 7). The ATRA ester 19 was isolated as yellow crystals 
and was stable when stored at –20 °C under an inert atmosphere whereas the oily tert-butyl 
ester of 19 decomposes upon less than one month of storage. This highlights the 
importance of storing ATRA-analogues as solids in order to avoid decomposition. The 
corresponding linker-molecule of 12viii was synthesized by a Steglich coupling102 with 22 
followed by a deprotection of the tert-butyl ester with TFA in CH2Cl2 (Scheme 7). In 
contrast to the ATRA-analogues no decomposition of the synthetic derivatives of 12 
                                                 
viii Compound 12 is commercially available (CAS no. 59662-49-6), but in this work 12 was synthesized in 
one step from the corresponding nitrile (CAS no. 52709-84-9) by a NaOH mediated hydrolysis in 98% yield. 
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neither as oils nor solids was observed. The cytotoxicity of ATRA, 12, 19 and 20 were 
evaluated in three cancer cell lines and the retinoid esters had activities comparable to the 
acids (vide infra). 
 
Scheme 7. Synthesis of the retinoid esters.a 
 
a Reagents: (a) KOtBu, tBuOH; (b) (i) 22, DIAD, PPh3, THF; (ii) TMSOTf, 2,6-lutidine, CH2Cl2; (c) (i) 22, 
DCC, DMAP, CH2Cl2; (ii) TFA, triisopropylsilane, CH2Cl2. 
 
4.7 Synthesis of Retinoid Phospholipid Prodrugs 
The cytotoxicity of the esters 19 and 20 and the results from the MD simulations prompted 
to proceed with the synthesis of the corresponding sn-1-ether and sn-1-ester phospholipid 
prodrugs. As presented in section 2.4 PG lipids have previously been synthesized via 
isopropylidene proptection of the glycerol moiety in the headgroup and protection of the 
phosphate by the methyl ester however both deprotections require long reaction times 
hence it was desirable to access PG lipids in a more convenient way. Inspired by 
oligonucleotide synthesis 171  a new synthetic route to PG lipids was initiated with 
phosphoramidite 27 (Scheme 8) as the key building block. 
  
The synthesis of phosphoramidite 27 was accomplished in 5 steps from allyl alcohol (23, 
Scheme 8). Treatment of allyl alcohol with 4-methoxybenzoyl chloride gave the desired 
allylic ester 24. The key step in the synthesis was the asymmetric dihydroxylation172,173 of 
24, which occurred with excellent enantioselectivity (ee 97%, chiral HPLC) and TBDMS 
protection of the diol gave 25 in an excellent yield (Scheme 8). Reduction of 25 with 
diisobutylaluminium hydride (DIBAL-H) at –78 °C afforded the TBDMS-protected 
glycerol 26. The coupling between 26 and the commercially available phosphorylating 
agent (i-Pr)2NPClO(CH2)2CN resulted in the desired phosphoramidite 27 in a very 
satisfactory yield, isolated as a 1:1 diastereomeric mixture as evident from 31P NMR 
(Scheme 8). The synthesis of phosphoramidite 27 was achieved on gram scale and when 
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stored at –20 °C the stability of the compound was found to be at least one year. The 
glycerol moiety in phosphoramidite 27 was designed to be the (S)-stereoisomer because 
Andresen et al.68 have demonstrated that the (S)-stereoisomer of lysolipids, like 17, are 
significantly more cytotoxic than the corresponding (R)-stereoisomer.    
 
Scheme 8. Synthesis of the phosphoramidite 27.a 
 
 
 
aReagents: (a) 4-Methoxybenzoyl chloride, Et3N, DMAP, CH2Cl2; (b) (i) K2OsO4·2H2O, 
(DHQD)2PHAL, K3Fe(CN)6, K2CO3, tBuOH, H2O; (ii) TBDMSCl, imidazole, DMF; (c) 
DIBAL-H, CH2Cl2; (d) 2-cyanoethyl N,N-diisopropylchlorophosphoramidite, DIPEA, CH2Cl2. 
 
With the phosphoramidite 27 in hand the backbone of the sn-1-ether prodrugs was 
constructed by a tetrazole mediated coupling of alcohol 5b and phosphoramidite 27, 
followed by an oxidation of the phosphite to the phosphate with tBuOOH (Scheme 9).   
 
Scheme 9. Synthesis of the sn-1-ether phospholipid precursor 30.a 
 
a Reagents: (a) 4-Methoxybenzyl chloride, KOH, toluene; (b) (i) tetrazole, CH2Cl2, MeCN; (ii) tBuOOH; (iii) 
DDQ, H2O, CH2Cl2; (c) (i) 28, DCC, DMAP, CH2Cl2; (ii) DDQ, H2O, CH2Cl2.  
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Deprotection of the PMB group in moist CH2Cl2 with DDQ afforded the secondary alcohol 
29 in 73% yield from 5b. The linker moiety was introduced by coupling of carboxylic acid 
28 (Scheme 9) and the secondary alcohol 29 to give an ester and removal of the introduced 
PMB-group afforded alcohol 30 in an overall yield of 93% (Scheme 9). To avoid migration 
of the phosphate headgroup from the sn-3 position to the sn-2 position it was crucial that 
the secondary alcohol 29 was esterified promptly after isolation. Furthermore, it was 
observed that subjection of 29 to Keck acylation conditions129 to some extent caused 
migration while that was prevented by using Steglich conditions.102  
 
The sn-1-ester phospholipid precursor 35 was synthesized from 2,3-O-isopropylidene-sn-
glycerol (31, Scheme 10). Acylation with stearic acid gave the desired ester and applying 
the conditions published by Gaffney et al.87 the following isopropylidene deprotection 
occurred without racemization to give diol 32 (Scheme 10). Selective TBDMS protection 
of the primary alcohol in 32 was achieved using the procedure from Burgos et al.98 Diester 
34 was obtained by coupling of 28 and 33 and the following TBDMS deprotection was 
best achieved using NBS in a mixture of DMSO, THF and H2O (Scheme 10),98,99 while 
alternative conditions like TBAF and imidazole in THF90 or HF in MeCN led to a 
significant degree of acyl migration. Mosher ester analysis100 of 34 showed that the 
enantiomeric purity was >95%. The PG headgroup was attached in the same way as for the 
sn-1-ether phospholipids and PMB deprotection gave the primary alcohol 35 (Scheme 10). 
 
Scheme 10. Synthesis of the sn-1-ester phospholipid precursor 35.a 
 
 
a Reagents: (a) (i) C17H35COOH, DCC, DMAP, CH2Cl2; (ii) TFA, B(OEt)3, CF3CH2OH; (b) TBDMSCl, 
imidazole, THF; (c) (i) 28, EDCI, DMAP, CH2Cl2; (ii) NBS, DMSO, THF, H2O; (d) (i) phosphoramidite 
27, tetrazole, CH2Cl2, MeCN; (ii) tBuOOH; (iii) DDQ, H2O, CH2Cl2. 
 
The phospholipid precursors 30 and 35 were converted to the desired prodrugs of ATRA 
and 12 (Scheme 11). The ATRA moiety was introduced either by the Mitsunobu reaction 
or the Steglich coupling and the final prodrugs 13 and 14 were obtained after removal of 
the base labile cyanoethyl group with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 
TBDMS-deprotection mediated by HF in a mixture of MeCN, CH2Cl2 and H2O (Scheme 
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11). Thereby the novel route to PG lipids was completed and compared to previous routes 
(see Table 16) shorter reaction timesix are a major improvement making the chemistry 
convenient and applicable. Prodrugs 15 and 16 were accessed by coupling between 12 and 
the primary alcohols 30 and 35, after which the remaining chemistry was similar to the 
synthesis of 13 and 14 (Scheme 11). 31P NMR of the synthesized prodrugs showed one 
signal resonating between –1 ppm and 2 ppm, demonstrating high diastereomeric and 
regioisomeric purity (>95%). 
 
Scheme 11. Synthesis of the sn-1-ether and sn-1-ester prodrugs 13, 14, 15 and 16.a  
 
 
a Reagents: (a) (i) 30, ATRA, DIAD, PPh3, THF or 35, ATRA, DCC, DMAP, Et3N, Et2O; (ii) DBU, CH2Cl2;
(iii) HF, H2O, CH2Cl2, MeCN; (b) (i) 12, DCC, DMAP, CH2Cl2; (ii) DBU, CH2Cl2; (iii) HF, H2O, CH2Cl2,
MeCN. 
 
For the cytotoxicity studies access to lysolipids 17 and 18 are needed as standards for 
comparison with the tested phospholipid prodrugs and while sn-1-ester lysolipid 18 is 
commercially available lysolipid 17 was synthesized in two steps from alcohol 29 (Scheme 
12). Likewise access to phospholipids with stearic acid in the sn-2 position instead of the 
retinoid esters are needed and while 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) 
is commercially available 1-O-stearyl-2-stearoyl-sn-glycero-3-phosphoglycerol (1-O-
DSPG) was synthesized in three steps from alcohol 29 (Scheme 12). 
  
                                                 
ix The last two deprotections in Scheme 11 were achieved within reaction times of 1 h and 3.5 h, respectively.   
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Scheme 12. Synthesis of lysolipid 17 and 1-O-DSPG.a  
 
a
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O
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CN
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a Reagents: (a) (i) DBU, CH2Cl2; (iii) HF, H2O, CH2Cl2, MeCN; (b) (i) C17H35COOH, 
DCC, DMAP, CH2Cl2, (ii) DBU, CH2Cl2; (iii) HF, H2O, CH2Cl2, MeCN.  
 
4.8 Biophysical Characterization and Enzyme Activity 
The phospholipid prodrugs (13–16) were formulated as liposomes by extrusion in HEPES 
buffer using the dry lipid film technique,130 yielding clear solutions. The particle size of the 
formulated phospholipids was measured by DLS. The DLS analysis revealed that all of the 
phospholipids were able to form particles with a diameter around 100 nm (Table 22) and 
with a low polydispersity, indicating formation of unilamellar vesicles.  
 
Table 22. Measurement of particle size with DLS  
 Particle size 
Prodrug Diameter (nm) PdI 
13 94 0.08 
14 97 0.13 
15 118 0.16 
16 118 0.05 
 
DSC scans (15–65 °C) of the phospholipid solutions of 13 and 15 displayed no phase 
transitions in the tested temperature range indicating that the phospholipid bilayers are in a 
fluid state. This was not surprising taking into account the bulky and stiff nature of the 
substituents in the sn-2-position, which precludes well-ordered chain packing. 
 
The ability of sPLA2 to hydrolyze the formulated phospholipids at 37 °C was investigated 
with MALDI-TOF MS. In Figure 30 the obtained MS data for the sn-1-ether prodrug 13 
subjected to purified sPLA2 from snake (Agkistrodon piscivorus piscivorus) venom is 
shown. Gratifying and as evident from the spectra (Figure 30) the prodrug (M+H+) is 
consumed by the enzyme and the desired constituents, lysolipid 17 (M+H+) and ATRA 
ester 19 (M+Na+) are released.  
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Figure 30. MALDI-TOF MS monitoring of snake (Agkistrodon piscivorus piscivorus) venom sPLA2 activity 
on the sn-1-ether prodrug 13. The spectra demonstrate that the prodrug 13 (top right) is consumed and that 
the lysolipid 17 (top left) and the ATRA ester 19 (bottom) are released. 
 
The MALDI-TOF MS analysis of the sn-1-ether prodrugs 13 and 15 and the sn-1-ester 
prodrugs 14 and 16 revealed that all of the prodrugs were degraded by the enzyme (Table 
23) and the desired molecules were released. The observation that the sn-1-ether prodrugs 
were consumed by sPLA2 to the same extent as the sn-1-ester prodrugs illustrate and 
confirm that sn-1-ether phospholipids are excellent substrates for sPLA2. Based on the 
MALDI-TOF MS analysis of the sPLA2 activity for the various prodrugs it can be 
concluded that the incorporation of an aliphatic C6-linker between ATRA and the 
phospholipid backbone resolved the issue of sPLA2 activity on ATRA-phospholipid 
prodrugs. The experimental observations are in agreement with the outcome from the MD 
simulations, illustrating the power and potential of using MD simulations in the design of 
sPLA2 degradable phospholipid prodrugs. In order to rule out that the degradation of the 
prodrugs was caused by non-enzymatic hydrolysis, a sample of each prodrug was 
subjected to the reaction conditions in the absence of sPLA2. As evident from the spectra in 
Figure 30 no degradation of the prodrugs was observed within 48 h and none of the release 
products were detectable. Finally, the enzyme activity of the purified sPLA2 from snake 
(Agkistrodon piscivorus piscivorus) venom and commercially available sPLA2 from snake 
(Naja mossambica mossambica) venom was compared and as can be seen in Table 23, 
both enzymes were able to hydrolyze the substrates and no significant differences in 
hydrolysis rate or extent were observed. 
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Table 23. Measurement of sPLA2 activity on the prodrugs 13–16 
by MALDI-TOF MS.  
 Hydrolysis by snake venom sPLA2a 
Prodrug Agkistrodon piscivorus 
piscivorus 
Naja mossambica 
mossambica 
13 + nd 
14 + + 
15 +b +b 
16 + + 
aDetermined by MALDI-TOF MS after 48 h incubation at 37 °C 
with purified sPLA2 from snake (Agkistrodon piscivorus 
piscivorus or Naja mossambica mossambica) venom, see 
Pedersen et al.174 for all MS spectra; bAfter 48 h a small signal 
for prodrug 15 remains; nd = not determined. 
 
As described in section 4.3 ATRA has been reported as an inhibitor for sPLA2, with IC50 
values of <50 µM152 and 10 µM.153 However, it was shown that DPPG is fully hydrolyzed 
by sPLA2 in the presence of 0.1 eq. and 1.0 eq. ATRA, proving that the lack of hydrolysis 
for the ATRA-phospholipid prodrug 8 is not a consequence of inhibition by ATRA. These 
observations were further supported by determination of the IC50 value and the inhibition 
constant (Ki) for ATRA and ATRA ester 19.x It was found that 19 (IC50 = 8 µM, Ki = 6 
µM) inhibits sPLA2 at the same level as ATRA (IC50 = 15 µM, Ki = 11 µM), and whereas 
the ATRA-phospholipid prodrug 8 is not consumed by the enzyme the prodrugs 13 and 14 
are fully degraded. This demonstrates that under the conditions used, the released ATRA 
ester 19 does not inhibit sPLA2 and the difference in degradation of the prodrugs therefore 
solely relies on the ability of sPLA2 to hydrolyze the different prodrugs. Additionally, 
Cunningham et al. have reported Ki values <100 nM 175  for potent sPLA2 inhibitors, 
illustrating that ATRA and 19 are weak inhibitors.  
 
4.9 Cytotoxicity   
The cytotoxicity of ATRA, 12, 19 and 20 were evaluated in MT-3 breast, HT-29 colon and 
Colo205 colon cancer cell lines (Table 24). Interestingly, the retinoid esters were either 
more active than ATRA and 12 or equal in potency in the tested cell lines. A possible 
explanation for the enhanced activity of these molecules is that the derivatization increases 
the lipophilicity of the drugs, augmenting transport over the cell membrane. RARβ2 
agonists 12 and 20 showed very little activity against HT-29 cells, and presumably this is 
because growth inhibition in this cell line is induced by RARα agonists176 and 12 has a low 
affinity for that receptor.163,164,165 The result is also an indicator that the cytotoxicity of 20 
in MT-3 and Colo205 originate from RARβ2 activation. 
  
                                                 
x The work was performed by collaborator Dr. Ahmad Arouri, see Pedersen et al. for further details.174 
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Table 24. IC50 (µM) values for the retinoids in three cancer cell lines.a   
Compound MT-3 
IC50 (µM) 
HT-29 
IC50 (µM) 
Colo205 
IC50 (µM) 
ATRA 30 ± 4 4.3 ± 0.2 37 ± 1 
19 17 ± 1 3.6 ± 1.8 17 ± 2 
12 51 ± 3 >200 >200 
20 14 ± 1 >200 127 ± 18 
a Cytotoxicity was measured using the MTT assay as cell viability 48 h after 
incubation with the indicated substances for 24 h and shown by mean ± SD (n = 3). 
 
The cytotoxicity of the prodrugs 13–16 was investigated in HT-29 and Colo205 colon 
cancer cells. HT-29 cells do not secrete sPLA2, which allowed evaluation of the activity in 
the presence and absence of sPLA2. As evident from Table 25 and the dose-response curve 
for 13 and 15 (Figure 31) none of the prodrugs were able to induce significant cell death in 
the absence of sPLA2, whereas upon sPLA2 addition all of the prodrugs displayed IC50 
values below 10 µM in HT-29 cells (Table 25) and complete cell death was obtained when 
higher concentrations were applied (see Figure 31). Evidently, the cytotoxicity is induced 
by sPLA2 triggered breakdown of the prodrugs into 19 or 20 and the lysolipids. 
Interestingly, it was observed that the sn-1-ester prodrug 16 in the presence of sPLA2 
displayed almost the same cytotoxicity towards HT-29 cells as the corresponding sn-1-
ether prodrug 15 and taking the low activity of 20 in HT-29 cells (Table 25) into account 
these results indicate that sn-1-ester lysolipids (18) contribute with the same degree of 
potency as sn-1-ether lysolipids (17). These findings were verified when the free lysolipids 
17 and 18 were tested against HT-29 cells. Both lysolipids displayed IC50 values close to 
10 µM and similar results were obtained for DSPG and 1-O-DSPG in the presence of 
sPLA2 (Table 25). It is conclude that even though sn-1-ester lysolipids generally are 
rapidly metabolized, under these in vitro conditions there is no significant metabolism of 
the phospholipid backbone and therefore an equal potency of the two lysolipids is 
observed. With the control experiments in hand it is possible to determine the origin of the 
cytotoxicity of the prodrugs in HT-29 cells and as evident from Table 24 and Table 25 the 
majority of the activity arises from the lysolipids in prodrug 15 and 16 while for the 
prodrugs 13 and 14 there appear to be an equal contribution from the lysolipids (17 and 18) 
and the ATRA ester 19. Colo205 cells express sPLA2 and encouragingly the four prodrugs 
induce cell death with IC50 values below 20 µM (Table 25) and complete cell death was 
obtained when higher concentrations were applied (see Figure 31), indicating that the 
secreted sPLA2 in Colo205 cells provides the desired hydrolysis and release of the 
anticancer agents. Additionally, the prodrugs 13 and 14 displayed IC50 values below the 
free lysolipids but similar to 19, indicating that the majority of the cytotoxicity can be 
ascribed to the released ATRA ester 19. For prodrugs 15 and 16 the IC50 values indicate a 
cumulative effect, since these prodrugs are more potent than both of the released 
compounds, demonstrating the advantage of the prodrug formulation.  
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Table 25. IC50 (µM) values for the prodrugs 13–16, the lysolipids 17 and 18, DSPG and 1-O-
DSPG in HT-29 and Colo205 cancer cell lines.a   
Compound HT-29 
IC50 (µM) 
HT-29 + sPLA2b 
IC50 (µM) 
Colo205 
IC50 (µM) 
13 >200 7 ± 2 16 ± 4 
14 >200 6 ± 1 12 ± 3 
15 >200 3 ± 1 7 ± 6 
16 >200 8 ± 1 19 ± 4 
17 11 ± 6 nd 25 ± 2 
18 7 ± 1 nd 22 ± 3 
DSPG >200 25 ± 11 54 ± 7 
1-O-DSPG >200 9 ± 2 33 ± 4 
C17H35COOH >200 nd >200 
sPLA2 c c c 
a Cytotoxicity was measured using the MTT assay as cell viability 48 h after incubation with 
the indicated substances for 24 h and shown by mean ± SD (n ≥ 3); nd = not determined; b 
Snake (Agkistrodon piscivorus piscivorus) venom sPLA2 was added to a final concentration of 
5 nM; c No change in cell viability was observed after 24 h. 
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Figure 31. Dose–response curves for the treatment of HT-29 cells (left) with the sn-1-ether prodrugs 13 (●), 
13 + sPLA2 (■), 15 (♦) and 15 + sPLA2 (▲). Dose–response curves for the treatment of Colo205 cells (right) 
with sn-1-ester prodrugs 14 (■) and 16 (▲). 
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4.10 Conclusion 
The ATRA phospholipid prodrug was synthesized but sPLA2 was not able to hydrolyze the 
desired ester bond and MD simulations confirmed that 8 has an imperfect positioning in 
sPLA2. Based on MD simulations, a revised prodrug strategy for enzyme triggered delivery 
of retinoids was developed in which an aliphatic C6-linker was incorporated between the 
glycerol backbone of the phospholipids and the retinoids. The phospholipid prodrugs of 
retinoids (13–16) were synthesized and gratifyingly, it was demonstrated that they can be 
formulated as liposomes that are degraded by sPLA2. The cytotoxicity studies showed that 
prodrug 13–16 require sPLA2 in order to induce significant cell death. It is therefore 
evident that the revised prodrug strategy presents a solution to liposomal formulation of 
retinoids. 
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5. Enzymatic Studies on Vitamin E Succinate Phospholipid Conjugates 
 
5.1 Introduction  
Vitamin E’s are important antioxidants which protect cell membranes against oxidation by 
scavenging of lipid peroxidation produced radicals.177 Vitamin E is a family of α, β, γ, and 
δ-tocopherol (Figure 32) and the corresponding four tocotrienols177 and while all vitamin 
E’s are non-toxic and have low cytotoxicty against cancer cells, vitamin E succinates are 
potent growth inhibitors towards various cancer cells, with α-tocopheryl succinate as the 
most active member of the family (Figure 32).77,78 Like the vitamin E compounds, the 
succinates do not display toxicity towards healthy cells.77 The skeleton of the family of 
vitamin E compounds are divided into three domains178 (Figure 32) and for the functional 
domain (I in Figure 32) structure activity relationship (SAR) studies have shown that the 
attachment of short dicarboxylic acids (like malonic acid or succinic acid) provide the most 
cytotoxic agents, whereas longer dicarboxylic acids provide less potent agents.78 
Furthermore, SAR studies have demonstrated that the carboxylate is crucial for the 
anticancer activity, since e.g. the methyl ester of α-tocopheryl succinate is completely 
inactive.78 It is believed that the role of the carboxylate is to cause destabilization of cell 
membranes via a detergent-like behavior leading to a higher drug uptake.179 SAR studies 
on the other domains, the signaling and the hydrophobic (II and III in Figure 32, 
respectively) revealed that both domains are needed for maintaining activity, however 
modifications in the length of the hydrophobic domain are tolerated.78  
 
 
Figure 32. Structure of the four tocopherols from the vitamin E family (left). The three domains (I, II and III)
are indicated. Structure of α-tocopheryl succinate (right), which is the most potent vitamin E succinate and
selected for incorporation into the investigated drug delivery system. 
 
The use of vitamin E derivatives in cancer treatment is restricted due to their low water 
solubility hampering an intravenous administration route, and an oral administration route 
of the vitamin E succinates may not be effective due to hydrolysis of the ester bond by 
esterases during the transport through the intentinal tract.178 Therefore incorporation into a 
liposomal drug delivery system could be beneficial. The carboxylic acid moiety allows 
direct attachment to the sn-2 position of the phospholipid backbone making vitamin E 
succinates applicable as drug candidate for the investigated drug delivery system. 
Furthermore, the liposomal formulation will scavenge the biological important carboxylate 
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moiety by formation of an ester bond hence only tissue with an over expression of sPLA2 
will be affected by the injected liposomes. α-Tocopheryl succinate was selected as the 
vitamin E succinate to study, since this compound is commercially available, cheap and 
potent. The target phospholipid prodrugs are shown in Figure 33 and in order to examine 
differences in biophysical and biological properties along with enzyme activity both the sn-
1-ester and the sn-1-ether phospholipid prodrug were synthesized.    
 
 
Figure 33. Structure of the target α-tocopheryl succinate phospholipid prodrugs. 
 
5.2 Synthesis of α-Tocopheryl Succinate Phospholipid Prodrugs 
The sn-1-ether phospholipid prodrug 36 was accessible in three synthetic steps from the 
previously prepared secondary alcohol 29 (Scheme 13). Acylation of 29 with α-tocopheryl 
succinate gave the desired ester bond and the following deprotections of the cyanoethyl 
and the TBDMS groups were achieved using the same conditions as in synthesis of 13–16 
(Scheme 11), giving the sn-1-ether phospholipid prodrug 36 in 61% yield over the three 
steps (Scheme 13). 
 
Scheme 13. Synthesis of the sn-1-ether phospholipid prodrug 36.a 
 
 
 
aReagents: (a) (i) α-Tocopheryl succinate, EDCI, DMAP, EtOAc, CH2Cl2; (ii) DBU, 
CH2Cl2; (iii) HF, H2O, CH2Cl, MeCN.  
 
The synthesis of the sn-1-ester phospholipid prodrug 37 (Scheme 14) was initiated from 
the previously prepared secondary alcohol 33 (Scheme 10). Alcohol 33 was reacted with α-
tocopheryl succinate creating the ester bond and the TBDMS group was removed by the 
NBS mediated desilylation method, also applied in the synthesis of 34 (Scheme 10), and no 
migration or degradation of the α-tocopheryl succinyl moiety was observed. The phosphate 
headgroup was inserted via reaction with the phosphoramidite 27 applying the established 
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coupling procedure (see e.g. Scheme 9) and after the final deprotections the sn-1-ester 
phospholipid prodrug 37 was accessed in 44% yield from 38 (Scheme 14).          
 
Scheme 14. Synthesis of the sn-1-ester phospholipid prodrug 37.a
 
 
aReagents: (a) (i) α-tocopheryl succinate, EDCI, DMAP, CH2Cl2; (ii) NBS, DMSO, THF, H2O; (b) (i)
phosphoramidite 27, tetrazole, CH2Cl2, MeCN; (ii) tBuOOH; (iii) DBU, CH2Cl2; (iv) HF, H2O, CH2Cl,
MeCN.  
 
5.3 Enzyme Activity and Cytotoxicity 
The α-tocopheryl succinate phospholipid prodrugs 36 and 37 were hydrated in HEPES 
buffer yielding milky solutions and a DSC scan (20–65 °C) was obtained. But no Tm was 
observed in the tested range, indicating that 36 and 37 are in a fluid state at 20 °C. These 
findings were further supported during the formulation where it was possible to extrude the 
solutions of 36 and 37 through a 100 nm filter at 20 °C, yielding clear and transparent 
solutions. DLS analysis of the formulated phospholipids revealed that particles with an 
average diameter of 115 nm and a low polydispersity was formed (Table 26), indicating 
formation of unilamellar vesicles.  
 
Table 26. DLS analysis of phospholipid solutions 
hydrated in HEPES buffer and extruded through a 
100 nm filter.  
Compound Particle size 
 Diameter (nm) PdI 
36 115 0.09 
37 115 0.06 
40 80 0.14 
41a 191 0.23 
41 115 0.49 
42a 168 0.33 
42 100 0.35 
aNot extruded 
 
In order to study the enzyme activity snake (Naja mossambica mossambica) venom sPLA2 
was added to the phospholipid solutions and the mixtures were incubated at 37 °C for 48 h. 
The activity was monitored by MALDI-TOF MS but disappointingly and as evident from 
the MS spectra in Figure 34 both phospholipids are poor substrates for the enzyme and 
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based on the MS spectra no significant degradation has occurred, however small amounts 
of the lysolipids and α-tocopheryl succinate were detected in the MS spectra (data not 
shown). The inability of sPLA2 to release α-tocopheryl succinate was verified by 
evaluation of the cytotoxicity in HT-29 and Colo205 cells. As evident from Figure 35 no 
significant cell death was obtained when 36 and 37 were subjected to HT-29 cells neither 
in absence nor presence of sPLA2 and likewise no cell death was observed in the sPLA2 
secreting Colo205 cells (Figure 35). In contrast to the phospholipids α-tocopheryl 
succinate induced significant cell death in both cell lines.  
 
Figure 34. MALDI-TOF MS monitoring of snake (Naja mossambica mossambica) venom sPLA2 activity on 
α-tocopheryl succinate conjugates 36 (left) and 37 (right). 
 
Figure 35. Dose-response curves for the treatment of HT-29 cells (left) with α-tocopheryl succinate (♦) 
and the phospholipid prodrugs, 36 (■), 36 + sPLA2 (●), 37 (▲), 37 + sPLA2 (▼). Dose-response curves 
for the treatment of Colo205 cells (right) with α-tocopheryl succinate (▲) and the phospholipid prodrugs, 
36 (■) and 37 (●). The cytotoxicity was measured using the MTT assay as cell viability 48 h after 
incubation with the indicated substances for 24 h and shown by mean + SD (n=3). Snake (Agkistrodon 
piscivorus piscivorus) venom sPLA2 was added to a final concentration of 5 nM in studies of HT-29 cells. 
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5.4 Synthesis and Enzyme Activity of Alkyl and Phenyl Succinate Phospholipids 
The low extent of sPLA2 activity that was observed on prodrug 36 and 37 prompted to an 
investigation of which structural features of α-tocopheryl succinate that hinders the 
hydrolysis to occur efficiently. Recent MD studies180 on the chlorambucil prodrugs (1 and 
2) and DPPG have indicated that water enter the active site of the enzyme via the 
hydrophobic channel in the protein51 following a specific route controlled by the aromatic 
residues in Phe5 and Tyr51. Interestingly, the studies indicated that the aromatic moiety in 
the chlorambucil prodrugs increase the diameter of the hydrophobic channel without 
affecting the orientation of the residues in the active site meaning water molecules more 
freely can reach the catalytic region in complexes of sPLA2 and the chlorambucil prodrugs 
than in the sPLA2–DPPG complex. The extensive substitution of the phenyl ring in α-
tocopherol may therefore block the hydrophopic channel hampering the flow of water into 
the active site meaning the hydrolysis rate will be slowed down. In order to study the 
hypothesis a SAR study was initiated, in which the octyl succinate phospholipid 40, the 
phenyl succinate phospholipid 41 and the 2,6-dimethylphenyl succinate phospholipid 42 
were synthesized (Scheme 15). The succinate moiety was attached to the phospholipid 
backbone by coupling of building block 29 and benzyl succinate (44, see Scheme 15) and 
hydrogenolysis of the benzyl ester gave 39 (Scheme 15). The carboxylic acid 39 was 
diversified into the desired phospholipids 40, 41 and 42, by first a Steglich coupling with 
the corresponding alcohol, followed by deprotections of the cyanoethyl and TBDMS 
groups (Scheme 15). 
   
Scheme 15. Synthesis of the succinate phospholipids 40, 41 and 42 and benzyl succinate (44).a 
 
 
aReagents: (a) (i) 44, DCC, DMAP, CH2Cl2; (ii) H2, Pd/C, EtOAc, MeOH; (b) (i) C8H17OH, PhOH or 
2,6-dimethylphenol, DCC, DMAP, CH2Cl2; (ii) DBU, CH2Cl2; (iii) HF, H2O, CH2Cl, MeCN; (c) 
BnOH, DMAP, CH2Cl2.  
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Hydration of 41 and 42 in HEPES buffer at 20 °C gave clear solutions and DLS analysis 
revealed that particles with an average diameter of 190 nm for 41 and 168 nm for 42 
(Table 26) were present, indicating that some kind of non-multilamellar vesicles were 
formed. Surprisingly, it was not possible to extrude the clear phospholipid solutions of 41 
and 42 through a 100 nm filter at 20 °C and the extrusion was therefore performed at 65 
°C. DLS analysis of the extrude solutions showed that the average diameter was decreased 
to 115 and 100 nm for the phospholipid solutions of 41 and 42, respectively whereas the 
polydispersity was increased (Table 26). The results from the DLS analysis and the 
extrusions indicate that some form of robust particles with a diameter >100 nm is formed 
spontaneously upon subjection to HEPES buffer and it is likely this can be associated with 
the molecular structure of 41 and 42. The significant shorter chain in the sn-2 position than 
in the sn-1 position gives phospholipids with a different curvature and hence packing 
properties than phospholipids having chains of (almost) the same length, like in DPPG. But 
as these results were obtained in last part of the Ph.D. study there was not time for further 
investigations. Hydration of 40 in HEPES buffer at 20 °C gave the same milky solution as 
observed for the α-tocopheryl succinate phospholipid prodrugs 36 and 37 and the 
following extrusion through a 100 nm filter at 20 °C gave a clear solution with particles 
having an average diameter of 80 nm as measured by DLS (Table 26). The extruded 
solutions of 40, 41 and 42 were subjected to snake (Naja mossambica mossambica) venom 
sPLA2 and the enzyme activity was monitored by MALDI-TOF MS. As evident from 
Figure 36 the octyl succinate phospholipid 40 was completely degraded by the enzyme 
within 24 h, demonstrating that it is not the succinate moiety that hinders sPLA2 in 
releasing α-tocopheryl succinate. The enzyme activity on the phenyl succinate 
phospholipids 41 and 42 was almost as good as on 40, although small peaks for 41 and 42 
remain in the MS spectra (Figure 36). Beyond the information that 40, 41 and 42 were 
consumed by sPLA2 the MS spectra also revealed that the desired lysolipid 17 was released 
in the three experiments (Figure 36). The enzymatic studies could indicate that the 
attachment of a phenyl moiety to the succinate to some extent reduce the enzyme activity, 
but compared to the α-tocopheryl succinate phospholipids the degree of hydrolysis is 
significantly higher for 41 and 42 by which the lack of hydrolysis on 36 and 37 cannot 
directly be associated with either the phenyl ring or the two methyl groups ortho to the 
hydroxyl group in α-tocopherol. It is therefore necessary to extend the SAR study with 
attachment of further phenols to the succinate moiety and likewise it will be interesting to 
examine other tocopherols like δ-tocopherol (see Figure 32) in order to get valuable 
information about the consequence of the methyl groups on the phenyl ring. Furthermore, 
MD simulations of vitamin E succinate phospholipid conjugates in the active site of sPLA2 
would be interesting to obtain in order to study which structural features that hamper the 
enzyme activity.  
 
Potentially, the low degree of hydrolysis on 36 and 37 could also be related to an inhibition 
of sPLA2 by α-tocopheryl succinate. α-Tocopherol are reported as an inhibitor of sPLA2 by 
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Chandra et al.,181 whereas no information is available on esters of α-tocopherol. The ability 
of α-tocopheryl succinate to inhibit sPLA2 was therefore investigated by the same assay as 
applied during the inhibitions studies of ATRA and the ATRA ester 19. Gratifyingly, the 
studies demonstrated that α-tocopheryl succinate is a weaker inhibitor than ATRA ester 19 
meaning that the low enzyme activity is not due to inhibition.     
 
 
Figure 36. MALDI-TOF MS monitoring of snake (Naja mossambica mossambica) venom sPLA2 activity 
on the succinate phospholipid 40 (top left), 41 (top right) and 42 (bottom left). The lysolipid 17 (bottom 
right) was detected in all three experiments and shown from the enzyme study on 41.  
 
5.5 Conclusion 
The α-tocopheryl succinate phospholipid prodrugs 36 and 37 were prepared in good yields 
utilizing previously developed chemistry, however the extent of hydrolysis by sPLA2 was 
low. Thus an investigation of the structural features preventing hydrolysis from occurring 
efficiently was initiated and the succinate phospholipids 40, 41 and 42 were synthesized. 
The enzymatic studies demonstrated that the succinate moiety is tolerated by the enzyme, 
whereas the studies indicated that the phenyl ring to some extent hampers the activity, but 
more phenyl succinate phospholipid analogues are needed in order to localize which 
structural motifs in α-tocopheryl succinate that reduce the enzyme activity.   
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6. Prostaglandin Phospholipid Conjugates with Unusual Properties 
 
6.1 Introduction 
Since von Euler182 and Goldblatt183 independently isolated and studied prostaglandins for 
the first time these fatty acids have attracted attention due to their involvement in many 
important biological functions.184,185,186 The biosynthetic precursor for protaglandins is 
arachidonic acid, which by a number of enzyme catalyzed reactions is converted into the 
diverse selections of prostaglandins known today.184,185,186  
 
 
 
Figure 37. Potent antiproliferative prostaglandins. 
 
Many prostaglandins have shown antiproliferative activity in tumor cells, but among the 
most studied and active prostaglandins are the dienone prostaglandins like Δ12-PGJ2 and 
Δ7-PGA1 (see Figure 37).187 Likewise, 15-deoxy-Δ12,14-PGJ2, a metabolic derivative of Δ12-
PGJ2 (Figure 37) has demonstrated high antitumor activity against L1210 leukemia cells79 
and for incorporation into the investigated drug delivery system that compound is more 
suitable than the former prostaglandins since 15-deoxy-Δ12,14-PGJ2 has a higher 
lipophilicity. The 15-deoxy-Δ12,14-PGJ2 phospholipid conjugates was designed to have the 
PG headgroup and C18 chains in the sn-1-position linked through either an ether-bond or 
ester-bond (see Figure 38).  
 
 
Figure 38. Targeted 15-deoxy-Δ12,14-PGJ2 phospholipid conjugates. 
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6.2 Synthesis of Prostaglandin Phospholipid Conjugates 
The sn-1-ether conjugate 45 (Scheme 16) was prepared by Steglich acylation102 of the 
phospholipid precurcor 29 with 15-deoxy-Δ12,14-PGJ2 after which the PG headgroup was 
deprotected under the same conditions as in the synthesis of 13–16 (Scheme 11). Access to 
the corresponding sn-1-ester conjugate 46 was attempted via the same route as applied in 
the synthesis of α-tocopheryl succinate prodrug 37 (Scheme 14), but the NBS mediated 
deprotection of the TBDMS group caused decomposition of the prostaglandin moiety. 
Therefore an approach similar to the synthesis of the sn-1-ether phospholipid prodrugs was 
initiated from alcohol 32 (Scheme 17). The secondary alcohol was PMB protected via 
subjection to PMBTCA in an acidic solution of toluene and the TBDMS group was 
removed with NBS in a moist mixture of DMSO and THF to afford 47 (Scheme 17). 
Conversion to phospholipid precursor 48 (Scheme 17) was achieved in the same way as 29 
was obtained from 5b (Scheme 9). Then, freshly prepared 48 was acylated with 15-deoxy-
Δ12,14-PGJ2 and deprotection of the PG headgroup led to the desired conjugate 46 (Scheme 
16). Urea formation was observed during the carbodiimide mediated acylations with 15-
deoxy-Δ12,14-PGJ2 which resulted in low yields of 45 and 46 (Scheme 16) but since 15-
deoxy-Δ12,14-PGJ2 is expensive the compound was not used in excess and alternative 
acylation methods was not examined.  
 
Scheme 16 Synthesis of the 15-deoxy-Δ12,14-PGJ2 phospholipid conjugates 45 and 46.a 
 
 
 
aReagents: (a) (i) 15-deoxy-Δ12,14-PGJ2, DCC, DMAP, CH2Cl2; (ii) DBU, CH2Cl2; (iii) HF, H2O, CH2Cl2, 
MeCN. 
 
Scheme 17. Synthesis of sn-1-ester phospholipid precursors.a 
 
 
 
aReagents: (a) (i) PMBTCA, La(OTf)3, toluene; (ii) NBS, DMSO, THF, H2O; (b) (i) 
phosphoramidite 27, tetrazole, CH2Cl2, MeCN; (ii) tBuOOH; (iii) DDQ, H2O, CH2Cl2.  
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6.3 Biophysical Characterization and Enzymatic Studies 
The prostaglandin conjugates 45 and 46 were hydrated in HEPES buffer at 20 °C yielding 
clear solutions. DLS analysis of the phospholipid suspension of 46 revealed that particles 
with a average diameter of around 100 nm were formed (Table 27), indicating that the 
prostaglandin conjugates spontaneously form unilamellar vesicles at 20 °C. Self-
aggregation into unilamellar vesicles upon dispersion in a buffer is very rare for 
phospholipids and has only been reported in the literature once before.71 Extrusion through 
a 100 nm filter at 20 °C narrowed the average diameter and the polydispersity of the 
vesicles (Table 27), presumably because filtration removed the minor population of 
flocculated particles. Twelve days after formulation, the particle distribution of the 
phospholipid suspensions was investigated with DLS again. As evident from Table 27, 
neither the diameter nor the polydispersity changed significantly, showing that the vesicles 
formed maintain their size and does not aggregate into larger particles.  
 
Table 27. DLS analysis of the 15-deoxy-Δ12,14-PGJ2 conjugates formulated by 
extrusion. Data was obtained immediately after the formulation and 12 days later.  
 0 days 12 daysb 
Compound Diameter PdI Diameter PdI 
45 51 0.26 61 0.26 
46a 112 0.45 98 0.39 
46 81 0.35 76 0.41 
aNot extruded. bThe lipid suspensions were stored at 4 °C for 12 days. 
 
The formulated phospholipid suspensions of 45 and 46 were investigated for their 
susceptibility to sPLA2 hydrolysis. Purified snake venom sPLA2 from Agkistrodon 
piscivorus piscivorus and Naja mossambica mossambica were used and the enzyme 
activity was investigated with MALDI-TOF MS. 
 
Figure 39. MALDI-TOF MS monitoring of snake (Naja mossambica mossambica) venom sPLA2 activity on 
the 15-deoxy-Δ12,14-PGJ2 conjugates 45 (left) and 46 (right). 
 
The formulated phospholipids 45 and 46 were subjected to sPLA2 and stirred at 37 °C and 
samples for MALDI-TOF analysis were taken after 2, 24 and 48 h. As evident from the 
MS spectra in Figure 39 the sn-1-ester conjugate 46 was completely consumed by sPLA2 
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after 24 h. However, the sn-1-ether conjugate 45 was not completely degraded after 48 h 
and the conversion was estimated to 70%. This difference in hydrolysis rate and extent for 
the sn-1-ester versus the sn-1-ether phospholipids is remarkable and to your knowledge has 
not been observed before, but the observation verifies that sn-1-ester phospholipids are 
better substrates for sPLA2 than sn-1-ether phospholipids.131 For both conjugates 15-
deoxy-Δ12,14-PGJ2 and the lysolipid 17 and 18 were detected as the released products (data 
not shown). Also evident from Figure 39 is the requirement for sPLA2 for hydrolysis of 
both 45 and 46.  
 
6.4 Cytotoxicity 
The cytotoxicity of the conjugates was evaluated in two colon cancer cell lines, HT-29 and 
Colo205 (Table 28). The activity of the conjugates towards HT-29 cells was investigated in 
the presence and in the absence of sPLA2. Surprisingly, it was observed that the conjugates 
induced significant cell death (see Table 28 and Figure 40) also in the absence of the 
enzyme, albeit to a lesser degree than when sPLA2 was present. Despite having studied a 
number of other phospholipid prodrugs, like 1, 13 and 15 this is the first time cytotoxicity 
of the phospholipid conjugates in the absence of sPLA2 has been observed. It can be 
speculated that this behavior is due to a spontaneous cellular uptake of the 15-deoxy-Δ12,14-
PGJ2 conjugates followed by metabolic breakdown in the cytosol. This facile uptake is 
likely a consequence of the dynamic behavior of the 15-deoxy-Δ12,14-PGJ2 conjugates, 
which also manifests itself during formulation, where self-aggregation into unilamellar 
vesicles was observed (vide supra). 
 
Table 28. IC50 values for 15-deoxy-Δ12,14-PGJ2 and the conjugates 45 and 46 in HT-29 and 
Colo205 colon cancer cell lines.a  
 HT-29 HT-29 + sPLA2b  Colo205 
Compound IC50 (µM) IC50 (µM) IC50 (µM) 
15-deoxy-Δ12,14-PGJ2 1.6 ± 0.3 nd 4 ± 2 
45 6 ± 1 2.2 ± 0.2 9 ± 2 
46 32 ± 2 6.4 ± 0.4 17 ± 5 
aCytotoxicity was measured using the MTT assay as cell viability 48 h after incubation with 
the indicated substances for 24 h and shown by mean ± SD (n ≥ 3); nd = not determined; 
bsPLA2 was added to a final concentration of 5 nM.  
 
The cytotoxicity of the released compounds 15-deoxy-Δ12,14-PGJ2 (Table 28) and the 
lysolipids 17 and 18 (Table 25) was obtained also. As evident the IC50 values for the 
released compounds are in the same range as for the conjugates 45 and 46 indicating that 
the activity originate from 15-deoxy-Δ12,14-PGJ2 and the lysolipids, released either extra- or 
intracellularly. The conjugates were also able to induce cell death in Colo205 cells, with 
IC50 values below 20 µM (Table 28) and complete cell death was observed when higher 
concentrations were used (Figure 40). However, since Colo205 cells secrete sPLA2 it is not 
possible to conclude whether the hydrolysis of the conjugates occurs extra- or 
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intracellularly, but it is promising that the 15-deoxy-Δ12,14-PGJ2 conjugates show activity in 
this cancer cell line as well. 
 
Figure 40. Dose-response curves for the treatment of HT-29 cells (left) with the 15-deoxy-Δ12,14-PGJ2 
conjugates; 45 (■), 45 + sPLA2 (●), 46 (▲) and 46 + sPLA2 (▼). Dose-response curves for the treatment 
of Colo205 cells (right) with the conjugates 45 (■) and 46 (●). 
 
6.5 Conclusion 
The conjugates 45 and 46 form unilamellar vesicles spontaneously, upon dispersion in 
HEPES buffer, which is rare for phospholipids. Furthermore, a significant difference in 
rate and extent of sPLA2 hydrolysis between the sn-1-ester and the sn-1-ether conjugates 
was observed. In the cytotoxicity studies it was observed that 45 and 46 induce cell death 
in Colo205 cells and in HT-29 cells both in the presence and absence of sPLA2, however 
this is not desirable in regard to a prodrug strategy. Therefore based on the observed results 
incorporation of 15-deoxy-Δ12,14-PGJ2 into the investigated drug delivery system does not 
seem the way to go. But this is an exceptional example on how differently phospholipids 
can behave and further investigations of the ability to self-aggregate into unilamellar 
vesicles and a better understanding of the compounds permeability and membrane 
properties will have impact, not only on the design of phospholipid prodrug but also as a 
platform for designing highly permeable or membrane destabilizing phospholipids.  
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7. Towards Liposomal Delivery of Calcitriol 
 
7.1 Introduction 
At this stage of the project it became evident that the potency of the incorporated drugs 
was not strong enough to separate the effect from the lysolipids. Therefore it was necessary 
to come up with a more potent drug and calcitriol, a biological active metabolite of vitamin 
D3, was chosen as the new drug candidate (Figure 41). Calcitriol plays a crucial role in 
calcium and phosphorus homeostatis, but it has also been established that it inhibits 
proliferation and causes differentiation in various cancer cells.188,189 Calcitriol mediates its 
activity through the vitamin D receptor (VDR), and the hydroxyl groups at C-1 (1α-OH) 
and C-25 are important for binding (see Figure 41).190  
 
Figure 41. Structure of vitamin D3 and calcitriol.  
 
The absence of a carboxylic acid moiety in calcitriol obstructs direct attachment to the 
phospholipid backbone while incorporation of a linker is necessary. The results from the 
liposomal formulation of retinoids, in which sPLA2 sensitive phospholipids were achieved 
by incorporation of an aliphatic linker between the retinoid and the phospholipid backbone 
(section 4.5), inspired an incorporation of a dicarboxylic acid, such as succinic acid or 
adipic acid (Figure 42). For this prodrug strategy to be successful it is crucial that the 
calcitriol analogues 51 and 52 retain the affinity for the VDR, either by direct binding or 
upon hydrolysis (e.g. by esterases) of the ester bond.  
 
 
Figure 42. Schematic overview of the “dicarboxylic acid linker” based prodrug strategy for sPLA2 
triggered delivery of calcitriol analogues.   
 
Initial studies have revealed that phospholipids with a carbonate in the sn-2 position are 
substrates for sPLA2 191 and with this in hand a second strategy for enzyme triggered 
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release of calcitriol was investigated (Figure 43). The strategy relies on that upon sPLA2 
activation the released carbonate 54 will decompose to CO2 and alcohol 55, which then 
cyclize to δ-valerolactone under release of calcitriol. Drug release upon lactonization has 
previously been demonstrated by Wang et al.192    
  
 
Figure 43. Schematic overview of the carbonate based prodrug strategy for sPLA2 triggered 
delivery of calcitriol.   
 
7.2 Calcitriol Esters 
It is crucial for the prodrug strategy presented in Figure 42 that calcitriol analogues, like 51 
and 52 retain their cytotoxicty and ability to bind to the VDR and in order to study that, the 
synthesis of the calcitriol esters 51 and 52 was initiated. Monoesterification of calcitriol 
and other 1α-hydroxyvitamin D3 analogues is challenging due to the presence of two 
secondary hydroxyl groups at C-1 and C-3, and only low isolated yields have been 
reported.193 The hydroxyl group at C-1 is important for the binding to the VDR hence 
esterification of the hydroxyl group at C-3 is desirable.  
 
 
Figure 44. Conformational equilibrium between the α-chair and 
β-chair in the A-ring of Calcitriol (compare with Figure 41).195 
 
Conformational studies of the A-ring (see Figure 41) by NMR194,195,196 have demonstrated 
that the α-chair and β-chair conformation (see Figure 44) of the A-ring exist in a 1:1 ratio 
by which the two hydroxyl groups cannot be differentiated by their steric surroundings. 
The similarity in reactivity of the hydroxyl groups was confirmed when calcitriol was 
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subjected to succinic anhydride and DMAP (Figure 45 and Table 29), since 1-O-51 and 3-
O-51 was formed in a 1:1 ratio as inseparable isomers. Reisolation of calcitriol (56%) 
compensates for the somewhat low yield, which very likely also can be associated with the 
low solubility of calcitriol in CH2Cl2 that made it necessary to add THF as a co-solvent. 
When calcitriol was treated with adipic anhydride and DMAP no conversion of calcitriol 
was observed, despite reaction of vitamin D2 under identical conditions afforded the 
desired product in a good yield (data not shown).  
 
Figure 45. Synthesized calcitriol esters, see also Table 29. 
 
Table 29. Synthesis of calcitriol esters, compare with Figure 45. 
Compound Ratioa Reagentsb Yield 
1-O-51 and 3-O-51  1:1 a 29% 
1-O-52 and 3-O-52 1:3 b 19% 
1-O-56 and 3-O-56c 0:1 c 8% 
1-O-56 and 3-O-56c 1:1 c 17% 
aRatio between the 1-O-calcitriol ester and the 3-O-calcitriol ester. bReagents: (a) 
calcitriol, succinic anhydride, DMAP, CH2Cl2, THF; (b) (i) calcitriol, carboxylic acid 58, 
EDCI, DMAP, CH2Cl2, THF; (ii) TBAF, THF; (c) calcitriol, CH3CH2CF2COOH, EDCI, 
DMAP, CH2Cl2, THF. cSame Experiment. 
 
After idea from Blæhr et al.193 the desired adipate analogue of calcitriol was assessed by a 
two step synthesis starting with an esterification of calcitriol with carboxylic acid 58 
(Table 29). It was found that a Fischer esterification197,198 of adipic acid (57) was the most 
appropriate method for making carboxylic acid 58 (Scheme 18). Interesting the Keck 
acylation129 of calcitriol showed selectivity towards acylation of the hydroxyl group at C-3 
and trimethylsilylethyl protected 1-O-52 and 3-O-52 was isolated in a 1:3 ratio. 
Furthermore, diacylation was observed to some extent as well. Deprotection of the 
trimethylsilylethyl protection group was achieved with TBAF in THF affording the 
mixture of 1-O-52 and 3-O-52 in 19 % yield over the two steps. The biological studies of 
the calcitriol analogues 51 and 52 revealed that the cytotoxicity was retained but the ability 
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to induce transcription of vitamin D-responsive genes was 10 times lower than for 
calcitriol (vide infra) demonstrating a low affinity towards the VDR. Therefore studies of 
α,α-difluoro esters of calcitriol was initiated, since α,α-difluoro esters are more labile 
towards chemical hydrolysis than aliphatic esters. 199  2,2-Difluorobutyric acid is 
commercially available and became the starting point for the investigation. The attachment 
to calcitriol was achieved using a Keck acylation (Table 29) and gratifying it was possible 
by column chromatography to isolate 3-O-56 in 8% yield (see Figure 46 for the down-field 
part of the 1H NMR spectrum) whereas a 1:1 mixture of 1-O-56 and 3-O-56 also was 
isolated in 17 % yield (Table 29). As evident from the 1H NMR spectra in Figure 46 upon 
acylation the chemical shifts for H-1 and H-3 increase with ~1.2 ppm making the 
identification of the 1-O-esters and 3-O-esters of calcitriol possible. Furthermore, the 1H 
NMR spectra illustrate that the signals for other protons in the down-field region separate 
for the two regioisomers which allows the determination of the ratio between them.  
 
 
 
 
Figure 46. Snapshot from the down-field part of the 500 MHz 1H NMR spectra 
for pure 3-O-56 (top) and the 1:1 mixture of 1-O-56 and 3-O-56 (bottom). 
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Scheme 18. Synthesis of carboxylic acid 58.a 
 
 
 
a Reagents: (a) Me3SiCH2CH2OH, TsOH·H2O, toluene. 
 
Encouraging the biological studies demonstrated that 1-O-56 and 3-O-56 binds to the VDR 
to the same extent as calcitriol (vide infra) hence attachment of a α,α-difluoro dicarboxylic 
acid to calcitriol was initiated. In order to get the same linker length as in the carbonate 
based prodrug strategy (Figure 43) it was decide to attach 2,2-difluoroheptanedioic acid. 
Applying chemistry developed by Burton and co-workers200 coupling of the commercially 
available α,α-difluoro ester 61 and alkene 60 was successfully achieved and 
hydrogenolysis of the benzyl ester gave the desired carboxylic acid 62 in 46% yield 
(Scheme 19). Access to 62 was also achieved in 55% from 61 (Scheme 19) using a three 
steps procedure involving a dithionite mediated alkylation.201,202 Elimination of iodide by 
DBU gave the corresponding alkene which was reduced during hydrogenolysis of the 
benzyl ester.  
 
Scheme 19. Synthesis of α,α-difluoro esters.a 
 
 
a Reagents: (a) BnOH, EDCI, DMAP, CH2Cl2; (b) (i) 60, NiCl2·6H2O, Zn, THF; (ii) H2, Pd/C, 
EtOAc; (c) (i) 60, Na2S2O4, NaHCO3, MeCN, H2O; (ii) DBU, Et2O; (iii) H2, Pd/C, EtOAc; (d) 
(i) Me3SiCH2CH2OH or tBuOH, 2,4,6-Cl3C6H2COCl, DMAP, THF; (ii) LiOH, H2O, THF. 
 
Trimethylsilylethyl protection of the carboxylic acid was efficient in the synthesis of 52 
(Table 29), and building block 63 (Scheme 19) was prepared via a Yamaguchi 
esterification203 followed by selective hydrolysis of the α,α-difluoro ethyl ester with LiOH 
in a cold mixture of H2O and THF (Scheme 19). At this stage of the project the Yamaguchi 
esterification proved to be advantageous for acylations of calcitriol since better conversion 
and selectivity towards the 3-O-ester was observed compared to the previously applied 
carbodiimide chemistry. Exemplified by the coupling of 63 and calcitriol (Scheme 20) 
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which in 30 % yield gave the 1-O-ester and the 3-O-ester in a 1:10 ratio. Disappointingly 
treatment with TBAF in THF led to hydrolysis of the α,α-difluoro ester instead of the 
trimethylsilylethyl ester and alternatives like HF in MeCN at 20 °C did not give any 
conversion while heating to 60 °C caused complete decomposition of the calcitriol 
skeleton. Instead the tert-butyl protection group was examined, and building block 64 was 
made in the same way as 63 (Scheme 19). Acylation of calcitriol applying the Yamaguchi 
esterification gave almost exclusively the 3-O-ester (the ratio between the 3-O-ester and 
the 3-O-ester was >10:1), but selective deprotection of the tert-butyl ester was not possible 
(Scheme 20). TMSOTf and 2,6-lutidine in CH2Cl2 which was efficient in the synthesis of 
ATRA ester 19 (Scheme 7), did not give any conversion, whereas TFA or ZnBr2169 in 
CH2Cl2 led to decomposition of the calcitriol skeleton and that was also observed for SiO2 
in hot (90 °C) toluene.204 Finally KOtBu in THF205 resulted in release of calcitriol instead 
of the desired tert-butyl deprotection. These results were obtained in the end of the Ph.D. 
study and therefore there was not time for further synthetic studies towards the desired 
calcitriol ester 65 (Scheme 20). As presented in the next section synthesis of the 
corresponding phospholipid prodrug 69 was achieved.    
 
Scheme 20. Synthetic studies towards calcitriol ester 65.a 
 
 
a Reagents: (a) Calcitriol, 2,4,6-Cl3C6H2COCl, DMAP, THF. 
 
7.3 Synthesis of Phospholipid in Conjugate with α,α-Difluoro Calcitriol Ester 
To evaluate the stability in aqueous environments of phospholipids having a α,α-difluoro 
ester moiety the simple model phospholipid 66 (Scheme 21) was synthesized prior to 
phospholipid prodrug 69 (Scheme 22). Phsopholipid 66 was accessed in 67 % yield from 
precursor 29. The stability studies demonstrated that no significant degradation of 
phospholipid 66 occurs during subjection to HEPES buffer (vide infra) and the synthesis of 
69 was initiated.  
 
The α,α-difluoro benzyl ester 67 was synthesized in two steps from 64 (Scheme 22) and 
with no acid sensitive functionalities in the molecule, the tert-butyl deprotection was 
achieved using TFA in CH2Cl2. Attachment of 67 to the phospholipid precursor 29 and 
hydrogenolysis of the benzyl ester gave carboxylic acid 68 (Scheme 22). Then calcitriol 
was introduced via the Yamaguchi esterification and the final deprotections of the PG 
headgroup was achieved using the well known conditions without decomposition of the 
calcitriol skeleton, emphasizing the substrate scope and applicability of this synthetic route 
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to PG lipids. As a consequence of the Yamaguchi coupling phospholipid prodrug 69 was 
isolated as a 6:1 mixture of 3-O-69 and 1-O-69 confirming the selectivity trend towards the 
3-O-ester of calcitriol (Scheme 22).   
 
Scheme 21. Synthesis of phospholipid 66.a 
 
 
 
a Reagents: (a) (i) Carboxylic acid 62, 2,4,6-Cl3C6H2COCl, DMAP, THF; (ii) DBU, 
CH2Cl2; (iii) HF, H2O, CH2Cl2, MeCN. 
 
Scheme 22. Synthesis of phospholipid prodrug 69.a 
 
 
a Reagents: (a) (i) BnOH, 2,4,6-Cl3C6H2COCl, DMAP, THF; (ii) TFA, triisopropylsilane, CH2Cl2; (b) 
(i) alcohol 29, 2,4,6-Cl3C6H2COCl, DMAP, THF; (ii) H2, Pd/C, EtOAc, THF; (c) (i) calcitriol, 2,4,6-
Cl3C6H2COCl, DMAP, THF; (ii) DBU, CH2Cl2; (iii) HF, H2O, CH2Cl2, MeCN. 
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7.4 Synthesis of Phospholipid Carbonate in Conjugate with Calcitriol Ester 
The synthesis of phospholipid prodrug 53 was initiated from building block 5b. TBDMS 
protection of the primary alcohol followed by removal of the PMP group with DDQ in 
moist CH2Cl2 gave the seconady alcohol 71 in 82% yield (Scheme 23).  
 
Scheme 23. Synthesis of phospholipid prodrug 53.a 
 
 
a Reagents: (a) (i) NaOH, H2O; (ii) BnBr, Bu4NBr, MeCN, acetone; (b) (i) TBDMSCl, imidazole, THF; 
(ii) DDQ, H2O, CH2Cl2; (c) (i) triphosgene, pyridine, CH2Cl2; (ii) alcohol 70, pyridine; (iii) NBS, DMSO, 
THF, H2O; (d) (i) phosphoramidite 27, tetrazole, CH2Cl2, MeCN (ii) tBuOOH; (iii) H2, Pd/C, EtOAc, 
THF; (e) calcitriol, 2,4,6-Cl3C6H2COCl, DMAP, THF; (ii) DBU, CH2Cl2; (iii) HF, H2O, CH2Cl2, MeCN. 
 
Alcohol 70 required for the carbonate formation was synthesized via a hydroxide mediate 
ring opening of δ-valerolactone after which the carboxylate was reacted with benzyl 
bromide (Scheme 23). Installation of the carbonate functionality was achieved via 
treatment of 71 with triphosgene after which the carbonochloridate was trapped in situ with 
alcohol 70. The desired alcohol 72 was formed by removal of the TBDMS group applying 
the NBS mediated desilylation method and no migration of the carbonate moiety was 
observed. The phosphate headgroup was attached via coupling with phosphoramidite 27 
using the established procedure described previously and hydrogenolysis of the benzyl 
ester gave carboxylic acid 73. With 73 in hand the next step was incorporation of calcitriol 
and a significant improvement in conversion of 73 into the calcitriol ester was observed 
when Yamaguchi conditions were applied in contrast to application of carbodiimide based 
coupling reagents (e.g. EDCI), where the undesired urea formation was observed to a 
major extent as well. Determined by 1H NMR the final phospholipid prodrug 53 was 
isolated as a 3:1 mixture of 3-O-53 and 1-O-53 (Scheme 23).   
7. Towards Liposomal Delivery of Calcitriol 
85 
 
7.5 Biophysical Characterization and Enzyme Activity 
Interesting upon hydration in HEPES buffer at 20 °C phospholipid 66 behaves in the same 
way as 41 and 42 (section 5.4) and a clear solution was obtained. DLS analysis showed 
that particles with an average diameter of 238 nm (PdI = 0.43) was formed and like 
observed for 41 and 42 extrusion through a 100 nm filter was not possible at 20 °C but at 
65 °C it was accomplished and as determined by DLS a phospholipid solution with smaller 
particles (113 nm in average diameter) but a higher polydispersity (PdI = 0.62) was 
obtained. These observations contribute to the hypothesis that some kind of robust particles 
are formed spontaneously upon hydration for phospholipids like 41 and 42. MALDI-TOF 
MS analysis of the formulated solution of 66 revealed that the α,α-difluoro ethyl ester in 66 
was stable during the formulation and to incubation at 37 °C in HEPES buffer for 48 h 
(Figure 47). Subjection of snake (Naja mossambica mossambica) venom sPLA2 to the 
phospholipid solution resulted in a complete digestion of 66 within 0.5 h and release of 
lysolipid 17 (Figure 47). The other release product carboxylic acid 62 was not visible in the 
MS spectra.  
 
 
Figure 47. MALDI-TOF MS monitoring of snake (Naja mossambica mossambica) venom sPLA2 activity 
on model phospholipid 66. The spectra demonstrate that 66 (right) is degraded by the enzyme while no 
degradation occur in the absence of sPLA2. Furthermore, the desired lysolipid 17 (left) is detected upon 
sPLA2 addition.  
 
The phospholipid prodrugs 53 and 69 were hydrated in HEPES buffer but extrusion 
through a 100 nm filter was not possible hence co-formulation with DSPC was 
investigated. By mixing 53 and 69 with DSPC in a 1:1 ratio extrusion at 65 °C through a 
100 nm filter became possible and DLS analysis of the lipid solutions revealed that 
particles with an average diameter close to 100 nm was formed. DSPC was chosen for the 
co-formulation as it is an uncharged phospholipid and hence providing a reduction in the 
negative surface charge, which is necessary in order to avoid complement activation upon 
in vivo administration. However, the overall surface charge of the liposomes remain 
negative and therefore human sPLA2 will have affinity towards the mixed liposomes of 
DSPC and 53 or 69.56,61  
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The enzymatic activity was evaluated both with snake (Naja mossambica mossambica) 
venom and human sPLA2 IIA. MALDI-TOF MS analysis of the phospholipid mixtures of 
69 and DSPC showed that sPLA2 from snake venom consume 69 within 0.5 h whereas 
DSPC was completely degraded within 24 h (Figure 48).xi Furthermore, the lysolipid from 
DSPC (lyso-SPC) was visible in the MS spectra (data not shown) whereas the lysolipid 17 
only appear with a small signal and neither calcitriol nor the calcitriol ester 65 was 
detectable. But in the absence of sPLA2 no degradation occurs meaning the disappearance 
of the signals for 69 (M+2K+, 1151 m/z) in the MS spectra must be associated with the 
enzyme. The enzymatic study of human sPLA2 activity showed that 69 is not consume to 
the same extent as with the enzyme from snake venom (Figure 48) and also the 
consumption of DSPC is significantly lower (data not shown). Detection of lyso-SPC 
(Figure 48) demonstrates that the two phospholipids 69 and DSPC mix in the formation of 
bilayers since pure DSPC is not degrade by human sPLA2 IIA.   
 
Figure 48. MALDI-TOF MS monitoring of snake (Naja mossambica mossambica) venom and human sPLA2
activity on liposomes of phospholipid prodrug 69 and DSPC in a 1:1 mixture. The spectra demonstrate that
the lipid mixture of 69 (top right) and DSPC (top left) are degraded by the enzyme from snake venom
whereas less consumption of 69 (bottom right) is observed upon subjection to the human enzyme. Lyso-SPC
(bottom left) was detected upon subjection to both enzymes, here illustrated for the study with human sPLA2. 
 
The enzymatic studies on carbonate phospholipid prodrug 53 showed that the amount of 53 
decreased during the incubation with the enzyme from snake venom but within 48 h 
complete degradation was not obtained as evident from the MS spectra in Figure 49 
                                                 
xi  Application of a CF3COOK based DHB matrix gave a better signal to noisy ratio for 69 than the 
corresponding CF3COONa based matrix hence 69 appears as the 2K+ adduct. 
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whereas full consumption of DSPC was seen after 0.5 h. As observed for 69, lysolipid 17 
was only detected to a very low extent by MALDI-TOF MS (data not shown) despite that 
17 has been detected multiple times before (see e.g. Figure 47). Furthermore, calcitriol or 
the calcitriol ester 55 (compare with Figure 43) could not be detected hence it cannot be 
proven from the MALDI-TOF MS analysis that sPLA2 trigger the release of calcitriol upon 
lactonization. But it can be concluded that addition of sPLA2 provides a reduction in the 
prodrug level thus the absent of signals corresponding to calcitriol in the MS spectra can be 
due to a poor extraction of calcitriol into the organic layer during the MS sample 
preparation or due to limitations in the detection technique, which was supported by a low 
signal to noisy ratio when a pure sample of calcitriol was subjected to MALDI-TOF MS 
analysis (data not shown). Additional stearic acid released from DSPC also could not be 
detected by MALDI-TOF MS showing that this method has limitations in detection of 
degradation constituents from enzyme activity studies on phospholipids. When human 
sPLA2 was used as the enzyme source results similar to those obtained with the enzyme 
from snake venom were obtained (Figure 49), however the hydrolysis of DSPC occurred 
significantly slower and less efficiently. Like for the mixture of 69 and DSPC, lyso-SPC 
was detected demonstrating that mixed bilayers of 53 and DSPC are formed.    
 
Figure 49. MALDI-TOF MS monitoring of snake (Naja mossambica mossambica) venom and human sPLA2
activity on liposomes of phospholipid prodrug 53 and DSPC in a 1:1 mixture. The spectra demonstrate that
53 (top right) is partly degraded whereas DSPC (top left) is fully degraded by the enzyme from snake venom.
Likewise partly degradation of 53 (bottom right) and DSPC (bottom left) is observed upon subjection to the
human enzyme.  
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7.6 Biological Studies of the Calcitriol Esters 
The cytotoxicity of calcitriol and the calcitriol esters 51 and 52 were evaluated in MCF-7 
cancer cells and as evident from the dose-response curves in Figure 50 the esters 51 and 52 
displayed potency similar to calcitriol itself. The IC50 values <100 nM emphasize the 
superior potency of calcitriol in contrast to the previously applied drugs, like ATRA. To 
investigate that the cytotoxicity origins from an activation of the VDR the ability to induce 
transcription of vitamin D-responsive genes was examined using the 24-hydroxylase 
luciferase reporter gene assay206 in MCF-7 cells. It was established that the mixture of 1-O-
51 and 3-O-51 along with the mixture of 1-O-52 and 3-O-52 had 10 times lower activity 
with respect to calcitriol (Figure 51) demonstrating that the affinity towards the VDR for 
51 and 52 is low and the displayed cytotoxicity must therefore be induced via some 
unspecific pathways. Gratifying 3-O-56 and the mixture of 1-O-56 and 3-O-56 induce 
transcription to same extent as calcitriol (Figure 51), and taking into account that the 
hydroxyl group at C-1 is essential for binding to the VDR the results indicate that 
hydrolysis of the α,α-difluoroesters occur prior to VDR binding.   
 
 
Figure 50. Dose-response curves for the treatment of MCF-7 cells 
with calcitriol (■), the 1:1 mixture of 1-O-51 and 3-O-51 (▲) and 
the 1:3 mixture of 1-O-52 and 3-O-52 (●). The cytotoxicity was 
measured using the MTT assay as cell viability 48 h after 
incubation with the indicated substances for 24 h and shown by 
mean + SD (n=3). 
 
The biological evaluation of the calcitriol phospholipid prodrugs 53 and 69 was not 
completed at the end of the Ph.D. study hence these results cannot be presented. The 
biological evaluation will be important in order to clarify the somewhat inconclusive 
results obtained in the enzymatic studies, particular the 24-hydroxylase luciferase reporter 
gene assay will provide some valuable information concerning the degree of calcitriol 
release from the enzyme triggered breakdown of the calcitriol phospholipid prodrugs.   
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Figure 51: Relative affinity towards the VDR with respect to calcitriol 
measured by the 24-hydroxylase luciferase reporter gene assay in 
MCF-7 cells after incubation for 48 h with 100 nM of the investigated 
compound. Reported as mean ± SD (n = 3). 
 
7.7 Conclusion 
As calcitriol does not have a carboxylic acid moiety new ways for incorporation and drug 
release was necessary and two drug delivery strategies utilizing sPLA2 triggering was 
investigated. Attachment of a dicarboxylic acid linker was studied and it was found that 
α,α-difluoroesters induce transcription of vitamin D-responsive genes to the same extent as 
calcitriol and hence synthesis of calcitriol ester 65 was initiated but not accomplished and 
further synthetic studies are necessary. However the corresponding phospholipid prodrug 
69 was synthesized and when co-formulated with DSPC, particles with a diameter close to 
100 nm were obtained after extrusion at 65 °C. Likewise a strategy relying on sPLA2 
mediated hydrolysis of a phospholipid carbonate conjugate was investigated and the 
desired phsopholipid prodrug 53 was synthesized and co-formulated with DSPC. The 
enzymatic studies with snake venom and human sPLA2 showed that the signals in the MS 
spectra for the phospholipid prodrug decrease but the released products were not detectable 
in the MS spectra hence no clear conclusions can be made. The results from the biological 
studies will be highly interesting in order to evaluate the potential of the investigated 
strategies for liposomal delivery of calcitriol to tumors.      
 
In addition, it was discovered that acylation of calcitriol using the Yamaguchi coupling 
displayed selectivity towards the 3-O-calcitriol esters and gave better conversion why this 
coupling procedure will be preferable to use in the future. 
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8. Conclusion: Liposomal Drug Delivery 
 
During the work towards a new generation of liposomal drug delivery systems for 
anticancer agents several phospholipid prodrugs have been synthesized. The synthesized 
phospholipids had either a PC or PG headgroup and they were accessed via short synthetic 
routes in which derivatization into the various prodrugs was accomplished in the later part 
of the synthesis.  
 
Various know anticancer drugs, like chlorambucil, ATRA and α-tocopheryl succinate have 
been examined for their ability to be incorporated into the investigated drug delivery 
system. Initial screening parameters were investigated including the ability of the 
phospholipid prodrugs to form liposomes, the ability of sPLA2 to liberate the cytotoxic 
agents and finally the ability of the prodrugs to remain non-toxic in absence of the enzyme.  
 
Gratisfyingly, the majority of the phospholipid prodrugs were able to form particles with a 
diameter close to 100 nm upon extrusion at 20 °C indicating formation of unilamellar 
vesicles. This demonstrate that incorporation of structures like chlorambucil or ATRA 
which contrast naturally occurring fatty acids do not hamper the ability of the synthetic 
phospholipids to form bilayers. However it was necessary to co-formulate the calcitriol 
prodrugs 53 and 69 with DSPC in order to achieve phospholipid suspensions suitable for 
extrusion.  
 
The ability of sPLA2 to mediate hydrolysis of the ester bond at the sn-2 position and 
release the incorporated anticancer drug was studied and in general it was observed that the 
enzyme is sensitive to substituents in close vicinity of the sn-2 position exemplified by 
ATRA prodrug 8, which was not degraded. But for substrates with no branching in 
proximity to the sn-2 position, like the chlorambucil prodrugs, full hydrolysis was 
observed and when the enzyme activity was analyzed with MALDI-TOF MS, that was 
reliable and convenient to use, it was possible to verify that the desired constituents, the 
lysolipids and the anticancer drug were released.  
 
The cytotoxicity studies revealed that the phospholipid prodrugs in the presence of sPLA2 
were able to induce cell death towards various cancer cell lines and IC50 values below 10 
µM was obtained. In the absence of the enzyme the phospholipid prodrugs remain non-
toxic and no significant cell death was observed, verifying that the displayed cytotoxicity 
arise from a sPLA2 triggered breakdown of the prodrugs. The non-toxic behavior of the 
unactivated prodrugs is crucial for the drug delivery concept meaning that the prodrugs 
during the transport in the body will not harm healthy tissue. The prostaglandin prodrugs 
45 and 46 was in this regard an outlier as significant cell death was displayed also in the 
absence of the enzyme in HT-29 cells.       
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The overall conclusion from the studies of the phospholipid prodrugs of chlorambucil, 
retinoids, prostaglandin and α-tocopheryl succintate (chapter 3–6) is that the cytotoxic 
effect from the incorporated anticancer drug is hard to separate from the cytotoxicity 
caused by the lysolipids. Hence the next obstacle to overcome in order to bring this drug 
delivery concept one step further is to indentify or develop a more potent lipophilic drug 
having a carboxylic acid moiety but no substituents α, β or γ to the carbonyl, because the 
results described in thesis clearly demonstrate that the concept has potential in future 
cancer therapy and many valuable experiences and results have been obtained throughout 
the described work. 
 
Work towards incorporation of the more potent calcitriol was initiated however the 
biological studies remains to be done so the potential of this drug in the investigated drug 
delivery system cannot be evaluated at this stage.  
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9. Experimental: Liposomal Drug Delivery 
 
9.1 General Experimental 
Starting materials, reagents, and solvents were purchased from Sigma-Aldrich Chemical 
Co. and used without further purification. 15-deoxy-Δ12,14-Prostaglandin J2 and calcitriol 
were purchased from Cayman Chemical, USA. The purified snake venom sPLA2 from 
Agkistrodon piscivorus piscivorus was donated by Dr. R. L. Biltonen (University of 
Virginia) and sPLA2 from Naja mossambica mossambica was purchased from Sigma-
Aldrich Chemical Co. CH2Cl2 was dried over 4 Å molecular sieves and THF was dried 
over sodium/benzophenone and distilled before use. Evaporation of solvents was done 
under reduced pressure (in vacuo). Thin layer chromatography (TLC) was performed on 
Merck aluminum sheets precoated with silica gel 60 F254. Compounds were visualized by 
charring after dipping in a solution of 6.25 g of (NH4)6Mo7O24 and 1.5 g of Ce(SO4)2 in 
250 mL of 10% aqueous H2SO4, in an ethanolic solution of phosphomolybdenic acid (48 
g/L) or in a solution of 10 mL of p-anialdehyde, 10 ml of a concentrated aqueous solution 
of H2SO4 and 250 mL EtOH. Column chromatography was performed using Matrex 60 Å 
silica gel. The purity of the tested compounds was found to be >95% by HPLC. HPLC was 
performed on a Waters Alliance HPLC equipped with a diode array detector, using a 
LiChrospher Si 60 column and eluting with water/isopropanol/hexane mixtures. 207 , 208 
NMR spectra were recorded using a Bruker AC 200 MHz spectrometer, a Varian Mercury 
300 MHz spectrometer or a Varian Unity Inova 500 MHz spectrometer. Chemical shifts 
were measured in ppm and coupling constants in Hz, and the field is indicated in each case. 
IR analysis was carried out on a Bruker Alpha FT-IR spectrometer and optical rotations 
were measured with a Perkin-Elmer 341 polarimeter, units for 20589][  are 10-1 deg cm2 g-1. 
HRMS was recorded on an Ionspec Ultima Fourier transform mass spectrometer. Melting 
points were measured by a Buch & Holm melting point apparatus and given in degrees 
Celsius (°C) uncorrected. Elemental analyses were obtained from H. Kolbe, 
Mikroanalytisches Laboratorium, Mülheim/Ruhr, Germany.  
 
9.2 Procedures for Biophysical and Biological Characterization 
 
Liposome Preparation and Particle Size Determination  
The phospholipid prodrugs were dissolved in CHCl3 in a test tube and dried under vacuum 
for 15 h to form a thin film. The phospholipid prodrugs (2 mM) were solubilized by 
addition of aqueous buffer (0.15 M KCl, 30 µM CaCl2, 10 µM EDTA, 10 mM HEPES, pH 
7.5) and vortexed periodically over 1 h at 20 C. Subsequently, the solutions were extruded 
through a 100 nm polycarbonate cutoff membrane (20-30 repetitions) using a Hamilton 
syringe extruder (Avanti Polar Lipids, Birmingham, AL). The particle size distribution of 
the formulated lipids was measured by DLS. The DLS measurements were obtained using 
a Zetasizer Nano Particle Analyzer (ZS ZEN3600, Malvern Instrument, Westborough, 
MA).  
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sPLA2 Activity Measurements Monitored by MALDI-TOF MS and HPLC 
The formulated phospholipid prodrugs (0.40 mL, 2 mM) were diluted in an aqueous buffer 
(2.1 mL, 0.15 M KCl, 30 µM CaCl2, 10 µM EDTA, 10 mM HEPES, pH 7.5) and the 
mixture was stirred at 37 °C in a test tube protected from light. The catalytic reaction was 
initiated by addition of snake (Agkistrodon piscivorus piscivorus (20 µL, 42 µM) or Naja 
mossambica mossambica (12 µL, 71 µM)) venom sPLA2 or human sPLA2 IIA (40 µL tear 
fluid). Sampling was done after 0, 2, 24 and 48 h by collecting 100 µL of the reaction 
mixture and rapidly mixing it with a solution of CHCl3/MeOH/H2O/AcOH 4:8:1:1 (0.5 
mL) in order to stop the reaction. The mixture was washed with water (0.5 mL) and the 
organic phase (80 µL) was isolated by extraction and then concentrated in vacuo. For the 
MALDI-TOF MS analysis the extract was mixed with 9 µL of DHB matrix (0.5 M DHB, 2 
mM CF3COONa, 1 mg/mL DPPG in MeOH), and 0.5 µL of this mixture was used for the 
MS analysis. For HPLC 30-75 μL of the organic phase was injected on a 5 μm diol column 
and eluted with an isocratic eluent (CHCl3/MeOH/H2O 730:230:30 for 1a and 1b; 
CHCl3/MeOH/25% aqueous NH3 800:195:5 for 2a and 2b). An evaporative light scattering 
detector was used for detection. Tear fluid was used as the source for human sPLA2 IIA. 
Tear fluid was collected from healthy volunteers exposed to tiger balm fumes. Tear fluid 
has a high concentration of sPLA2 IIA and is the only prevalent sPLA2 species found in 
tears. The sPLA2 IIA content in tears in healthy subjects (54.5 µg/ml) is one of the highest 
amounts of sPLA2 IIA content reported in human secretions.209,210,211 
 
Alkylating Assay136,137,138 
The formulated chlorambucil phospholipid prodrugs (0.40 mL, 2 mM) were diluted in an 
aqueous buffer (2.1 mL, 0.15 M KCl, 30 μM CaCl2, 10 μM EDTA, 10 μM HEPES, pH = 
7.5) and 4-nitrobenzyl pyridine (63 mg, 0.29 mmol) was added and the mixture was stirred 
at 37 °C. When sPLA2 was used to degrade the liposomes, the catalytic reaction was 
initiated by addition of snake (Agkistrodon piscivorus piscivorus) venom sPLA2 (20 μL, 42 
μM). After 1.5 h incubation 2-amino-1-propanol in tert-butyl alcohol (25% v/v, 3.0 mL) 
was added and the colaration of the reaction mixture was measured using a UV-visible 
spectrophometer (PerkinElmer, Lambda 25 UV/Vis Spectrometer) at 450–700 nm with a 
maximum absorption at 560 nm for the colored pigment. Measurements of pure 
chlorambucil samples in HEPES buffer with and without 4-nitrobenzyl pyridine, of 
HEPES buffer with and without sPLA2 and of pure 4-nitrobenzyl pyridine in HEPES 
buffer were obtained as controls (see Pedersen et al.135). 
 
Cytotoxicity 
Colon cancer HT-29 and ovarian cancer ES-2 cells were cultured in McCoy’s 5A medium 
in the presence of 10% fetal calf serum and 1% Pen-Strep (InVitrogen). Breast cancer MT-
3 and colon cancer Colo205 cells were cultured in RPMI 1640 supplemented with 10 % 
fetal calf serum and 1% Pen-Strep in a humidified atmosphere containing 5 % CO2. 
Colo205 cells secrete sPLA2-IIA, however as the cytotoxicity assay was made with low 
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cell density and for a short incubation period, inadequate concentrations were reached in 
the medium, and therefore a conditioned medium was used. The conditioned medium was 
made as follows: Colo205 cells were grown to confluency for 72h, at which point the cells 
were pelleted and the medium, which contained approximately 100 ng/ml, was collected 
and used for the assay. Cells were plated in 96-well plates at a density of 1 × 104 cells per 
well for HT-29 and 2 × 104 cells per well for Colo205 cells, 24 h prior to addition of the 
tested compound. Chlorambucil, ATRA, ATRA ester 19, 12, 20, 15-deoxy-Δ12,14-PGJ2 and 
α-tocopheryl succinate were solubilized in DMSO and water (final DMSO concentration ≤ 
0.5%). Liposomes were diluted in PBS, and initial phospholipid concentrations in the 
liposome solutions were determined by phosphorus analysis.212 After 24 h of incubation, 
the substances were removed and the cells were washed and incubated in complete 
medium for another 48 h. Cytotoxic activity was assessed using a standard 3-(4,5-
dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay (Cell Proliferation Kit I, 
Roche, Germany).213 Cell viability is expressed as percentage reduction of incorporated 
MTT. 
 
Molecular Dynamics Simulations  
The crystal structures of bee-venom (Apis Mellifera) phospholipase A2 complexed with the 
transition-state analog, 1-O-Octyl-2-heptylphosphonyl-sn-glycero-3-phosphoethanolamine 
(diC8(2Ph)PE),51 resolved to 2.0 Å and human phospholipase A2 IIA complexed with 6-
phenyl-4-(R)-(7-phenyl-heptanoylamino)-hexanoic acid214 resolved to 2.1 Å were obtained 
from the Protein Data Bank215 (entry codes: 1poc and 1kqu, respectively). The initial 
modeling step involved placing diC8(2Ph)PE into the binding cleft of human 
phospholipase A2 IIA, as described previously.131 A previously assembled sPLA2-substrate 
complex131 was used as the template to place phospholipid prodrugs into the active site. 
The optimized phospholipid prodrugs were manually overlapped with the pre-existing 
substrate, which was subsequently deleted. NAMD software216 with the Charmm27 all-
atom parameter set and TIP3 water model was used for all simulations. 217  The 
phospholipid prodrugs were first energy-minimized for 1000 steps before using them in 
simulations. Missing force field parameters for the prodrug molecules were taken from 
similar atom types in the CHARMM27 force field. The sPLA2–phospholipid complexes 
were solvated using the program SOLVATE.218 Eighteen water molecules were randomly 
replaced with chloride ions to neutralize the systems. Ultimately, the system contained 
~4900 water molecules in a simulation cell of dimensions 52.7 x 51.7 x 67.3 Å3. An initial 
energy minimization of the complex was carried out for 1000 steps, and the system was 
further minimized for 100, 200, 300, 400 and 500 steps to generate different starting 
structures. Periodic boundary conditions were applied in x,y, and z directions. Initial MD 
simulations were conducted for ~100 ps in which each system was slowly heated to 300 K. 
Simulations were carried out for 13 ns in the NPT ensemble; i.e. at constant number of 
atoms (N), pressure (P) and temperature (T). A time step of 1 fs and an isotropic pressure 
of 1 atm using the Langevin piston method219 were employed. Electrostatic forces were 
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calculated using the particle mesh Ewald method with a uniform grid spacing of ~1 Å.220 A 
12 Å cut-off was used for terminating the van der Waals interactions in combination with a 
switching function starting at 10 Å. Analysis of the trajectories were performed using the 
Visualization Molecular Dynamics (VMD) software suite.221  
 
9.3 Experimental Data for Compounds 
 
4-Methoxybenzyl trichloroacetimidate (PMBTCA)222 
NaH (60% in mineral oil, 81 mg, 2.03 mmol) was washed with heptane (2 × 3 mL) and 
THF (11 mL) was added followed by dropwise addition of 4-methoxybenzyl alcohol (2.52 
mL, 20.3 mmol). The reaction mixture was stirred at 20 °C for 30 min and then cooled to 
0 °C. Cl3CCN (2.2 mL, 22.3 mmol) was added dropwise and the reaction mixture was 
stirred at 0 °C for 1 h and then at 20 °C for 45 min. The reaction mixture was concentrated 
in vacuo yielding an orange oil which was treated with a mixture of pentane and MeOH 
(12 mL, pentane/MeOH 275:1) and stirred for 30 min. Then the mixture was filtered 
through a pad of celite and the filtrate was evaporated in vacuo to afford 5.72 g (99%) of 
PMBTCA as a yellow oil. 1H NMR (300 MHz, CDCl3): δ 8.37 (s, 1H), 7.39 (d, J = 8.8 Hz, 
2H), 6.92 (d, J = 8.8 Hz, 2H), 5.29 (s, 2H), 3.83 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 
162.7, 159.8, 129.8 (2C), 127.6, 114.0 (2C), 91.6, 70.8, 55.4. 
 
1-O-Hexadecyl-2-(4-(4-(bis-(2-chloroethyl)-amino)-phenyl)-butanoyl)-sn-glycero-3-
phosphocholine (1a)  
Compound 6a (67 mg, 0.14 mmol) was dissolved in 1,2-dichloroethane (3.5 mL) and the 
mixture was heated to reflux. DMAP (10 mg, 0.082 mmol), chlorambucil (64 mg, 0.21 
mmol) and DCC (1 M in CH2Cl2, 0.2 mL, 0.2 mmol) were added and after 5 h and 19 h 
additional portions of chlorambucil (64 mg, 0.21 mmol) and DCC (1 M in CH2Cl2, 0.2 mL, 
0.2 mmol) were added. After 27 h the mixture was concentrated in vacuo and purified by 
column chromatography (CH2Cl2/MeOH 4:1 then CH2Cl2/MeOH/H2O 30:20:1) to give 80 
mg (75%) of 1a as a colorless amorphous solid. Rf = 0.18 (CH2Cl2/MeOH/H2O 30:20:1). 
1H NMR (500 MHz, CDCl3/CD3OD 4:1): δ 7.08 (d, J = 8.6 Hz, 2H), 6.65 (d, J = 8.6 Hz, 
2H), 5.16 (p, J = 5.9 Hz, 1H), 4.22 (s, 2H), 4.03–3.99 (m, 2H), 3.72 (t, J = 7.1 Hz, 4H), 
3.64 (t, J = 7.1 Hz, 4H), 3.63–3.59 (m, 2H), 3.56 (s, 2H), 3.49–3.39 (m, 2H), 3.19 (s, 9H), 
2.56 (t, J = 7.6 Hz, 2H), 2.36 (t, J = 7.6 Hz, 2H), 1.90 (p, J = 7.6 Hz, 2H), 1.54 (p, J = 6.8 
Hz, 2H), 1.32-1.26 (m, 26H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3/CD3OD 
4:1) δ 174.1, 144.8, 130.8, 130.0 (2C), 112.6 (2C), 72.2 (d, J = 8.2 Hz), 72.1, 69.6, 66.8, 
64.4 (d, J = 5.2 Hz), 59.2 (d, J = 5.2 Hz), 54.5, 54.4, 54.4, 53.9 (2C), 40.9 (2C), 34.2, 34.0, 
32.3, 30.1 (8C), 29.9, 29.9, 29.7, 27.2, 26.4, 23.0, 14.3. IR (neat) 2923, 2852, 2366, 1734, 
1091 cm-1 HRMS (ESI+) C38H69Cl2N2O7P, m/z [M+H+] 767.4298, found 767.4312. 
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1-O-Octadecyl-2-(4-(4-(bis-(2-chloroethyl)-amino)-phenyl)-butanoyl)-sn-glycero-3-
phosphocholine (1b) 
Compound 6b (67 mg, 0.13 mmol) was dissolved in CHCl3 (4 mL) and the mixture was 
heated to reflux. DMAP (10 mg, 0.082 mmol), chlorambucil (40 mg, 0.13 mmol) and DCC 
(1 M in CH2Cl2, 130 μL, 0.13 mmol) were added and after 3, 6.5, 23.5, 26.5 and 31 h 
additional portions of chlorambucil (40 mg, 0.13 mmol) and DCC (1 M in CH2Cl2, 130 μL, 
0.13 mmol) were added. After 48 h the mixture was concentrated in vacuo and purified by 
column chromatography (CH2Cl2/MeOH 4:1 then CH2Cl2/MeOH/H2O 30:20:1) to give 79 
mg (76%) of 1b as a colorless amorphous solid. Rf = 0.15 (CH2Cl2/MeOH/H2O 30:20:1). 
1H NMR (500 MHz, CDCl3/CD3OD 4:1) δ 7.07 (d, J = 8.5 Hz, 2H), 6.65 (d, J = 8.5 Hz, 
2H), 5.16 (p, J = 5.8 Hz, 1H), 4.22 (s, 2H), 4.06–3.94 (m, 2H), 3.72 (t, J = 6.8 Hz, 4H), 
3.64 (t, J = 6.8 Hz, 4H), 3.63–3.59 (m, 2H), 3.56 (s, 2H), 3.48–3.40 (m, 2H), 3.20 (s, 9H), 
2.56 (t, J = 7.5 Hz, 2H), 2.36 (t, J = 7.5 Hz, 2H), 1.90 (p, J = 7.5 Hz, 2H), 1.54 (m, 2H), 
1.32–1.26 (m, 30H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3/CD3OD 4:1) δ 
174.1, 144.9, 130.8, 130.1 (2C), 112.6 (2C), 72.3 (d, J = 8.6 Hz), 72.1, 69.6, 66.9, 64.5 (d, 
J = 5.2 Hz), 59.4 (d, J = 5.2 Hz), 54.5, 54.4, 54.4, 53.9 (2C), 40.9 (2C), 34.3, 34.0, 32.3, 
30.1 (10C), 29.9, 29.9, 29.8, 27.3, 26.4, 23.1, 14.3. IR (neat) 2923, 2852, 2366, 1734, 
1518, 1247, 1088, 750 cm-1. HRMS (ESI+) C40H73Cl2N2O7P, m/z [M+Na+] 817.4425, 
found 817.4430. 
 
1-O-Hexadecyl-3-(p-toluenesulfonyl)-sn-glycerol (4a)68 
(R)-Glycidyl tosylate (2.0 g, 8.76 mmol) and hexadecanol (3.0 g, 12.37 mmol) were 
dissolved in CH2Cl2 (40 mL) and BF3·OEt2 (0.5 mL) was added. The solution was stirred 
for 24 h at 20 °C and concentrated in vacuo. A white solid was formed and recrystallized 
from hexane (35 mL) to give 2.75 g of 4a. The filtrate, which contain some product, was 
concentrated in vacuo and purified by column chromatography (CH2Cl2/Et2O 10:1) to give 
0.98 g of 4a (89% overall). Rf = 0.58 (CH2Cl2/Et2O 10:1); mp = 53–55 °C (lit.223 53–54 
°C). 1H NMR (300 MHz, CDCl3): δ 7.81 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 
4.12–3.93 (m, 3H), 3.48–3.27 (m, 4H), 2.46 (s, 3H), 2.18 (s, 1H), 1.51 (t, J = 6.4 Hz, 2H), 
1.32–1.26 (m, 26H), 0.88 (t, J = 6.7 Hz, 3H).  
 
1-O-Octadecyl-3-(p-toluenesulfonyl)-sn-glycerol (4b)68 
Performed as for 4a using (R)-Glycidyl tosylate (5.25 g, 23.0 mmol) and octadecanol (8.7 
g, 32.2 mmol) to afford 11.2 g (97 %) of 4b as white crystals. Rf = 0.65 (CH2Cl2/Et2O 
10:1); mp = 66–68 °C (lit.224 67–68 °C). 1H NMR (300 MHz, CDCl3): δ 7.80 (d, J = 8.1 
Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 4.05-3.95 (m, 3H), 3.45-3.35 (m, 4H), 2.43 (s, 3H), 2.10 
(s, 1H), 1.51 (m, 2H), 1.35-1.23 (m, 30H), 0.90 (t, J = 6.7 Hz, 3H).  
 
1-O-Hexadecyl-2-O-(4-methoxybenzyl)-sn-glycerol (5a) 
Alcohol 4a (1.19 g, 2.53 mmol) and PMBTCA (1.10 g, 3.89 mmol) were dissolved in 
toluene (21 mL) and La(OTf)3 (70 mg, 0.12 mmol) was added. The reaction mixture was 
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stirred at 20 °C for 2.5 h, then concentrated in vacuo to give a white solid that was 
dissolved in DMSO (20 mL) and DMF (5 mL). CsOAc (1.49 g, 7.38 mmol) was added and 
the mixture was heated to 60 °C and stirred for 14 h, after which the reaction mixture was 
washed with H2O (30 mL) and the organic layer was isolated via extraction with Et2O 
(3x50 mL). The combined organic phases were dried over MgSO4 and filtration followed 
by concentration in vacuo gave a solid that was dissolved in MeOH (40 mL). NaOMe (140 
mg, 2.59 mmol) was added and the mixture was heated to 40 °C and stirred for 16 h. The 
mixture was neutralized by addition of concentrated aqueous solution of HCl, washed with 
H2O (20 mL) and the organic layer was isolated via extraction with CH2Cl2 (3x20 mL). 
The combined organic phases were dried over MgSO4 and after concentration in vacuo the 
residue was purified by column chromatography (heptane/EtOAc 1:1) yielding 772 mg 
(70%) of 5a as a greasy solid. Rf = 0.46 (heptane/EtOAc 1:1). 1H NMR (300 MHz, 
CDCl3): δ 7.29 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 4.66 (d, J = 11.4 Hz, 1H), 
4.56 (d, J = 11.4 Hz, 1H), 3.81 (s, 3H), 3.78–3.50 (m, 5H), 3.44 (t, J = 6.7 Hz, 2H), 1.61–
1.53 (m, 2H), 1.26 (br.s. 26H), 0.88 (t, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 
159.4, 130.5, 129.6 (2C), 114.0 (2C), 77.5, 72.0, 71.9, 71.3, 63.2, 55.4, 32.1, 29.8 (9C), 
29.6, 29.5, 26.3, 22.9, 14.3. Anal. Calcd. C27H48O4: C 74.26, H 11.08; Found: C 74.26, H 
11.03. IR (neat) 3374, 2923, 1695 1613, 1513, 1466, 1248, 1110, 824 cm-1. 
 
1-O-Hexadecyl-2-O-(4-methoxybenzyl)-sn-glycerol (5a) using NaNO2 
Alcohol 4a (842 mg, 1.79 mmol) and PMBTCA (859 mg, 3.04 mmol) were dissolved in 
toluene (15 mL) and La(OTf)3 (52 mg, 0.09 mmol) was added. The reaction mixture was 
stirred at 20 °C for 2.5 h and concentration in vacuo gave a white solid, that along with 
NaNO2 (3.69 g, 53.6 mmol) were dissolved in degassed DMSO (35 mL). The mixture was 
stirred at 40 °C for 17 h, then a saturated aqueous solution of NaHCO3 (10 mL) was added 
and the mixture was stirred for 20 min further after which the organic layer was isolated 
via extraction with Et2O (3×100 mL). The combined organic phases were dried over 
MgSO4, filtered, concentrated in vacuo and purified by column chromatography 
(heptane/EtOAc 1:1) to give 731 mg (94%) of 5a as a greasy solid.  
 
1-O-Octadecyl-2-O-(4-methoxybenzyl)-sn-glycerol (5b) 
Performed as for 5a, starting from alcohol 4b (2.211 g, 4.433 mmol) and affording 1.60 g 
(78%) of 5b as a greasy solid. 1H NMR (300 MHz, CDCl3): δ 7.29 (d, J = 8.6Hz, 2H), 6.89 
(d, J = 8.6Hz, 2H), 4.66 (d, J = 11.4Hz, 1H), 4.56 (d, J = 11.4 Hz, 1H), 3.81 (s, 3H), 3.78–
3.50 (m, 5H), 3.44 (t, J = 6.7 Hz, 2H), 1.62–1.53 (m, 2H), 1.26 (br.s. 30H), 0.88 (t, J = 6.7 
Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 159.4, 130.5, 129.6 (2C), 114.0 (2C), 77.5, 72.0, 
71.9, 71.3, 63.2, 55.4, 32.1, 29.8 (11C), 29.6, 29.5, 26.3, 22.8, 14.3. Anal. Calcd. 
C29H52O4: C 74.95, H 11.28; Found: C 75.08, H 11.24. IR (neat) 3524, 2916, 1709 1612, 
1511, 1472, 1253, 1108, 1032, 824 cm-1.  
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1-O-Octadecyl-2-O-(4-methoxybenzyl)-sn-glycerol using NaNO2 (5b) 
Performed as for 5a, starting from alcohol 4a (440 mg, 0.882 mmol) and affording 291 mg 
(71%) of 5b as a greasy solid.  
 
1-O-Hexadecyl-2-lyso-sn-glycero-3-phosphocholine (6a) 
To a solution of POCl3 (28 μL, 0.30 mmol) in CH2Cl2 (1.2 mL) at 0 °C was added a 
solution of 5a (104 mg, 0.24 mmol) along with Et3N (44 μL, 0.31 mmol) in CH2Cl2 (1.7 
mL) dropwise over 20 min. The reaction was stirred 30 min at 20 °C, after which pyridine 
(0.15 mL, 1.9 mmol) and choline tosylate (132 mg, 0.48 mmol) were added. The reaction 
was stirred for 19 h at 20 °C, then H2O (0.15 mL) was added and stirring was continued for 
40 min. Continuous concentration with EtOH/toluene 1:1 (6 mL) gave the crude product as 
a white foam. The residue was dissolved in THF/H2O 9:1 and slowly passed through an 
MB-3 column. The solvent was removed by continuous concentration with EtOH/toluene 
1:1 (6 mL). The crude product was purified by column chromatography (CH2Cl2/MeOH 
then CH2Cl2/MeOH/H2O 65:25:4) giving 100 mg that was dissolved in CH2Cl2/H2O 18:1 
(10 mL) along with DDQ (76 mg, 0.34 mmol). The mixture was stirred for 2 h after which 
it was concentrated in vacuo and the residue was purified by column chromatography 
(MeOH until the eluent was colorless, then CH2Cl2/MeOH/H2O 65:25:4) to give 80 mg 
(69%) of 6a as a colorless amorphous solid. Rf = 0.10 (CH2Cl2/MeOH/H2O 65:25:4). 1H 
NMR (500 MHz, CDCl3/CD3OD 4:1): δ 4.26 (s, 2H), 3.99–3.82 (m, 3H), 3.61–3.60 (m, 
2H), 3.48–3.44 (m, 4H), 3.21 (s, 9H), 1.59–1.54 (m, 2H), 1.32–1.26 (m, 26H), 0.88 (t, J = 
6.9 Hz, 3H).68  
 
1-O-Octadecyl-2-lyso-sn-glycero-3-phosphocholine (6b) 
Performed as for 6a starting from 5b (127 mg, 0.27 mmol) affording 70 mg (36%) of 6b as 
a colorless amorphous solid. Rf = 0.10 (CH2Cl2/MeOH/H2O 30:10:2). 1H NMR (300 MHz, 
CDCl3/CD3OD 4:1): δ 4.26 (s, 2H), 3.99–3.82 (m, 3H), 3.61–3.60 (m, 2H), 3.48–3.44 (m, 
4H), 3.21 (s, 9H), 1.59–1.54 (m, 2H), 1.32–1.26 (m, 30H), 0.88 (t, J = 6.9 Hz, 3H).68  
 
1-O-Hexadecyl-2-all-trans-retinoyl-sn-glycero-3-phosphocholine (7) 
To a solution of POCl3 (32 μL, 0.35 mmol) in CH2Cl2 (1.5 mL) at 0 °C was added a 
solution of alcohol 11 (166 mg, 0.28 mmol) along with Et3N (50 μL, 0.36 mmol) in 
CH2Cl2 (4 mL) dropwise over 15 min. The reaction mixture was stirred at 20 °C for 30 
min, after which pyridine (180 μL, 2.23 mmol) and choline tosylate (153 mg, 0.55 mmol) 
were added. The reaction mixture was stirred at 20 °C for 16.5 h, then H2O (0.2 mL) was 
added and stirring was continued for 40 min. Continuous concentration with EtOH/toluene 
1:1 (20 mL) gave a yellow residue which was redissolved in THF/H2O 9:1 and slowly 
passed through a MB-3 column. The solvent was removed by continuous concentration 
with EtOH/toluene 1:1 (20 mL). The crude product was purified by column 
chromatography (CH2Cl2/MeOH 4:1 then CH2Cl2/MeOH/H2O 15:10:1) giving 84 mg 
(40%) of 7 as a yellow oil. Rf = 0.30 (CH2Cl2/MeOH/H2O 15:10:1). 1H NMR (500 MHz, 
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CDCl3/CD3OD 4:1): δ 7.03 (dd, J = 15.0, 11.5 Hz, 1H), 6.30 (d, J = 16.0 Hz, 1H), 6.29 (d, 
J = 15.0 Hz, 1H), 6.15 (d, J = 16.0 Hz, 1H), 6.15 (d, J = 11.5 Hz, 1H), 5.79 (s, 1H), 5.20–
5.16 (m, 1H), 4.23 (br.s, 2H), 4.09–4.02 (m, 2H), 3.67–3.62 (m, 2H), 3.58 (br.s, 2H), 3.49–
3.42 (m, 2H), 3.20 (s, 9H), 2.34 (s, 3H), 2.05–2.00 (m, 5H), 1.72 (s, 3H), 1.66–1.60 (m, 
2H), 1.57–1.51 (m, 2H), 1.49–1.47 (m, 2H) 1.26 (s, 26H), 1.03 (s, 6H), 0.88 (t, J = 6.9 Hz, 
3H). 13C NMR (75 MHz, CDCl3/CD3OD 4:1): δ  167.2, 154.2, 140.5, 138.0, 137.6, 135.1, 
132.0, 130.4, 129.7, 129.3, 118.3, 72.1, 71.6 (d, J = 8.6 Hz), 69.6, 66.9, 64.6 (d, J = 5.3 
Hz), 59.2 (d, J = 5.0 Hz), 54.5, 54.5, 54.4, 39.9, 34.6, 33.4, 32.3, 30.0 (9C), 29.8, 29.7, 
29.2 (2C), 26.3, 23.0, 21.9, 19.5, 14.3, 14.1, 13.1. 20589][  = –7.7 (c = 0.64, CHCl3). IR 
(neat) 2923, 2853, 2490, 1706, 1458, 1238, 1152, 1085, 967 cm-1. HRMS (ESI+) 
C44H78NO7P, m/z [M+Na+] 786.5408, found 786.5422.  
 
3-O-Hexadecyl-sn-glycerol (9) 
(S)-Glycidyl tosylate (2.0 g, 8.76 mmol) and hexadecanol (2.97 g, 12.3 mmol) were 
dissolved in CH2Cl2 (40 mL) and BF3·OEt2 (0.5 mL) was added. The reaction mixture was 
stirred at 20 °C for 19 h and then concentrated in vacuo yielding a white solid that was 
dissolved in DMSO (73 mL) and DMF (18 mL). CsOAc (5.89 g, 30.7 mmol) was added 
and the reaction mixture was heated to 60 °C and stirred for 14 h, after which the mixture 
was washed with H2O (50 mL) and the organic layer was isolated via extraction with Et2O 
(3x200 mL). The combined organic phases were dried over Na2SO4 and filtration followed 
by concentration in vacuo gave a white solid that was dissolved in MeOH (90 mL) along 
with NaOMe (482 mg, 8.76 mmol). The reaction mixture was heated to 40 °C and stirred 
for 12 h, then the mixture was neutralized by addition of concentrated aqueous solution of 
HCl and concentrated in vacuo. The residue was purified by column chromatography 
(heptane/EtOAc 1:1) yielding 1.80 g (65%) of 9 as white crystals. Rf = 0.18 
(heptane/EtOAc 1:1). mp = 61–63°C (hexane) (lit.225 63–64 °C). 1H NMR (300 MHz, 
CDCl3):226 δ 3.91–3.90 (m, 1H), 3.80–3.63 (m, 2H), 3.53 (t, J = 4.8 Hz, 2H), 3.50–3.45 (m, 
2H), 2.61 (d, J = 5.2 Hz, 1H, OH), 2.17 (dd, J = 7.0, 5.2 Hz, 1H, OH), 1.60–1.56 (m, 2H), 
1.26 (s, 26H), 0.89 (t, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 72.7, 72.0, 70.5, 
64.5, 32.1, 29.8 (9C), 29.6, 29.5, 26.2, 22.9, 14.3.  
 
1-O-tert-Butyldimethylsilyl-3-O-hexadecyl-sn-glycerol (10) 
Alcohol 9 (187 mg, 0.59 mmol), Et3N (190 μL, 1.36 mmol) and DMAP (58 mg, 0.47 
mmol) were dissolved in CH2Cl2 (5 mL) and DMF (0.5 mL). tert-Butyldimethylsilyl 
chloride (107 mg, 0.71 mmol) was added and the mixture was stirred at 20 °C for 2 days 
after which concentration in vacuo followed by purification with column chromatography 
afforded 228 mg (89%) of 10 as clear oil. Rf = 0.48 (heptanes/EtOAc 4:1). 1H NMR (300 
MHz, CDCl3):227 δ 3.84–3.80 (m, 1H), 3.67–3.63 (m, 2H), 3.48–3.40 (m, 4H), 2.49 (d, J = 
4.5 Hz, OH), 1.62–1.53 (m, 2H), 1.26 (s, 26H), 0.91–0.90 (m, 12H), 0.08 (s, 6H). 13C 
NMR (75 MHz, CDCl3): δ 71.8, 71.5, 70.8, 64.2, 32.1, 29.9 (9C), 29.6, 29.5, 26.3, 26.0 
(3C), 22.9, 18.5, 14.3, –5.3 (2C). 20589][ = +1.5 (c = 1.05, CHCl3).   
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1-O-Hexadecyl-2-all-trans-retinoyl-sn-glycerol (11) 
Alcohol 10 (300 mg, 0.70 mmol), ATRA (314 mg, 1.05 mmol) and PPh3 (365 mg, 1.39 
mmol) were dissolved in THF (18 mL) and cooled to 0 °C. DIAD (280 μL, 1.42 mmol) 
was added dropwise and the reaction mixture was allowed to reach 20 °C and stirred for 3 
h, then concentrated in vacuo and purified by column chromatography (heptane/EtOAc 
9:1) to give 207 mg of a yellow oil, that was dissolved in MeCN (15 mL) and cooled to 0 
°C. Aqueous HF (40%, 0.6 mL) was added dropwise and the reaction mixture was allowed 
to reach 20 °C and after stirring for 8 h the reaction was quenched by addition of a 
saturated aqueous solution of NaHCO3 (40 mL). The organic layer was isolated via 
extraction with CH2Cl2 (3x50 mL) and the combined organic phases were concentrated in 
vacuo and the residue was purified by column chromatography (heptane/EtOAc 1:1) to 
afford 144 mg (35%) of 11 as a yellow oil. 1H NMR (300 MHz, CDCl3): δ 7.03 (dd, J = 
15.0, 11.3 Hz, 1H), 6.31–6.26 (m, 2H), 6.17–6.12 (m, 2H), 5.84 (s, 1H), 5.05 (p, J = 4.7 
Hz, 1H), 3.88–3.84 (m, 2H), 3.71–3.61 (m, 2H), 3.51–3.43 (m, 2H), 2.36 (s, 3H), 2.06–
2.00 (m, 5H), 1.72 (s, 3H), 1.64–1.45 (m, 4H), 1.26 (s, 26H), 1.03 (s, 6H), 0.88 (t, J = 6.7 
Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 166.9, 154.1, 140.1, 137.8, 137.3, 135.0, 131.6, 
130.2, 129.6, 129.0, 118.1, 72.4, 72.1, 70.3, 63.4, 39.7, 34.4, 33.3, 32.1, 29.9 (9C), 29.6, 
29.5, 29.1 (2C), 26.2, 22.8, 21.9, 19.3, 14.3, 14.1, 13.1. 20589][  = +17.1 (c = 1.55, CHCl3). 
IR (neat) 3447, 2924, 2855, 1708, 1584, 1458, 1358, 1240, 1152 cm-1. HRMS (ESI+) 
C39H66O4, m/z [M+Na+] 621.4859, found 621.4848. 
 
4’-octyl-4-phenylbenzoic acid (12) 
4’-octyl-4-biphenylcarbonitrile (1.38 g, 4.74 mmol) was dissolved in a mixture of DMSO 
(200 mL) and H2O (100 mL). NaOH (44.1 g, 1.10 mol) was added and the reaction mixture 
was heated to 180 °C for 16 h after which the solution was cooled to 20 °C and neutralized 
by addition of aqueous HCl (37%). The organic layer was isolated by extraction with 
EtOAc (4x200 mL) and the combined organic layers were concentrated in vacuo and 
purified by column chromatography (heptane/EtOAc 1:1) to give 1.39 g (95 %) of 12 as a 
white solid. Rf = 0.11 (heptane/EtOAc 1:1). mp = 148–152 °C (CH2Cl2). 1H NMR (300 
MHz, CDCl3): δ 8.17 (d, J = 8.2 Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.1Hz, 2H), 
7.30 (d, J = 8.1 Hz, 2H), 2.67 (t, J = 7.7 Hz, 2H), 1.71–1.61 (m, 2H), 1.40–1.27 (m, 10H), 
0.89 (t, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 172.0, 146.6, 143.5, 137.2, 130.9 
(2C), 129.2 (2C), 127.7, 127.3 (2C), 127.1 (2C), 35.8, 32.0, 31.6, 29.6, 29.5, 29.4, 22.8, 
14.3.  
 
1-O-Octadecyl-2-(6-(all-trans-retinoyloxy)-hexanoyl)-sn-glycero-3-phospho-(S)-
glycerol (13) 
Alcohol 30 (13 mg, 0.014 mmol), ATRA (6 mg, 0.019 mmol) and PPh3 (9 mg, 0.043 
mmol) were dissolved in THF (1.0 mL). DIAD (11 µL, 0.043 mmol) was added and the 
reaction mixture was stirred at 20 °C for 1 h, then concentrated in vacuo and purified by 
column chromatography (heptane/EtOAc 2:1 then heptane/EtOAc 1:2) to give 13 mg that 
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was dissolved in CH2Cl2 (1.0 mL) and DBU (2 µL, 0.012 mmol) was added. The reaction 
mixture was stirred for 30 min at 20 °C and then purified directly by column 
chromatography (heptane/EtOAc 1:1 then CH2Cl2/MeOH 9:1) to afford 8 mg that was 
dissolved in MeCN (0.9 mL) and CH2Cl2 (0.3 mL) and cooled to 0 °C. Aqueous HF (40%, 
30 µL) was added dropwise and the reaction mixture was allowed to reach 20 °C. After 3.5 
h the reaction was quenched by dropwise addition of MeOSiMe3 (0.3 mL) and the mixture 
was stirred for 30 min, after which NaHCO3 (6 mg, 0.07 mmol) was added and the mixture 
was concentrated in vacuo and purified by column chromatography (CH2Cl2/MeOH 10:1 
then CH2Cl2/MeOH 4:1) to afford 4 mg (31%) of 13 as a yellow amorphous solid. Rf = 
0.44 (CH2Cl2/MeOH 4:1). 1H NMR (500 MHz, CDCl3/CD3OD 4:1): δ 7.02 (dd, J = 15.0, 
11.4 Hz, 1H), 6.32–6.27 (m, 2H), 6.15 (d, J = 11.4 Hz, 1H), 6.14 (d, J = 16.2 Hz, 1H), 5.77 
(s, 1H), 5.18–5.13 (m, 1H), 4.11 (t, J = 6.6 Hz, 2H), 4.03–3.94 (m, 2H), 3.94–3.90 (m, 
2H), 3.82–3.77 (m, 1H), 3.62 (t, J = 5.2 Hz, 2H), 3.60–3.57 (m, 2H), 3.49–3.39 (m, 2H), 
2.39–2.33 (m, 5H), 2.05–2.00 (m, 5H), 1.72 (s, 3H), 1.71–1.60 (m, 6H), 1.57–1.51 (m, 
2H), 1.50–1.45 (m, 2H), 1.45–1.40 (m, 2H), 1.31–1.23 (m, 30H), 1.03 (s, 6H), 0.88 (t, J = 
6.9 Hz, 3H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 174.0, 168.0, 153.7, 140.0, 138.0, 
137.7, 135.3, 131.7, 130.3, 129.8, 129.2, 118.5, 72.2 (2C), 71.2, 69.4, 66.7, 64.5, 64.1, 
62.7, 40.0, 34.5 (2C), 33.4, 32.3, 30.1, 29.7 (12C), 29.2 (2C), 28.7, 26.4, 25.9, 24.9, 23.0, 
22.0, 19.6, 14.3, 14.1, 13.3. IR (neat) 3325, 2923, 2853, 1733, 1709, 1609, 1584, 1457, 
1259, 1064, 798 cm-1. HRMS (ESI+) C50H86O11PNa, m/z [M+H+] 917.5879, found 
917.5834. 
 
1-Stearoyl-2-(6-(all-trans-retinoyloxy)-hexanoyl)-sn-glycero-3-phospho-(S)-glycerol 
(14) 
Alcohol 35 (47 mg, 0.052 mmol), ATRA (31 mg, 0.10 mmol), DMAP (13 mg, 0.10 mmol) 
and Et3N (72 µL, 0.52 mmol) were dissolved in Et2O (1.2 mL). DCC (27 mg, 0.13 mmol) 
was added and the reaction mixture was stirred at 20 °C for 22 h, then concentrated in 
vacuo and purified by column chromatography (toluene then toluene/EtOAc 5:1) to give 
32 mg that was dissolved in CH2Cl2 (2.2 mL) and DBU (4.2 µL, 0.028 mmol) was added. 
The reaction mixture was stirred for 30 min at 20 °C and then purified directly by column 
chromatography (heptane/EtOAc 1:1 then CH2Cl2/MeOH 9:1) to afford 21 mg that was 
dissolved in MeCN (1.5 mL) and CH2Cl2 (0.5 mL) and cooled to 0 °C. Aqueous HF (40%, 
90 µL) was added dropwise and the reaction mixture was allowed to reach 20 °C. After 3.5 
h the reaction was quenched by dropwise addition of MeOSiMe3 (0.3 mL) and the mixture 
was stirred for 30 min, after which NaHCO3 (6 mg, 0.07 mmol) was added and the mixture 
was concentrated in vacuo and purified by column chromatography (CH2Cl2/MeOH 10:1 
then CH2Cl2/MeOH 4:1 then CH2Cl2/MeOH/H2O 65:25:1) to afford 15 mg (31%) of 14 as 
a yellow amorphous solid. Rf = 0.56 (CH2Cl2/MeOH 5:1). 1H NMR (500 MHz, 
CDCl3/CD3OD 4:1): δ 7.02 (dd, J = 15.0, 11.4 Hz, 1H), 6.32–6.27 (m, 2H), 6.15 (d, J = 
11.4 Hz, 1H), 6.15 (d, J = 16.2 Hz, 1H), 5.77 (s, 1H), 5.25–5.20 (m, 1H), 4.39 (dd, J = 
12.0, 3.3 Hz, 1H), 4.16 (dd, J = 12.0, 6.6 Hz, 1H), 4.11 (t, J = 6.6 Hz, 2H), 3.99–3.91 (m, 
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4H), 3.83–3.78 (m, 1H), 3.63 (t, J = 5.1 Hz, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.34 (s, 3H), 
2.31 (t, J = 7.6 Hz, 2H), 2.05–2.00 (m, 5H), 1.71 (s, 3H), 1.71–1.65 (m, 4H), 1.65–1.57 (m, 
4H), 1.50–1.45 (m, 2H), 1.45–1.41 (m, 2H), 1.34–1.21 (m, 28H), 1.03 (s, 6H), 0.88 (t, J = 
7.0 Hz, 3H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 174.2, 173.5, 168.0, 153.6, 140.1, 
138.0, 137.6, 135.3, 131.6, 130.3, 129.7, 129.1, 118.5, 71.2, 70.7, 66.8, 64.0 (2C), 62.6 
(2C), 39.9, 34.3 (3C), 33.4, 32.2, 29.9 (12C), 29.2 (2C), 28.7, 25.8, 25.1, 24.8, 23.0, 21.9, 
19.5, 14.3, 14.1, 13.1. 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ –0.08. IR (neat): 3390, 
2924, 2853, 1734, 1709, 1661, 1458, 1260, 1237, 1153, 1050, 805 cm-1. HRMS (ESI+) 
C50H84O12PNa, m/z [M+H+] 931.5676, found 931.5712. 
 
1-O-Octadecyl-2-(6-(4'-octyl-4-phenylbenzoyloxy)-hexanoyl)-sn-glycero-3-phospho-
(S)-glycerol (15) 
Alcohol 30 (62 mg, 0.068 mmol), carboxylic acid 12 (43 mg, 0.14 mmol) and DMAP (25 
mg, 0.20 mmol) were dissolved in CH2Cl2 (4.5 mL). DCC (42 mg, 0.20 mmol) was added 
and the reaction mixture was stirred at 20 °C for 18 h. The mixture was concentrated in 
vacuo and purified by column chromatography (toluene then toluene/EtOAc 5:1) to give 
65 mg that was dissolved in CH2Cl2 (5.0 mL) and DBU (9 µL, 0.06 mmol) was added. The 
reaction mixture was stirred for 35 min at 20 °C and then purified directly by column 
chromatography (heptane/EtOAc 1:1 then CH2Cl2/MeOH 10:1) to afford 58 mg that was 
dissolved in mixture of MeCN (4.2 mL) and CH2Cl2 (1.4 mL) and cooled to 0 °C. Aqueous 
HF (40%, 250 µL) was added dropwise and the reaction mixture was allowed to reach 20 
°C. After 3.5 h, the reaction was quenched by dropwise addition of MeOSiMe3 (0.93 mL) 
and the mixture was stirred for 30 min, after which NaHCO3 (8 mg, 0.095 mmol) was 
added and the mixture was concentrated in vacuo and purified by column chromatography 
(CH2Cl2/MeOH 10:1 then CH2Cl2/MeOH 4:1) to afford 24 mg (38%) of 15 as a colorless 
amorphous solid. Rf = 0.23 (CH2Cl2/MeOH 4:1). 1H NMR (500 MHz, CDCl3/CD3OD 
4:1): δ 8.08 (d, J = 8.3 Hz, 2H), 7.67 (d, J = 8.3 Hz, 2H), 7.55 (d, J = 8.1 Hz, 2H), 7.29 (d, 
J = 8.1 Hz, 2H), 5.19–5.14 (m, 1H), 4.34 (t, J = 6.6 Hz, 2H), 4.06–3.93 (m, 4H), 3.85–3.80 
(m, 1H), 3.66–3.61 (m, 2H), 3.60–3.56 (m, 2H), 3.48–3.38 (m, 2H), 2.66 (t, J = 7.7 Hz, 
2H), 2.40 (t, J = 7.5 Hz, 2H), 1.86–1.79 (m, 2H), 1.76–1.70 (m, 2H), 1.69–1.62 (m, 2H), 
1.56–1.49 (m, 4H), 1.39–1.19 (m, 40H), 0.89 (t, J = 6.8 Hz, 3H), 0.88 (t, J = 6.9 Hz, 3H). 
13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 173.9, 167.3, 146.1, 143.6, 137.5, 130.3 (2C), 
129.3 (2C), 128.9, 127.4 (2C), 127.1 (2C), 72.1 (2C), 71.3, 69.3, 66.7, 65.2, 64.6, 62.6, 
35.9, 34.5, 32.1 (2C), 31.8, 30.0, 29.7 (15C), 28.8, 26.3, 25.8, 24.9, 23.0 (2C), 14.3 (2C). 
31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ –1.02. IR (neat): 3320, 2920, 2851, 1717, 
1276, 1102, 1069 cm-1. HRMS (ESI+) C51H84O11PNa, m/z [M+H+] 927.5727, found 
927.5766. 
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1-Stearoyl-2-(6-(4'-octyl-4-phenylbenzoyloxy)-hexanoyl)-sn-glycero-3-phospho-(S)-
glycerol (16) 
The synthesis was performed as for 15, starting from alcohol 35 (70 mg, 0.077 mmol) and 
affording 51 mg (70%) of 16 as a colorless amorphous solid. Rf = 0.54 (CH2Cl2/MeOH 
5:1). 1H NMR (500 MHz, CDCl3/CD3OD 4:1): δ 8.08 (d, J = 8.3 Hz, 2H), 7.67 (d, J = 8.3 
Hz, 2H), 7.56 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.27–5.22 (m, 1H), 4.39 (dd, J 
= 12.0, 3.2 Hz, 1H), 4.34 (d, J = 6.6 Hz, 2H), 4.17 (dd, J = 12.0, 6.6 Hz, 1H), 4.05–4.00 
(m, 2H), 3.98–3.91 (m, 2H), 3.85–3.80 (m, 1H), 3.65–3.61 (m, 2H), 2.66 (t, J = 7.7 Hz, 
2H), 2.40 (t, J = 7.5 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.86–1.78 (m, 2H), 1.76–1.69 (m, 
2H), 1.68–1.62 (m, 2H), 1.62-1.56 (m, 2H), 1.55–1.49 (m, 2H), 1.39–1.20 (m, 38H), 0.89 
(t, J = 6.7 Hz, 3H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 
174.4, 173.6, 167.4, 146.3, 143.7, 137.6, 130.4 (2C), 129.4 (2C), 129.0, 127.5 (2C), 127.2 
(2C), 71.2, 70.8, 67.1, 65.2, 64.4, 62.7 (2C), 36.0, 34.4 (2C), 32.3 (2C), 31.8, 29.9 (15C), 
28.8, 25.9, 25.2, 24.9, 23.0 (2C), 14.3 (2C). 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ –
1.30. IR (neat): 3314, 2921, 2851, 1737, 1467, 1277, 1103 cm-1. HRMS (ESI+) 
C51H82O12PNa, m/z [M+H+] 941.5520, found 941.5549. 
 
1-O-Octadecyl-2-lyso-sn-glycero-3-phospho-(S)-glycerol (17) 
Alcohol 29 (92 mg, 0.12 mmol) was dissolved in CH2Cl2 (10.0 mL) and DBU (20 µL, 0.14 
mmol) was added. The reaction mixture was stirred for 2 h at 20 °C and then purified 
directly by column chromatography (heptane/EtOAc 1:1 then CH2Cl2/MeOH 9:1) to afford 
63 mg, that was dissolved in MeCN (7.0 mL) and CH2Cl2 (2.3 mL) and cooled to 0 °C. 
Aqueous HF (40%, 0.24 mL) was added dropwise and the reaction mixture was allowed to 
reach 20 °C. After 3.5 h the reaction was quenched by dropwise addition of MeOSiMe3 
(1.6 mL) and the mixture was stirred for 30 min, after which NaHCO3 (13 mg, 0.15 mmol) 
was added and the mixture was concentrated in vacuo and purified by column 
chromatography (CH2Cl2/MeOH 20:1 then CH2Cl2/MeOH/H2O 65:25:4) to give 31 mg 
(69%) of 17 as an amorphous solid. Rf = 0.47 (CH2Cl2/MeOH/H2O 65:25:4). 1H NMR 
(300 MHz, CDCl3/CD3OD 4:1):68 δ 4.01–3.87 (m, 5H), 3.85–3.78 (m, 1H), 3.65–3.42 (m, 
6H), 1.62–1.52 (m, 2H), 1.36–1.24 (m, 30H), 0.88 (t, J = 6.6 Hz, 3H).  
 
1-O-Octadecyl-2-stearoyl-sn-glycero-3-phospho-(S)-glycerol (1-O-DSPG) 
Alcohol 29 (70 mg, 0.090 mmol), stearic acid (51 mg, 0.18 mmol) and DMAP (11 mg, 
0.090 mmol) were dissolved in CH2Cl2 (2.0 mL). DCC (56 mg, 0.27 mmol) was added and 
the reaction mixture was stirred at 20 °C. After 19 h the mixture was concentrated in vacuo 
and purified by column chromatography (heptane then heptane/EtOAc 3:1) to give 90 mg, 
that was dissolved in CH2Cl2 (5.5 mL) along with DBU (14 µL, 0.095 mmol). The reaction 
mixture was stirred for 1 h at 20 °C and then purified directly by column chromatography 
(heptane/EtOAc 1:1 then CH2Cl2/MeOH 9:1) to afford 71 mg, that was dissolved in MeCN 
(5.8 mL) and CH2Cl2 (2.0 mL) and cooled to 0 °C. Aqueous HF (40%, 0.35 mL) was 
added dropwise and the reaction mixture was allowed to reach 20 °C. After 4 h the excess 
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reagent was quenched by dropwise addition of MeOSiMe3 (1.2 mL) and the mixture was 
stirred for 30 min, after which NaHCO3 (12 mg, 0.14 mmol) was added and the mixture 
was concentrated in vacuo and purified by column chromatography (CH2Cl2/MeOH 9:1 
then CH2Cl2/MeOH 4:1 then CH2Cl2/MeOH/H2O 65:25:4) to give 47 mg (66%) of 1-O-
DSPG as an amorphous colorless solid. Rf = 0.54 (CH2Cl2/MeOH 4:1). 1H NMR (300 
MHz, CDCl3/CD3OD 4:1): δ 5.20–5.12 (m, 1H) 4.00–3.87 (m, 4H), 3.83–3.76 (m, 1H), 
3.66–3.56 (m, 4H), 3.49–3.39 (m, 2H), 2.33 (t, J = 7.7 Hz, 2H), 1.66–1.48 (m, 4H), 1.40–
1.18 (m, 58H), 0.91–0.85 (m, 6H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 174.4, 72.1, 
71.3, 69.5, 66.9, 64.4, 62.8, 34.7, 32.3 (2C), 29.7 (26C), 26.4, 25.3, 23.0 (2C), 14.3 (2C). 
31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ 2.20. IR (neat): 3382, 2917, 2850, 1721, 1468, 
1252, 1062 cm-1. MALDI-TOF (ES+) C42H84O9PNa, m/z [M+H+] 787.58, found 787.33.  
 
6-(all-trans-Retinoyloxy)-hexanoic acid (19) 
ATRA (67 mg, 0.22 mmol), tert-butyl 6-hydroxyhexanoate (22, 126 mg, 0.67 mmol) and 
PPh3 (226 mg, 1.12 mmol) were dissolved in THF (3.4 mL) and cooled to 0 °C. DIAD 
(0.29 mL, 1.12 mmol) was added dropwise. The mixture was stirred for 1 h after which the 
mixture was concentrated in vacuo and purified by column chromatography 
(heptane/EtOAc 4:1) to give 78 mg of a yellow oil that was dissolved in CH2Cl2 (12 mL) 
and cooled to 0 °C. 2,6-Lutidine (58 μL, 0.50 mmol) and TMSOTf (60 μL, 0.33 mmol) 
were added and the mixture was stirred at 0 °C for 1 h after which an additional portion of 
2,6-lutidine (40 μL, 0.34 mmol) and TMSOTf (0.60 μL, 0.33 mmol) were added and 3 h 
later another portion of 2,6-lutidine (20 μL, 0.17 mmol) and TMSOTf (0.30 μL, 0.16 
mmol) were added. After 5.5 h the excess reagent was quenched by addition of a cold 
saturated aqueous solution of NH4Cl (10 mL) and the organic layer was isolated by 
extraction with Et2O (1x30 mL). The combined organic phases were dried over Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by column chromatography 
(heptane/EtOAc 2:1) to give 58 mg (62%) of 19 as yellow crystals. Rf = 0.27 
(heptane/EtOAc 2:1). mp = 97–100 °C (CH2Cl2). 1H NMR (300 MHz, CDCl3): δ 7.00 (dd, 
J = 15.0 Hz and 11.4 Hz, 1H), 6.31–6.26 (m, 2H), 6.15 (d, J = 11.4 Hz, 1H), 6.14 (d, J = 
16.0 Hz, 1H), 5.77 (s, 1H), 4.12 (t, J = 6.5 Hz, 2H), 2.41–2.36 (m, 5H), 2.05–2.00 (m, 5H), 
1.71–1.57 (m, 9H), 1.49–1.45 (m, 4H), 1.03 (s, 6H). 13C NMR (75 MHz, CDCl3): δ 178.1, 
167.4, 153.0, 139.8, 137.8, 137.4, 135.3, 131.2, 130.2, 129.6, 128.8, 118.6, 63.6, 39.7, 
34.4, 33.7, 33.2, 29.1 (2C), 28.6, 25.7, 24.5, 21.9, 19.4, 14.0, 13.1. IR (neat): 2926, 1706, 
1578, 1458, 1356, 1238, 1152, 966 cm-1. HRMS (ESI+) C26H38O4, m/z [M+Na+] 437.2663, 
found 437.2657. 
 
6-(4'-Octyl-4-phenylbenzoyloxy)-hexanoic acid (20) 
4’-octyl-4-phenylbenzoic acid (12, 72 mg, 0.23 mmol), tert-butyl 6-hydroxyhexanoate (22, 
131 mg, 0.69 mmol) and DMAP (113 mg, 0.93 mmol) were dissolved in CH2Cl2 (7.2 mL). 
DCC (1M in CH2Cl2, 0.94 mL, 0.94 mmol) was added dropwise. The mixture was stirred 
for 1.5 h after which the mixture was concentrated in vacuo and purified by column 
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chromatography (heptane/toluene 1:1 then heptane/EtOAc 20:1) to give 82 mg of the 
desired ester that was dissolved in CH2Cl2 (5 mL). TFA (0.39 mL, 5.12 mmol) and 
triisopropylsilane (176 μL, 0.86 mmol) were added and the mixture was stirred at 20 °C. 
Additional portions of TFA (0.20 mL, 2.61 mmol) were added after 7.5 and 23.5 h. After 
27.5 h toluene (10 mL) was added and the mixture was concentrated in vacuo and purified 
by column chromatography (heptane/EtOAc 1:1) to give 63 mg (64%) of 20 as white 
crystals. Rf = 0.24 (heptane/EtOAc 1:1). mp = 90–92 °C (CH2Cl2). 1H NMR (300 MHz, 
CDCl3): δ 8.09 (d, J = 8.4 Hz, 2H), 7.66 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.1 Hz, 2H), 7.29 
(d, J = 8.1 Hz, 2H), 4.35 (t, J = 6.5 Hz, 2H), 2.66 (t, J = 7.7 Hz, 2H), 2.42 (t, J = 7.4 Hz, 
2H), 1.88–1.50 (m, 8H), 1.41–1.27 (m, 10H), 0.89 (t, J = 6.6 Hz, 3H). 13C NMR (75 MHz, 
CDCl3): δ 179.1, 166.7, 145.7, 143.3, 137.4, 130.2 (2C), 129.1 (2C), 128.9, 127.2 (2C), 
126.9 (2C), 64.8, 35.8, 33.9, 32.0, 31.6, 29.6, 29.5, 29.4, 28.6, 25.7, 24.5, 22.8, 14.3. IR 
(neat): 2921, 1711, 1275, 1123, 766 cm-1. HRMS (ESI+) C27H36O4, m/z [M+Na+] 
447.2512, found 447.2501. 
 
tert-Butyl 6-hydroxyhexanoate (22)228 
6-Caprolactone (21, 2.00 g, 17.5 mmol) and KOtBu (2.16 g, 19.3 mmol) were dissolved in 
tBuOH (55 mL) and heated to reflux. After 24 h H2O (20 mL) was added and the organic 
layer was isolated by extraction with Et2O (2x75 mL). The combined organic phases were 
concentrated in vacuo and purification by column chromatography (heptane/EtOAc 1:1) 
gave 1.29 g (39%) of 22 as a colorless oil. Rf = 0.38 (heptane/EtOAc 1:1). 1H NMR (300 
MHz, CDCl3): δ 3.64 (t, J = 6.5 Hz, 2H), 2.23 (t, J = 7.4 Hz, 2H), 1.68–1.54 (m, 4H), 1.44 
(s, 9H), 1.41–1.38 (m, 2H). 13C NMR (75 MHz, CDCl3): δ 173.3, 80.2, 62.8, 35.6, 32.5, 
28.3 (3C), 25.3, 24.9. 
 
Allyl 4-Methoxybenzoate (24) 
Allyl alcohol (23, 5.0 mL, 73.5 mmol), Et3N (15.4 mL, 110.3 mmol) and DMAP (0.45 g, 
3.7 mmol) were dissolved in CH2Cl2 (250 mL). 4-Methoxybenzoyl chloride (11.9 mL, 88.2 
mmol) was added dropwise and the reaction mixture was stirred at 20 °C for 2 h after 
which H2O (200 mL) was added and the organic layer was isolated via extraction with 
CH2Cl2 (3x300 mL). The combined organic phases were dried over MgSO4 and then 
concentrated in vacuo yielding 14.1 g (100%) of 24 as colorless oil. Rf = 0.77 
(heptane/EtOAc 1:1). 1H NMR (300 MHz, CDCl3):173 δ 8.03 (d, J = 9.0 Hz, 2H), 6.93 (d, J 
= 9.0 Hz, 2H), 6.05 (ddt, J = 17.2, 10.5, 5.6 Hz, 1H), 5.41 (dd, J = 17.2, 1.6 Hz, 1H), 5.31–
5.26 (m, 1H), 4.81 (dt, J = 5.6, 1.4 Hz, 2H), 3.78 (s, 3H). 
 
1-(4-Methoxybenzoyl)-2,3-O-di-tert-butyldimethylsilyl-sn-glycerol (25) 
K2OsO4·2H2O (271 mg, 0.74 mmol), (DHQD)2PHAL (687 mg, 0.88 mmol), K3Fe(CN)6 
(72.6 g, 220.6 mmol) and K2CO3 (30.5 g, 220.6 mmol) were dissolved in a mixture of 
tBuOH (370 mL) and H2O (370 mL) and stirred at 20 °C for 15 min after which 24 (14.1 g, 
73.5 mmol) was added. After 2 h excess reagent was quenched by addition of Na2SO3 (111 
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g, 0.88 mol) and the organic layer was isolated by extraction with EtOAc (3x500 mL). 
Toluene (200 mL) was added to the combined organic phases and concentration in vacuo 
afforded (S)-1-O-(4-methoxybenzoyl)-glycerol as a white solid, 1H NMR was similar to 
the data reported.173  300 MHz 1H NMR of the crude product indicates that further 
purification was not necessary and the enantiomeric excess (>97%) was determined from 
chiral HPLC. HPLC (chiral) Chiralpak AS-H at at 20 °C, λ= 254 nm, hexane/2-propanol 
75:25, retention times 17.8 min (S), 23.4 min (R) at 0.4 mL/min flow rate. The crude 
product of (S)-1-O-(4-methoxybenzoyl)-glycerol and imidazole (16.0 g, 235.3 mmol) were 
dissolved in DMF (78 mL) and heated to 60 °C after which TBDMSCl (33.2 g, 220.6 
mmol) was added. After 4 h an extra portion of TBDMSCl (5.5 g, 36.5 mmol) and 
imidazole (2.5 g, 36.7 mmol) were added. After 6 h H2O (50 mL) and Et2O (150 mL) were 
added and the organic layer was isolated by extraction with Et2O (3x150 mL mL). The 
combined organic phases were washed with a saturated aqueous solution of  NaHCO3 (100 
mL). Toluene (200 mL) was added to the combined organic phases and concentration in 
vacuo gave a colorless oil which was purified by column chromatography (heptane/EtOAc 
8:1) to give 32.6 g (99%) of 25 as clear oil. Rf = 0.28 (heptane/EtOAc 10:1). 1H NMR (300 
MHz, CDCl3): δ 8.01 (d, J = 9.0 Hz, 2H), 6.93 (d, J = 8.6 Hz, 2H), 4.41 (dd, J = 11.3, 4.0 
Hz, 1H), 4.25 (dd, J = 11.2, 6.1 Hz), 4.06–4.00 (m, 1H), 3.89 (s, 3H), 3.65–3.63 (m, 2H), 
0.90 (s, 9H), 0.88 (s, 9H), 0.10–0.07 (m, 12H). 13C NMR (75 MHz, CDCl3): δ 166.4, 
163.4, 131.8 (2C), 122.9, 113.7 (2C), 71.5, 66.5, 65.0, 55.5, 26.1 (3C), 25.9 (3C), 18.5, 
18.2, –4.4, –4.6, –5.2, –5.3. Anal. Calcd. C23H42O5Si2: C 60.75, H 9.31; Found C 60.83, H 
9.38. IR (neat) 2955, 2857, 1718, 1607, 1512, 1472, 1256, 1102, 840, 774 cm-1. 
 
2,3-O-Di-tert-butyldimethylsilyl-sn-glycerol (26) 
Ester 25 (9.80 g, 21.6 mmol) was dissolved in CH2Cl2 (75 mL) and cooled to –78 °C under 
atmosphere of N2. DIBAL-H (1 M in hexane, 41.0 mL) was added dropwise and the 
reaction mixture was kept at –78 °C. After 2.5 h an additional portion of DIBAL-H (1 M in 
hexane, 6.5 mL) was added dropwise. After 3 h MeOH (2.0 mL) was added and 1 h later 
Rochelle’s salt (2.0 mL) was added and the mixture was allowed to reach 20 °C. H2O (100 
mL) was added and the organic layer was isolated via extraction with EtOAc (3x200 mL). 
The combined organic phases were concentrated in vacuo and purified by column 
chromatography (CH2Cl2) to give 6.05 g (88%) of 26 as a clear oil. Rf = 0.45 (CH2Cl2). 1H 
NMR (300 MHz, CDCl3): δ 3.81–3.71 (m, 1H), 3.69–3.56 (m, 4H), 2.17 (dd, J = 7.5, 5.1 
Hz, 1H, OH), 0.89 (br. s, 18H), 0.09 (s, 6H), 0.06 (s, 6H). 13C NMR (75 MHz, CDCl3): δ 
72.7, 65.0, 64.9, 26.0 (3C), 25.9 (3C), 18.4, 18.2, –4.4, –4.7, –5.3, –5.4. 20589][ = +18.5° (c 
0.6, CHCl3). HRMS (ESI+) C15H36O3Si2, m/z [M+Na+] 343.2101, found 343.2110. 
 
(2,3-O-Di-tert-butyldimethylsilyl)-sn-glycero-2-cyanoethyl-N,N-
diisopropylphosphoramidite (27) 
Alcohol 26 (904 mg, 2.82 mmol) and diisopropylethylamine (1.0 mL, 5.92 mmol) were 
dissolved in CH2Cl2 (10 mL). 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite (1.0 g, 
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4.22 mmol) was added dropwise and the reaction mixture was stirred at 20 °C for 1.5 h 
after which EtOAc (20 mL) and a saturated aqueous solution of NaHCO3 (50 mL) were 
added and the organic layer was isolated by extraction with EtOAc (2x50 mL). The 
combined organic phases were concentrated in vacuo and the residue was purified by 
column chromatography (EtOAc) to give 1.35 g (92%) of 27 (two diastereoisomers 1:1) as 
a clear oil. Rf = 1.0 (EtOAc). 1H NMR (300 MHz, CDCl3, two diastereoisomers): δ 3.87–
3.46 (m, 5H), 2.67–2.61 (m, 2H), 1.20–1.17 (m, 12H), 0.90 (s, 9H), 0.89 (s, 9H), 0.09–0.06 
(m, 12H). 13C NMR (75 MHz, CDCl3, two diastereoisomers); δ 117.8 (0.5C), 117.7 (0.5C), 
73.3 (d, J = 7.3 Hz, 0.5C), 73.2 (d, J = 8.3 Hz, 0.5C), 65.1 (d, J = 15.2 Hz, 0.5C), 65.0 
(0.5C), 64.9 (0.5C), 64.8 (d, J = 15.7 Hz, 0.5C), 58.7 (d, J = 11.9 Hz, 0.5C), 58.4 (d, J = 
12.5 Hz, 0.5C), 43.2 (d, J = 4.7 Hz), 43.1 (d, J = 4.6 Hz), 26.1 (3C), 26.0 (3C), 24.8, 24.7 
(2C), 24.6, 20.6 (0.5C), 20.5 (0.5C), 18.5, 18.3, –4.3 (0.5C), –4.4 (0.5C), –4.5, –5.2, –5.3. 
31P NMR (202 MHz, CDCl3): δ 149.0, 148.4. HRMS (ESI+) C24H53N2O4PSi2, m/z 
[M+Na+] 543.3179, found 543.3186. IR (neat): 2958, 2929, 2883, 2857 cm-1. 
 
6-(4-Methoxybenzyloxy)-hexanoic acid (28) 
6-Caprolactone (21, 1.0 g, 8.76 mmol), KOH (2.46 g, 43.8 mmol) and 4-methoxybenzyl 
chloride (3.6 mL, 26.3 mmol) were dissolved in toluene (15 mL) and heated to reflux. 
After 18 h H2O (50 mL) was added and the solution was acidified until pH 2 with aqueous 
HCl (37%). The organic layer was isolated by extraction with Et2O (2×100 mL) and the 
combined organic phases were concentrated in vacuo and purified by column 
chromatography (heptane/EtOAc 3:2) to give 1.6 mg (74%) of 28 as a colorless clear oil. 
Rf = 0.15 (heptane/EtOAc 3:2). 1H NMR (300 MHz, CDCl3):229 δ 7.27 (d, J = 8.7 Hz, 2H), 
6.89 (d, J = 8.7 Hz, 2H), 4.39 (s, 2H), 3.81 (s, 3H), 3.45 (t, J = 6.5 Hz, 2H), 2.37 (t, J = 7.5 
Hz, 2H), 1.71–1.59 (m, 4H), 1.48–1.39 (m, 2H). 13C NMR (75 MHz, CDCl3): δ 179.7, 
159.2, 130.7, 129.4 (2C), 113.9 (2C), 72.7, 69.9, 55.4, 34.1, 29.5, 25.8, 24.6. 
 
1-O-Octadecyl-sn-glycero-3-(2-cyanoethylphospho)-(S)-2,3-O-di-tert-
butyldimethylsilyl-glycerol (29) 
Alcohol 5b (268 mg, 0.58 mmol) and phosphoramidite 27 (405 mg, 0.77 mmol) were 
dissolved in CH2Cl2 (4.3 mL), tetrazole (0.45 M in MeCN, 1.7 mL, 0.77 mmol) was added 
and the mixture was stirred for 30 min at 20 °C after which tBuOOH (5.5 M in nonane, 
0.14 mL, 0.77 mmol) was added. After 70 min the mixture was concentrated in vacuo and 
purified by column chromatography (heptane/EtOAc 3:1) to afford 452 mg that was 
dissolved in CH2Cl2 (10 mL) and H2O (0.6 mL). DDQ (171 mg, 0.75 mmol) was added 
and the mixture was stirred at 20 °C for 1.5 h after which Na2SO4 (15 g) was added and the 
mixture was purified directly by column chromatography (CH2Cl2 then heptane/EtOAc 
1:1) to give 328 mg (73%) of 29 (two distereoisomers 1:1) as a colorless oil. Rf = 0.21 
(heptane/EtOAc 1:1). 1H NMR (300 MHz, CDCl3, two diastereoisomers): δ 4.32–3.97 (m, 
8H), 3.92–3.84 (m, 1H), 3.59–3.43 (m, 6H), 2.78 (t, J = 6.3 Hz, 2H), 1.59–1.52 (m, 2H), 
1.33–1.24 (m, 30H), 0.92–0.86 (m, 21H), 0.10 (s, 3H), 0.09 (s, 3H), 0.06 (s, 6H). 13C NMR 
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(75 MHz, CDCl3, two diastereoisomers): δ 116.5, 77.4, 72.0, 70.8, 70.8, 69.7 (0.5C), 69.6 
(0.5C), 69.5 (0.5C), 69.5 (0.5C), 64.0, 62.1 (0.5C), 62.0 (0.5C), 32.1, 29.9 (12C), 29.6, 
29.5, 26.2, 26.0 (3C), 25.9 (3C), 22.9, 19.8 (0.5C), 19.7 (0.5C), 18.4 (0.5C), 18.2 (0.5C), 
14.3, –4.5, –4.6, –5.3, –5.3. 31P NMR (202 MHz, CDCl3): δ –0.10 and –0.19. HRMS 
(ESI+) C39H82NO8PSi2, m/z [M+Na+] 802.5209, found 802.5205. 
 
1-O-Octadecyl-2-(6-hydroxyhexanoyl)-sn-glycero-3-(2-cyanoethylphospho)-(S)-2,3-O-
di-tert-butyldimethylsilyl-glycerol (30) 
Alcohol 29 (65 mg, 0.083 mmol), carboxylic acid 28 (42 mg, 0.17 mmol) and DMAP (0.5 
mg, 0.004 mmol) were dissolved in CH2Cl2 (4.0 mL) and EtOAc (1.4 mL). DCC (0.25 mL, 
1 M in CH2Cl2, 0.25 mmol) was added and the reaction mixture was stirred at 20 °C. After 
70 min 28 (42 mg, 0.17 mmol) and DCC (0.25 mL, 1 M in CH2Cl2, 0.25 mmol) were 
added and the reaction mixture was stirred for additional 21 h after which the mixture was 
concentrated in vacuo and purified by column chromatography (toluene/EtOAc 5:1) to 
give a residue that was dissolved in CH2Cl2 (6 mL) and H2O (0.3 mL) along with DDQ (28 
mg, 0.12 mmol). The reaction mixture was stirred at 20 °C for 1 h after which Na2SO4 was 
added and the mixture was purified directly by column chromatography (heptane/EtOAc 
2:1 then EtOAc/heptane 1:2) to give 70 mg (93%) of 30 as a colorless oil. Rf = 0.50 
(heptane/EtOAc 1:2). 1H NMR (300 MHz, CDCl3, two diastereoisomers): δ 5.23–5.16 (m, 
1H), 4.31–4.14 (m, 5H), 4.04–3.96 (m, 1H), 3.92–3.84 (m, 1H), 3.65 (t, J = 6.3 Hz, 2H), 
3.59–3.54 (m, 4H), 3.47–3.40 (m, 2H), 2.77 (td, J = 6.3 and 2.0 Hz, 2H), 2.39 (t, J = 7.3 
Hz, 2H), 1.74–1.63 (m, 2H), 1.63–1.51 (m, 4H), 1.49–1.39 (m, 2H), 1.33–1.23 (m, 30H), 
0.92–0.86 (m, 21H), 0.11 (s, 3H), 0.10 (s, 3H), 0.07 (s, 6H). 31P NMR (202 MHz, CDCl3): 
δ –0.87 and –1.08. IR (neat): 3443, 2925, 2854, 1741, 1463, 1255, 1101, 1035, 836 cm-1. 
HRMS (ESI+) C45H92NO10PSi2, m/z [M+Na+] 893.5890, found 893.5878. 
 
1-Stearoyl-sn-glycerol (32) 
2,3-O-Isopropylidene-sn-glycerol (31, 1.12 g, 8.47 mmol), octadecanol (3.13 g, 11.0 
mmol) and DMAP (259 mg, 2.12 mmol) were dissolved in CH2Cl2 (75 mL) and DCC 
(3.49 g, 16.9 mmol) was added. The mixture was stirred at 20 °C for 2 h, then concentrated 
in vacuo and purified by column chromatography (CH2Cl2) to give a white solid that was 
dissolved in B(OEt)3 (45 mL) and CF3CH2OH (5.6 mL). CF3COOH (5.6 mL) was added 
and the reaction mixture was stirred at 20 °C for 5 h, then toluene (2×50 mL) was added 
and the resulting solution was concentrated in vacuo. The residue was dissolved in MeOH 
(120 mL) and carefully H2O (120 mL) was added. A colorless precipitate was formed and 
collected by filtration, washed with H2O, then dissolved in Et2O (200 mL) and dried over 
Na2SO4. After filtration the mixture was concentrated in vacuo and the residue was 
crystallized from first hexane and then CH2Cl2 to give 1.77 g (58%) of 32 as white crystals. 
Rf = 0.24 (heptane/EtOAc 1:1). mp = 78–80 °C (lit.87 69 °C). 1H NMR (300 MHz, CDCl3): 
δ 4.25–4.13 (m, 2H), 3.99–3.91 (m, 1H), 3.75–3.66 (m, 1H), 3.65–3.56 (m, 1H), 2.51 (d, J 
= 5.1 Hz, 1H, OH), 2.36 (t, J = 7.5 Hz, 2H), 2.06 (d, J = 6.2 Hz, 1H, OH), 1.69–1.59 (m, 
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2H), 1.39–1.20 (m, 28H), 0.89 (t, J = 6.2 Hz, 3H). 20589][ = +3.47 (c = 3.0, pyridine) (lit.98 
25
D][ =+3.55 (c = 5.24, pyridine). 
 
1-Stearoyl-3-O-tert-butyldimethylsilyl-sn-glycerol (33) 
Alcohol 32 (300 mg, 0.84 mmol) and imidazole (142 mg, 2.09 mmol) were dissolved in 
THF (8.5 mL) and tert-butyldimethylsilyl chloride (202 mg, 1.34 mmol) was added. The 
reaction mixture was stirred at 20 °C for 2 h, then concentrated in vacuo and purified by 
column chromatography (heptane/EtOAc 3:1) to give 350 mg (88%) of 33 as a colorless 
oil. Rf = 0.75 (heptane/EtOAc 1:1). 1H NMR (300 MHz, CDCl3):98 δ 4.17 (dd, J = 10.7, 
4.2 Hz, 1H), 4.11 (dd, J = 10.7, 5.1 Hz, 1H), 3.93–3.84 (m, 1H), 3.69 (dd, J = 10.1, 4.6 Hz, 
1H), 3.61 (dd, J = 10.1, 5.6 Hz, 1H), 2.51 (d, J = 5.4 Hz, 1H, OH), 2.35 (t, J = 7.5 Hz, 2H), 
1.69–1.59 (m, 2H), 1.37–1.22 (m, 28H), 0.92–0.86 (m, 12H), 0.09 (s, 6H). 13C NMR (50 
MHz, CDCl3): δ 174.1, 70.2, 65.1, 63.9, 34.4, 32.1, 29.8 (8C), 29.6, 29.5, 29.4, 29.3, 26.0 
(3C), 25.1, 22.8, 18.4, 14.3, –5.3 (2C). 20589][ = +1.79 (c = 5.2, CHCl3) (lit.98 20D][ =+1.70 
(c = 6.0, CHCl3). 
 
1-Stearoyl-2-(6-(4-methoxybenzyloxy)hexanoyl)-sn-glycerol (34) 
Alcohol 33 (89 mg, 0.19 mmol), carboxylic acid 28 (95 mg, 0.38 mmol) and DMAP (53 
mg, 0.44 mmol) were dissolved in CH2Cl2 (2.7 mL) and EDCI (79 mg, 0.41 mmol) was 
added. The reaction mixture was stirred at 20 °C for 20 h, then concentrated in vacuo and 
purified by column chromatography (heptane/EtOAc 7:1) to give 126 mg of the desired 
ester, that was dissolved in a mixture of DMSO (3.4 mL), THF (2.8 mL) and H2O (0.34 
mL) in a flask protected from light. NBS (149 mg, 0.84 mmol) was added and the reaction 
mixture was stirred at 20 °C for 21 h, after which excess reagent was quenched by addition 
of a aqueous solution of Na2S2O3 (1%, 7.7 mL). The mixture was stirred at 20 °C for 10 
min, then the organic layer was isolated by extraction with Et2O (3x20 mL). The combined 
organic phases were dried over Na2SO4, filtrated, concentrated in vacuo and purified by 
column chromatography (heptane/EtOAc 1:1) to give 87 mg (78%) of 34 as a colorless oil. 
Rf = 0.44 (heptane/EtOAc 1:1). 1H NMR (300 MHz, CDCl3): δ 7.26 (d, J = 8.3 Hz, 2H), 
6.88 (d, J = 8.3 Hz, 2H), 5.12–5.05 (m, 1H), 4.43 (s, 2H), 4.32 (dd, J = 11.9 and 4.6 Hz, 
1H), 4.23 (dd, J = 11.9 and 5.7 Hz, 1H), 3.81 (s, 3H), 3.73–3.71 (m, 2H), 3.45 (dt, J = 6.3 
and 1.1 Hz, 2H), 2.36 (t, J = 7.4 Hz, 2H), 2.32 (t, J = 7.5 Hz, 2H), 1.71–1.58 (m, 6H), 
1.48–1.38 (m, 2H), 1.33-1.24 (m, 28H), 0.88 (t, J = 6.7 Hz, 3H). 13C NMR (75 MHz, 
CDCl3): δ 174.0, 173.5, 159.4, 130.8, 129.5 (2C), 114.0 (2C), 72.8, 72.4, 70.0, 62.2, 61.7, 
55.5, 34.4, 32.2, 29.9 (10C), 29.7, 29.6, 29.5, 29.4, 25.9, 25.1, 25.0, 23.0, 14.4. 20589][ = –
2.58 (c = 2.4, CHCl3). IR (neat): 3466, 2923, 2853, 1739, 1513, 1247, 1171, 1098 cm-1. 
HRMS (ESI+) C35H60O7, m/z [M+Na+] 615.4231, found 615.4256. 
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Mosher ester analysis of compound 34 
1-Stearoyl-2-(6-(4-methoxybenzyloxy)hexanoyl)-3-((R)-
methoxytrifluoromethylphenylacetoyl)-sn-glycerol (Mosher (R)-ester) 
Alcohol 34 (21 mg, 0.035 mmol) was dissolved in pyridine (0.35 mL) and (R)-
methoxytrifluoromethylphenylacetyl chloride (27 mg, 0.11 mmol) was added and the 
mixture was stirred at 20 °C. After 45 min a saturated aqueous solution of NaHCO3 (4 mL) 
was added and the organic layer was isolated by extraction with CH2Cl2 (3×4 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to 
give 26 mg of the crude ester which was subjected to NMR analysis. 1H NMR (300 MHz, 
CDCl3): δ 7.53–7.39 (m, 5H), 7.26 (d, J = 8.3 Hz, 2H), 6.88 (d, J = 8.3 Hz, 2H), 5.34–5.27 
(m, 1H), 4.60 (dd, J = 11.9 and 3.9 Hz, 1H), 4.43 (s, 2H), 4.37 (dd, J = 11.9 and 5.6 Hz, 
1H), 4.27 (dd, J = 11.9 and 4.8 Hz, 1H), 4.12 (dd, J = 11.9 and 5.7 Hz, 1H), 3.81 (s, 3H), 
3.54 (s, 3H), 3.43 (t, J = 6.5 Hz, 2H), 2.33–2.23 (m, 4H), 1.65–1.54 (m, 6H), 1.43–1.34 (m, 
2H), 1.33–1.21 (m, 28H), 0.88 (t, J = 6.7 Hz, 3H). 19F NMR (282 MHz, CDCl3): δ –72.05. 
 
1-Stearoyl-2-(6-(4-methoxybenzyloxy)hexanoyl)-3-((S)-
methoxytrifluoromethylphenylacetoyl)-sn-glycerol (Mosher (S)-ester) 
Alcohol 34 (21 mg, 0.035 mmol) was dissolved in pyridine (0.35 mL) and (S)-
methoxytrifluoromethylphenylacetyl chloride (27 mg, 0.11 mmol) was added and the 
mixture was stirred at 20 °C. After 45 min a saturated aqueous solution of NaHCO3 (4 mL) 
was added and the organic layer was isolated by extraction with CH2Cl2 (3×4 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to 
give 23 mg of the crude ester which was subjected to NMR analysis. 1H NMR (300 MHz, 
CDCl3): δ 7.53–7.40 (m, 5H), 7.26 (d, J = 8.3 Hz, 2H), 6.88 (d, J = 8.3 Hz, 2H), 5.33–5.26 
(m, 1H), 4.60 (dd, J = 11.9 and 3.9 Hz, 1H), 4.43 (s, 2H), 4.37 (dd, J = 11.9 and 5.8 Hz, 
1H), 4.28 (dd, J = 11.9 and 4.7 Hz, 1H), 4.08 (dd, J = 11.9 and 5.6 Hz, 1H), 3.81 (s, 3H), 
3.53 (s, 3H), 3.43 (t, J = 6.5 Hz, 2H), 2.33–2.24 (m, 4H), 1.65–1.55 (m, 6H), 1.43–1.34 (m, 
2H), 1.33–1.23 (m, 28H), 0.88 (t, J = 6.7 Hz, 3H). 19F NMR (282 MHz, CDCl3): δ –72.06. 
 
1-Stearoyl-2-(6-hydroxyhexanoyl)-sn-glycero-3-(2-cyanoethylphospho)-(S)-2,3-O-di-
tert-butyldimethylsilyl-glycerol (35)  
Alcohol 34 (75 mg, 0.13 mmol) and phosphoramidite 27 (88 mg, 0.17 mmol) were 
dissolved in CH2Cl2 (0.90 mL) and tetrazole (0.45 M in MeCN, 193 µL, 0.17 mmol) was 
added and the mixture was stirred 20 °C for 30 min after which tBuOOH (5.5 M in nonane, 
31 µL, 0.17 mmol) was added. After 90 min the reaction mixture was concentrated in 
vacuo and purified by column chromatography (heptane/EtOAc 1:1) to give 118 mg that 
was dissolved in CH2Cl2 (2.3 mL) and H2O (0.13 mL). DDQ (39 mg, 0.17 mmol) was 
added and the reaction mixture was stirred for 1.5 h at 20 °C. Na2SO4 was added and the 
mixture was purified directly by column chromatography (heptane/EtOAc 3:1 then 
heptane/EtOAc 1:1) to give 85 mg (74%) of 35 (two diastereoisomers 1:1) as a colorless 
oil. Rf = 0.12 (heptane/EtOAc 1:1). 1H NMR (300 MHz, CDCl3, two diastereoisomers): δ 
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5.30–5.22 (m, 1H), 4.38–4.11 (m, 7H), 4.05–3.96 (m, 1H), 3.90–3.83 (m, 1H), 3.63 (t, J = 
6.3 Hz, 2H), 3.59–3.52 (m, 2H), 2.77 (t, J = 6.3 Hz, 2H), 2.37 (t, J = 7.3 Hz, 2H), 2.32 (t, J 
= 7.6 Hz, 2H), 1.74–1.53 (m, 6H), 1.48–1.38 (m, 2H), 1.33–1.23 (m, 28H), 0.92–0.86 (m, 
21H), 0.10 (s, 3H), 0.09 (s, 3H), 0.06 (s, 6H). IR (neat) 3507, 2925, 2855, 1743, 1463, 
1255, 1147, 1102, 1037, 836 cm-1. HRMS (ESI+) C45H90NO11PSi2, m/z [M+Na+] 
930.5688, found 930.5649. 
 
1-O-Octadecyl-2-(4-(α-tocopheroxy)-4-oxobutanoyl)-sn-glycero-3-phospho-(S)-
glycerol (36) 
Alcohol 29 (48 mg, 0.062 mmol), α-tocopheryl succinate (0.032 M in EtOAc, 1.5 mL, 
0.048 mmol) and DMAP (18 mg, 0.14 mmol) were dissolved in CH2Cl2 (4 mL). EDCI (28 
mg, 0.14 mmol) was added and the reaction mixture was stirred for 1 h at 20 °C, then 
concentrated in vacuo and purified by column chromatography (heptane/EtOAc 2:1 then 
heptane/EtOAc 1:2) to give 61 mg of the desired ester, that was dissolved in CH2Cl2 (1.3 
mL) along with DBU (8 µL, 0.050 mmol). The reaction mixture was stirred at 20 °C for 40 
min and then purified directly by column chromatography (CH2Cl2/MeOH 10:1) to afford 
41 mg that was dissolved in MeCN (2.3 mL) and CH2Cl2 (0.8 mL) and cooled to 0 °C. 
Aqueous HF (40%, 0.14 mL) was added dropwise and the reaction mixture was allowed to 
reach 20 °C. After 3 h the reaction was quenched by dropwise addition of MeOSiMe3 (0.6 
mL) and the mixture was stirred for 30 min, after which NaHCO3 (5 mg, 0.059 mmol) was 
added and the mixture was concentrated in vacuo and purified by column chromatography 
(CH2Cl2/MeOH 20:1 then CH2Cl2/MeOH 4:1) to give 30 mg (61%) of 36 as a colorless 
amorphous solid. Rf = 0.09 (CH2Cl2/MeOH 9:1). 1H NMR (300 MHz, CDCl3/CD3OD 
4:1): δ 5.22–5.14 (m, 1H), 4.05–3.98 (m, 2H), 3.98–3.90 (m, 2H), 3.86–3.79 (m, 1H), 
3.67–3.56 (m, 4H), 3.47–3.40 (m, 2H), 2.98–2.90 (m, 2H), 2.83–2.76 (m, 2H), 2.60 (t, J = 
6.4 Hz), 2.09 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H), 1.84–1.74 (m, 2H), 1.59–1.48 (m, 7H), 
1.47–1.01 (m, 49H), 0.91–0.83 (m, 15H). 13C NMR (75 MHz, CDCl3/CD3OD 4:1): δ 
172.4, 171.8, 149.7, 140.7, 126.9, 125.2, 123.3, 117.8, 75.4, 72.6, 72.1, 71.1, 69.1, 66.7, 
64.4, 62.4, 39.7 (2C), 37.7 (3C), 37.6, 33.1, 33.0, 32.2, 31.4, 30.0 (13C), 29.3, 29.0, 28.2, 
26.3, 25.1, 24.7, ~24, 23.0, 22.9, 22.8, 21.3, 20.9, 20.0, 19.9, 14.3, 13.1, 12.2, 12.0. 31P 
NMR (202 MHz, CDCl3/CD3OD 4:1): δ 3.43. IR (neat) 3423, 2923, 2853, 1722, 1696, 
1660, 1397, 1264, 1062, 804 cm-1. HRMS (ESI+) C57H102O12PNa, m/z [M+H+] 1033.7085, 
found 1033.7094. 
 
1-Stearoyl-2-(4-(α-tocopheroxy)-4-oxobutanoyl)-sn-glycero-3-phospho-(S)-glycerol 
(37) 
Alcohol 38 (56 mg, 0.064 mmol) and phosphoramidite 27 (45 mg, 0.087 mmol) were 
dissolved in CH2Cl2 (0.45 mL) and the mixture was stirred for 15 min at 20 °C before 
tetrazole (0.45 M in MeCN, 193 µL, 0.087 mmol) was added. 30 min later tBuOOH (5.5 M 
in nonane, 15 µL, 0.087 mmol) was added and the reaction mixture was stirred for 70 min 
after which the mixture was concentrated in vacuo and purified by column chromatography 
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(heptane/EtOAc 2:1) to give 76 mg that was dissolved in CH2Cl2 (4.5 mL) and DBU (10 
µL, 0.064 mmol) was added. The reaction mixture was stirred for 1 h at 20 °C and then 
purified directly by column chromatography (heptane/EtOAc 1:1 then CH2Cl2/MeOH 9:1) 
to afford 58 mg that was dissolved in MeCN (3.8 mL) and CH2Cl2 (1.3 mL) and cooled to 
0 °C. Aqueous HF (40%, 125 µL) was added dropwise and the reaction mixture was 
allowed to reach 20 °C. After 4 h the reaction was quenched by dropwise addition of 
MeOSiMe3 (0.84 mL) and the mixture was stirred for 30 min, after which NaHCO3 (7 mg, 
0.083 mmol) was added and the mixture was concentrated in vacuo and purified by column 
chromatography (CH2Cl2/MeOH 20:1 then CH2Cl2/MeOH 4:1) to give 30 mg (44%) of 37 
as a colorless amorphous solid. Rf = 0.26 (CH2Cl2/MeOH 4:1). 1H NMR (500 MHz, 
CDCl3/CD3OD 4:1): δ 5.29–5.24 (m, 1H), 4.37 (dd, J = 12.0, 3.4 Hz, 1H), 4.20 (dd, J = 
12.0, 6.5 Hz, 1H), 4.08–4.04 (m, 2H), 4.00–3.91 (m, 2H), 3.83–3.78 (m, 1H), 3.65–3.58 
(m, 2H), 2.97–2.92 (m, 2H), 2.80 (t, J = 6.7 Hz, 2H), 2.60 (t, J = 6.6 Hz, 2H), 2.28 (t, J = 
7.6 Hz, 2H), 2.09 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H), 1.85–1.74 (m, 2H), 1.60–1.03 (m, 
54H), 0.90–0.85 (m, 15H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 174.3, 172.2, 171.6, 
149.8, 140.8, 126.9, 125.2, 123.3, 117.8, 75.5, 71.1 (2C), 67.2, 64.3, 62.6 (2C), 40 (br), 
39.7, 37.8 (4C), 34.3, 33.1 (2C), 32.2, 31.5, 30.0 (12C), 29.4, 29.0, 28.3, 25.1 (2C), 24.7, 
~24, 22.9 (3C), 21.3, 20.9, 20.0 (2C), 14.3, 13.1, 12.2, 12.0. 31P NMR (202 MHz, 
CDCl3/CD3OD 4:1): δ –0.88. IR (neat) 3406, 2924, 2853, 1728, 1518, 1449, 1247, 1144, 
1105, 740 cm-1. HRMS (ESI+) C57H100O13PNa, m/z [M+H+] 1047.6879, found 1047.6858.  
 
1-Stearoyl-2-(4-(α-tocopheroxy)-4-oxobutanoyl)-sn-glycerol (38) 
Alcohol 33 (63 mg, 0.13 mmol), α-tocopheryl succinate (84 mg, 0.16 mmol) and DMAP 
(26 mg, 0.21 mmol) were dissolved in CH2Cl2 (1.9 mL). EDCI (38 mg, 0.20 mmol) was 
added and the reaction mixture was stirred at 20 °C for 2 h, then concentrated in vacuo and 
purified by column chromatography (heptane/EtOAc 7:1) to give 122 mg of the desired 
ester, that was dissolved in a mixture of DMSO (2.4 mL), THF (2.0 mL) and H2O (0.24 
mL) in a flask protected from light. NBS (104 mg, 0.58 mmol) was added and the reaction 
mixture was stirred at 20 °C for 70 h, after which the reaction was quench by addition of 
aqueous Na2S2O3 (1%, 5.4 mL). The mixture was stirred at 20 °C for 10 min, then the 
organic layer was isolated via extraction with Et2O (3x14 mL). The combined organic 
phases were dried over Na2SO4, filtrated, concentrated in vacuo and purified by column 
chromatography (heptane/EtOAc 1:1) to give 56 mg (48%) of 38 as a colorless oil. Rf = 
0.45 (heptane/EtOAc 1:1). 1H NMR (300 MHz, CDCl3): δ 5.16–5.09 (m, 1H), 4.33 (dd, J = 
12.0, 4.7 Hz, 1H), 4.26 (dd, J = 12.0, 5.6 Hz, 1H), 3.77 (dd, J = 12.3, 4.4 Hz, 1H), 3.71 
(dd, J = 12.3, 5.1 Hz, 1H), 3.01–2.94 (m, 2H), 2.83–2.76 (m, 2H), 2.59 (t, J = 6.4 Hz. 2H), 
2.32 (t, J = 7.5 Hz, 2H), 2.09 (s, 3H), 2.02 (s, 3H), 1.97 (s, 3H), 1.85–1.72 (m, 2H), 1.66–
1.02 (m, 54H), 0.92–0.84 (m, 15H). 13C NMR (50 MHz, CDCl3): δ 173.9, 171.9, 171.2, 
149.6, 140.6, 126.7, 125.0, 123.2, 117.6, 75.2, 73.1, 62.0, 61.5, 40.3, 39.5, 37.6 (3C), 37.4, 
34.2, 32.9 (2C), 32.1, 31.2, 29.8 (12C), 29.3, 29.1, 28.1, 25.0 (2C), 24.6, 24, 22.8 (3C), 
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21.2, 20.7, 19.8 (2C), 14.3, 13.1, 12.2, 12.0. IR (neat) 3493, 2923, 2853, 1741, 1462, 1377, 
1146 cm-1. HRMS (ESI+) C54H94O8, m/z [M+Na+] 893.6847, found 893.6817. 
 
1-O-Octadecyl-2-(4-hydroxy-4-oxobutanoyl)-sn-glycero-3-(2-cyanoethylphospho)-(S)-
2,3-di-O-tert-butyldimethylsilyl-glycerol (39) 
Alcohol 29 (96 mg, 0.12 mmol) and carboxylic acid 44 (51 mg, 0.25 mmol) were dissolved 
in CH2Cl2 (2.5 mL). DCC (76 mg, 0.37 mmol) and DMAP (15 mg, 0.12 mmol) were added 
and the reaction mixture was stirred at 20 °C for 1 h, then concentrated in vacuo and 
purified by column chromatography (heptane then heptane/EtOAc 2:1) to afford 81 mg of 
the desired ester, that was dissolved in a mixture of EtOAc (0.7 mL) and MeOH (0.7 mL). 
Pd/C (10 wt%, 12 mg, 0.012 mmol) was added and the mixture was stirred under an 
atmosphere of H2 for 2 h at 20 °C, after which filtration through celite gave 74 mg (73%) 
of 39 (two diastereoisomers 1:1) as a colorless oil. 1H NMR (300 MHz, CDCl3, two 
diastereoisomers): δ δ 5.23–5.16 (m, 1H), 4.32–4.13 (m, 5H), 4.06–3.97 (m, 1H), 3.92–
3.84 (m, 1H), 3.62–3.53 (m, 4H), 3.48–3.39 (m, 2H), 2.77 (t, J = 6.3 Hz, 2H), 2.70–2.64 
(m, 4H), 1.59–1.49 (m, 2H), 1.32–1.23 (m, 30H), 0.92–0.86 (m, 21H), 0.10 (s, 3H), 0.09 
(s, 3H), 0.07 (s, 6H). 13C NMR (50 MHz, CDCl3, two diastereoisomers): δ 175.1, 171.5, 
116.5, 72.1 (2C), 71.2, 69.7, 68.2, 66.7, 64.1, 62.2, 32.1, 29.8 (13C), 29.0 (2C), 26.0 (7C), 
22.8, 19.6, 18.4 (2C), 14.2, -4.6 (2C), -5.3 (2C). IR (neat): 2924, 2854, 1737, 1463, 1252, 
1152, 1102. HRMS (ESI+) C43H86NO11PSi2, m/z [M+Na+] 902.5370, found 902.5415. 
 
1-O-Octadecyl-2-(4-octanoxy-4-oxobutanoyl)-sn-glycero-3-phospho-(S)-glycerol (40) 
Carboxylic acid 39 (26 mg, 0.031 mmol) and octanol (7.2 µL, 0.045 mmol) were dissolved 
in CH2Cl2 (0.5 mL). DCC (8 mg, 0.04 mmol) and DMAP (2 mg, 0.016 mmol) were added 
and the reaction mixture was stirred at 20 °C for 1 h, after which the mixture was purified 
directly by column chromatography (heptane/EtOAc 4:1 then heptane/EtOAc 2:1) to give 
12 mg of the desired ester, that was dissolved in CH2Cl2 (1.1 mL) along with DBU (1.9 
µL, 0.013 mmol). The reaction mixture was stirred for 1 h and then purified directly by 
column chromatography (heptane/EtOAc 1:1 then CH2Cl2/MeOH 9:1) to give 11 mg of a 
colorless oil, that was dissolved in a mixture of MeCN (1.0 mL) and CH2Cl2 (0.33 mL) and 
cooled to 0 °C. Aqueous HF (40%, 60 µL) was added dropwise and the reaction mixture 
was allowed to reach 20 °C. After 3.5 h excess reagent was quenched by dropwise addition 
of MeOSiMe3 (225 µL) and the mixture was stirred for 30 min, after which NaHCO3 (3 
mg, 0.035 mmol) was added and the mixture was concentrated in vacuo and purified by 
column chromatography (CH2Cl2/MeOH 10:1 then CH2Cl2/MeOH 4:1) to give 7 mg 
(31%) of 40 as a colorless amorphous solid. Rf = 0.38 (CH2Cl2/MeOH 4:1). 1H NMR (300 
MHz, CDCl3/CD3OD 4:1): δ 5.18–5.11 (m, 1H), 4.08 (t, J = 6.8 Hz, 2H), 3.97–3.90 (m, 
4H), 3.85–3.79 (m, 1H), 3.66–3.62 (m, 2H), 3.60–3.55 (m, 2H), 3.47–3.40 (m, 2H), 2.68–
2.61 (m, 4H), 1.67–1.58 (m, 2H), 1.58–1.50 (m, 2H), 1.35–1.23 (m, 40H), 0.89 (t, J = 6.0 
Hz, 3H), 0.88 (t, J = 5.8 Hz, 3H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 172.3, 172.0, 
71.8 (2C), 70.4, 68.1, 67.3, 65.1 (2C), 62.2, 31.7 (2C), 29.6 (18C), 25.8, 24.0, 22.5 (2C), 
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13.8 (2C). IR (neat): 3352, 2922, 2853, 1736, 1220, 1162, 1118, 1053. HRMS (ESI-) 
C36H70O11P, m/z [M-] 709.4660, found 709.4687. 
 
1-O-Octadecyl-2-(4-phenoxy-4-oxobutanoyl)-sn-glycero-3-phospho-(S)-glycerol (41) 
The synthesis was performed as for 40, starting from carboxylic acid 39 (30 mg, 0.034 
mmol) and phenol (10 mg, 0.10 mmol) and affording 6 mg (25 %) of 41 as a colorless 
amorphous solid. Rf = 0.14 (CH2Cl2/MeOH 4:1). 1H NMR (500 MHz, CDCl3/CD3OD 4:1): 
δ 7.38 (t, 2H, J = 7.8 Hz), 7.24 (t, J = 7.8 Hz, 1H), 7.09 (d, J = 7.8 Hz, 2H), 5.22–5.17 (m, 
1H), 4.05–3.96 (m, 2H), 3.93–3.89 (m, 2H), 3.79–3.76 (m, 1H), 3.63–3.57 (m, 4H), 3.47–
3.38 (m, 2H), 2.90 (t, J = 6.7 Hz, 2H), 2.79 (t, J = 6.7 Hz, 2H), 1.55–1.49 (m, 2H), 1.31–
1.22 (m, 30H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 172.5, 
171.7, 150.9, 129.8 (2C), 126.3, 121.8 (2C), 72.6, 72.2, 71.2, 69.2, 66.8, 64.5, 62.5, 32.2, 
30.0 (15C), 26.3, 23.0, 14.3. 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ –0.64. IR (neat): 
3333, 2922, 2852, 1763, 1737, 1251, 1198, 1131, 1068. HRMS (ESI+) C34H58O11P, m/z 
[M-] 673.3721, found 673.3702. 
 
1-O-Octadecyl-2-(2,6-dimethylphenoxy-4-oxobutanoyl)-sn-glycero-3-phospho-(S)-
glycerol (42) 
The synthesis was performed as for 40, starting from carboxylic acid 39 (71 mg, 0.086 
mmol) and 2,6-dimethylphenol (32 mg, 0.26 mmol) and affording 9 mg (14 %) of 42 as a 
colorless amorphous solid. Rf = 0.09 (CH2Cl2/MeOH 4:1). 1H NMR (500 MHz, 
CDCl3/CD3OD 4:1): δ 7.06–7.05 (m, 3H), 5.20–5.15 (m, 1H), 4.05–3.97 (m, 2H), 3.95–
3.89 (m, 2H), 3.82–3.77 (m, 1H), 3.63–3.56 (m, 4H), 3.47–3.38 (m, 2H), 2.95 (t, J = 6.7 
Hz, 2H), 2.80 (t, J = 6.7 Hz, 2H), 2.14 (s, 6H), 1.55–1.49 (m, 2H), 1.30–1.22 (m, 30H), 
0.88 (t, J = 6.9 Hz, 3H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 172.4, 171.1, 148.3, 
130.4 (2C), 129.0 (2C), 126.3, 72.6, 72.2, 71.2, 69.2, 66.8, 64.5, 62.5, 32.2, 30.0, 29.3 
(13C), 28.9, 26.3, 23.0, 16.4 (2C), 14.3. 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ –2.62. 
IR (neat): 3331, 2922, 2853, 1753, 1738, 1233, 1139, 1058. HRMS (ESI-) C36H62O11P, m/z 
[M-] 701.7034, found 701.4017. 
 
Benzyl succinate (44)230 
Succinic anhydride (43, 1.0 g, 9.93 mmol), benzyl alcohol (1.12 mL, 10.9 mmol) and 
DMAP (1.22 g, 10.0 mmol) were dissolved in CH2Cl2 (10 mL). The reaction mixture was 
stirred at 20 °C for 20.5 h, after which CH2Cl2 (50 mL) and a saturated aqueous solution of 
NH4Cl (50 mL) were added and the organic layer was isolated by extraction with CH2Cl2 
(2×50 mL). The combined organic phases were dried over Na2SO4 and concentration in 
vacuo gave 1.27 g (61%) of 44 as a colorless oil. 1H NMR (300 MHz, CDCl3): δ 7.31–7.22 
(m, 5H), 5.07 (s, 2H), 2.68–2.57 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 176.9, 173.2, 
136.2, 128.5 (2C), 128.0 (3C), 66.1, 30.8, 30.3.  
  
Liposomal Drug Delivery 
116 
 
1-O-Octadecyl-2-(11-oxo-(5Z,9Z,12E,14E)-prostatetraenoyl)-sn-glycero-3-phospho-
(S)-glycerol (45) 
Alcohol 29 (16 mg, 0.021 mmol), DMAP (0.4 mg, 0.003 mmol) and 15-deoxy-Δ12,14-
prostaglandin J2 (0.5 mL, 0.032 M in MeOAc, 0.016 mmol) were dissolved in CH2Cl2 (1.5 
mL) and DCC (40 µL, 1.0 M in CH2Cl2, 0.04 mmol) was added. The reaction mixture was 
stirred for 4.5 h at 20 °C after which the mixture was concentrated in vacuo and purified by 
column chromatography (heptane/EtOAc 2:1 then heptane/EtOAc 1:2) to give 11 mg of 
the desired ester that was dissolved in CH2Cl2 (0.8 mL). DBU (2 µL, 0.011 mmol) was 
added and the reaction mixture was stirred for 1 h at 20 °C and then purified directly by 
column chromatography (CH2Cl2/MeOH 10:1) to give 8 mg, that was dissolved in MeCN 
(0.9 mL) and CH2Cl2 (0.3 mL) and cooled to 0 °C. Aqueous HF (40%, 30 µL) was added 
dropwise and the reaction mixture was allowed to reach 20 °C. After 2.5 h the reaction was 
quenched by dropwise addition of MeOSiMe3 (0.2 mL) and the mixture was stirred for 30 
min, after which NaHCO3 (5 mg, 0.06 mmol) was added and the mixture was concentrated 
in vacuo and purified by column chromatography (CH2Cl2/MeOH 10:1 then 
CH2Cl2/MeOH 4:1 then CH2Cl2/MeOH/H2O 65:25:1) to give 4 mg (22%) of 45 as a 
colorless amorphous solid. Rf = 0.22 (CH2Cl2/MeOH 4:1). 1H NMR (500 MHz, 
CDCl3/CD3OD 4:1): δ 7.55 (dd, J = 5.8, 1.8 Hz, 1H), 6.96 (d, J = 11.0 Hz, 1H), 6.39–6.32 
(m, 2H), 6.30 (dt, J = 15.0, 6.6 Hz, 1H), 5.47 (dt, J = 10.4, 7.2 Hz, 1H), 5.36 (dt, J = 10.4, 
7.2 Hz, 1H), 5.16–5.12 (m, 1H), 3.99–3.91 (m, 4H), 3.81–3.79 (m, 1H), 3.66–3.61 (m, 
3H), 3.59–3.56 (m, 2H), 3.49–3.40 (m, 2H), 2.64–2.59 (m, 1H), 2.35–2.30 (m, 3H), 2.28–
2.24 (m, 2H), 2.04 (q, J = 7.2 Hz, 2H), 1.68–1.62 (m, 2H), 1.54–1.52 (m, 2H), 1.49–1.45 
(m, 2H), 1.34–1.31 (m, 4H), 1.30–1.23 (m, 30H), 0.92–0.87 (m, 6H). 13C NMR (50 MHz, 
CDCl3/CD3OD 4:1): δ 198.9, 173.9, 162.5, 148.3, 135.3 (2C), 133.1, 131.9, 126.0(2C), 
72.1 (2C), 71.3, 69.5, 66.7, 64.5, 62.6, 44.0, 34.1, 33.9, 32.3, 31.8, 30.9, 30.1 (12C), 29.7, 
28.2, 27.0, 26.4, 25.1, 23.0, 22.9, 14.3 (2C). 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ 
3.60. IR (neat) 3364, 2923, 2853, 1733, 1695, 1632, 1464, 1259, 1207, 1097, 1058, 800 
cm-1. HRMS (ESI+) C44H76O10PNa, m/z [M+H+] 819.5147, found 819.5166.  
 
1-Stearoyl-2-(11-oxo-(5Z,9Z,12E,14E)-prostatetraenoyl)-sn-glycero-3-phospho-(S)-
glycerol (46) 
Alcohol 47 (18 mg, 0.037 mmol) and phosphoamidite 27 (26 mg, 0.050 mmol) were 
dissolved in CH2Cl2 (260 µL) and the mixture was stirred for 15 min at 20 °C before 
tetrazole (0.45 M in MeCN, 111 µL, 0.050 mmol) was added. 30 min later tBuOOH (5.5 M 
in nonane, 9 µL, 0.050 mmol) was added and the reaction mixture was stirred for 30 min 
after which the mixture was concentrated in vacuo and purified by column chromatography 
(heptane/EtOAc 3:1) to give 30 mg that was dissolved in CH2Cl2 (0.70 mL) and H2O (40 
µL). DDQ (12 mg, 0.052 mmol) was added and the reaction mixture was stirred for 3 h at 
20 °C. Na2SO4 was added and the mixture was purified directly by column 
chromatography (CH2Cl2 then heptane/EtOAc 1:1) to afford 21 mg of 48, which was 
dissolved in CH2Cl2 (0.40 mL) along with 15-deoxy-Δ12,14-prostaglandin J2 (10 mg, 0.32 
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mmol) and DMAP. DCC (13 mg, 0.065 mmol) was added and the reaction mixture was 
stirred for 2.5 h at 20 °C, then purified directly by column chromatography (toluene then 
toluene/EtOAc 5:1) to afford 15 mg that was dissolved in CH2Cl2 (1.2 mL) and treated 
with DBU (2.2 µL, 0.015 mmol). The reaction mixture was stirred for 30 min at 20 °C and 
then purified directly by column chromatography (heptane/EtOAc 1:1 then CH2Cl2/MeOH 
9:1) to afford 7 mg, that was dissolved in MeCN (560 µL), CH2Cl2 (352 µL) and H2O (34 
µL) and cooled to 0 °C. Aqueous HF (40%, 34 µL) was added dropwise and the reaction 
mixture was allowed to reach 20 °C. After 3.5 h the reaction was quenched by dropwise 
addition of MeOSiMe3 (120 µL) and the mixture was stirred for 30 min, after which 
NaHCO3 (1 mg, 0.012 mmol) was added and the mixture was concentrated in vacuo and 
purified by column chromatography (CH2Cl2/MeOH 20:1 then CH2Cl2/MeOH 5:1 then 
CH2Cl2/MeOH/H2O 65:25:1) to give 4 mg (13%) of 46 as a colorless amorphous solid. Rf 
= 0.63 (CH2Cl2/MeOH 5:1). 1H NMR (300 MHz, CDCl3/CD3OD 4:1): δ 7.54 (dd, J = 6.5, 
2.5 Hz, 1H), 6.96 (d, J = 10.5 Hz, 1H), 6.40–6.28 (m, 3H), 5.51–5.35 (m, 2H), 5.25–5.18 
(m, 1H), 4.39 (dd, J = 12.1, 3.4 Hz, 1H), 4.16 (dd, J = 12.1, 6.4 Hz, 1H), 3.99–3.85 (m, 
4H), 3.82–3.77 (m, 1H), 3.66–3.60 (m, 3H), 2.67–2.56 (m, 1H), 2.41–2.21 (m, 7H), 2.05 
(q, J = 7.0 Hz, 2H), 1.70–1.55 (m, 4H), 1.51–1.40 (m, 2H), 1.38–1.22 (m, 32H), 0.91 (t, J 
= 7.0 Hz, 3H), 0.88 (t, J = 6.2 Hz, 3H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 197.2, 
174.3, 173.4, 162.3, 148.2, 135.3 (2C), 132.8, 131.7, 126.1, 126.0, 71.2, 70.9, 66.8, 64.0, 
62.8, 62.6, 43.9, 34.4, 33.8, 32.4, 31.7, 30.0 (14C), 28.8, 26.9, 25.2, 25.0, 23.0, 22.8, 14.3 
(2C). IR (neat) 3391, 2924, 2854, 1737, 1697, 1633, 1459, 1377, 1227, 1103, 1066, 816 
cm-1. HRMS (ESI+) C44H74O11PNa, m/z [M+H+] 833.4939, found 833.4958. 
 
1-Stearoyl-2-O-(4-methoxybenzyl)-sn-glycerol (47) 
Alcohol 32 (189 mg, 0.091 mmol) and PMBTCA (193 mg, 0.70 mmol) were dissolved in 
toluene (4.0 mL) and La(OTf)3 (12 mg, 0.02 mmol) was added. The reaction mixture was 
stirred at 20 °C for 3.5 h, then concentrated in vacuo and purified by column 
chromatography (heptane then heptane/EtOAc 7:1) to give 194 mg that subsequently was 
dissolved in a mixture of DMSO (6.5 mL), THF (5.4 mL) and H2O (0.65 mL) in a flask 
protected from light. NBS (274 mg, 1.54 mmol) was added and the reaction mixture was 
stirred at 20 °C for 17 h, after which the reaction was quenched by addition of an aqueous 
solution of Na2S2O3 (1%, 15 mL). The mixture was stirred at 20 °C for 10 min, then the 
organic layer was isolated by extraction with Et2O (3x40 mL). The combined organic 
phases were dried over Na2SO4, filtered, concentrated in vacuo and purified by column 
chromatography (heptane/EtOAc 2:1) to give 120 mg (63%) of 47 as a colorless oil. Rf = 
0.51 (heptane/EtOAc 1:1). 1H NMR (300 MHz, CDCl3): δ 7.27 (d, J = 8.7 Hz, 2H), 6.89 
(d, J = 8.7 Hz, 2H), 4.65 (d, J = 11.3 Hz, 1H), 4.52 (d, J = 11.3 Hz, 1H), 4.23-4.20 (m, 
2H), 3.81 (s, 3H), 3.71–3.56 (m, 3H), 2.32 (t, J = 7.5 Hz, 2H), 1.67–1.55 (m, 2H), 1.33–
1.21 (m, 28H), 0.88 (t, J = 6.3 Hz, 3H). 13C NMR (50 MHz, CDCl3): δ 174.0, 159.6, 130.1, 
129.7 (2C), 114.1 (2C), 77.3, 72.0, 62.9, 62.2, 55.4, 38.2, 34.4, 29.6 (12C), 25.1, 22.8, 
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14.3. IR (neat) 2926, 2855, 1740, 1514, 1464, 1251, 1106, 1036, 836 cm-1. HRMS (ESI+) 
C29H50O5, m/z [M+Na+] 501.3550, found 501.3560. 
 
1-O-(4-hydroxy-4-oxobutanoyl) 1α,25-dihydroxyvitamin D3 (1-O-51) and 3-O-(4-
hydroxy-4-oxobutanoyl) 1α,25-dihydroxyvitamin D3 (3-O-51) 
Calcitriol (10 mg, 024 mmol), succinic anhydride (2.4 mg, 0.024 mmol) and DMAP (2.9 
mg, 0.024 mmol) were dissolved in a mixture of CH2Cl2 (0.66 mL) and THF (80 µL). The 
reaction mixture was stirred at 20 °C for 40 h and then purified directly by column 
chromatography (heptane/EtOAc 1:3 then CH2Cl2/MeOH 4:1) to afford 3.6 mg (29%) as a 
1:1 mixture of 1-O-51 and 3-O-51 (deterimed by 300 MHz 1H NMR). Also, 5.6 mg (56%) 
of Calcitriol was reisolated. 1H NMR (300 MHz, CDCl3, for 1-O-51): δ 6.37 (d, J = 11.2 
Hz, 1H), 5.91 (d, J = 11.2 Hz, 1H), 5.53–5.46 (m, 1H), 5.30 (s, 1H), 5.03 (s, 1H), 4.18–
4.09 (m, 1H), 2.87–2.24 (m, 7H), 2.20-0.80 (m, 20H), 1.21 (s, 6H), 0.93 (d, J = 5.5 Hz, 
3H), 0.51 (s, 3H). 1H NMR (300 MHz, CDCl3, for 3-O-51): δ 6.32 (d, J = 11.2 Hz, 1H), 
6.02 (d, J = 11.2 Hz, 1H), 5.36 (s, 1H), 5.27–5.20 (m, 1H), 5.03 (s, 1H), 4.42–4.35 (m, 
1H), 2.87–2.24 (m, 7H), 2.20–0.80 (m, 20H), 1.21 (s, 6H), 0.93 (d, J = 5.5 Hz, 3H), 0.54 
(s, 3H). MALDI-TOF (ES+) Calcd. for C31H48O6 (M+Na+) 539.33. Found: 539.20. 
 
1-O-(6-hydroxy-6-oxohexanoyl) 1α,25-dihydroxyvitamin D3 (1-O-52) and 3-O-(6-
hydroxy-6-oxohexanoyl) 1α,25-dihydroxyvitamin D3 (3-O-52) 
Calcitriol (10 mg, 0.024 mmol) and carboxylic acid 58 (7 mg, 0.03 mmol) were dissolved 
in CH2Cl2 (0.66 mL) and THF (80 µL). EDCI (6 mg, 0.03 mmol) and DMAP (4 mg, 0.03 
mmol) were added and the reaction mixture was stirred at 20 °C. After 2 h further amounts 
of the carboxylic acid 58 (2 mg, 0.008 mmol), EDCI (2 mg, 0.01 mmol) and DMAP (2 mg, 
0.016 mmol) were added and the mixture was stirred for 3 h more, then concnetrated in 
vacuo and purified by column chromatography (heptane/EtOAc 3:1 then heptane/EtOAc 
1:1) to afford 4.1 mg, that was dissolved in THF (0.5 mL) and TBAF (1.0 M in THF, 20 
µL, 0.019 mmol) was added and the reaction mixture was stirred at 20 °C. After 2 h an 
additional amount of TBAF (1.0 M in THF, 20 µL, 0.019 mmol) was added and the 
mixture was stirred for 1 h more, then EtOAc (1.5 mL) and heptane (1.5 mL) were added 
and the mixture was purified directly by column chromatography (heptane/EtOAc 1:1 then 
CH2Cl2/MeOH 10:1) to afford 2.5 mg (19%) as a 1:3 mixture of 1-O-52 and 3-O-52 
(determined by 500 MHz 1H NMR). 1H NMR (500 MHz, CDCl3, for 1-O-52): δ 6.38 (d, J 
= 11.2 Hz, 1H), 5.89 (d, J = 11.2 Hz, 1H), 5.52–5.50 (m, 1H), 5.34 (s, 1H), 5.05 (s, 1H), 
4.18–4.13 (m, 1H), 2.85–2.79 (m, 1H), 2.65 (dd, J = 13.0, 3.7 Hz, 1H), 2.44–0.80 (m, 
29H), 1.23 (s, 6H), 0.93 (d, J = 6.5 Hz, 3H), 0.52 (s, 3H). 1H NMR (500 MHz, CDCl3, for 
3-O-52): δ 6.33 (d, J = 11.4 Hz, 1H), 6.03 (d, J = 11.4 Hz, 1H), 5.36 (s, 1H), 5.26–5.22 (m, 
1H), 5.03 (s, 1H), 4.44–4.40 (m, 1H), 2.85–2.79 (m, 1H), 2.59 (dd, J = 13.4, 2.7 Hz, 1H), 
2.44–0.80 (m, 29H), 1.23 (s, 6H), 0.95 (d, J = 6.5 Hz, 3H), 0.55 (s, 3H). IR (neat): 3399, 
2930, 2871, 1732, 1457, 1376, 1260, 1064. MALDI-TOF (ES+) Calcd. for C33H52O6  
(M+Na+) 567.37. Found: 567.19.   
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1-O-Octadecyl-2-((5-((5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol-1-
oxy)-5-oxopentyloxy)-carbonyl)-sn-glycero-3-phospho-(S)-glycerol (1-O-53) and 1-O-
Octadecyl-2-((5-((5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,25-diol-3-oxy)-
5-oxopentyloxy)-carbonyl)-sn-glycero-3-phospho-(S)-glycerol (3-O-53) 
Carboxylic acid 72 (20 mg, 0.022 mmol) and calcitriol (9 mg, 0.022 mmol) were dissolved 
in THF (1.3 mL). 2,4,6-Trichlorobenzoyl chloride (4.4 µL, 0.029 mmol) and then DMAP 
(5 mg, 0.044 mmol) were added and the mixture was stirred at 20 °C for 1.5 h, then 
concentrated in vacuo and purified by column chromatography (CH2Cl2 then 
CH2Cl2/EtOAc 1:1) to give 15 mg of a colorless oil, that was dissolved in CH2Cl2 (1.0 mL) 
along with DBU (1.8 µL, 0.012 mmol). The reaction mixture was stirred at 20 °C for 1 h 
and then purified directly by column chromatography (heptane/EtOAc 1:3 then 
CH2Cl2/MeOH 9:1) to give 13 mg of a colorless oil, that was dissolved in a mixture of 
MeCN (1.0 mL), CH2Cl2 (0.33 mL) and H2O (0.16 mL) and cooled to 0 °C. Aqueous HF 
(40%, 60 µL) was added and the reaction mixture was allowed to reach 20 °C. After 3 h 
excess reagent was quenched by dropwise addition of MeOSiMe3 (0.20 mL) and the 
mixture was stirred for 30 min, after which NaHCO3 (3 mg, 0.036 mmol) was added and 
the mixture was concentrated in vacuo and purified by column chromatography 
(CH2Cl2/MeOH 9:1 then CH2Cl2/MeOH 4:1) to give 7 mg (30%) as a 1:4 mixture of 1-O-
53 and 3-O-53 (determined by 500 MHz 1H NMR) as a colorless amorphous solid. Rf = 
0.10 (CH2Cl2/MeOH 4:1). 1H NMR (500 MHz, CDCl3/CD3OD 4:1, for 1-O-53): δ 6.37 (d, 
J = 11.1 Hz, 1H), 5.90 (d, J = 11.1 Hz, 1H), 5.48–5.45 (m, 1H), 5.33 (s, 1H), 5.05 (s, 1H), 
5.00–4.95 (m, 1H), 4.16–4.07 (m, 3H), 4.06–3.99 (m, 2H), 3.96–3.89 (m, 2H), 3.83–3.77 
(m, 1H), 3.66–3.59 (m, 4H), 3.49–3.40 (m, 2H), 2.63–2.59 (m, 1H), 2.47–2.40 (m, 1H), 
2.40–2.30 (m, 3H), 2.16–0.93 (m, 56H), 1.20 (s, 6H), 0.94 (d, J = 6.4 Hz, 3H), 0.88 (t, J = 
6.9 Hz, 3H), 0.51 (s, 3H). 1H NMR (500 MHz, CDCl3/CD3OD 4:1, for 3-O-53): δ 6.29 (d, 
J = 11.1 Hz, 1H), 6.05 (d, J = 11.1 Hz, 1H), 5.38 (s, 1H), 5.23–5.19 (m, 1H), 5.01 (s, 1H), 
5.00–4.95 (m, 1H), 4.38–4.34 (m, 1H), 4.16–4.07 (m, 2H), 4.06–3.99 (m, 2H), 3.96–3.89 
(m, 2H), 3.83–3.77 (m, 1H), 3.66–3.59 (m, 4H), 3.49–3.40 (m, 2H), 2.87–2.77 (m, 1H), 
2.58–2.53 (m, 1H), 2.40–2.30 (m, 3H), 2.16–0.93 (m, 56H), 1.20 (s, 6H), 0.94 (d, J = 6.4 
Hz, 3H), 0.88 (t, J = 6.9 Hz, 3H), 0.55 (s, 3H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1, for 
3-O-53): δ 173.5, 155.2, 147.9, 143.2, 133.2, 124.7, 117.5, 111.6, 75.6, 72.3 (2C), 71.2, 
71.0, 70.7, 69.8, 68.8, 68.2, 65.4, 62.7, 57.0, 56.7, 46.3, 44.6, 41.6, 40.9, 40.0, 36.8, 36.5, 
34.3, 32.3, 30.0 (16C), 28.0, 26.3 (2C), 24.0, 23.0, 22.5, 21.5, 21.2, 19.0, 14.3, 12.2. IR 
(neat): 3371, 2923, 2853, 1737, 1641, 1464, 1377, 1261, 1104, 1065. HRMS (ESI-) 
C57H100O14P, m/z [M-] 1039.6856, found 1039.6833. 
 
1-O-(2,2-difluorobutanoyl) 1α,25-dihydroxyvitamin D3 (1-O-56) and 3-O-(2,2-
difluorobutanoyl) 1α,25-dihydroxyvitamin D3 (3-O-56) 
Calcitriol (5.0 mg, 0.012 mmol) and 2,2-difluorobutanoic acid (1.5 µL, 0.014 mmol) were 
dissolved in CH2Cl2 (0.33 mL) and THF (40 µL). EDCI (3 mg, 0.016 mmol) and DMAP (2 
mg, 0.016 mmol) were added and the reaction mixture was stirred at 20 °C. After 2 h 
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further amounts of 2,2-difluorobutanoic acid (1.5 µL, 0.014 mmol), EDCI (3 mg, 0.016 
mmol) and DMAP (2 mg, 0.016 mmol) were added and the mixture was stirred for 18 h 
more, then concnetrated in vacuo and purified by column chromatography (heptane/EtOAc 
3:1 then heptane/EtOAc 1:1) to afford 0.5 mg (8%) of pure 3-O-56 and 1.1 mg (17%) as a 
1:1 mixture of 1-O-56 and 3-O-56 (determined by 500 MHz 1H NMR). Also, 2.0 mg 
(40%) of calcitriol was reisolated. 1H NMR (500 MHz, CDCl3, for 1-O-56): δ 6.42 (d, J = 
11.2 Hz, 1H), 5.89 (d, J = 11.2 Hz, 1H), 5.64–5.61 (m, 1H), 5.43 (s, 1H), 5.14 (s, 1H), 
4.22–4.17 (m, 1H), 2.83 (dd, J = 10.6, 3.5 Hz, 1H), 2.67 (dd, J = 12.2, 4.2 Hz, 1H), 2.32 
(dd, J = 12.2, 9.5 Hz, 1H), 2.24–0.80 (m, 22H), 1.23 (s, 6H), 1.01 (t, J = 7.5 Hz, 3H), 0.94 
(d, J = 6.2 Hz, 3H), 0.50 (s, 3H). 1H NMR (500 MHz, CDCl3, for 3-O-56): δ 6.37 (d, J = 
11.2 Hz, 1H), 6.00 (d, J = 11.2 Hz, 1H), 5.40–5.35 (m, 2H), 5.05 (s, 1H), 4.47–4.43 (m, 
1H), 2.80 (dd, J = 12.1, 4.1 Hz, 1H), 2.68 (dd, J = 13.4, 3.0 Hz, 1H), 2.49 (dd, J = 13.4, 6.8 
Hz, 1H), 2.16–0.80 (m, 22H), 1.23 (s, 6H), 1.02 (t, J = 7.5 Hz, 3H), 0.95 (d, J = 6.4 Hz, 
3H), 0.55 (s, 3H). MALDI-TOF (ES+) Calcd. for C31H48F2O4  (M+Na+) 545.34. Found: 
545.05. 
 
2-Trimethylsilylethyl adipate (58)198 
Adipic acid (57, 730 mg, 5.0 mmol), 2-trimethylsilylethanol (1.01 mL, 7.1 mmol) and 
TsOH·H2O (5 mg, 0.025 mmol) were dissolved in toluene (5.0 mL). A Dean Stark 
distilling trap was attached to the reaction flask and the reaction mixture was heated to 
reflux. After 2.5 h the mixture was purified directly by column chromatography (heptane 
then heptane/EtOAc 3:1) to afford 587 mg (48%) of 58 as a colorless oil. 1H NMR (300 
MHz, CDCl3): δ 11.6 (s, 1H, OH), 4.17–4.11 (m, 2H), 2.39–2.26 (m, 4H), 1.69–1.61 (m, 
4H), 1.00–0.92 (m, 2H), 0.01 (s, 9H). 13C NMR (75 MHz, CDCl3): δ 179.7, 173.6, 62.7, 
34.1, 33.8, 24.4, 24.2, 17.4, –1.4 (3C).  
 
Benzyl 4-pentenoate (60) 
4-Pentenoic acid (59, 2.0 g, 20.0 mmol), BnOH (3.1 mL, 30.0 mmol) and DMAP (1.2 g, 
10.0 mmol) were dissolved in CH2Cl2 (50 mL). EDCI (5.0 g, 26.0 mmol) was added and 
the reaction mixture was stirred at 20 °C for 1.5 h, then the mixture was concentrated in 
vacuo and purified by column chromatography (heptane then heptane/EtOAc 5:1) to afford 
2.46 g (65%) of 60 as a colorless oil. Rf = 0.77 (heptane/EtOAc 1:1). 1H NMR (300 MHz, 
CDCl3):231 δ 7.30–7.24 (m, 5H), 6.05 (tdd, J = 5.8, 10.3, 16.5 Hz, 1H), 5.04 (s, 2H), 5.01–
4.89 (m, 2H), 2.41–2.30 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 172.9, 136.7, 136.1, 128.6 
(2C), 128.3 (3C), 115.7, 66.3, 33.6, 28.9. 
 
7-Ethoxy-6,6-difluoro-7-oxoheptanoic acid (62) using NiCl2 and Zn  
NiCl2·6H2O (110 mg, 0.46 mmol) and Zn (312 mg, 4.80 mmol) were dissolved in THF 
(4.8 mL), one drop of H2O was added and the mixture was stirred at 20 °C for 10 min 
under N2 atmosphere. Then alkene 60 (913 mg, 4.80 mmol) in THF (0.9 ml) and ethyl 2,2-
difluoro-2-iodo-acetate (61, 600 mg, 2.40 mmol) in THF (0.9 mL) were added. The 
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reaction mixture was stirred at 20 °C for 16 h and then transferred to a flask with a 
saturated aqueous solution of NH4Cl (15 mL) and Et2O (30 mL). The black solid was 
removed by filtration and the organic layer was isolated by extraction with Et2O (2×20 
mL), the combined organic layers were dried over Na2SO4 and concentrated in vacuo. The 
residue was purified by column chromatography (heptane/EtOAc 10:1) to afford 344 mg of 
a colorless oil, that was dissolved in EtOAc (12 mL) and Pd/C (10 wt%, 51 mg, 0.058 
mmol) was added. The mixture was stirred at 20 °C for 1 h under an atmosphere of H2, 
after which filtration through celite gave 245 mg (46%) of 62 as a colorless oil. 1H NMR 
(300 MHz, CDCl3): δ 11.4 (s, 1H, OH), 4.33 (q, J = 7.1 Hz, 2H), 2.39 (t, J = 7.3 Hz, 2H), 
2.17–2.01 (m, 2H), 1.71 (p, J = 7.3 Hz, 2H), 1.61–1.50 (m, 2H), 1.36 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ 179.7, 164,4 (t, J = 33 Hz), 116,2 (t, J = 250 Hz), 63.0, 34.2 
(t, J = 23.4 Hz), 33.8, 24.1, 21.1 (t, J = 4.4 Hz), 14.1. 19F NMR (282 MHz, CDCl3): δ –
106.5 (t, J = 16.8 Hz). IR (neat): 2944, 2878, 1760, 1706, 1181, 1095, 1020. HRMS (ESI+) 
C9H14O4F2, m/z [M+NH4+] 224.1204, found 224.1200. 
 
7-Ethoxy-6,6-difluoro-7-oxoheptanoic acid (62) using Na2S2O4 
Alkene 60 (456 mg, 2.40 mmol) and ethyl 2,2-difluoro-2-iodo-acetate (61, 600 mg, 2.40 
mmol) were dissolved in a mixture of MeCN (7.2 mL) and H2O (2.4 mL) and cooled to 0 
°C. A mixture of Na2S2O4 (692 mg, 3.60 mmol) and NaHCO3 (302 mg) was added and the 
reaction mixture was allowed to reach 20 °C. After 15.5 h H2O (10 mL) was added and the 
organic layer was isolated by extraction with Et2O (2×40 mL), the combined organic layers 
were dried over Na2SO4, filtered and concentrated in vacuo. The residue was dissolved in 
Et2O (4.3 mL) and DBU (0.32 mL, 2.12 mmol) was added and the mixture was stirred at 
20 °C. After 3.5 h a saturated aqueous solution of NH4Cl (40 mL) was added and the 
organic layer was isolated by extraction with Et2O (2×60 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. The residue was purified by 
column chromatography (heptane/EtOAc 6:1 then heptane/EtOAc 3:1) to afford 415 mg of 
a colorless oil that was dissolved in EtOAc (18.3 mL) along with Pd/C (10 wt%, 79 mg, 
0.065 mmol). The mixture was stirred at 20 °C for 3 h under an atmosphere of H2, after 
which filtration through celite gave 298 mg (55%) of 62 as a colorless oil. 
 
Lithium 2,2-difluoro-7-oxo-7-(2-(trimethylsilyl)-ethoxy)-heptanoate (63) 
Carboxylic acid 62 (81 mg, 0.36 mmol) and 2-trimethylsilyl ethanol (67 µL, 0.47 mmol) 
were dissolved in THF (3.6 mL). 2,4,6-Trichlorobenzoyl chloride (61 µL, 0.40 mmol) and 
then DMAP (88 mg, 0.72 mmol) were added. The mixture was stirred at 20 °C for 50 min, 
then concentrated in vacuo and purified by column chromatography (heptane/EtOAc 8:1) 
to give 117 mg of a colorless oil, that was dissolved in THF (5.5 mL) and H2O (1.4 mL) 
and cooled to 0 °C. To the cold solution LiOH (2.9 mg, 0.12 mmol) was added and after 20 
min and 40 min the same amount of LiOH (2.9 mg, 0.12 mmol) was added. After 1 h 
toluene (40 mL) was added and the mixture was concentrated in vacuo to afford 108 mg 
(99%) of 63 as a colorless amorphous solid. 1H NMR (300 MHz, CDCl3): δ 4.19–4.12 (m, 
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2H), 2.26 (t, J = 7.2 Hz, 2H), 2.06–1.85 (m, 2H), 1.65–1.51 (m, 2H), 1.50–1.36 (m, 2H), 
1.02–0.92 (m, 2H), 0,03 (s, 9H). 13C NMR (50 MHz, CDCl3): δ 175.0, 171.1 (t, J = 33 Hz), 
118.3 (t, J = 244 Hz), 63.1, 34.2, 33.6 (t, J = 23 Hz), 24.4, 21.4, 17.2, –1.4. 19F NMR (282 
MHz, CDCl3): δ  –106.1. IR (neat): 2954, 2899, 1731, 1639, 1452, 1249, 1099 cm-1. 
HRMS (ESI+) C12H22O4F2Si, m/z [M+NH4+] 314.1599, found 314.1598.  
 
Lithium 7-(tert-butoxy)-2,2-difluoro-7-oxoheptanoate (64) 
The synthesis was performed as for 63, starting from carboxylic acid 62 (64 mg, 0.29 
mmol) and tert-butanol (53 µL, 0.57 mmol) and affording 74 mg (86 %) of 64 as a 
colorless amorphous solid. 1H NMR (300 MHz, CDCl3): δ 2.26–2.12 (m, 2H), 2.05–1.83 
(m, 2H), 1.63–1.48 (m, 2H), 1.48–1.35 (m, 11H). 13C NMR (75 MHz, CDCl3): δ 174.4, 
171.2 (t, J = 29.0  Hz), 118.2 (t, J = 249 Hz), 81.0, 35.4, 33.9 (t, J = 24.7 Hz), 28.1 (3C), 
24.6, 21.1. 19F NMR (282 MHz, CDCl3): δ –106.2 (t, J = 17.2 Hz). IR (neat): 3468, 2978, 
2936, 1727, 1637, 1451, 1368, 1152, 1100. HRMS (ESI+) C11H18O4F2, m/z [M+NH4+] 
270.1517, found 270.1517. 
 
1-O-Octadecyl-2-(7-ethoxy-6,6-difluoro-7-oxoheptanoyl)-sn-glycero-3-phospho-(S)-
glycerol (66) 
Alcohol 29 (40 mg, 0.051 mmol) and carboxylic acid 62 (17 mg, 0.077 mmol) were 
dissolved in THF (1.0 mL). 2,4,6-Trichlorobenzoyl chloride (12 µL, 0.077 mmol) and then 
DMAP (13 mg, 0.10 mmol) were added and the reaction mixture was stirred at 20 °C for 1 
h, then concentrated in vacuo and purified by column chromatography (heptane/EtOAc 5:1 
then hepatne/EtOAc 3:1) to afford 43 mg of a colorless oil, that was dissolved in CH2Cl2 
(4.0 mL) along with DBU (6.0 µL, 0.040 mmol). The reaction mixture was stirred at 20 °C 
for 1 h and then purified directly by column chromatography (heptane/EtOAc 1:1 then 
CH2Cl2/MeOH 9:1) to give 38 mg of a colorless oil, that was dissolved in a mixture of 
MeCN (3.3 mL) and CH2Cl2 (1.1 mL) and cooled to 0 °C. Aqueous HF (40%, 0.20 mL) 
was added and the reaction mixture was allowed to reach 20 °C. After 3.5 h excess reagent 
was quenched by dropwise addition of MeOSiMe3 (0.75 mL) and the mixture was stirred 
for 30 min, after which NaHCO3 (10 mg, 0.12 mmol) was added and the mixture was 
concentrated in vacuo and purified by column chromatography (CH2Cl2/MeOH 10:1 then 
CH2Cl2/MeOH 4:1) to give 25 mg (67%) of 66 as a colorless amorphous solid. Rf = 0.11 
(CH2Cl2/MeOH 4:1). 1H NMR (500 MHz, CDCl3/CD3OD 4:1): δ 5.19–5.14 (m, 1H), 4.33 
(q, J = 7.1 Hz, 2H), 4.12–4.03 (m, 2H), 4.01–3.95 (m, 2H), 3.80–3.85 (m, 1H), 3.64–3.61 
(m, 2H), 3.59–3.57 (m, 2H), 3.49–3.39 (m, 2H), 2.39 (t, J = 7.4 Hz, 2H), 2.14–2.04 (m, 
2H), 1.73–1.67 (m, 2H), 1.57–1.51 (m, 4H), 1.36 (t, J = 7.1 Hz, 3H), 1.32–1.23 (m, 30H), 
0.88 (t, J = 6.9 Hz, 3H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 173.4, 164.8, 116.5 (t, 
J = 250 Hz), 72.2, 71.7, 71.0, 69.0, 67.7, 65.4, 63.4, 62.2, 34.1 (t, J = 23 Hz), 33.9, 32.3, 
29.8 (13C), 26.3, 24.6, 23.0, 21.3, 14.3, 14.1. 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ 
–0.47. IR (neat): 3406, 2924, 2853, 1765, 1738, 1452, 1241, 1098, 1065, 1044 cm-1. 
HRMS (ESI-) C33H62O11F2P, m/z [M-] 703.4002, found 703.3981. 
9. Experimental: Liposomal Drug Delivery 
123 
 
7-Benzyloxy- 6,6-difluoro-7-oxoheptanoic acid (67) 
Lithium salt 64 (31 mg, 0.12 mmol) and benzyl alcohol (19 µL, 0.18 mmol) were dissolved 
in THF (1.1 mL). 2,4,6-Trichlorobenzoyl chloride (21 µL, 0.14 mmol) and then DMAP (29 
mg, 0.24 mmol) were added and the mixture was stirred at 20 °C for 3 h, then concentrated 
in vacuo and purified by column chromatography (heptane/EtOAc 10:1) to give 27 mg of a 
colorless oil, that was dissolved in CH2Cl2 (2.0 mL). Triisopropylsilane (79 µL, 0.40 
mmol) and TFA (0.36 mL, 4.74 mmol) were added and after stirring for 1 h at 20 °C 
toluene (5 mL) was added and the mixture was concentrated in vacuo. The residue was 
purified by column chromatography (heptane/EtOAc 10:1 then heptane/EtOAc 2:1) to give 
13 mg (38%) of 67 as a colorless oil. 1H NMR (300 MHz, CDCl3): δ 7.40–7.38 (m, 5H), 
5.29 (s, 2H), 2.34 (t, J = 7.3 Hz, 2H), 2.17–2.00 (m, 2H), 1.67 (p, J = 7.3 Hz, 2H), 1.55–
1.44 (m, 2H). 13C NMR (75 MHz, CDCl3): δ 179.2, 164.2 (t, J = 33 Hz), 134.4, 129.0, 
128.9, 128.6, 116.2 (t, J = 250 Hz), 68.4, 34.3 (s, J = 23 Hz), 33.6, 24.1, 21.1 (t, J = 4.4 
Hz). 19F NMR (282 MHz, CDCl3): δ –106.2 (t, J = 16.8 Hz). IR (neat): 3036, 2949, 1763, 
1706, 1456, 1293, 1172, 1098. HRMS (ESI+) C14H16O4F2, m/z [M+NH4+] 304.1361, found 
304.1358. 
 
1-O-Octadecyl-2-(7-hydroxy-6,6-difluoro-7-oxoheptanoyl)-sn-glycero-3-(2-
cyanoethylphospho)-(S)-2,3-di-O-tert-butyldimethylsilyl-glycerol (68) 
Alcohol 29 (25 mg, 0.032 mmol) and carboxylic acid 67 (13 mg, 0.045 mmol) were 
dissolved in THF (1.0 mL). 2,4,6-Trichlorobenzoyl chloride (6.9 µL, 0.045 mmoL) and 
then DMAP (8 mg, 0.064 mmol) were added and the reaction mixture was stirred at 20 °C 
for 21 h, then concentrated in vacuo and purified by column chromatography 
(heptane/EtOAc 10:1 then hepatane/EtOAc 3:1) to afford 20 mg of the desired ester, that 
was dissolved in a mixture of EtOAc (2.0 mL) and THF (1.0 mL). Pd/C (10 wt%, 10 mg, 
0.01 mmol) was added and the mixture was stirred under an atmosphere of H2 for 4 h at 20 
°C, after which filtration through celite gave 16 mg (52%) of 68 (two diastereoisomers 1:1) 
as a colorless oil. 1H NMR (300 MHz, CDCl3, two diastereoisomers): δ 5.21–5.12 (m, 1H), 
4.32–4.11 (m, 5H), 4.03–3.95 (m, 1H), 3.90–3.83 (m, 1H), 3.60–3.50 (m, 4H), 3.46–3.38 
(m, 2H), 2.78 (t, J = 5.7 Hz, 2H), 2.37 (t, J = 6.8 Hz, 2H), 2.10–1.92 (m, 2H), 1.72–1.60 
(m, 2H), 1.60–1.42 (m, 4H), 1.35–1.17 (m, 30H), 0.93–0.81 (m, 21H), 0.10 (s, 3H), 0.09 
(s, 3H), 0.07 (s, 6H). 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ –1.27, –1.47. IR (neat): 
2924, 2854, 1737, 1655, 1463, 1251, 1099, 1036. HRMS (ESI+) C46H90O11F2NPSi2, m/z 
[M+Na+] 980.5651, found 980.5623.  
 
1-O-Octadecyl-2-(7-((5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,25-diol-3-
oxy)-6,6-difluoro-7-oxoheptanoyl)-sn-glycero-3-phospho-(S)-glycerol (3-O-69) 
Carboxylic acid 68 (31 mg, 0.033 mmol) and calcitriol (14 mg, 0.033 mmol) were 
dissolved in THF (2.0 mL). 2,4,6-Trichlorobenzoyl chloride (5.0 µL, 0.033 mmol) and 
then DMAP (8 mg, 0.066 mmol) were added and the mixture was stirred at 20 °C for 4 h, 
then concentrated in vacuo and purified by column chromatography (CH2Cl2 then 
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CH2Cl2/EtOAc 2:1) to give 14 mg of a colorless oil, that was dissolved in CH2Cl2 (2.0 mL) 
along with DBU (1.6 µL, 0.010 mmol). The reaction mixture was stirred at 20 °C for 1 h 
and then purified directly by column chromatography (heptane/EtOAc 1:3 then 
CH2Cl2/MeOH 9:1) to give 9 mg of a colorless oil, that was dissolved in a mixture of 
MeCN (1.0 mL) and CH2Cl2 (0.33 mL) and cooled to 0 °C. Aqueous HF (40%, 60 µL) was 
added and the reaction mixture was stirred at 0 °C. After 3 h excess reagent was quenched 
by dropwise addition of MeOSiMe3 (0.25 mL) and the mixture was stirred for 30 min, after 
which NaHCO3 (4 mg, 0.048 mmol) was added and the mixture was concentrated in vacuo 
and purified by column chromatography (CH2Cl2/MeOH 9:1 then CH2Cl2/MeOH 4:1) to 
give 8 mg (22%) of 1:6 mixture of 1-O-69 and 3-O-69 (determined by 500 MHz 1H NMR) 
as a colorless amorphous solid. Rf = 0.14 (CH2Cl2/MeOH 4:1). 1H NMR (500 MHz, 
CDCl3/CD3OD 4:1 for 3-O-69): δ 6.31 (d, J = 11.1 Hz, 1H), 6.05 (dd, J = 11.1 Hz, 1H), 
5.40 (s, 1H), 5.37–5.33 (m, 1H), 5.19–5.13 (m, 1H), 5.04 (s, 1H), 4.39–4.34 (m, 1H), 4.18–
4.06 (m, 2H), 4.06–3.96 (m, 2H), 3.85–3.81 (m, 1H), 3.65–3.56 (m, 4H), 3.49–3.41 (m, 
2H), 2.81 (dd, J = 11.8, 3.4 Hz, 1H), 2.66–2.61 (m, 1H), 2.52 (dd, J = 14.1, 5.8 Hz, 1H), 
2.41–2.35 (m, 2H), 2.19–0.98 (m, 58H), 1.20 (s, 6H), 0.94 (d, J = 6.4 Hz, 3H), 0.88 (t, J = 
6.9 Hz, 3H), 0.55 (s, 3H). 13C NMR (50 MHz, CDCl3/CD3OD 4:1 for 3-O-69): δ 173.2, 
164 (missing), 147.2, 143.7, 131.9, 125.2, 117.3, 116.0, 112.2, 73.6, 72.2 (2C), 71.2, 70.8, 
69.7, 68.8, 68.0, 65.7, 62.6, 56.9, 56.6, 46.2, 44.5, 44.0, 41.3, 40.8, 36.7, 36.4, 34.4, 34.0, 
32.2, 30.0 (15C), 27.9, 26.3 (2C), 24.5, 23.8, 23.0, 22.5, 21.2 (2C), 19.0, 14.3, 12.1. IR 
(neat): 3337, 2925, 2854, 1737, 1717, 1658, 1585, 1479, 1259, 1198, 1146, 1073, 1045. 
HRMS (ESI+) C58H100O13F2PNa, m/z [M+H+] 1097.6840, found 1097.6872. 
 
Benzyl 5-hydroxypentanoate (70) 
δ-Valerolactone (5.90 g, 59.2 mmol) and NaOH (2.37 g, 59.2 mmol) were dissolved in 
H2O (59 mL) and the mixture was stirred at 70 °C for 5.5 h. Concentration in vacuo gave a 
white solid, which was concentrated with toluene (2×20 mL) to remove traces of H2O. The 
white solid was dissolved in a mixture of MeCN (60 mL) and acetone (60 mL) along with 
benzyl bromide (8.46 mL, 71.1 mmol) and Bu4NBr (955 mg, 2.96 mmol). The reaction 
mixture was stirred at 55 °C for 22 h, then concentrated in vacuo and purified by column 
chromatography (heptane/EtOAc 1:1) to afford 6.20 g (54%) of 70 as a colorless oil. 1H 
NMR (300 MHz, CDCl3):232 δ 7.33–7.29 (m, 5H), 5.08 (s, 2H), 3.57 (t, J = 6.2 Hz, 2H), 
2.69 (s, 1H, OH), 2.36 (t, J = 7.3 Hz, 2H), 1.74–1.64 (m, 2H), 1.59–1.49 (m, 2H). 13C 
NMR (75 MHz, CDCl3): δ 173.5, 135.9, 128.4 (2C), 128.1, 128.0 (2C), 66.1, 61.8, 33.8, 
31.9, 21.1.  
 
1-O-Octadecyl-3-O-(tert-butyldimethylsilyl)-sn-glycerol (71)  
Alcohol 5b (500 mg, 1.08 mmol) was dissolved in THF (3 mL), TBDMSCl (206 mg, 1.37 
mmol) and imidazole (138 mg, 2.03 mmol) were added and the reaction mixture was 
stirred at 20 °C for 1 h and then concentrated in vacuo. The residue was purified by column 
chromatography (heptane then heptane/EtOAc 5:1) to afford 642 mg of a white solid, that 
9. Experimental: Liposomal Drug Delivery 
125 
 
was dissolved in CH2Cl2 (8 mL) followed by addition of DDQ (277 mg, 1.22 mmol) and 
H2O (0.44 mL). The reaction mixture was stirred at 20 °C for 1 h, then Na2SO4 was added 
and the mixture was purified directly by column chromatography (heptane then 
heptane/EtOAc 10:1) to give 407 mg (82%) of 71 as a colorless oil. 1H NMR (300 MHz, 
CDCl3):233 δ 3.87–3.85 (m, 1H), 3.70–3.60 (m, 2H), 3.50–3.41 (m, 4H), 2.48 (d, J = 4.5 
Hz, OH), 1.67–1.53 (m, 2H), 1.26 (s, 30H), 0.91–0.88 (m, 12H), 0.08 (s, 6H). 13C NMR 
(75 MHz, CDCl3): δ 71.8, 71.5, 70.8, 64.2, 32.1, 29.9 (11C) 29.6, 29.5, 26.3, 26.0 (3C), 
22.9, 18.4, 14.3, –5.3 (2C). 20589][ = + 0.7 (c = 2.0, CHCl3).  
 
1-O-Octadecyl-2-((5-benzyloxy-5-oxopentyloxy)-carbonyl)-sn-glycerol (72) 
Alcohol 71 (100 mg, 0.22 mmol) was dissolved in CH2Cl2 (1.1 mL) and cooled to 0 °C. 
Triphosgene (33 mg, 0.11 mmol) and pyridine (30 µL, 0.35 mmol) were added and the 
reaction mixture was stirred at 0 °C for 1.5 h after which alcohol 70 (124 mg, 0.65 mmol) 
and pyridine (30 µL, 0.35 mmol) were added. The reaction mixture was allowed to reach 
20 °C and after 19.5 h the mixture was purified directly by column chromatography 
(toluene then toluene/EtOAc 10:1) to afford 117 mg of a colorless oil that was dissolved in 
a mixture of DMSO (4.3 mL), THF (3.5 mL) and H2O (0.43 mL) in a flask protected from 
light. NBS (184 mg, 1.03 mmol) was added and the reaction mixture was stirred at 20 °C 
for 18 h after which excess reagents were quenched by addition of an aqueous solution of 
Na2S2O3 (1%, 9.5 mL). The mixture was stirred for 10 min at 20 °C, then the organic layer 
was isolated by extraction with Et2O (3×25 mL). The combined organic phases were dried 
over Na2SO4, concentrated in vacuo and purified by column chromatography 
(heptane/EtOAC 5:1 then heptane/EtOAc 3:1) to give 82 mg (65%) of 72 as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 7.39–7.33 (m, 5H), 5.12 (s, 2H), 4.89–4.82 (m, 1H), 4.19–
4.14 (m, 2H), 3.88–3.83 (m, 2H), 3.67 (dd, J = 10.5 and 5.1 Hz, 1H), 3.63 (dd, J = 10.5 
and 5.2 Hz, 1H), 3.52–3.40 (m, 2H), 2.41 (t, J = 7.1 Hz, 2H), 2.25 (t, J = 6.4 Hz, 1H), 
1.77–1.71 (m, 4H), 1.59–1.52 (m, 2H), 1.33–1.22 (m, 30H), 0.89 (t, J = 6.7 Hz, 3H). 13C 
NMR (50 MHz, CDCl3): δ 173.2, 155.1, 136.1, 128.7 (2C), 128.4 (3C), 77.0, 72.1, 69.8, 
67.8, 66.4, 62.8, 33.8, 32.1, 29.8 (13C), 28.2, 26.2, 22.8, 21.4, 14.3. 20589][  = – 3.3 (c = 1.4, 
CHCl3). IR (neat): 3479, 2917, 2805, 1737, 1466, 1257, 1162, 1030. HRMS (ESI+) 
C34H58O7, m/z [M+Na+] 601.4075, found 601.4048. 
 
1-O-Octadecyl-2-((5-hydroxy-5-oxopentyloxy)-carbonyl)-sn-glycero-3-(2-
cyanoethylphospho)-(S)-2,3-di-O-tert-butyldimethylsilyl-glycerol (73) 
Alcohol 72 (80 mg, 0.14 mmol) and phosphoramidite 27 (99 mg, 0.19 mmol) were 
dissolved in CH2Cl2 (1.0 mL) and tetrazole (0.45 M in MeCN, 0.42 mL, 0.19 mmol) was 
added and the mixture was stirred for 30 min at 20 °C after which tBuOOH (5.5 M in 
nonane, 35 µL, 0.19 mmol) was added. After 80 min the mixture was concentrated in 
vacuo and purified by column chromatography (heptane/EtOAc 3:1 then heptane/EtOAc 
1:1) to afford 108 mg of colorless oil, that was dissolved in mixture of EtOAc (0.8 mL) 
and THF (0.8 mL). Pd/C (10 wt%, 5 mg, 0.005 mmol) was added and the mixture was 
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stirred under an atmosphere of H2 for 5 h at 20 °C, then concentrated in vacuo and purified 
by column chromatography (heptane/EtOAc 1:1 then CH2Cl2/MeOH 9:1) to afford 77 mg 
(61%) of 73 (two diastereoisomers 1:1) as a colorless oil. 1H NMR (300 MHz, CDCl3, two 
diastereoisomers): δ 5.05–4.97 (m, 1H), 4.41–4.12 (m, 7H), 4.07–3.96 (m, 1H), 3.92–3.83 
(m, 1H), 3.66–3.52 (m, 4H), 3.49–3.40 (m, 2H), 2.78 (t, J = 6.3 Hz, 2H), 2.43–2.37 (m, 
2H), 1.81–1.72 (m, 4H), 1.60–1.50 (m, 2H), 1.38–1.22 (m, 30H), 0.91–0.88 (m, 21H), 0.10 
(s, 3H), 0.09 (s, 3H), 0.06 (s, 6H). 13C NMR (50 MHz, CDCl3, two diastereoisomers): δ 
177.5, 154.6, 116.5, 74.6, 72.1 (2C), 69.7, 68.1 (2C), 66.6, 64.0, 62.2, 33.8, 32.1, 29.8 
(13C), 28.0, 25.9 (7C), 22.8, 21.4, 19.6, 18.2 (2C), 14.2, –4.7 (2C), –5.3 (2C). 31P NMR 
(202 MHz, CDCl3): δ –1.05, –1.27. HRMS (ESI+) C45H90NO12PSi2, m/z [M+Na+] 
946.5641, found 946.5649. 
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10. Synthesis of Small Natural-Product-Like Molecules 
 
10.1 Introduction 
This part of the thesis describes the synthesis of small natural-product-like molecules using 
a diversity-oriented synthesis (DOS) based strategy. The work was carried out during a six 
month research stay at University of Leeds under supervision of Professor Adam Nelson. 
This chapter constitutes an independent part of the thesis and have no relation with the 
investigation of liposomal drug delivery presented in the first part. 
  
In the aspiration to discover novel small molecules with biological activity the exploration 
of unknown chemical space has been suggested as a reasonable way to go.234,235 The 
introduction of combinatorial chemistry and DOS234,236,237,238 have liberated libraries of 
small molecules with high substitutional, stereochemical and/or scaffold 
diversity,239,240,241,242,243 but a lot of the chemical space remain unexplored. Recent studies 
by Lipkus et al. of the scaffold for known cyclic organic molecules244 have revealed that 
50% of the compounds are described by 0.25% of the known hetero frameworks (Table 
30) and the similarity in molecular skeletons for known organic molecules is even more 
significant when the scaffold analysis is made on graph frameworks (Table 30). Lipkus et 
al.244 conclude that the uneven distribution of frameworks amongst known organic 
compounds can reflects the way in which chemical space is usually explored, whereas 
Schreiber and co-workers see the lack of structural diversity as a potential bottleneck in the 
discovery of new drugs.234,244    
 
Table 30. Scaffold analysis for known cyclic organic molecules, registred in the CAS registry244 – 
examples of the terms hetero framework and graph framework is illustrated in the bottom of the Table.  
Hetero frameworks Graph frameworks 
●  2 594 176 frameworks in total. ● 836 708 frameworks in total. 
●  50% of the compounds are described by 
0.25% of the frameworks. 
● 70% of the compounds are described by 
0.20% of the frameworks. 
● 17% of the compounds have one of the 30 
most common frameworks. 
● 36% of the compounds have one of the 30 
most common frameworks. 
● 51% of the frameworks were found in just one 
compound. 
● 47% of the frameworks were found in just 
one compound. 
 
 
 
Thus there is a need for new synthetic strategies for making diverse molecules and 
recently, Nelson and co-workers245 have prepared a DOS library using a “double branching 
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then folding”xii strategy by which the synthesis of over 80 distinct scaffolds were achieved 
in 4 or 5 steps from simple building blocks using not more than six different reaction types 
(see Figure 53). The powerful strategy involved the attachment of pairs of unsaturated 
building blocks to a fluorous-tagged linker246 to give compounds like 81 and 82 (Figure 
53). The fluorous tag allowed removal of excess reagents at each stage by fluorous-solid 
phase extraction (F-SPE) only. 247  Metathesis cascades were used, as the “folding” 
pathway, to “reprogram” the scaffolds of the metathesis substrates and the design of the 
fluorous-tagged linker246 allowed only cyclised products to be released from the linker. 
Desilylation of the cyclic silaketals afforded the final products (like 85 and 86), and 
applying this strategy Nelson and co-workers synthesized more than 90 natural-product-
like molecules with an unprecedented structural diversity. 248 , 249 , 250  The synthesized 
molecules have many of the structural features that are present in natural products, 
including isolated, fused and spirocyclic ring systems, hydrogen bonding moieties, 
unsaturated carbon atoms and chiral centers, by which the molecules can be classified as 
natural-product-like. Known alkaloids like morphine, piperine and anabasine ( 
Figure 52) are examples on natural products having the mentioned features.  
 
 
 
 
Figure 52. Biological active alkaloids – which have some of the 
same structural features as in the natural-product-like molecules 
prepared by Nelson and co-workers.245   
 
 
Many of the natural-product-like molecules prepared by Nelson and co-workers have, due 
to the 2-nitrophenylsulfonyl (nosyl or Ns) protected amine, a scope for further 
derivatisation and the aim of this work was to prepare in a similar and elegant way a small 
library of natural-product-like molecules which after nosyl deprotection can be 
functionalized with various electrophiles. 
 
                                                 
xii In DOS terminology a “branching pathway”238,243 is when the same substrate is exposed to different 
reactions conditions (e.g. attachment of various building blocks using different reaction types) and a “folding 
pathway”238,242 is when different substrates are exposed to the same reaction conditions (e.g. a metathesis 
cascade).  
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Figure 53. Outline of the “double branching then folding” strategy used by Nelson and 
co-workers245 in the preparation of over 90 natural-product-like molecules with an 
unprecedented scaffold diversity.248,249,250  
  
10.2 Project Outline 
The DOS approach to synthesis of natural-product-like molecules in this work is outlined 
in Figure 54 and using DOS terminology the approach can be seen as a “branching-then-
folding-then-branching” strategy. The coupling between the fluorous-tagged building 
blocks and the non-fluorous-tagged building blocks using the Fukuyama-Mitsunobu 
reaction251 represents the first branching pathway. The fluorous tag can be seen as an 
anchor, which allows removal of excess reagents at each stage by F-SPE only.247 
Subjection of the coupling products (90 and 91 in Figure 54) to a metathesis catalyst 
provide a metathesis cascade, the folding pathway, in which the catalyst “zips up” and 
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recombines the skeleton of the unsaturated substrates yielding a different molecular 
scaffold in the products (92 and 93 in Figure 54). Removal of the nosyl group252,253 allows 
derivatisation of the amines with various electrophiles and with the fluorous tag remained 
in the molecules the second branching pathway can be done in parallel and with F-
SPE254,255,256 purification. Removal of the fluorous tag completes the approach to prepare 
diverse molecules with natural-product-like features.       
 
 
Figure 54. Outline of the approach to prepare natural-product-like molecules  
using a DOS based strategy. 
10. Synthesis of Small Natural-Product-Like Molecules 
131 
 
10.3 Synthesis of Fluorous-Tagged Building Blocks 
The fluorous tagged version (FDIPES) of diisopropylethylsilyl (DIPES) was introduced 
from the corresponding hydrosilane 96 through a NBS activation, yielding the silyl 
bromide 97 which in situ was reacted with primary alcohols yielding the desired 
attachment (Scheme 25 and Scheme 28). The hydrosilane 96 was purchased from 
commercial suppliers, Fluorous Technoligies Inc. or Sigma Aldrich, or synthesized from 
alcohol 94 that was converted into the iodide 95 and then into the desired silane 96 in 
excellent yields (Scheme 24), applying the conditions given by Carrel et al.257  
 
Scheme 24: Synthesis of the fluorous-tagged silane 24.a 
 
 
 
aReagents: (a) I2, PPh3, imidazole, Et2O, MeCN; (b) (i) tBuLi, Et2O; (ii) chlorodiisoproylsilane, Et2O. 
 
The fluorous-tagged building block 99 was made in one step from 2-methylene-1,3-
propanediol (98) and the hydrosilane 24 (Scheme 25) via the NBS activation, using the 
procedure used within the Nelson group to form silaketals.245,258 However the isolated 
yield never became higher than 39%.xiii The silianol was the major by-product indicating 
some moisture in the reaction mixture, whereas none of the starting hydrosilane 96 was re-
isolated demonstrating a good conversion into the silyl bromide 97.  
 
Scheme 25: Synthesis of the fluorous-tagged building block 99 via NBS activation of silane 96.a 
 
 
 
aReagents: (a) NBS, CH2Cl2; (b) 2-methylene-1,3-propanediol (98), DMAP; CH2Cl2. 
 
Conversion of the fluorous-tagged building block 99 into the corresponding sulfonamide 
87 was achieved via the Fukuyama-Mitsunobu reaction253 in a moderate yield on 45% 
(Scheme 26) applying the reagents 2-nitrophenylsulfonamide, PPh3 and DEAD in excess. 
Unfortunately, the reaction gave a couple of unindentified by-products hence it was 
necessary after the F-SPE purification to purify the compound by column chromatography. 
To increase the overall yield a two step procedure, starting with a Fukuyama-Mitsunobu 
                                                 
xiii Recent studies in the Nelson group have revealed that imidazole provides significantly better yields for these kinds of 
reactions than DMAP.  
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reaction between the alcohol 99 and the Boc-protected sulfonamide 100xiv followed by a 
Boc-deprotection, was attempted. Fukuyama et al.259 and Leach et al.246 have in almost 
quantitatively yield applied this strategy for the conversions of alcohols into sulfonamides. 
The Fukuyama-Mitsunobu reaction between 99 and sulfonamide 100 (Scheme 26) 
proceeded smoothly using F-SPE purification only to give the sulfonamide 101 in an 
excellent yield and good purity.xv  
 
Scheme 26: Conversion of the fluorous-tagged alcohol 99 into sulfonamides using the Fukuyama-
Mitsunobu reaction. 101 was isolated using F-SPE only with a mass recovery on 94% and a purity 
>95%.a 
 
aReagents: (a) NsNH2, PPh3, DEAD, THF; (b) NHNsBoc (100), PPh3, DEAD, THF. 
 
Unfortunately, the following Boc-deprotecting of 101 was not achievable (Scheme 27). 
Under standard Boc-deprotecting conditions, 5% TFA in CH2Cl2, the fluorous-tagged silyl 
ether was cleaved much faster (1 h) than the Boc-group, showing that the stability of 
FDIPES in an acid environment is limited and compared to the traditionally TIPS 
protecting group the stability is considerably lower. Application of TMSOTf and 2,6-
lutidine170 in CH2Cl2 did not gave any conversion of 101, and the starting material was re-
isolated with F-SPE. Finally, treatment of 101 in refluxing DMSO260 was attempted, but 
that resulted in deprotection of both the Boc-group and the FDIPES-group to give alcohol 
102. 
 
Scheme 27: Attempted Boc-deprotection of 101 using three different reactions 
conditions.a 
aReagents: (a) 5% TFA, CH2Cl2; (b) TMSOTf, 2,6-lutidine, CH2Cl2; (c) DMSO, 180 °C. 
 
                                                 
xiv Sulfonamide 100 was donated by Dr. Catherine O´Leary-Steele from the Nelson group, and was synthesised in one 
step from (Boc)2O, 2-nitrophenylsulfonamide, Et3N and DMAP in CH2Cl2 in 85% yield.  
xv The purity of the products purified by F-SPE only was determined by 500 MHz 1H NMR using signals from the 
fluorous tag as an internal standard. 
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The synthesis of the fluorous-tagged building block 88 was initiated from (R)-glycidol 
(103). The fluorous tag was introduced through the same NBS activation procedure as 
applied in the synthesis of 99 to give the desired silyl ether 104 (Scheme 28) in a similar 
yield as obtained for 99. The following expoxide opening was achieved with allyl 
magnesium bromide and Li2CuCl4, (Kochi’s Catalyst)261,262 to afford the fluorous-tagged 
alcohol 88 (Scheme 28). 
 
Scheme 28. Preparation of the fluorous-tagged building block 88.a  
 
 
 
aReagents: (a) Silyl bromide 97, DMAP, CH2Cl2; (b) allyl magnesium bromide, Li2CuCl4, Et2O. 
  
As for 99 it was desirable to convert the fluorous-tagged alcohol 88 into the corresponding 
sulfonamide (Scheme 29). The conditions applied for the conversion of 99 to 87 (Scheme 
26) were attempted, but none of the desired product was isolated, instead NMR of the 
isolated material revealed that a 1,2-silyl-migration had occurred to give alcohol 106.   
 
Scheme 29: Attempted conversion of the alcohol 16 into the corresponding sulfonamide 
34, which instead resulted in a 1,2-silyl-migration.a 
 
 
 
 
aReagents: (a) NsNH2, PPh3, DEAD, THF. 
 
Since the transformation of 88 into the corresponding sulfonamide 105 was not feasible in 
our hands a sulfonamide functionality was introduced by a Steglich coupling102 between 
the alcohol 88 and the amino acid derivate 108 to give the sulfonamide 109 (Scheme 30). 
108 was synthesized in one step from L-alanine (107) and 2-nitrophenylsulfonyl chloride 
(Scheme 30) via a procedure published by Ciolli et al.263  
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Scheme 30. Synthesis of amino acid derivate 108 and the fluorous-tagged building block 109.a 
 
 
aReagents: (a) Carboxylic acid 108, DCC, DMAP, CH2Cl2; (b) NsCl, NaOH, H2O, THF. 
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10.4 Synthesis of Non-Fluorous-Tagged Building Blocks 
The building blocks applied in this work are shown in Figure 55. Sulfonamide 80xvi and 
alcohol 111xvii were donated from members of the Nelson group.  
 
 
Figure 55. The applied non-fluorous-tagged building blocks –  two kinds of building blocks 
were used; sulfonamides and alcohols.   
 
The sulfonamide 110 was synthesized from the commercial available amine 113 and 2-
nitrophenylsulfonyl chloride (Scheme 31) in a 71% yield as white needles. It was crucial 
that the recrystallisation from 1:1 toluene–hexane removed all traces of 2-
nitrophenylsulfonyl derivates; otherwise it was observed that the Fukuyama-Mitsunobu 
reaction between 110 and various alcohols did not occur.    
 
The vinylacetate 112 was synthesized by a Steglich coupling102 between the diol 114 and 
vinylacetic acid (115, Scheme 31) in a poor yield on 31%. Although the reaction was 
carried out under dilute conditions (0.01 M) the diester 116 was also isolated in 11% yield. 
 
Scheme 31. Synthesis of the sulfonamide 110 and the ester 112.a 
 
H2N
a
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O
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aReagents: (a) NsCl, K2CO3, CH2Cl2; (b) DCC, DMAP, CH2Cl2. 
 
                                                 
xvi Alcohol 111 was donated by Dr. Stuart Leach, former member of the Nelson group, and was synthesised from 1,4-
butyndiol, allyl bromide and NaH in DMF in 63% yield. 
xvii Sulfonamide 80 was donated by Dr. Catherine O´Leary-Steele from the Nelson group and was synthesised over two 
step in 72%. The first step was a Fukuyama-Mitsunobu coupling between the alcohol 111 and the sulfonamide 100 
activated by PPh3 and DEAD in THF, followed by a Boc-deprotection with 10% TFA in CH2Cl2. 
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The last building block 89 was prepared in an excellent yield (Scheme 32) from the 
enantiomerically pure acetate 117xviii using a four step TBDMS-protection, deacetylation, 
allylation, desilylation sequence in which no purification of the intermediates was 
necessary.258  
 
Scheme 32. Four step synthesis of alcohol 89.a 
 
 
aReagents: (a) (i) TBDMSCl, imidazole, CH2Cl2; (ii) saturated solution 
of NH3 in MeOH; (iii) allyl bromide, NaH, DMF; (iv) TBAF, THF.  
 
                                                 
xviii Acetate 117 was donated by Dr. Thomas Woodhall, former member of the Nelson group. 
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10.5 Coupling of Building Blocks  
The coupling between the various fluorous-tagged building blocks and the non-fluorous-
tagged building blocks was achieved under mild conditions using the Fukuyama-
Mitsunobu reaction,251 and the fluorous tag allowed the use of reagents in excess due to the 
following F-SPE purification. The results are summarised in Table 31 and sulfonamide 118 
(entry 1) and 119 (entry 2) were obtained in good yields and purities after F-SPE 
purification only. To illustrate the potential of the F-SPE purification the 500 MHz 1H 
NMR spectrum for 119 is shown in Figure 56, emphasizing the good purity the fast and 
simple F-SPE purification delivers. In the preparation of sulfonamide 90 (entry 3), 91 
(entry 4) and 121 (entry 6) it was necessary after the F-SPE to purify the products by 
column chromatography, since a significant amount of other fluorous-tagged compounds 
also were formed. But the removal of excess reagents by F-SPE was still very valuable 
making the following purification by column chromatography much simpler than it would 
have been without the F-SPE step. The product formed from the coupling between 109 and 
112 (entry 6) was not the desired, the terminal double bond in the vinylacetate moiety was 
migrated forming 3-methylacryloate 121 instead. 
 
Figure 56. The 500 MHz 1H NMR spectrum for the Fukuyma-Mitsunobu coupling product 119 purified by F-
SPE only. 
 
  
0.05.010.0
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Table 31: Attachment of non-fluorous-tagged building blocks to the fluorous tagged building blocks using
the Fukuyama-Mitsunobu alkylation reaction.  
Entry Fluorous-tagged     
building block 
Non-fluorous-tagged 
building block 
Methoda Product 
(mass recovery) [purity] b 
1 
  
A 
 
2 
 
A 
3 
 
B 
4 
 
A 
5 
 
 
B 
6 
 
B 
aMethods: A: (i) fluorous-tagged alcohol (1 eq.), sulfonamide (4 eq.), PPh3 (4 eq.), DEAD (4 eq.), THF. (ii) 
F–SPE; B: fluorous-tagged sulfonamide (1 eq.), alcohol (4 eq.), PPh3 (4 eq.), DEAD (4 eq.), THF, when 
necessary additional amounts of alcohol, PPh3 and DEAD were used – see experimental section for details. 
(ii) F–SPE. bThe purity, determined by 500 MHz 1H-NMR spectroscopy, after F–SPE purification only. 
cYield after F–SPE and column chromatography purification.    
 
10. Synthesis of Small Natural-Product-Like Molecules 
139 
 
10.6 Metathesis Cascade Reactions 
The key step in the approach to prepare natural product-like molecules was the ring-
closing metathesis cascade which was used to “reprogram” the scaffold of the metathesis 
substrates (90, 91, 118, 119 and 120) into diverse molecules, having a rare but also natural 
product-like scaffold. Various ruthenium and molybdenum based catalysts have been 
developed for ring-closing metathesis,264,265,266 and particularly the stable and functional 
group tolerant ruthenium based catalysts, like G I267 and HG II268 (Figure 57) have been 
widely used in organic chemistry to formation of cyclic molecules, including numerous of 
natural products like callystatin,269 migrastatin,270 and cyclophellitol.271 
 
Figure 57. The applied metathesis catalysts; Grubbs Catalyst, 1st 
generation (G I) and Hoveyda-Grubbs Catalyst, 2nd generation (HG II)  
 
In this work HG II in refluxing CH2Cl2 (0.5 mM) was used in the metathesis cascades. 
Previous results from the Nelson group has demonstrated that HG II works well in 
metathesis cascades on similar substrates.245,246 In the ring-closing metathesis forming the 
six-membered ring in compound 112 (Table 32, entry 1) G I was applied. To prevent 
further metathesis reactions to occur during the work-up the catalyst was quenched by 
addition of P(CH2OH)3, Et3N and silica followed by filtration through celite. 272  This 
changed the color of the reaction mixture from green (for HG II) or purple (for G I) to 
almost colorless.  
 
 
Figure 58. Illustration of the supposed reaction pathway for the metathesis cascade in 
formation of the fused tricyclic 93. 
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The results for the metathesis cascades are summarised in Table 32, and gratifying the 
desired cascades occurred yielding the products in low to good yields. The “reprogram” of 
90 led to the formation of the fused tricyclic 92 (entry 3) and making the assumption that 
the metathesis cascade initiate at the terminal alkene273 the cascade proceed as illustrated in 
Figure 58. For some of the cascades (entry 2, 5 and 6) having an enyne ring-closing 
metathesis as part of the cascade more than more product was isolated and identified. In 
the literature it is an on-going discussion whether the mechanism for the enyne ring-
closing metathesis proceed by a ”yne-then-ene” pathway or by a "ene-then-yne" pathway. 
Recent studies indicate that the "ene-then-yne" pathway seems to be the most 
predominant, 274 , 275  but it depends on the substrate and the catalyst.274,275 Making the 
assumption that the transformation occurs by the “ene-then-yne” pathway the formation of 
the observed products (in entry 2, 5 and 6) can be explained by first an enyne ring-closing 
metathesis (step a in Figure 59) and then either a cycloaddition with the next double bond 
in the molecule (step b in Figure 59) forming the desired cascade product 123 or a 
cycloaddition with a terminal double bond in another molecule (step c in Figure 59) 
forming the pure enyne ring-closing metathesis product 124. In the metathesis cascade of 
substrate 120 (entry 5) the desired 10-membered ring in 125 was formed but in a much 
lower yield than the pure enyne ring-closing metathesis product 126. Presumably the 
explanation for this is that the intramolecular cycloaddition between the terminal alkene in 
the hexenyl moiety and the ruthenium carbene complex is less feasible in 120 than in 
substrates like 91 and 119, due to an increased flexibility and mobility. To increase the 
formation of the desired product the metathesis cascade was attempted in refluxing 
benzene (entry 6), but the yield of 125 was not improved and in addition to 125 and 126 
these conditions also forced the cross-metathesis product of 126 to be formed giving 127.  
 
 
 
Figure 59. The proposed reaction pathways to the metathesis cascade product 123 and to the 
pure enyne ring-closing metathesis product 124. 
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Table 32: Metathesis cascade reactions.  
Entry Metathesis substrate 
[purity] 
Catalysta 
(loading) 
Time Product(s) 
(yield)  
1 
 
G-I  
(5 mol%) 
2 h NNsFDIPESO
122 (95%)c
 
 
2 
 
 
 
 
HG-II  
(5 mol%) 
 
 
22 h 
 
 
3 
 
 
HG-II  
(5+10 mol%)
 
47 h 
 
4 
 
 
HG-II  
(5 mol%) 
 
22 h 
 
 
5 
  
 
HG-II  
(5+15 mol%)
 
 
19 h 
 
 
 
 
6 
  
 
 
HG-IIb  
(10 mol%) 
 
 
 
14.5 h
aReaction conditions: (i) Metathesis substrate, metathesis catalyst (G-I or HG-II), CH2Cl2 (0.5 mM), 45 °C; 
(ii) Et3N (86 eq.), P(CH2OH)3 (86 eq.) then silica then filter through celite; (iii) purification by column
chromatography unless otherwise stated. bReaction conditions: (i) Metathesis substrate, HG-II, benzene 
(0.5 mM), 80 °C; (ii) Et3N (86 eq.), P(CH2OH)3 (86 eq.) then silica then filter through celite; (iii) 
purification by column chromatography. cPurification by F-SPE only, mass recovery 95% and purity >90% 
purity (determined by 500 MHz 1H NMR).    
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10.7 Diels Alder Reaction with Cookson’s Reagent 
To increase the complexity of the dihydropyrrole 123 a Diels Alder reaction with the 
dienophile 128, called Cookson’s reagent,240,276,277 was attempted and achieved in a good 
yield (Scheme 33).   
 
Scheme 33: Diels-Alder reaction between the diene 123 and Cookson’s reagent 128. 
 
 
 
10.8 Nosyl Deprotection 
Nosyl became applicable as protecting group for amines when Fukuyama et al.251 
discovered that nosyl groups can be removed under mild conditions using thiolate 
nucleophiles. In general upon treatment with PhSH and K2CO3 in DMF251,252 at room 
temperature the nosyl group is cleaved off in good yields. But reaction conditions like 
PhSH and DBU in MeCN278 and the odourless decanethiol and NaH in DMF279 are also 
reported. The mechanism for the deprotection is believed to go through a Meisenheimer 
complex (Figure 60).251,252 
 
 
 
Figure 60. Mechanism for nosyl deprotection.251,252 
 
In this work the standard conditions, PhSH and K2CO3 in DMF was used and the nosyl 
deprotections were achieved in good yields (Table 33) within short reaction times (1 h) and 
the amines were isolated by F-SPE in good purity. In the F-SPE purification it was crucial 
to add 0.5% Et3N to the eluent systems otherwise it was observed that the amine stuck to 
the silica in the F-SPE cartridges. In the deprotection of 123 (entry 2 in Table 33) NMR 
analysis of the isolated material revealed that an aromatisation had occurred giving the 
pyrrole 131. The aromatisation was observed for the dihydropyrrole 123 only. 
  
10. Synthesis of Small Natural-Product-Like Molecules 
143 
 
Table 33: Nosyl deprotection using PhSH and K2CO3 in DMF.a  
Entry Nosyl  substratea Product 
(mass recovery) [purity] b 
1 
 
 
2 
 
3 
 
4 
 
133 (107%, [>80%]
FDIPESO
HN
O
 
5 
 
aReaction conditions: (i) nosyl substrate (1 eq.), K2CO3 (4 eq), PhSH (3 eq.), 
DMF; (ii) purification by F-SPE only unless otherwise stated. bThe purity, 
determined by 500 MHz 1H-NMR spectroscopy, after F–SPE purification 
only. cYield after purification by F-SPE and column chromatography.    
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10.9 Synthesis of the Final Products 
With the secondary amines in hand the next target was the functionalization with various 
electrophiles followed by removal of the fluorous-tag to give the final products. Four kinds 
of elctrophiles (acid chlorides, isocyanates, isothiocyanates and sulfonyl chlorides) were 
included in the preliminary screening for suitable candidates and the candidates were tested 
on amine 130 (Scheme 34 and Table 34). Benzoyl chloride (entry 1 in Table 34), phenyl 
isocyanate (entry 4), benzyl isothiocyanante (entry 6) and benzene sulfonyl chloride (entry 
7) were selected as representative for each type of electrophile. The electrophiles were 
reacted with the amine and the desired products were isolated in good yields and purities 
(Table 34) after F-SPE purification only. To make F-SPE applicable in purification of 
multiple reaction mixtures at the same time the F-SPE cartridges were placed in a 10 port 
SPE vacuum manifold (Figure 61).  
 
Scheme 34. Example on functionalization of fluorous-tagged amine with electrophile followed by removal of 
the fluorous tag on the silylated product in order to give the final product. For the silylated product the 
number in brackets and square brackets refers to the mass recovery and the purity, respectively.a 
 
 
aReagents: (a) (i) Benzoyl chloride, DMAP, CH2Cl2; (ii) F-SPE; (b) (i) HF, H2O, MeCN, CH2Cl2; (ii) column 
chromatography. 
 
The preliminary results revealed that acid chlorides, isocyanates, isothiocyanates and 
sulfonyl chlorides all were suitable electrophiles and further electrophiles, 2-
thiophenecarbonyl chloride (entry 2 in Table 34), 5-carbonylisoxazole chloride (entry 3), 
furfuryl isocyanate (entry 5) and methanesulfonyl chloride (entry 8) were selected and 
derivatization of amine 130 with these electrophiles was performed in parallel and purified 
by F-SPE only applying the “10 port SPE vacuum manifold” (Figure 61) and the desired 
products were obtained in good yields and purities. The electrophiles was selected with the 
aim that they should contribute with heteroatoms, which often are crucial for biological 
activity, and/or (different) ring-systems, which would diversify the molecular skeleton in 
the final products. The removal of the fluorous-tag was achieved with HF in a moist 
mixture of MeCN and CH2Cl2 and the desired products were isolated in moderate to good 
yields (Table 34, entry 1-4 and 6-8). It was attempted to isolate the final products by F-SPE 
purification, but that purification technique was not capable to deliver the required purity 
thus the reaction mixtures were purified by column chromatography. For the furfuryl urea 
76 (entry 5) none of the desired product was isolated after the HF-mediated deprotection, 
presumably as a consequence of decomposition of the acid sensitive furfuryl moiety. With 
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the promising results from the functionalization of amine 130 in hand the same 
transformations were performed on the other amines 132, 133 and (±)-134 (Table 34). 
When limited amounts of the amine (like for 132 and (±)-134) was produced fewer 
derivatives were made. As evident from Table 34 the derivatization of the amines 132, 133 
and (±)-134 with various electrophiles was achieved with good isolated yields and purities 
and in general also the removal of the fluorous tag was obtained in good yields. For the 
nosyl protected amine 92 (entry 21) a one-pot procedure was applied for the nosyl 
deprotection and the functionalization with phenyl isocyanate. The nosyl was deprotected 
using PhSH and DBU in MeCN and when TLC deduced full conversion (1.5 h) phenyl 
isocyanate was added and after 2 h the product 155 was isolated by F-SPE like the other 
silylated products. In total 20 final and novel products were synthesized. 
 
 
Figure 61. Pictures of 10 port SPE vacuum manifold with F-SPE cartridges. 
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Table 34. Functionalization of the amines (130, 132, 133 and (±)-134) with various electrophiles followed by
removal of the fluorous-tag to give the final products. 
Entry Fluorous-tagged Amine 
[purity] 
Electrophile Methoda Silylated product 
(mass recovery) 
[purity]b 
Final productc 
(yield) 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 135 
(78%) [>80%] 
2  
 
A 
 
136 
(88%) [>85%] 
3 
 
 
A 
 
137 
(83%) [>80%] 
 
4  
 
B 
 
138 
(73%) [>90%] NHO
159 (89%)
O
N
H
5 
 
B 139 
(88%) [>80%] 
none 
6  
 
C 
 
140 
(60%) [>90%] 
7  
 
D 141 
(83%) [>95%] 
8  
 
D 
 
142 
(77%) [>80%] 
NHO
162 (75%)
S
O CH3
O
9 
 
 
 
B 143 
(95%) [>75%] 
10  
 
 
 
 A 144 
(98%) [>85%] 
11  
 
A 145 
(98%) [>90%] 
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12  
 
 
 
 
 
 
 
 
 
A 146 
(91%) [>70%] 
13  
 
B 147 
(98%) [>85%] 
 
14  
 
C 148 
(77%) [>80%] 
 
15  D 149 
(86%) [>80%] 
16  
 
D 150 
(92%) [>80%] 
17  
 
 
 
 
 
 
 
 
A (±)-151 
(86%) [>95%] 
18  
 
A (±)-152 
(68%) [>80%] 
19  
 
 
B (±)-153 
(84%) [>95%] 
20  
 
D (±)-154 
(91%) [>95%] 
21 
 
 
 
 
E 155 
(100%) [>75%] 
aMethods: A: (i) fluorous-tagged amine (1 eq.), acid chloride (4 eq.), DMAP (5 eq.), CH2Cl2; (ii) parallel F-SPE; B: (i)
fluorous-tagged amine (1 eq.), isocyanate (4 eq.), CH2Cl2; (ii) parallel F-SPE; C: fluorous-tagged amine (1 eq.),
isothiocyanate (4 eq.), CH2Cl2; (ii) parallel F-SPE; D: (i) fluorous-tagged amine (1 eq.), sulfonyl chloride (4 eq.), DMAP
(5 eq.), CH2Cl2; (ii) parallel F-SPE; E: One-pot procedure – (i) nosyl protected amine (1 eq.), PhSH (3 eq.), K2CO3 (4
eq.), MeCN; (ii) isocyanate (8 eq.); (iii) parallel F-SPE. bThe purity, determined by 500 MHz 1H NMR spectroscopy, after
F-SPE purification only. cReagents: (i) HF, H2O, MeCN, CH2Cl2; (ii) purification by column chromatography.  
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10.10 Scaffold Analysis 
The molecular scaffold of the prepared library of natural-product-like molecules was 
analyzed using the framework concept proposed by Bemis et al.280 and introduced in the 
beginning of this chapter (Table 30). The analysis revealed that 15 different graph 
frameworks were prepared (Figure 62) and no graph framework was prepared more than 
two times. Gratifying, all 20 molecules have their own hetero framework (Figure 62), 
illustrating that the developed chemistry afford molecules with a broad diversity and that 
the functionalization of the secondary amines with various electrophiles contribute with a 
valuable increase in the complexity of the molecular scaffolds. Beyond the 
tetrahydropyridine compounds (156-162) none of the prepared molecules have a graph or 
hetero framework that there are amongst the 30 most common in the investigation done by 
Lipkus et al.244 (highlighted in Table 30) confirming the rarity and diversity of the 
prepared molecules.    
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Figure 62: Scaffold analysis on the synthesized molecules, showing that the 20 different molecules (red
numbers) have 15 different graph frameworks (blue structures) and 20 different hetero frameworks (green 
structures). 
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10.11 Conclusion 
In total 20 novel compounds with a broad structural diversity were prepared using a short 5 
or 6 steps “branching-then-folding-then-branching” strategy in overall yields from 75% to 
5% (36% in average). A limited number of reaction types were applied, including the 
Fukuyama-Mitsunobu reaction and the ring closing metathesis cascade as the key 
reactions. Furthermore, in average the rapid F-SPE purification was sufficient in 3 out of 5 
steps limiting the use of column chromatography. The prepared natural-product-like 
molecules are subjected to biological testing and it will be interesting to see whether some 
of the molecules will provide a biological response and potentially be a novel lead 
compound in the development of a new drug.     
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11. Experimental: Natural-Prodruct-Like Molecules 
 
11.1 General Experimental 
Starting materials, reagents and solvents were purchased from Sigma–Aldrich, Alfa Aesar 
or Fluorous Technologies and used without further purification unless otherwise stated. 
DMF, MeCN and CH2Cl2 were dried over 4 Å molecular sieves. THF was freshly distilled 
from Na, using benzophenone as a self-indicator. Saturated NH3 in MeOH (ca. 0.025 M) 
was prepared by bubbling NH3 gas through MeOH for a minimum of 30 min. NBS was 
recrystallised from water and dried under vacuum prior to use. Solvents were removed 
under reduced pressure using a Büchi rotary evaporator and a Vacuubrand diaphragm 
pump or a Genevac HT-4 evaporation system. Petrol refers to petroleum spirit (bp 40–
60 °C). Column chromatography was carried out using silica (35-70 μm particles). TLC 
was carried out on commercially available pre-coated plates (Merck silica Kieselgel 
60F254). 1H and 13C NMR spectra were recorded on a Bruker Avance 500, Avance 
DPX300 or DRX500 spectrophotometer with an internal deuterium lock. Chemical shifts 
are quoted in ppm downfield of tetramethylsilane and values of coupling constants are 
given in Hz. 13C NMR spectra were recorded with broad band proton decoupling. Melting 
points were determined on a Reichert hot stage apparatus and are uncorrected. Infrared 
spectra were recorded on a Perkin Elmer spectrum one FT-IR infrared spectrophotometer. 
Mass spectra were recorded using a Micromass LCT-KA111 electrospray mass 
spectrometer (for ES+ mode) or a Quatro II triple quadrupole instrument (for EI mode). 
Optical activity measurements were recorded at room temperature (20 °C) on an AA-1000 
polarimeter; units for  20D  are 10–1 deg cm2 g–1. 
 
11.2 General Procedures 
 
General Procedure for F-SPE Purification 
Fluorous–Solid Phase Extraction (F–SPE) was carried out using pre-packed FluoroFlash® 
cartridges purchased from Fluorous Technologies Inc. The F–SPE cartridges were washed 
extensively with acetone and were pre-conditioned with 8:2 MeOH–H2O. Crude reaction 
mixtures were loaded onto cartridges using CH2Cl2 or 8:2 MeOH–H2O, and eluted using 
8:2 MeOH–H2O as the fluorophobic eluent, and then MeOH as the fluorophilic eluent; 
compressed air was used in a manner similar to that described by Curran et al.247 
 
Procedure for Parallel F-SPE Purification  
The F–SPE cartridges (2 g) were placed in the ports of a 10 port SPE vacuum manifold and 
washed extensively with acetone and pre-conditioned with 160:40:1 MeOH–H2O–Et3N. 
The crude reaction mixtures were loaded onto the F–SPE cartridge by CH2Cl2 (0.2 mL), 
and the reaction flasks were rinsed with 160:40:1 MeOH–H2O–Et3N (1 mL) which was 
added to F–SPE cartridge as well. Elution under vacuum (ca. 100 mmHg) with 160:40:1 
MeOH–H2O–Et3N (3×3 mL) gave the fluorofrobic fraction which were collected in 17.5 
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mL vials after which elution under vacuum (ca. 100 mmHg) with 200:1 MeOH–Et3N (3×3 
mL) gave the fluorophilic fraction which were collected in 17.5 mL vials. The vials 
containing the fluorophilic fractions were concentrated on a Genevac EZ-2 vacuum 
centrifuge to give the purified products. The purity of the products purified by F-SPE only 
was determined by 500 MHz 1H NMR using signals from the fluorous tag as an internal 
standard. 
 
General Procedure A: Method for Fukuyama–Mitsunobu Reactions of Fluorous-
tagged Alcohols with a non-Fluorous-tagged Sulfonamide. 
The fluorous-tagged alcohol (1 eq.), the sulfonamide (4 eq.) and PPh3 (4 eq.) were 
dissolved in THF (0.022 M in alcohol) and cooled to 0 °C. DEAD (4 eq.) was added 
dropwise and the reaction mixture was allowed to reach room temperature and stirred for 1 
h after which the mixture was concentrated under reduced pressure and purified by F–SPE.  
 
General Procedure B: Method for Ring-closing Metathesis Reactions of Fluorous-
tagged Substrates. 
The metathesis substrate (1 eq.) was dissolved in CH2Cl2 (0.5 mM) and heated to reflux. 
Grubbs Catalyst, 1st generation (5 mol%) or Hoveyda-Grubbs Catalyst, 2nd generation (5 
mol%) was added and the reaction mixture was stirred until completion was indicated by 
TLC. The reaction mixture was cooled to room temperature, Et3N (86 eq.) and 
tris(hydroxymethyl)phosphine (86 eq.) were added and the mixture was stirred for 15 min 
after which silica (ca. 10 g per mmol of substrate) was added and the mixture was stirred 
for another 15 min. The suspension was filtrated through a pad of celite, washed with 
EtOAc, concentrated under reduced pressure and purified by F-SPE or column 
chromatography.  
 
General Procedure C: Method for 2-Nitrophenylsulfonyl Deprotection of Fluorous-
tagged Sulfonamides.  
The fluorous-tagged sulfonamide (1 eq.) and K2CO3 (4 eq.) were dissolved in DMF (0.05 
M). PhSH (3 eq.) was added dropwise and the reaction mixture was stirred at room 
temperature for 1 h. A solution of 160:40:1 MeOH–H2O–Et3N (5 mL per mL DMF) was 
added and the mixture was purified directly by F–SPE, eluting with 160:40:1 MeOH–
H2O–Et3N then 200:1 MeOH–Et3N.  
 
General Procedure D: Method for Amide Formation from Fluorous-tagged Amines. 
The fluorous-tagged amine (0.030 mmol) and DMAP (18 mg, 0.15 mmol) were dissolved 
in CH2Cl2 (0.5 mL) and the acid chloride (0.12 mmol) was added. The reaction mixture 
was stirred for 2 h at room temperature, concentrated under a flow of N2 and purified by F–
SPE. 
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General Procedure E: Method for Urea Formation from Fluorous-tagged Amines. 
The fluorous-tagged amine (0.030 mmol) was dissolved in CH2Cl2 (0.5 mL) and the 
isocyanate (0.12 mmol) was added. The reaction mixture was stirred for 2 h at room 
temperature, concentrated under a flow of N2 and purified by F–SPE.  
 
General Procedure F: Method for Thiourea Formation from Fluorous-tagged 
Amines. 
The fluorous-tagged amine (0.030 mmol) was dissolved in CH2Cl2 (0.5 mL) and the 
isothiocyanate (0.12 mmol) was added. The reaction mixture was stirred for 2 h at room 
temperature, concentrated under a flow of N2 and purified by F–SPE.   
 
General Procedure G: Method for Sulfonamide Formation from Fluorous-tagged 
Amines. 
The fluorous-tagged amine (0.030 mmol) and DMAP (18 mg, 0.15 mmol) were dissolved 
in CH2Cl2 (0.5 mL) and the sulfonyl chloride (0.12 mmol) was added. The reaction 
mixture was stirred for 2 h at room temperature, concentrated under a flow of N2 and 
purified by F–SPE. 
 
General Procedure H: Method for the FDIPES-deprotection  
The fluorous-tagged silyl ether (0.030 mmol) was dissolved in MeCN (0.5 mL) and 
CH2Cl2 (0.4 mL) and HF (50% aq, 0.1 mL) was added. The reaction mixture was stirred 
for 1.5 h at room temperature after which MeOSiMe3 (0.36 mL) was added and the 
mixture was stirred for another 1.5 h, concentrated under a flow a of N2 and purified by 
column chromatography, eluting with either 20:1 CH2Cl2–MeOH or 25:1 CH2Cl2–MeOH.    
 
11.3 Experimental Data for Compounds 
 
N-(3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-Heptadecafluorodecyl)-
diisopropyl-silyloxy)-2-methylene-propyl) 2-nitrobenzenesulfonamide (87) 
By general procedure A, the alcohol 99 (600 mg, 0.93 mmol), 2-nitrophenylsulfonamide 
(726 mg, 3.59 mmol), PPh3 (942 mg, 3.59 mmol) and DEAD (0.57 mL, 3.59 mmol) in 
THF (55 mL) gave a crude product which was purified by column chromatography, eluting 
with CH2Cl2, to give the sulfonamide 87 (349 mg, 45%) as a colorless oil, Rf 0.10 (10:1 
petrol–EtOAc); νmax/cm-1 (neat) 3348, 2948, 2869, 1542, 1359, 1208; δH (500 MHz, 
CDCl3) 8.12–8.10 (1H, m, nosyl 3-H), 7.87–7.85 (1H, m, nosyl 5-H), 7.74–7.72 (2H, m, 
nosyl 4-H and 6-H), 5.53 (1H, t, J 5.8, NH), 5.10–5.09 (1H, m, 2-CH2a), 5.05–5.04 (1H, m, 
2-CH2b), 4.17–4.16 (2H, m, 3-H2), 3.79–3.77 (2H, m, 1-H2), 2.14–2.02 (2H, m, 2'-H2), 
1.08-1.00 (14H, m, iPr), 0.87–0.83 (2H, m, 1'-H2); δC (75 MHz, CDCl3) 143.0, 133.7, 
132.8, 131.2, 125.4, 113.3, 64.7, 46.2, 17.6 (2C), 17.5 (2C), 12.5 (2C) (the signals for 
nosyl 1-C, 2-C, 1'-C, 2'-C and C8F17 are missing); m/z (ES+) (Found: MNa+ 855.1177, 
C26H29F17N2O5SSi requires MNa 855.1187).   
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(S)-(3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-Heptadecafluorodecyl)-
diisopropylsilyl 2-hydroxy-5-hexenyl ether (88) 
The epoxide 104 (658 mg, 1.04 mmol) was dissolved in Et2O (15 mL) and the mixture was 
cooled to –30 °C. Li2CuCl4 (0.1 M in THF, 0.26 mL, 0.025 mmol) and then allyl 
magnesium bromide (1 M in Et2O, 1.50 mL, 1.50 mmol) were added dropwise and the 
reaction mixture was stirred for 2 h at -30 °C, after which a saturated aqueous solution of 
NH4Cl (6 mL) was added and the mixture was allowed to reach room temperature and H2O 
(60 mL) was added. The organic layer was isolated by extraction with Et2O (3×60 mL) and 
the combined organic phases were concentrated under reduced pressure and purified by 
column chromatography, eluting with 97:3 petrol–EtOAc, to give the alcohol 88 (374 mg, 
53%) as a clear colorless oil, Rf 0.60 (9:1 petrol–EtOAc);  20D –3.0 (c 0.009 in CHCl3); δH 
(500 MHz, CDCl3) 5.83 (1H, ddt, J 17.0, 10.2 and 6.7, 5-H), 5.05 (1H, ddd, J 17.0, 3.4 and 
1.2, 6-Ha), 4.98 (1H, ddt, J 10.2, 2.1 and 1.2, 6-Hb), 3.70–3.67 (2H, m, 1-Ha and 2-H), 3.49 
(1H, dd, J 10.6 and 8.2, 1-Hb), 2.31 (1H, d, J 3.5, OH), 2.28–2.07 (4H, m, 4-H2 and 2'-H2), 
1.58–1.47 (2H, m, 3-H2), 1.08–1.03 (14H, m, iPr), 0.91–0.87 (2H, m, 1'-H2).  
 
Allyl (((1S,2S,3R,4R)-3-hydroxymethyl-7-oxa-bicyclo[2.2.1]-5-hepten-2-yl)-methyl) 
ether (89)258 
The alcohol 117 (1.35 g, 7.25 mmol) and imidazole (0.98 g, 14.5 mmol) were dissolved in 
CH2Cl2 (73 mL) and TBDMSCl (1.64 g, 10.9 mmol) was added. The reaction mixture was 
stirred at room temperature for 1.5 h after which the reaction mixture was concentrated 
under reduced pressure to give the crude ((1S,2S,3R,4R)-3-((tert-butyldimethylsilyloxy)-
methyl)-7-oxa-bicyclo[2.2.1]-hept-5-en-2-yl)-methyl acetate, Rf 0.82 (1:1 Petrol–EtOAc). 
The crude product was redissolved in a saturated solution of NH3 in MeOH (150 mL, 
0.025 M) and stirred at room temperature for 3 days after which the reaction mixture was 
concentrated under reduced pressure to give a colorless amorphous solid, which was 
treated with a saturated aqueous solution of NH4Cl (10 mL), H2O (150 mL) and Et2O (150 
mL). The organic layer was isolated by extraction with Et2O (2×150 mL) and the 
combined organic phases were concentrated under reduced pressure to give the crude 
((1S,2S,3R,4R)-3-((tert-butyldimethylsilyloxy)-methyl)-7-oxa-bicyclo[2.2.1]-hept-5-en-2-
yl)-methanol, Rf 0.10 (3:1 petrol–EtOAc). The crude product and allyl bromide (2.50 mL, 
29.0 mmol) were dissolved in  DMF (30 mL) and cooled to 0 °C. NaH (700 mg, 60% 
suspension) was added and the reaction mixture was stirred at room temperature for 16 h 
after which the reaction was quenched by addition of a saturated aqueous solution of 
NH4Cl (10 mL) and H2O (150 ml). The organic layer was isolated by extraction with Et2O 
(3×150 mL). The combined organic phases were concentrated under reduced pressure to 
give the crude allyl ((1S,2S,3R,4R)-3-((tert-butyldimethylsilyloxy)-methyl)-7-oxa-
bicyclo[2.2.1]-hept-5-en-2-yl)-methyl ether, Rf 0.68 (3:1 petrol–EtOAc). The crude product 
was dissolved in THF and TBAF (29 mL, 1.0 M in THF) was added. The reaction mixture 
was stirred at room temperature for 3 h after which the mixture was concentrated under 
reduced pressure and purified by column chromatography, eluting with 1:1 Petrol–EtOAc, 
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to give the alcohol 89 (1.34 g, 94%) as a yellow oil, Rf 0.19 (1:1 Petrol–EtOAc); δH (500 
MHz, CDCl3) 6.41 (1H, dd, J 5.8 and 1.6, 5-H or 6-H), 6.38 (1H, dd, J 5.8 and 1.6, 5-H or 
6-H), 5.92 (1H, ddt, J 17.2, 10.4 and 5.8, allyl 2-H), 5.30 (1H, ddd, J 17.2, 2.9 and 1.4, 
allyl 3-Htrans), 5.22 (1H, ddd, J 10.4, 2.4 and 1.1, allyl 3-Hcis), 4.74–4.72 (1H, m, 1-H or 4-
H), 4.71–4.69 (1H, m, 1-H or 4-H), 4.06–3.99 (2H, m, allyl 1-H2), 3.83 (1H, dd, J 11.1 and 
8.1, 3-CH2a), 3.71–3.65 (1H, m, 3-CH2b), 3.67 (1H, t, J 9.1, 3-CH2a), 3.60 (1H, dd, J 9.1 
and 6.6, 3-CH2b), 3.12–3.07 (1H, m, OH), 2.04 (1H, ddd, J 9.1, 8.1 and 6.6, 2-H), 1.94 
(1H, td, J 8.1 and 5.8, 3-H).  
 
N-(((1R,2R,3S,4S)-3-(Allyloxymethyl)-7-oxa-bicyclo[2.2.1]-5-hepten-2-yl)-methyl) N-
((3-(3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl-
silyloxy)-2-methylene-propyl) 2-nitrobenzenesulfonamide (90) 
The sulfonamide 87 (20 mg, 0.024 mmol), the alcohol 89 (19 mg, 0.096 mmol) and PPh3 
(25 mg, 0.096 mmol) were dissolved in THF (1.1 mL) and cooled to 0 °C. DEAD (0.15 
µL, 0.096 mmol) was added dropwise and the reaction mixture was allowed to reach room 
temperature. After 1 h  PPh3 (25 mg, 0.096 mmol) and DEAD ((0.15 µL, 0.096 mmol) 
were added and after 4 h the mixture was concentrated under reduced pressure and purified 
by F–SPE, eluting with 8:2 MeOH–H2O then MeOH, and by column chromatography, 
eluting with CH2Cl2, to give the sulfonamide 90 (11 mg, 46%) as a colorless oil, Rf 0.45 
(3:1 petrol–EtOAc);  20D –24.4 (c 0.0095 in CHCl3); νmax/cm-1 (neat) 3088, 2948, 2869, 
1547, 1371, 1241; δH (500 MHz, CDCl3) 8.07 (1H, dd, J 7.7 and 1.6, nosyl 3-H), 7.73–
7.64 (3H, m, nosyl 4-H, 5-H and 6-H), 6.32 (1H, dd, J 5.8 and 1.7, 5-H or 6-H), 6.19 (1H, 
dd, J 5.8 and 1.7, 5-H or 6-H), 5.89 (1H, ddt, J 17.0, 10.4 and 5.7, allyl 2-H), 5.29–5.23 
(2H, m, propyl 2-CH2a and allyl 3-Ha), 5.18 (1H, ddd, J 10.4, 2.7 and 1.3, allyl 3-Hb), 
5.12–5.09 (1H, m, propyl 2-CH2b), 4.76–4.74 (1H, m, 1-H or 4-H), 4.62–4.60 (1H, m, 1-H 
or 4-H), 4.15–3.94 (6H, m, propyl 1-H2, propyl 3-H2 and allyl 1-H2), 3.46–3.33 (4H, m, 2-
CH2 and 3-CH2), 2.16–2.05 (2H, m, 2'-H2), 1.96–1.85 (2H, m, 2-H and 3-H), 1.09–1.00 
(14H, m, iPr), 0.87–0.82 (2H, m, 1'-H2); δC (75 MHz, CDCl3) 148.1, 142.6, 136.3, 135.1, 
134.7, 133.8, 133.4, 131.8, 131.7, 124.4, 117.3, 113.8, 80.9, 80.4, 72.3, 69.7, 64.2, 50.3, 
47.2, 40.7, 38.0, 17.7 (2C), 17.6 (2C), 12.5, 12.5 (the signals for 1'-C, 2'-C and C8F17 are 
missing); m/z (ES+) (Found: MNa+ 1033.2155, C37H43F17N2O7SSi requires MNa 
1033.2181).  
 
(R)-N-(4-Allyloxy-2-butynyl) N-1-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-5-hexen-2-yl 2-nitrobenzenesulfonamide 
(91) 
By general procedure A, the alcohol 88 (195 mg, 0.29 mmol), the sulfonamide 80 (357 mg, 
1.15 mmol), PPh3 (300 mg, 1.15 mmol) and DEAD (0.18 mL, 1.15 mmol) in THF (13 mL) 
gave a crude product which was purified by column chromatography, eluting with 9:1 
petrol–EtOAc, to give the sulfonamide 91 (155 mg, 55%) as a clear colorless oil, Rf 0.38 
(9:1 petrol–EtOAc);  20D –6.9 (c 0.011 in CHCl3); νmax/cm-1 (neat) 2951, 2870, 1548, 
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1372, 1244, 1209; δH (500 MHz, CDCl3) 8.16 (1H, dd, J 7.4 and 2.0, nosyl 3-H), 7.70–
7.61 (3H, m, nosyl 4-H, 5-H and 6-H), 5.85 (1H, ddt, J 17.2, 10.3 and 5.7, allyl 2-H), 5.71 
(1H, ddt, J 17.1 10.1 and 6.5, 5-H), 5.27 (1H, ddd, J 17.2, 3.0 and 1.2, allyl 3-Htrans), 5.20 
(1H, ddd, J 10.4, 3.0 and 1.2, allyl 3-Hcis), 4.96–4.91 (2H, m, 6-H2), 4.36 (1H, dt, J 18.6 
and 1.7, 1-Ha), 4.26 (1H, dt, J 18.6 and 1.9, 1-Hb), 4.00 (2H, t, J 1.6, butynyl 1-H2 or 4-H2), 
3.95–3.89 (1H, m, 2-H), 3.94 (2H, dt, J 5.7 and 1.2, allyl 1-H2), 3.88–3.85 (2H, m, butynyl 
1-H2 or 4-H2), 2.14–2.03 (2H, m, 2'-H2), 1.99–1.80 (2H, m, 4-H2), 1.06–1.00 (14H, m, iPr), 
0.89–0.80 (4H, m, 3-H2 and 1'-H2); δC (75 MHz, CDCl3) 148.2, 137.4, 134.1, 134.0, 133.6, 
131.8, 131.6, 124.2, 117.8, 115.2, 82.3, 80.6, 70.7, 65.4, 59.4, 57.3, 34.1, 29.8, 28.6, 17.6 
(2C), 17.5 (2C), 12.3 (2C) (the signals for 1'-C, 2'-C and C8F17 are missing); m/z (ES+) 
(Found: MNa+ 991.2035, C35H41F17N2O6SSi requires MNa 991.2075).  
 
(1S,3R,9R,10S)-5-(((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
Heptadecafluorodecyl)-diisopropyl-silyloxy)-methyl) 7-(2-nitrobenzenesulfonyl)-2,12-
dioxa-7-azatricyclo[8.5.0.03,9]4,14-pentadecadiene (92) 
By general procedure B, after 47 h the metathesis substrate 90 (11 mg, 0.011 mmol) and 
Hoveyda-Grubbs Catalyst, 2nd generation (0.3 mg, 0.5 µmol and 0.6 mg, 0.001 mmol) in 
CH2Cl2 (22 mL) gave the crude product, which was purified by column chromatography, 
eluting with a gradient 5:1→1:1 petrol–EtOAc, to give the tricycle 92 (3 mg, 27%) as a 
colorless oil, Rf 0.62 (1:1 petrol–EtOAc);  20D –48.0 (c 0.0040 in CHCl3); νmax/cm-1 (neat) 
2946, 2868, 1546, 1371, 1240, 1205; δH (500 MHz, CDCl3) 7.99 (1H, dd, J 7.6 and 1.5, 
nosyl 3-H), 7.71 (1H, td, J 7.6 and 1.5, nosyl 5-H), 7.66 (1H, td, J 7.6 and 1.5, nosyl 4-H), 
7.62 (1H, dd, J 7.6 and 1.5, nosyl 6-H), 6.06–6.04 (2H, m, 4-H and 15-H), 5.69 (1H, ddt, J 
10.8, 5.2 and 2.8, 14-H), 4.61 (1H, d, J 9.8, 1-H ), 4.39 (1H, d, J 9.8, 3-H), 4.26–4.10 (4H, 
m, 5-CH2 and 13-H2), 4.02 (1H, d, J 17.3, 6-Ha), 3.88 (1H, dd, J 10.8 and 6.6, 11-Ha), 3.80 
(1H, d, J 17.3, 6-Hb), 3.76 (1H, dd, J 12.4 and 10.8, 11-Hb), 3.56 (1H, dd, J 12.4 and 5.3, 
8-Ha), 3.50 (1H, t, J 12.4, 8-Hb), 2.67 (1H, tdd, J 12.4, 9.8 and 6.6, 10-H), 2.46 (1H, tdd, J 
12.4, 9.8 and 5.3, 9-H), 2.19–2.06 (2H, m, 2’-H2), 1.11–0.99 (14H, m, iPr), 0.90–0.85 (2H, 
m, 1’-H2); δC (75 MHz, CDCl3) 147.7 (HMBC), 137.6, 133.8, 133.1, 132.4, 131.8, 131.0, 
129.5, 128.5, 124.3, 82.8, 82.2, 67.6, 67.4, 65.7, 47.5, 46.7, 46.5, 44.9, 17.7 (2C), 17.6 
(2C), 12.5 (2C) (the signals for 1'-C, 2'-C and C8F17 are missing); m/z (ES+) (Found: MNa+ 
1005.1826, C35H39F17N2O7SSi requires MNa 1005.1868).  
 
(R,Z)-6-(2,5-Dihydrofuran-3-yl)-2-(((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-methyl)-1-(2-nitrophenylsulfonyl)-
2,3,4,7-tetrahydro-1H-azepine (93) 
By general procedure B, after 22 h the metathesis substrate 91 (245 mg, 0.25 mmol) and 
Hoveyda-Grubbs Catalyst, 2nd generation (8 mg, 0.013 mmol) in CH2Cl2 (500 mL) gave 
the crude product, which was purified by column chromatography, eluting with CH2Cl2, to 
give the tetrahydro-1H-azepine  93 (162 mg, 69%) as a colorless oil, Rf 0.44 (CH2Cl2);  20D +22.9 (c 0.003 in CHCl3); νmax/cm-1 (neat) 2928, 2866, 1546, 1371, 1245, 1204; δH 
11. Experimental: Natural-Prodruct-Like Molecules 
157 
 
(500 MHz, CDCl3) 7.91 (1H, dd, J 7.8 and 1.3, nosyl 3-H), 7.64 (1H, td, J 7.8 and 1.3, 
nosyl 5-H), 7.55 (1H, td, J 7.8 and 1.3, nosyl 4-H), 7.52 (1H, dd, J 7.8 and 1.3, nosyl 6-H), 
5.86–5.84 (1H, m, dihydrofuran 4-H), 5.25-5.22 (1H, m, 5-H), 4.83–4.71 (2H, m, 
dihydrofuran 2-H2), 4.69 (1H, d, J 18.1, 7-Ha), 4.64–4.58 (1H, m, dihydrofuran 5-Ha), 
4.56–4.50 (1H, m, dihydrofuran 5-Hb), 4.33–4.27 (1H, m, 7-Hb), 4.20–4.14 (1H, m, 2-H), 
3.76 (1H, dd, J 10.0 and 5.5, 2-CH2a), 3.71 (1H, dd, J 10.0 and 3.8, 2-CH2a), 2.35–2.00 
(6H, m, 3-H2, 4-H2 and 2'-H2), 1.05–0.97 (14H, m, iPr), 0.84–0.81 (2H, m, 1'-H2); δC (75 
MHz, CDCl3) 138.6, 133.4, 131.2, 130.4, 123.7, 120.0, 76.9, 75.1, 66.7, 59.0, 44.1, 29.8, 
26.4, 17.5 (2C), 17.5 (2C), 12.3, 12.3 (the signals for 4 unsaturated C, 1'-C, 2'-C and C8F17 
are missing); m/z (ES+) (Found: MNa+ 963.1758, C33H37F17N2O6SSi requires MNa 
963.1762).  
 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecane iodide (95)257 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecanol (8.60 g, 18.5 mmol), imidazole 
(3.80 g, 55.6 mmol) and PPh3 (7.29 g, 27.8 mmol) were dissolved in Et2O (46 mL) and 
MeCN (15 mL) and the mixture was cooled to 0 °C. I2 (7.06 g, 27.8 mmol) was added over 
15 min and the reaction mixture was stirred at 0 °C for 15 min and then at room 
temperature for 15 h. Et2O (200 mL) was added and the mixture was lead through a pad of 
celite and the celite was washed with Et2O (4×50 mL). The colorless organic mixture was 
concentrated under reduced pressure and purified by column chromatography, eluting with 
hexane, to give the iodide 95 (9.83 g, 92%) as a colorless amorphous solid, mp = 51.5–
52.0 °C (hexane), (lit.281 54.0–55.5 °C); Rf 0.76 (hexane); δH (500 MHz, CDCl3) 3.27–3.23 
(2H, m, 1-H2), 2.73–2.66 (2H, m, 2-H2).  
 
(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)-diisopropylsilane (96)257 
To a stirred solution of tBuLi (1.7 M in pentane, 20.1 mL, 34.2 mmol) ín Et2O (58 mL) at –
78 °C was added a solution of the iodide 95 (9.80 g, 17.1 mmol) in Et2O (80 mL) over 15 
min. The reaction mixture was stirred for 1 h at -78°C after which chlorodiisopropylsilane 
(2.06 g, 13.7 mmol) was added and the mixture was allowed to reach room temperature. 
After 2 h the reaction was quenched by carefully addition of a saturated aqueous solution 
of NH4Cl (50 mL). H2O (ca. 20 mL) was added until the aqueous phase was clear and the 
organic layer was isolated by extraction. The aqueous phase was washed with Et2O (2×100 
mL) and the combined organic phases were concentrated under reduced pressure and 
purified by column chromatography, eluting with hexane, to the give silane 96 (7.29 g, 
95%) as colorless oil, Rf 0.89 (hexane); δH (500 MHz, CDCl3) 3.49 (1H, s, Si-H), 2.18–
2.06 (2H, m, 2-H2), 1.08–1.00 (14H, m, iPr), 0.87–0.82 (2H, m, 1-H2).   
 
3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-Heptadecafluorodecyl)-diisopropyl-
silyloxy) 2-methylene-propanol (99) 
NBS (1.19 g, 6.68 mmol) was added to a stirred solution of silane 96 (3.76 g 6.68 mmol) 
along with 4 Å molecular sieves in CH2Cl2 (60 mL) at 0 °C. The reaction mixture was 
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allowed to reach room temperature and stirred for 20 min, after which the mixture was 
added to a solution of 2-methylene-1,3-propanediol (491 mg, 5.57 mmol), DMAP (1.70 g, 
13.9 mmol) and 4 Å molecular sieves in CH2Cl2 (500 mL). The reaction mixture was 
stirred at room temperature for 1.5 h, then the molecular sieves were removed by filtration 
and the filtrate was concentrated under reduced pressure and purified by column 
chromatography, eluting with 10:1 petrol–EtOAc, to give the silyl ether 99 (1.42 mg, 39%) 
as a clear colorless oil, Rf 0.40 (10:1 petrol–EtOAc); νmax/cm-1 (neat) 3338, 2927, 2870, 
1708, 1463, 1368, 1243, 1206; δH (500 MHz, CDCl3) 5.14–5.11 (2H, m, 2-CH2), 4.30 (2H, 
s, 1-H2), 4.18 (2H, d, J 6.0, 3-H2), 2.19–2.08 (2H, m, 2'-H2), 1.07–1.04 (14H, m, iPr) and 
0.91–0.83 (2H, m, 1'-H2); δC (75 MHz, CDCl3) 147.4, 111.3, 65.1, 64.5, 17.7, 17.6, 12.6 
(the signals for 1'-C, 2'-C and C8F17 are missing); m/z (ES+) (Found: MH+ 649.1398, 
C20H25F17O2Si requires MH 649.1425).  
 
N-tert-Butoxycarbonyl N-(3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-2-methylene-propyl) 2-
nitrobenzenesulfonamide (101) 
By general procedure A, the alcohol 99 (300 mg, 0.46 mmol), the sulfonamide 100 (559 
mg, 1.85 mmol), PPh3 (485 mg, 1.85 mmol) and DEAD (0.29 mL, 1.85 mmol) in THF (21 
mL) gave the sulfonamide 101 (404 mg, 94%, >95% purity by 500 MHz 1H NMR 
spectroscopy) as a colorless oil, Rf 0.15 (10:1 petrol–EtOAc); νmax/cm-1 (neat) 2946, 2869, 
1737, 1547, 1369, 1206; δH (500 MHz, CDCl3) (1H, m, nosyl 3-H), 7.77–7.74 (3H, m, 
nosyl 4-H, 5-H and 6-H), 5.27–5.25 (1H, m, 2-CH2a), 5.21–5.19 (1H, m, 2-CH2b), 4.39–
4.37 (2H, m, 1-H2 or 3-H2), 4.29–4.27 (2H, m, 1-H2 or 3-H2), 2.23–2.11 (2H, m, 2'-H2), 
1.35 (9H, s, tBu), 1.09–1.05 (14H, m, iPr), 0.92–0.88 (2H, m, 1'-H2); δC (75 MHz, CDCl3) 
143.6, 134.3, 133.9, 131.8, 124.5, 111.0, 85.2, 64.6, 49.6, 27.9, 17.7 (2C), 17.6 (2C), 12.6 
(2C) (the signals for nosyl 1-C, 2-C, C=O, 1'-C, 2'-C and C8F17 are missing); m/z (ES+) 
(Found: MNa+ 955.1724, C31H37F17N2O7SSi requires MNa 955.1711). 
 
(S)-(3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-Heptadecafluorodecyl)-
diisopropylsilyl oxiranylmethyl ether (104)  
NBS (548 mg, 3.08 mmol) was added to a stirred solution of silane 96 (1.73 g, 3.08 mmol) 
and 4 Å molecular sieves in CH2Cl2 (27 mL) at 0 °C. The reaction mixture was allowed to 
reach room temperature and stirred for 25 min, after which the mixture was added to a 
solution of (R)-glycidol (190 mg, 2.57 mmol), DMAP (786 mg, 6.43 mmol) and 4 Å 
molecular sieves in CH2Cl2 (225 mL). The reaction mixture was stirred at room 
temperature  for 1.5 h, then the molecular sieves were removed by filtration and the filtrate 
was concentrated under reduced pressure and purified by column chromatography, eluting 
with 45:1 petrol–EtOAc, to give the silyl ether 104 (660 mg, 40%) as a clear colorless oil, 
Rf 0.28 (45:1 petrol–EtOAc);  20D –8.5 (c 0.016 in CHCl3); δH (300 MHz, CDCl3) 3.95 
(1H, dd, J 11.8 and 2.9, 3-Ha), 3.68 (1H, dd, J 11.8 and 5.0, 3-Hb), 3.13–3.07 (1H, dddd, J 
5.0, 4.1, 2.9 and 2.7, 2-H), 2.78 (1H, dd, J 5.1 and 4.1, 1-Ha),  2.63 (1H, dd, J 5.1 and 2.7, 
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1-Hb), 2.25–2.06 (2H, m, 2'-H2), 1.08–1.02 (14H, m, iPr), 0.91–0.84 (2H, m, 1'-H2); δC (75 
MHz, CDCl3) 64.3, 52.5, 44.5, 24.6 (t, J 24), 17.7, 17.6, 12.6 (the signals for 1'-C and 
C8F17 are missing). 
 
L-N-(2-Nitrophenylsulfonyl) alanine (108) 
L-Alanine (1.50 g, 16.8 mmol) was dissolved in mixture of THF (18 mL) and aqueous 
NaOH (1M, 20 mL, 20 mmol) and cooled to 0 °C. A solution of 2-nitrobenzenesulfonyl 
chloride (4.48 g, 20.2 mmol) in aqueous NaOH (1M, 24 mL, 24 mmol) was added in small 
portions over 1 h and the reaction mixture was stirred at 0 °C for an additional 30 min after 
which THF was removed by concentration under reduced pressure. The remaining aqueous 
solution was washed with Et2O (2×15 mL) then the pH was adjusted to 1 via addition of 
concentrated HCl yielding a colorless amorphous solid in the aqueous solution. The solid 
was isolated by filtration and recrystallation from H2O gave the sulfonamide 108 (1.44 g, 
31%) as white needles, mp = 166.8–168.1 °C (H2O);  20D –137.6 (c 0.017 in acetone); 
νmax/cm-1 (neat) 3299, 3099, 1723, 1543, 1351, 1171; δH (500 MHz, acetone-d6) 8.15-8.13 
(1H, m, nosyl 3-H), 7.98–7.96 (1H, m, nosyl 5-H), 7.93–7.86 (2H, m, nosyl 4-H and 6-H), 
7.01–6.96 (1H, m, NH), 4.27–4.20 (1H, m, 2-H), 1.48 (3H, d, J 7.2, CH3); δC (75 MHz, 
acetone-d6) 173.1, 134.9, 133.6, 131.3, 125.9, 52.8, 29.8, 19.6 (the signal for nosyl 2-C is 
missing); m/z (ES+) (Found: MNa+ 297.0153, C9H10O6S requires MNa 297.0152). 
 
(S)-((S)-1-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-Heptadecafluorodecyl)-
diisopropyl-silyloxy)-5-hexen-2-yl) 2-(2-nitrophenylsulfonamido)-propanoate (109) 
The alcohol 88 (200 mg, 0.30 mmol), the carboxylic acid 108 (325 mg, 1.19 mmol) and 
DMAP (18 mg, 0.15 mmol) were dissolved in THF (22 mL) and cooled to 0 °C. A solution 
of DCC (246 mg, 1.19 mmol) in THF (8 mL) was added dropwise over 5 min. The reaction 
mixture was stirred at 0 °C for 1.5 h after which the mixture was concentrated under 
reduced pressure and purified by F–SPE, eluting with 8:2 MeOH–H2O then MeOH, and 
column chromatography, eluting with a gradient 9:1→6:1 Petrol–EtOAc, to give the ester 
109 (155 mg, 56%) as a slightly yellow oil, Rf 0.10 (9:1 Petrol–EtOAc);  20D –53.0 (c 
0.014 in CHCl3); νmax/cm-1 (neat) 2949, 2871, 1743, 1546, 1360, 1244, 1208; δH (500 
MHz, CDCl3) 8.10–8.07 (1H, m, nosyl 3-H), 7.94–7.92 (1H, m, nosyl 6-H), 7.73–7.67 
(2H, m, nosyl 4-H and 5-H), 6.16 (1H, d, J 7.3, NH), 5.68 (1H, ddt, J 16.9, 10.4 and 6.6, 
hexenyl 5-H), 4.96–4.90 (2H, m, hexenyl 6-H2), 4.78 (1H, dt, J 10.1 and 5.1, hexenyl 2-H), 
4.25 (1H, p, J 7.3, 2-H), 3.60 (2H, d, J 5.1, hexenyl 1-H2), 2.11–1.99 (2H, m, 2'-H2), 1.95–
1.81 (2H, m, hexenyl 4-H2), 1.61–1.49 (2H, m, hexenyl 3-H2), 1.48 (3H, d, J 7.3, 3-H3), 
1.03–0.98 (14H, m, iPr), 0.84–0.79 (2H, m, 1'-H2); δC (75 MHz, CDCl3) 171.6, 147.9, 
137.2, 134.7, 133.6, 133.0, 130.5, 125.8, 115.6, 75.8, 64.4, 52.7, 29.7, 29.4, 25.5 (t, J 23), 
20.0, 17.6, 17.5, 17.5 (2C), 12.4, 12.4 (the signals for 1'-C and C8F17 are missing); m/z 
(ES+) (Found: MNa+ 955.1691, C31H37N2O7SSi requires MNa 955.1711). 
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N-3-Butenyl 2-nitrobenzenesulfonamide (110)245  
3-Butenyl amine hydrochloride (790 mg, 7.34 mmol), 2-nitrobenzenesulfonyl chloride 
(1.63 g, 7.34 mmol) and K2CO3 (2.23 g, 16.1 mmol) were dissolved in CH2Cl2 (13 mL) 
and the reaction mixture was stirred for 64 h at room temperature. Carefully, H2O (1.3 mL) 
and an aqueous solution of HCl (10%, 13 mL) were added and the organic layer was 
isolated by extraction, washed with a saturated aqueous solution of Na2SO4 (12 mL) and 
dried over MgSO4. Concentration under reduced pressure and recrystallisation (1:1 
toluene–hexane) gave the sulfonamide 110 (1.33 mg, 71%) as white needles, mp = 53.0–
53.5 °C (1:1 toluene–hexane); Rf 0.55 (3:1 toluene–EtOAc); δH (300 MHz, CDCl3) 8.18–
8.13 (1H, m, nosyl 3-H), 7.90–7.86 (1H, m, nosyl 6-H), 7.78–7.73 (2H, m, nosyl 4-H and 
5-H), 5.73–5.59 (1H, m, 3-H), 5.33 (1H, br s, NH), 5.10–5.02 (2H, m, 4-H2), 3.19 (2H, dd, 
J 12.8 and 6.6, 1-H2) and 2.32–2.25 (2H, m, 2-H2).  
 
4-Hydroxy-2-butynyl vinylacetate (112) 
4-hydroxy-2-butynol (1.00 g, 11.6 mmol), vinylacetic acid (1.10 g, 12.8 mmol) and DMAP 
(280 mg, 2.3 mmol) were dissolved in CH2Cl2 (1160 mL). DCC (4.78 g, 23.2 mmol) in 
CH2Cl2 (20 mL) was added and the reaction mixture was stirred for 3 h, then concentrated 
under reduced pressure and purified by column chromatography, eluting with 4:1 CH2Cl2–
MeOH, to give the monoester 112, contaminated with DCC, hence the mixture was 
purified by column chromatography, eluting with 1:1 petrol–EtOAc, to give the pure 
monoester 112 (559 mg, 31%) as a colorless oil, Rf 0.70 (2:1 petrol–EtOAc); νmax/cm-1 
(neat) 3434, 1743, 1167, 1144, 1023, 986; δH (500 MHz, CDCl3) 5.92 (1H, ddt, J 16.7, 9.8 
and 6.9, 3-H), 5.22–5.17 (2H, m, 4-H2), 4.74 (2H, t, J 1.8, butynyl 1-H2), 4.31 (2H, dt, J 
6.1 and 1.8, butynyl 4-H2), 3.15 (2H, dt, J 6.9 and 1.4, 2-H2), 2.23 (1H, t, J 6.1, OH); δC 
(75 MHz, CDCl3) 171.0, 129.7, 119.1, 85.4, 79.6, 52.6, 51.0, 38.9; m/z (ES+) (Found: 
MNa+ 177.0516, C8H10O3 requires MNa 177.0522).  
 
N-3-Butenyl N-(3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy))-2-methylene-propyl 2-
nitrobenzenesulfonamide (118) 
By general procedure A, the alcohol 99 (260 mg, 0.40 mmol), the sulfonamide 110 (410 
mg, 1.60 mg), PPh3 (420 mg, 1.60 mmol) and DEAD (0.25 mL, 1.60 mmol) in THF (18 
mL) gave the sulfonamide 118 (338 mg, 95%, >85% purity by 500 MHz 1H NMR 
spectroscopy) as a colorless oil, Rf 0.37 (10:1 petrol–EtOAc); νmax/cm-1 (neat) 2926, 2869, 
1729, 1548, 1463, 1372, 1242, 1206; δH (500 MHz, CDCl3) 8.05 (1H, dd, J 7.4 and 1.8, 
nosyl 3-H), 7.71–7.62 (3H, m, nosyl 4-H, 5-H, 6-H), 5.66–5.57 (1H, m, butenyl 3-H), 
5.27–5.26 (1H, m, 2-CH2a), 5.10 (1H, d, J 1.0,  2-CH2b), 5.00 (1H, ddd, J 17.2, 3.0 and 1.4, 
butenyl 4-Htrans), 4.98–4.95 (1H, m, butenyl 4-Hcis), 4.08 (2H, s, 3-H2), 4.04 (2H, s, 1-H), 
3.36–3.33 (2H, m, butenyl 1-H2), 2.26–2.21 (2H, m, butenyl 2-H2), 2.15–2.05 (2H, m, 2'-
H2), 1.09–1.01 (14H, m, iPr), 0.86–0.82 (2H, m, 1'-H2); δC (75 MHz, CDCl3) 148.3, 142.7, 
134.5, 133.8, 131.9, 131.5, 124.6, 117.7, 114.0, 64.1, 50.0, 46.6, 32.5, 17.9 (2C), 17.8 
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(2C), 12.7 (2C) (the signals for 1''-C, 2''-C, C8F17 and nosyl 1-C are missing); m/z (ES+) 
(Found: MNa+ 909.1677, C30H35F17N2O5SSi requires MNa 909.1657).  
 
N-(4-Allyloxy-2-butynyl) N-3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-2-methylene-propyl 2-
nitrobenzenesulfonamide (119) 
By general procedure A, the alcohol 99 (200 mg, 0.31 mmol), the sulfonamide 80 (382 mg, 
1.23 mmol), PPh3 (322 mg, 1.23 mmol) and DEAD (0.19 mL, 1.23 mmol) in THF (14 mL) 
gave the sulfonamide 119 (280 mg, 96%, >85% purity by 500 MHz 1H NMR 
spectroscopy) as a colorless oil, Rf 0.10 (10:1 petrol–EtOAc); νmax/cm-1 (neat) 2947, 2868, 
1548, 1371, 1205; δH (500 MHz, CDCl3) 8.08–8.06 (1H, m, nosyl 3-H), 7.70–7.62 (3H, m, 
nosyl 4-H, 5-H and 6-H), 5.83 (1H, ddt, J 17.2, 10.4 and 5.7, allyl 2-H), 5.34–5.32 (1H, d, 
J 1.4, 2-CH2a), 5.24 (1H, ddd, J 17.2, 3.0 and 1.3, allyl 3-Htrans), 5.20 (1H, ddd, J 10.4, 3.0 
and 1.3, alllyl 3-Hcis), 5.18–5.17 (1H, m, 2-CH2b), 4.17 (2H, t, J 1.7, 1-H2 or 3-H2), 4.13 
(2H, s, butynyl 1-H2 or 3-H2), 4.05 (2H, s, butynyl 1-H2 or 3-H2), 3.97 (2H, t, J 1.8, 1-H2 
or 3-H2), 3.88 (2H, dt, J 5.7 and 1.3, allyl 1-H2), 2.17–2.06 (2H, m, 2'-H2), 1.05–1.02 (14H, 
m, iPr), 0.87–0.83 (2H, m, 1'-H2); δC (75 MHz, CDCl3) 161.0, 150.5, 141.6, 133.8, 131.7, 
131.3, 124-3, 118.0, 114.8, 112.8, 77.4, 70.7, 63.7, 61.1, 57.2, 49.4, 36.3, 17.7 (2C), 17.6 
(2C), 12.5 (2C) (the signals for 1'-C, 2'-C and C8F17 are missing); m/z (ES+) (Found: MNa+ 
963.1718, C33H37F17N2O6SSi requires MNa 963.1762).  
 
(S)-((S)-1-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-Heptadecafluorodecyl)-
diisopropyl-silyloxy)-5-hexen-2-yl) 2-N-(4-allyloxy-2-butynyl) 2-(2-
nitrophenylsulfonamido)-propanoate (120) 
The sulfonamide 109 (155 mg, 0.17 mmol), the alcohol 111 (105 mg, 0.83 mmol) and PPh3 
(218 mg, 0.83 mmol) were dissolved in THF (7.5 mL) and cooled to 0 °C. DEAD (0.13 
mL, 0.83 mmol) was added dropwise and the reaction mixture was stirred at room 
temperature. After 1 h PPh3 (109 mg, 0.41 mmol) and DEAD (0.07 mL, 0.41 mmol) were 
added and the reaction mixture was stirred for another 1.5 h after which the mixture was 
concentrated under reduced pressure and purified by F–SPE, eluting with 8:2 MeOH–H2O 
then MeOH, to give the sulfonamide 120 (120 mg, 68%, >75% purity by 500 MHz 1H 
NMR spectroscopy) as a colorless oil, Rf 0.64 (3:1 petrol–EtOAc); δH (500 MHz, CDCl3) 
8.19–8.16 (1H, m, nosyl 3-H), 7.70–7.64 (3H, m, nosyl 4-H, 5-H and 6-H), 5.88–5.79 (1H, 
m, allyl 2-H), 5.75 (1H, ddd, J 16.9, 10.1 and 6.6, hexenyl 5-H), 5.25 (1H, ddd, J 17.1, 3.0 
and 1.4, allyl 3-Htrans), 5.21–5.18 (1H, m, allyl 3-Hcis), 5.02–4.95 (2H, m, hexenyl 6-H2), 
4.93–4.88 (1H, m, hexenyl 2-H), 4.84 (1H, q, J 7.4, 2-H), 4.51 (1H, dt, J 18.8 and 1.8, 
butynyl 1-Ha), 4.11 (1H, dt, J 18.8 and 1.8, butynyl 1-Hb), 3.99–3.97 (2H, m, butynyl 3-
H2), 3.91 (2H, dt, J 5.8 and 1.4, allyl 1-H2), 3.67–3.65 (2H, m, hexenyl 1-H2), 2.15–1.99 
(4H, m, hexenyl 4-H2 and 2'-H2), 1.68–1.63 (2H, m, hexenyl 3-H2), 1.63 (3H, d, J 7.4, 3-
H3), 1.06–0.99 (14H, m, iPr), 0.86–0.81 (2H, m, 1'-H2); m/z (ES+) (Found: MNa+ 
1063.2240, C38H45F17N2O8SSi requires MNa 1063.2287). 
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3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-Heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl-1-(2-nitrophenylsulfonyl)-1,2,5,6-tetrahydropyridine (122) 
By general procedure B, after 2 h the metathesis substrate 118 (330 mg, 0.37 mmol) and 
Grubbs Catalyst, 1st generation (15 mg, 0.019 mmol) in CH2Cl2 (370 mL) gave the crude 
product, which was purified by F–SPE, eluting with 8:2 MeOH–H2O then MeOH, to give 
the tetrahydropyridine 122 (300 mg, 95%, >90% purity by 500 MHz 1H NMR 
spectroscopy) as a brown amorphous solid, Rf 0.33 (10:1 petrol–EtOAc); νmax/cm-1 (neat) 
2924, 2853, 1548, 1462, 1374, 1242, 1207; δH (500 MHz, CDCl3) 8.00 (1H, dd, J 7.7 and 
1.6, nosyl 3-H), 7.71–7.60 (3H, m, nosyl 4-H, 5-H and 6-H), 5.77–5.74 (1H, m, 4-H), 4.13 
(2H, s, 3-CH2), 3.81 (2H, d, J 1.8, 2-H2), 3.44 (2H, t, J 5.8, 6-H2), 2.26–2.22 (2H, m, 5-H2), 
2.15–2.04 (2H, m, 2'-H2), 1.09–1.00 (14H, m, iPr) and 0.88–0.83 (2H, m, 1'-H2); δC (75 
MHz, CDCl3) 148.0, 132.7, 132.5, 131.1, 130.4, 129.8, 123.1, 119.3, 64.2, 43.8, 41.6, 23.7, 
16.5 (2C), 16.4 (2C), 11.4 (2C) (the signals for 1'-C’, 2'-C and C8F17 are missing); m/z 
(ES+) (Found: MNa+ 881.1373, C28H31F17N2O5SSi requires MNa 881.1344).  
 
3-(2,5-Dihydro-3-furanyl)-4-(((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-methyl)-1-(2-nitrophenylsulfonyl)-2,5-
dihydro-pyrrole (123) 
By general procedure B, after 22 h the metathesis substrate 119 (246 mg, 0.26 mmol) and 
Hoveyda-Grubbs Catalyst, 2nd generation (8 mg, 0.013 mmol) in CH2Cl2 (500 mL) gave 
the crude product, which was purified by column chromatography, eluting with CH2Cl2, to 
give the dihydropyrrole 123 (136 mg, 57%) as a colorless amorphous solid, Rf 0.45 
(CH2Cl2); νmax/cm-1 (neat) 2949, 2868, 1548, 1372, 1206; δH (500 MHz, CDCl3) 8.01 (1H, 
dd, J 7.6 and 1.6, nosyl 3-H), 7.72–7.66 (2H, m, nosyl 4-H and 5-H), 7.63 (1H, dd, J 7.3 
and 1.8, nosyl 6-H), 5.80–5.78 (1H, m, dihydrofuran 4-H), 4.79–4.76 (2H, m, dihydrofuran 
2-H2 or 5-H2), 4.71–4.68 (2H, m, dihydrofuran 2-H2 or 5-H2), 4.50–4.45 (4H, m, 2-H2 and 
5-H2), 4.36–4.35 (2H, m, 3-CH2), 2.12–2.01 (2H, m, 2'-H2), 1.07–0.99 (14H, m, iPr), 0.87–
0.82 (2H, m, 1'-H2); δC (75 MHz, CDCl3) 133.9, 133.8, 132.1, 132.0, 131.7, 130.7, 126.6, 
124.3, 123.9; 75.4, 75.2, 59.1, 57.0, 56.9, 17.6 (2C), 17.5 (2C), 12.4 (2C) (the signals for 
nosyl 1-C, 1'-C, 2'-C and C8F17 are missing); m/z (ES+) (Found: MNa+ 935.1443, 
C31H33F17N2O6SSi requires MNa 935.1449).  
Also obtained was N-(2-(2,5-dihydrofuran-3-yl)-allyl)-N-(3-
(((3',3',4',4',5',5',6',6',7',7',8',8',9',9', 10',10',10'-heptadecafluorodecyl)-diisopropyl)-
silyloxy)-2-methylene-propyl)-2-nitrobenzenesulfonamide 124 (14 mg, 6 %) as a clear 
colorless oil; Rf 0.59 (CH2Cl2); δH (500 MHz, CDCl3) 8.05–8.03 (1H, m, nosyl 3-H), 7.70–
7.63 (3H, m, nosyl 4-H, 5-H and 6-H), 5.81–5.79 (1H, m, dihydrofuran 4-H), 5.21–5.19 
(1H, m, 2-CH2 or allyl 3-H), 5.01–4.99 (2H, m, 2-CH2 or allyl 3-H), 4.84–4.82 (1H, m, 2-
CH2 or allyl 3-H), 4.21–4.19 (2H, m, 1-H2, 3-H2 or allyl 1-H2), 4.15–4.12 (4H, m, 
dihydrofuran 2-H2 and 5-H2), 4.04–4.02 (2H, m, 1-H2, 3-H2 or allyl 1-H2), 4.02–4.00 (2H, 
m, 1-H2, 3-H2 or allyl 1-H2), 2.14–2.02 (2H, m, 2'-H2), 1.05–0.99 (14H, m, iPr), 0.84–0.81 
(2H, m, 1'-H2); δC (75 MHz, CDCl3) 147.9, 142.3, 138.1, 134.1, 133.7, 131.8, 131.5, 128.5, 
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127.2, 124.3, 113.4, 108.2, 69.7, 66.2, 64.0, 50.0, 47.6, 17.6 (2C), 17.5 (2C), 12.5 (2C) (the 
signals for 1’-C', 2’-C and C8F17 are missing); m/z (ES+) (Found: MNa+ 963.1742, 
C33H37F17N2O6SSi requires MNa 963.1762).  
 
(3S,10S,Z)-6-(2,5-Dihydrofuran-3-yl)-10-
(((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl)-
silyloxy)-methyl)-3-methyl-4-(2-nitrophenylsulfonyl)-4,5,9,10-tetrahydro-3H-1,4-
oxazecin-2(8H)-one (125) 
By general procedure B, after 19 h the metathesis substrate 120 (71 mg, 0.068 mmol) and 
Hoveyda-Grubbs catalyst, 2nd generation (2.3 mg, 0.004 mmol and 6.0 mg, 0.010 mmol) in 
CH2Cl2 (150 mL) gave the crude product, which was purified by column chromatography, 
eluting with 3:1 petrol–EtOAc, to give the tetrahydro-3H-1,4-oxazecin-2(8H)-one 125 (8 
mg, 12%) as a colorless oil, Rf 0.26 (3:1 petrol–EtOAc);  20D –10.0 (c 0.004 in CHCl3); 
νmax/cm-1 (neat) 2947, 2868, 1738, 1546, 1371, 1205; δH (500 MHz, CDCl3) 8.06 (1H, dd, J 
7.6 and 1.4, nosyl 3-H), 7.73 (1H, td, J 7.6 and 1.4, nosyl 5-H), 7.69 (1H, td, J 7.6 and 1.4, 
nosyl 4-H), 7.65 (1H, dd, J 7.6 and 1.4, nosyl 6-H), 5.99–5.94 (1H, m, 7-H), 5.79–5.77 
(1H, m, dihydrofuran 4-H), 4.95–4.89 (1H, m, 10-H), 4.85–4.64 (5H, m, 3-H, dihydrofuran 
2-H2 and 5-H2), 4.61–4.55 (1H, m, 5-Ha), 3.70–3.65 (2H, m, 10-CH2a and 5-Hb), 3.61 (1H, 
dd, J 10.4 and 5.6, 10-CH2b), 2.42–2.28 (2H, m, 8-H2), 2.14–2.03 (2H, m, 2'-H2), 1.86–
1.74 (2H, m, 9-H2), 1.11 (3H, d, J 7.0, 3-CH3), 1.06–0.98 (14H, m, iPr), 0.86–0.80 (2H, m, 
1'-H2); δC (75 MHz, CDCl3) 170.2, 137.2, 134.6, 133.9, 131.8, 131.0, 124.9, 124.4, 124.1, 
77.0, 76.1, 75.6, 65.4, 53.7, 47.1, 29.9, 28.0, 17.5, 17.5, 17.5 (2C), 13.3, 12.4, 12.4 (the 
signals for 5-C, nosyl 2-C, 1'-C, 2'-C and C8F17 are missing); m/z (ES+) (Found: MNa+ 
1035.1988, C36H41N2O8SSi requires MNa 1035.1974). 
Also obtained was (S)-((S)-1-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-5-hexen-2-yl) 2-N-(2-(2,5-dihydro-3-furanyl)-
allyl) 2-(2-nitrophenylsulfonamido)-propanoate 126 (36 mg, 51%) as a colorless oil, Rf 
0.52 (3:1 petrol–EtOAc);  20D –14.6 (c 0.015 in CHCl3); νmax/cm-1 (neat) 2947, 2867, 
1741, 1546, 1243, 1206, 1152; δH (500 MHz, CDCl3) 8.03 (1H, dd, J 7.6 and 1.6, nosyl 3-
H), 7.68 (1H, tt, J 7.6 and 1.6, nosyl 5-H), 7.64 (1H, tt, J 7.6 and 1.6, nosyl 4-H), 7.60 (1H, 
dd, J 7.6 and 1.6, nosyl 6-H), 5.96–5.94 (1H, m, dihydrofuran 4-H), 5.74 (1H, ddt, J 17.0, 
10.3 and 6.6, hexenyl 5-H), 5.27–5.25 (1H, m, allyl 3-Ha), 5.02–4.98 (1H, m, hexenyl 6-
Ha), 4.98–4.96 (1H, m, hexenyl 6-Hb), 4.90 (1H, t, J 7.4, 2-H), 4.86–4.81 (2H, hexenyl 2-H 
and allyl 3-Hb), 4.77–4.72 (2H, hexenyl 1-H2), 4.71–4.64 (3H, dihydrofuran 2-Ha and 5-
H2), 4.01 (1H, d, J 17.9, dihydrofuran 2-Hb), 3.64–3.61 (2H, m, allyl 1-H2), 2.13–1.96 (4H, 
hexenyl 4-H2 and 2'-H2), 1.68–1.57 (2H, hexenyl 3-H2), 1.48 (3H, d, J 7.4, 3-H3), 1.05–
0.98 (14H, m, iPr), 0.85–0.80 (2H, m, 1'-H2); δC (75 MHz, CDCl3) 171.1, 148.1, 137.4, 
137.1, 136.2, 133.7, 131.6, 131.5, 129.2, 124.1, 122.3, 115.5, 115.2, 76.9, 75.5, 75.3, 64.3, 
56.6, 48.2, 29.7, 29.3, 17.5 (2C), 17.5 (2C), 17.0, 12.4 (2C) (the signals for 1'-C, 2'-C and 
C8F17 are missing); m/z (ES+) (Found: MNa+ 1063.2278, C38H45F17N2O8SSi requires MNa 
1063.2287).  
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1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,27,27,28,28,29,29,30,30,31,31,32,32,33,33,34,34,34-
Tetratriacontafluoro-11,11,24,24-tetraisopropyl-12,23-dioxa-11,24-disilatetratriacont-
17-ene-14,21-diyl) bis(2-(N-(2-(2,5-dihydrofuran-3-yl)-allyl)-2-
nitrophenylsulfonamido)-propanoate) (127) 
The metathesis substrate 120 (120 mg, 0.12 mmol) was dissolved in benzene (230 mL) and 
heated to reflux. Hoveyda-Grubbs Catalyst, 2nd generation (7.2 mg, 0.011 mmol) was 
added and the reaction mixture was stirred for 14.5 h. The reaction mixture was cooled to 
room temperature, Et3N (1.5 mL, 10.3 mmol) and tris(hydroxymethyl)phosphine (500 mg, 
4.03 mmol) were added and the mixture was stirred for 15 min after which silica (1.5 g) 
was added and the mixture was stirred for another 15 min. The suspension was filtrated 
through a pad of celite, washed with EtOAc, concentrated under reduced pressure and 
purified by column chromatography, eluting with 3:1 petrol–EtOAc, to give the 11,24-
disilatetratriacont-17-ene 127 (24 mg, 10%) as a colorless oil, Rf 0.08 (3:1 petrol–EtOAc);  20D –16.0 (c 0.012 in CHCl3); νmax/cm-1 (neat) 2947, 2869, 1739, 1547, 1372, 1206, 1152; 
δH (500 MHz, CDCl3) 8.02 (2H, dd, J 7.8 and 1.4, nosyl 3-H), 7.71–7.60 (6H, m, nosyl 4-
H, 5-H and 6-H), 5.96–5.93 (2H, dihydrofuran 4-H), 5.34–5.31 (2H, 17-H and 18-H), 
5.23–5.21 (2H, allyl 3-Ha), 4.90 (2H, q, J 7.4, propanoate 2-H), 4.87–4.82 (2H, 14-H and 
21-H), 4.82–4.80 (2H, allyl 3-Hb), 4.76–4.65 (10H, allyl 1-Ha, dihydrofuran 2-H2 and 5-
H2), 4.03 (2H, d, J 18.1, allyl 1-Hb), 3.65–3.61 (4H, 13-H2 and 22-H2), 2.14–1.88 (8H, 9-
H2, 16-H2, 19-H2 and 26-H2), 1.59–1.53 (4H, 15-H2 and 20-H2), 1.48 (6H, d, J 7.4, 
propanoate 3-H3), 1.04–0.97 (28H, iPr), 0.85–0.80 (4H, 10-H2 and 25-H2); δC (75 MHz, 
CDCl3) 171.2 (2C), 148.0 (2C), 137.1 (2C), 136.2 (2C), 133.8 (2C), 133.7 (2C), 131.7 
(2C), 131.4 (2C), 129.9 (2C), 124.1 (2C), 122.3 (2C), 115.1 (2C), 76.9 (2C), 75.5 (2C), 
75.3 (2C), 64.5 (2C), 56.6 (2C), 48.1 (2C), 30.3 (2C), 28.1 (2C), 17.5 (2C), 17.5 (2C), 17.4 
(4C), 16.9 (2C), 12.4 (4C) (the signals for 9-C, 10-C, 24-C, 25-C and C8F17 are missing); 
m/z (ES+) (Found: MNa+ 2075.4348, C74H86F34N4O16S2Si2 requires MNa 2075.4368). 
Also obtained was 125 (11 mg, 9%) and 126 (32 mg, 27%). 
 
(3aR,8aS)-8a-(((3’,3’,4’,4’,5’,5’,6’,6’,7’,7’,8’,8’,9’,9’,10’,10’-Heptadecafluorodecyl)-
diisopropyl-silyloxy)-methyl)-10-(2-nitrophenylsulfonyl)-6-phenyl-3,3a,8a,9,10,11-
hexahydrofuro[3,4-e]pyrrolo[3,4-c][1,2,4]triazolo[1,2-a]pyridazine-5,7(1H,6H)-dione 
((±)-129) 
The diene 60 (97 mg, (0.089 mmol) was dissolved in CH2Cl2 
(3 mL) and 4-phenyl-[1,2,4]-triazole-3,5-dione (128, 156 mg, 
0.89 mmol) was added. The reaction mixture was stirred at 
room temperature for 1.5 h after which the mixture was 
concentrated under reduced pressure and purified by F–SPE, 
eluting with 8:2 MeOH–H2O then MeOH, and column 
chromatography, eluting with 3:1 Petrol–EtOAc, to give the 
tetracycle  (±)-129 (93 mg, 84%) as a colorless amorphous solid, Rf 0.10 (3:1 Petrol–
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EtOAc); νmax/cm-1 (neat) 2947, 2869, 1767, 1708, 1547, 1242, 1206; δH (500 MHz, CDCl3) 
8.09 (1H, dd, J 7.6 and 1.7, nosyl 3-H), 7.78–7.72 (2H, m, nosyl 4-H and 5-H), 7.67 (1H, 
dd, J 7.6 and 1.7, nosyl 6-H), 7.48–7.42 (4H, m, phenyl 2-H and 3-H), 7.39–7.34 (1H, m, 
phenyl 4-H), 4.75 (1H, dd, J 8.7 and 7.3, 9-Ha), 4.53–4.47 (2H, m, 3a-H and 1-Ha), 4.45–
4.41 (1H, m, 1-Hb), 4.33 (1H, d, J 10.4, 8a-CH2a), 4.27–4.24 (2H, m, 11-H2), 4.22 (1H, d, J 
10.7, 9-Ha), 3.76 (1H, d, J 10.4, 8a-CH2b), 3.62 (1H, dd, J 9.4 and 8.7, 3-Hb), 3.56 (1H, d, J 
10.7, 9-Hb), 2.08–1.95 (2H, m, 1'-H2), 1.02–0.94 (14H, m, iPr), 0.83–0.78 (2H, m, 2'-H2); 
δC (75 MHz, CDCl3) 150.1, 149.6, 148.2, 134.4, 133.0, 132.1, 131.6, 131.5, 131.2, 129.3 
(2C), 128.4, 125.2 (2C), 125.0, 124.5, 71.3, 67.3, 64.9, 63.7, 54.4, 53.9, 47.8, 17.4 (2C), 
17.4 (2C), 12.3, 12.2 (the signals for 1'-C, 2'-C and C8F17 are missing); m/z (ES+) (Found: 
MNa+ 1110.1800, C39H38F17N5O8SSi requires MNa 1110.1831).  
 
3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-Heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl-1,2,5,6-tetrahydropyridine (130) 
By general procedure C, the sulfonamide 122 (100 mg, 0.12 mmol), K2CO3 (64 mg, 0.46 
mmol) and PhSH (35 µL, 0.35 mmol) in DMF (2 mL) gave the tetrahydropyridine 130 (83 
mg, 106%, >80% purity by 500 MHz 1H NMR spectroscopy) as a colorless oil, νmax/cm-1 
(neat) 2926, 2868, 1463, 1368, 1241, 1206; δH (500 MHz, CDCl3) 5.75–5.72 (1H, m, 4-H), 
4.07 (2H, d, J 0.5, 3-CH2), 3.30 (2H, d, J 1.7, 2-H2), 2.92 (2H, t, J 5.7, 6-H2), 2.18–2.05 
(4H, m, 5-H2 and 2'-H2), 1.07–1.03 (14H, m, iPr) and 0.89–0.82 (2H, m, 1'-H2); δC (75 
MHz, CDCl3) 137.3, 120.8, 66.1, 45.6, 43.2, 29.9, 25.6, 17.7 (2C), 17.6 (2C) 12.6 (2C) (the 
signals for 1'-C and C8F17 are missing); m/z (EI+) (Found: M+ 673.1664, C22H28F17NOSi 
requires M 673.1669). 
 
(R,Z)-6-(2,5-Dihydrofuran-3-yl)-2-(((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-methyl)-2,3,4,7-tetrahydro-1H-azepine 
(133) 
By general procedure C, the sulfonamide 93 (155mg, 0.16 mmol), K2CO3 (88 mg, 0.64 
mmol) and PhSH (50 µL, 0.49 mmol) in DMF (3 mL) gave the tetrahydro-1H-azepine 133 
(129 mg, 107%, >80% purity by 500 MHz 1H NMR spectroscopy) as a colorless oil, Rf 
0.12 (2:1 petrol–EtOAc); νmax/cm-1 (neat) 2922, 2852, 1461, 1375, 1240, 1205; δH (500 
MHz, CDCl3) 5.73–5.71 (1H, m, dihydrofuran 4-H), 5.66–5.62 (1H, m, 5-H), 4.76–4.69 
(4H, m, dihydrofuran 2-H2 and 5-H2), 3.79 (1H, d, J 15.4, 7-Ha), 3.59–3.55 (2H, m, 2-
CH2), 3.51–3.47 (1H, m, 7-Hb), 2.99–2.94 (1H, m, 2-H), 2.44–2.37 (1H, m, 3-Ha), 2.33–
2.25 (1H, m, 3-Hb), 2.18–2.06 (2H, m, 2'-H2), 1.79–1.66 (1H, m, 4-Ha), 1.42–1.23 (1H, m, 
4-Hb), 1.10–0.98 (14H, m, iPr), 0.90–0.82 (2H, m, 1'-H2); m/z (ES+) (Found: MH+ 
756.2128, C27H35F17NO2Si requires MH 756.2160).  
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(3aR,8aS)-8a-(((3’,3’,4’,4’,5’,5’,6’,6’,7’,7’,8’,8’,9’,9’,10’,10’-Heptadecafluorodecyl)-
diisopropyl-silyloxy)-methyl)-6-phenyl-3,3a,8a,9,10,11-hexahydrofuro[3,4-
e]pyrrolo[3,4-c][1,2,4]triazolo[1,2-a]pyridazine-5,7(1H,6H)-dione ((±)-134) 
By general procedure C, the sulfonamide (±)-129 (113 mg, 0.10 mmol), K2CO3 (55 mg, 
0.40 mmol) and PhSH (31 µL, 0.30 mmol) in DMF (2.5 mL) gave the amine (±)-134 (89 
mg, 99%, >95% purity by 500 MHz 1H NMR spectroscopy) as a colorless amorphous 
solid, νmax/cm-1 (neat) 3335, 2949, 2870, 1755, 1693, 1426, 1203; δH (500 MHz, CDCl3) 
7.52–7.49 (2H, m, phenyl 2-H), 7.47–7.43 (2H, m, phenyl 3-H), 7.37–7.33 (1H, m, phenyl 
4-H), 4.76 (1H, dd, J 8.4 and 7.2, 3-Ha), 4.59–4.53 (1H, m, 3a-H), 4.47 (1H, ddd, J 13.6, 
3.5 and 2.0, 1-Ha), 4.39 (1H, ddd, J 13.6, 3.0 and 1.7, 1-Hb), 4.27 (1H, d, J 10.1, 8a-CH2a), 
3.81 (1H, d, J 10.1, 8a-CH2b), 3.74 (1H, d, J 11.8, 9-Ha), 3.69–3.66 (2H, m, 11-H2), 3.59 
(1H, dd, J 9.1 and 8.4, 3-Hb), 3.25 (1H, d, J 11.8, 9-Hb), 2.10–1.98 (2H, m, 2'-H2), 1.05–
0.98 (14H, iPr), 0.89–0.82 (2H, m, 1'-H2); δC (75 MHz, CDCl3) 149.8, 149.7, 131.6, 131.4, 
129.7 (2C), 128.1, 125.3 (2C), 71.6, 67.4, 66.1, 64.7, 54.9, 53.9, 47.4, 17.5 (2C), 17.5 (2C), 
12.4, 12.4, (the signals for 11a-C, 1'-C, 2'-C and C8F17 are missing); m/z (ES+) (Found: 
MH+ 903.2208, C33H35F17N4O4Si requires MH 903.2234). 
 
3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-Heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl-1-(furfuryl aminecarbonyl)-1,2,5,6-tetrahydropyridine (139) 
By general procedure E, the amine 130 (20 mg, 0.030 mmol) and furfuryl isocyanate (13 
µL, 0.12 mmol) gave 3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-methyl-1-(furfuryl aminecarbonyl)-1,2,5,6-
tetrahydropyridine 139 (21 mg, 88%, >80% purity by 500 MHz 1H NMR spectroscopy) as 
a colorless oil, δH (500 MHz, CDCl3) 7.34 (1H, dd, J 1.9 and 0.8, furfuryl 5-H), 6.31 (1H, 
dd, J 3.1 and 1.9, furfuryl 4-H), 6.23 (1H, dd, J 3.1 and 0.8, furfuryl 3-H), 5.83–5.80 (1H, 
m, 4-H), 4.71 (1H, t, J 5.4, NH), 4.44 (2H, d, J 5.4, furfuryl 3-CH2), 4.14–4.12 (2H, m, 3-
CH2), 3.82–3.80 (2H, m, 2-H2), 3.47 (2H, t, J 5.7, 6-H2), 2.19–2.05 (4H, m, 5-H2 and 2'-
H2), 1.09–1.00 (14H, m, iPr), 0.89–0.85 (2H, m, 1'-H2).  
 
3-hydroxymethyl-1-benzenecarbonyl-1,2,5,6-tetrahydropyridine (156) 
By general procedure D, the amine 130 (20 mg, 0.030 mmol), DMAP (18 mg, 0.12 mmol) 
and benzyl chloride (14 µL, 0.12 mmol) gave 3-
((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl-silyloxy)-
methyl-1-benzenecarbonyl-1,2,5,6-tetrahydropyridine 135 (18 mg, 78%, 55:45 mixture of 
rotamers, >80% purity by 500 MHz 1H NMR spectroscopy) as a colorless oil, δH (500 
MHz, CDCl3) 7.43–7.37 (5H, m, phenyl 2-H, 3-H and 4-H), 5.85–5.78 (1H, m, 4-H), 4.22–
4.15 (2H, 3-CH2), 4.04–3.99 (2H, 2-H2maj), 3.93–3.89 (2H, m, 2-H2min), 3.86–3.80 (2H, m, 
6-H2min), 3.49–3.42 (2H, m, 6-H2maj), 2.31–2.07 (4H, m, 5-H2 and 2'-H2), 1.13–0.73 (16H, 
m, 1'-H2 and iPr). 
By general procedure H, the silyl ether 135 (18 mg, 0.023 mmol) gave the amide 156 (3 
mg, 60%, 10:7 mixture of rotamers) as a colorless oil, Rf 0.46 (20:1 CH2Cl2–MeOH); 
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νmax/cm-1 (neat) 3396, 2926, 2854, 1614, 1447, 1255, 1137; δH (500 MHz, CDCl3) 7.45–
7.38 (5H, m, phenyl 2-H, 3-H and 4-H), 5.90–5.86 (1H, m, 4-H), 4.28–4.22 (2H, m, 2-
H2maj), 4.17–4.12 (4H, m, 2-H2min and 3-CH2min), 4.00–3.93 (2H, m, 3-CH2maj), 3.86–3.80 
(2H, m, 6-H2min), 3.49–3.43 (2H, m, 6-H2maj), 2.33–2.25 (2H, m, 5-H2min), 2.23–2.15 (2H, 
m, 5-H2maj); m/z (EI+) (Found: M+ 217.1107, C13H15NO2 requires M 217.1103).  
 
3-Hydroxymethyl-1-(2-thiophenecarbonyl)-1,2,5,6-tetrahydropyridine (157) 
By general procedure D, the amine 130 (20 mg, 0.030 mmol), DMAP (18 mg, 0.12 mmol) 
and 2-thiophenecarbonyl chloride (13 µL, 0.12 mmol) gave 3-
((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl-silyloxy)-
methyl-1-(2-thiophenecarbonyl)-1,2,5,6-tetrahydropyridine 136 (21 mg, 88%, >85% purity 
by 500 MHz 1H NMR spectroscopy) as a colorless oil, δH (500 MHz, CDCl3) 7.44 (1H, dd, 
J 5.0 and 1.1, thiophene 5-H), 7.32 (1H, dd, J 3.6 and 1.1, thiophene 3-H), 7.04 (1H, dd, J 
5.0 and 3.6, thiophene 4-H), 5.84–5.82 (1H, m, 4-H), 4.22–4.12 (4H, m, 2-H2 and 3-CH2), 
3.77 (2H, t, J 5.6, 6-H2), 2.29–2.25 (2H, m, 5-H2), 2.16–2.03 (2H, m, 2'-H2), 1.08–0.95 
(14H, m, iPr), 0.90–0.83 (2H, m, 1'-H2). 
By general procedure H, the silyl ether 136 (21 mg, 0.027 mmol) gave the amide 157 (5 
mg, 83%) as a colorless oil, Rf 0.27 (20:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3400, 2528, 
1601, 1443, 1084; δH (500 MHz, CD3OD) 7.65 (1H, dd, J 5.0 and 1.1, thiophene 5-H), 
7.46–7.44 (1H, m, thiophene 3-H), 7.13 (1H, dd, J 5.0 and 3.7, thiophene 4-H), 5.90–5.87 
(1H, m, 4-H), 4.31–4.22 (2H, m, 2-H2), 4.03–3.97 (2H, m, 3-CH2), 3.79 (2H, t, J 5.8, 6-
H2), 2.31–2.26 (2H, m, 5-H2); m/z (ES+) (Found: MNa+ 246.0553, C11H13NO2S requires 
MNa 246.0559).  
 
3-Hydroxymethyl-1-(5-isoxazolecarbonyl)-1,2,5,6-tetrahydropyridine (158) 
By general procedure D, the amine 130 (20 mg, 0.030 mmol), DMAP (18 mg, 0.12 mmol) 
and 5-isoxazolecarbonyl chloride (15 µL, 0.12 mmol) gave 3-
((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl-silyloxy)-
methyl-1-(5-isoxazolecarbonyl)-1,2,5,6-tetrahydropyridine 137 (19 mg, 83%, 55:45 
mixture of rotamers, >80% purity by 500 MHz 1H NMR spectroscopy) as a colorless oil, 
δH (500 MHz, CDCl3) 8.32 (1H, d, J 1.7, isoxazole 3-Hmaj) and 8.29 (1H, d, J 1.7, 
isoxazole 3-Hmin), 6.78–6.77 (1H, m, isoxazole 4-H), 5.86–5.82 (1H, m, 4-H2), 4.22–4.10 
(4H, m, 2-H2 and 3-CH2), 3.82 (2H, t, J 5.7, 6-Hmin) and 3.73 (2H, t, J 5.7, 6-Hmaj), 2.34–
2.26 (2H, m, 5-H2), 2.18–2.02 (2H, m, 2'-H2), 1.09–0.99 (14H, m, iPr), 0.91–0.83 (2H, m, 
1'-H2). 
By general procedure H, the silyl ether 137 (19 mg, 0.025 mmol) gave the amide 158 (4 
mg, 80%, 60:40 mixture of rotamers) as a colorless oil, Rf 0.21 (20:1 CH2Cl2–MeOH); 
νmax/cm-1 (neat) 3407, 2923, 2853, 1633, 1428; δH (500 MHz, CD3OD) 8.52 (1H, d, J 1.8, 
isoxazole 3-H), 6.86 (1H, d, J 1.8, isoxazole 4-Hmin) and 6.83 (1H, d, J 1.8, isoxazole 4-
Hmaj), 5.90–5.87 (1H, m, 4-H), 4.23–4.20 (2H, m, 3-CH2), 4.06–3.96 (2H, m, 2-H2), 3.82 
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(2H, t, J 5.8, 6-H2min) and 3.67 (2H, t, J 5.8, 6-H2maj), 2.34–2.26 (2H, m, 5-H2); m/z (ES+) 
(Found: MNa+ 231.0740, C10H12N2O3 requires MNa 231.0740). 
 
3-Hydroxymethyl-1-(phenyl-aminecarbonyl)-1,2,5,6-tetrahydropyridine (159) 
By general procedure E, the amine 130 (35 mg, 0.052 mmol) and phenyl isocyanate (23 
µL, 0.21 mmol) gave 3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-methyl-1-(phenyl-aminecarbonyl)-1,2,5,6-
tetrahydropyridine 138 (30 mg, 73%, >90% purity by 500 MHz 1H NMR spectroscopy) as 
a colorless oil, δH (500 MHz, CDCl3) 7.36 (2H, d, J 8.5, phenyl 2-H), 7.28 (2H, dd, J 8.5 
and 7.4, phenyl 3-H), 7.03 (1H, t, J 7.4, phenyl 4-H), 6.33 (1H, s, NH), 5.88–5.85 (1H, m, 
4-H), 4.18–4.16 (2H, m, 3-CH2), 3.96–3.94 (2H, m, 2-H2), 3.57 (2H, t, J 5.7, 6-H2), 2.26–
2.21 (2H, m, 5-H2), 2.18–2.07 (2H, m, 2'-H2), 1.08–1.03 (14H, m, iPr), 0.91–0.87 (2H, m, 
1'-H2).  
By general procedure H, the silyl ether 138 (30 mg, 0.038 mmol) gave the urea 159 (8 mg, 
89%) as a colorless oil, Rf 0.35 (20:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3318, 2916, 2854, 
1630, 1441; δH (500 MHz, CD3OD) 7.35 (2H, d, J 8.5, phenyl 2-H), 7.26 (2H, dd, J 8.5 
and 7.5, phenyl 3-H), 7.01 (1H, t, J 7.5, phenyl 4-H), 5.90–5.86 (1H, m, 4-H), 4.04–4.00 
(4H, m, 2-H2 and 3-CH2), 3.59 (2H, t, J 5.7, 6-H2), 2.26–2.21 (2H, m, 5-H2); δC (75 MHz, 
CD3OD) 158.1, 140.9, 136.9, 129.5 (2C), 124.1, 122.7, 122.3 (2C), 65.2, 45.5, 41.8, 25.9; 
m/z (ES+) (Found: MH+ 233.1280, C13H16N2O2 requires MH 233.1285). 
 
3-Hydroxymethyl-1-(benzyl-aminethiocarbonyl)-1,2,5,6-tetrahydropyridine (160) 
By general procedure F, the amine 130 (20 mg, 0.030 mmol) and benzyl isothiocyanate (16 
µL, 0.12 mmol) gave 3-((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-methyl-1-(benzyl-aminethiocarbonyl)-1,2,5,6-
tetrahydropyridine 140 (15 mg, 60%, >90% purity by 500 MHz 1H NMR spectroscopy) as 
a colorless oil, δH (500 MHz, CDCl3) 7.36–7.30 (5H, m, benzyl 3-H, 4-H and 5-H), 5.89–
5.87 (1H, m, 4-H), 5.56 (1H, t, J 4.7, NH), 4.89 (2H, d, J 4.7, benzyl 1-H2), 4.15–4.13 (2H, 
m, 3-CH2), 4.11 (2H, d, J 1.3, 2-H2), 4.00 (2H, t, J 5.7, 6-H2), 2.29–2.25 (2H, m, 5-H2), 
2.15–2.03 (2H, m, 2'-H2), 1.06–1.00 (14H, m, iPr), 0.90–0.82 (2H, m, 1'-H2).  
By general procedure H, the silyl ether 140 (15 mg, 0.018 mmol) gave the thiourea 160 (3 
mg, 60%) as a colorless oil, Rf 0.42 (20:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3304, 2920, 
2855, 1538, 1325; δH (500 MHz, CDCl3) 7.37–7.30 (5H, m, benzyl 3-H, 4-H and 5-H), 
5.96–5.93 (1H, m, 4-H), 5.66–5.63 (1H, m, NH), 4.90 (2H, d, J 4.8, benzyl 1-H2), 4.16–
4.14 (2H, m, 2-H2), 4.11–4.08 (2H, m, 3-CH2), 4.04 (2H, t, J 5.7, 6-H2), 2.30–2.26 (2H, m, 
5-H2), 1.43 (1H, t, J 5.6, OH); δC (75 MHz, CDCl3) 138.1, 134.4, 129.0 (2C), 128.4 (2C), 
128.0, 123.4, 65.2, 50.6, 47.2, 45.2, 24.8 (the signal for C=S is missing); m/z (ES+) 
(Found: MH+ 263.1207, C14H18OS requires MH 263.1213).  
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3-Hydroxymethyl-1-phenylsulfonyl-1,2,5,6-tetrahydropyridine (161) 
By general procedure G, the amine 130 (20 mg, 0.030 mmol), DMAP (18 mg, 0.12 mmol) 
and benzenesulfonyl chloride (15 µL, 0.12 mmol) gave 3-
((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl-silyloxy)-
methyl-1-phenylsulfonyl-1,2,5,6-tetrahydropyridine 141 (20 mg, 83%, >95% purity by 500 
MHz 1H NMR spectroscopy) as a colorless oil, δH (500 MHz, CDCl3) 7.80 (2H, d, J 7.4, 
phenyl 2-H), 7.59 (1H, t, J 7.4, phenyl 4-H), 7.52 (2H, t, J 7.4, phenyl 3-H), 5.70–5.67 
(1H, m, 4-H), 4.09–4.07 (2H, m, 3-CH2), 3.57–3.55 (2H, m, 2-H2), 3.17 (2H, t, J 5.7, 6-
H2), 2.24–2.19 (2H, m, 5-H2), 2.12–2.01 (2H, m, 2'-H2), 1.07–0.99 (14H, m, iPr), 0.87–
0.81 (2H, m, 1'-H2). 
By general procedure H, The silyl ether 141 (20 mg, 0.025 mmol) gave the sulfonamide 
161 (6 mg, 95%) as a colorless oil, Rf 0.38 (20:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3405, 
2924, 2854, 1446, 1335, 1158; δH (500 MHz, CDCl3) 7.81 (2H, d, J 7.3, phenyl 2-H), 7.60 
(1H, t, J 7.3, phenyl 4-H), 7.54 (2H, t, J 7.3, phenyl 3-H), 5.76–5.74 (1H, m, 4-H), 4.04–
4.02 (2H, m, 3-CH2), 3.64–3.61 (2H, m, 2-H2), 3.18 (2H, t, J 5.7, 6-H2), 2.27–2.22 (2H, m, 
5-H2), 1.37 (1H, br s, OH); δC (75 MHz, CDCl3) 136.7, 134.3, 132.9, 129.2 (2C), 127.9 
(2C), 121.8, 65.3, 45.5, 42.9, 25.2; m/z (ES+) (Found: MNa+ 276.0657, C12H15NO3S 
requires MNa 276.0665). 
 
3-Hydroxymethyl-1-methylsulfonyl-1,2,5,6-tetrahydropyridine (162) 
By general procedure G, the amine 130 (20 mg, 0.030 mmol), DMAP (18 mg, 0.12 mmol) 
and methanesulfonyl chloride (9 µL, 0.12 mmol) gave 3-
((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl-silyloxy)-
methyl-1-methylsulfonyl-1,2,5,6-tetrahydropyridine 142 (17 mg, 77%, >80% purity by 500 
MHz 1H NMR spectroscopy) as a colorless oil, δH (500 MHz, CDCl3) 5.82–5.79 (1H, m, 4-
H), 4.15–4.13 (2H, m, 3-CH2), 3.77–3.75 (2H, m, 2-H2), 3.36 (2H, t, J 5.8, 6-H2), 2.81 
(3H, s, CH3), 2.30–2.25 (2H, m, 5-H2), 2.17–2.06 (2H, m, 2'-H2), 1.09–1.01 (14H, m, iPr) 
and 0.90–0.82 (2H, m, 1'-H2).  
By general procedure H, the silyl ether 142 (17 mg, 0.023 mmol) gave sulfonamide 162 (3 
mg, 75%) as a colorless oil, Rf 0.25 (20:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3363, 2926, 
2855, 1323, 1147; δH (500 MHz, CD3OD) 5.84–5.81 (1H, m, 4-H), 4.01–3.99 (2H, m, 3-
CH2), 3.79–3.77 (2H, m, 2-H2), 3.33 (2H, t, J 5.8, 6-H2), 2.86 (3H, s, CH3) and 2.30–2.25 
(2H, m, 5-H2); δC (75 MHz, CD3OD) 136.1, 122.2, 65.0, 46.1, 43.6, 35.2, 25.9; m/z (ES+) 
(Found: MNa+ 214.0499, C7H13NO3S requires MNa 214.0508). 
 
1-N-(2-(2,5-Dihydrofuran-3-yl)-allyl)-1-N-(3-hydroxy-2-methylene-propyl)-3-N-
phenylurea (163) 
By general procedure C, the sulfonamide 124 (17 mg, 0.018 mmol), K2CO3 (8 mg, 0.054 
mmol) and PhSH (2.3 µL, 0.022 mmol) in DMF (1 mL) gave 1-N-(2-(2,5-dihydrofuran-3-
yl)-allyl)-(3-(((3',3',4',4',5',5',6',6',7',7',8',8',9',9', 10',10',10'-heptadecafluorodecyl)-
diisopropyl)-silyloxy)-2-methylene-propyl)-1-amine 132 (13 mg, 96%, >80% purity by 500 
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MHz 1H NMR spectroscopy) as a colorless oil, δH (500 MHz, CDCl3) 5.90–5.87 (1H, m, 
dihydrofuran 4-H), 5.15–5.14 (1H, m, 2-CH2 or allyl 3-H), 5.05–5.03 (2H, m, 2-CH2 or 
allyl 3-H), 4.85–4.83 (1H, m, 2-CH2 or allyl 3-H), 4.29–4.27 (2H, m, 1-H2, 3-H2 or allyl 1-
H2), 4.25–4.22 (4H, m, dihydrofuran 2-H2 and 5-H2), 3.40–3.38 (2H, m, 1-H2, 3-H2 or allyl 
1-H2), 3.28–3.26 (2H, m, 1-H2, 3-H2 or allyl 1-H2), 2.20–2.06 (2H, m, 2'-H2), 1.08–1.02 
(14H, m, iPr), 0.90–0.86 (2H, m, 1'-H2). 
By general procedure E, the amine 132 (13 mg, 0.017 mmol) and phenylisocyanate (7.5 
µL, 0.069 mmol) gave 1-N-(2-(2,5-dihydrofuran-3-yl)-allyl)-1-N-(3-
(((3',3',4',4',5',5',6',6',7',7',8',8',9',9', 10',10',10'-heptadecafluorodecyl)-diisopropyl)-
silyloxy)-2-methylene-propyl)-3-N-phenylurea 143 (14 mg, 95%, >75% purity by 500 MHz 
1H NMR spectroscopy) as a colorless oil, Rf 0.47 (5:1 petrol–EtOAc); δH (500 MHz, 
CDCl3) 7.33–7.30 (2H, m, phenyl 2-H), 7.28–7.25 (2H, m, phenyl 3-H), 7.02 (1H, tt, J 7.3 
and 1.2, phenyl 4-H), 6.71 (1H, s, NH), 5.85–5.82 (1H, m, dihydrofuran 4-H), 5.30–5.28 
(1H, m, 2-CH2 or allyl 3-H), 5.15–5.12 (2H, m, 2-CH2 or allyl 3-H), 4.91–4.88 (1H, m, 2-
CH2 or allyl 3-H), 4.33–4.29 (2H, m, 1-H2, 3-H2 or allyl 1-H2), 4.26–4.23 (4H, m, 
dihydrofuran 2-H2 and 5-H2), 4.23–4.21 (2H, m, 1-H2, 3-H2 or allyl 1-H2), 3.98–3.95 (2H, 
m, 1-H2, 3-H2 or allyl 1-H2), 2.19–2.05 (2H, m, 2'-H2), 1.08–1.03 (14H, m, iPr), 0.86–0.82 
(2H, m, 1'-H2).  
By general procedure H, the silyl ether 143 (14 mg, 0.016 mmol) gave the urea 163 (3 mg, 
60%) as a colorless amorphous solid, Rf 0.31 (20:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3418, 
2528, 1641, 1470, 1445, 1116, 1082; δH (500 MHz, CD3OD) 7.34–7.32 (2H, m, phenyl 2-
H), 7.27–7.23 (2H, m, phenyl 3-H), 7.03–6.99 (1H, m, phenyl 4-H), 5.83–5.82 (1H, m, 
dihydrofuran 4-H), 5.23–5.22 (1H, m, 2-CH2a or allyl 3-Ha), 5.12–5.11 (1H, m, 2-CH2a or 
allyl 3-Ha), 5.03–5.02 (1H, m, 2-CH2b or allyl 3-Hb), 4.92–4.91 (1H, m, 2-CH2b or allyl 3-
Hb), 4.29–4.27 (2H, m, 1-H2, 3-H2 or allyl 1-H2), 4.24–4.23 (4H, m, dihydrofuran 2-H2 and 
5-H2), 4.11–4.09 (2H, m, 1-H2, 3-H2 or allyl 1-H2), 4.04–4.03 (2H, m, 1-H2, 3-H2 or allyl 
1-H2); δC (75 MHz, CD3OD) 146.0, 140.2, 129.6 (2C), 127.4, 124.2, 122.1 (2C), 113.1, 
108.1, 70.6, 67.1, 64.2, 47.8 (the signals for four carbon atoms are missing); m/z (ES+) 
(Found: MH+ 315.1698, C18H23O3N2 requires MH 315.1703).  
 
(R,Z)-6-(2,5-Dihydrofuran-3-yl)-2-hydroxymethyl-1-phenylcarbonyl-2,3,4,7-
tetrahydro-1H-azepine (164)  
By general procedure D, the amine 133 (20 mg, 0.026 mmol), DMAP (16 mg, 0.13 mmol) 
and benzoyl chloride (12 µL, 0.10 mmol) gave (R,Z)-6-(2,5-dihydrofuran-3-yl)-2-
(((3',3',4',4',5',5',6',6',7',7',8',8',9',9', 10',10',10'-heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl)-1-phenylcarbonyl-2,3,4,7-tetrahydro-1H-azepine 144 (22 mg, 98%, 
70:30 mixture of rotamers, >85% purity by 500 MHz 1H NMR spectroscopy) as a colorless 
oil, δH (500 MHz, CDCl3) 7.46–7.27 (5H, m, phenyl 2-H, 3-H and 4-H), 6.00–5.98 (1H, m, 
dihydrofuran 4-Hmin), 5.63–5.59 (1H, m, 5-Hmaj), 5.52–5.49 (1H, m, 5-Hmin), 5.09–3.65 
(9H, m, 2-H, 2-CH2, 7-H2, dihydrofuran 2-H2 and 5-H2), 4.95–4.92 (1H, m, dihydrofuran 
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4-Hmaj), 2.54–1.99 (6H, m, 3-H2, 4-H2 and 2'-H2), 1.17–1.00 (14H, m, iPr), 0.93–0.81 (2H, 
m, 1'-H2). 
By general procedure H, the silyl ether 144 (22 mg, 0.026 mmol) gave the amide 164 (6 
mg, 77%, 60:40 mixture of rotamers) as a colorless oil, Rf 0.10 (25:1 CH2Cl2–MeOH); 
νmax/cm-1 (neat) 3400, 2922, 2842, 1612, 1446, 1425, 1077; δH (500 MHz, CD3OD) 7.47–
7.30 (5H, m, phenyl 2-H, 3-H and 4-H), 6.03–6.01 (1H, m, dihydrofuran 4-Hmin), 5.69–
5.66 (1H, m, 5-Hmaj), 5.60–5.57 (1H, m, 5-Hmin), 5.05–5.02 (1H, m, dihydrofuran 4-Hmaj), 
4.98–3.53 (9H, m, 2-H, 2-CH2, 7-H2, dihydrofuran 2-H2 and 5-H2), 2.55–1.70 (5H, m, 3-
H2, 4-H2 and OH); m/z (ES+) (Found: MNa+ 322.1412, C18H21NO3 requires MNa 
322.1414). 
 
(R,Z)-6-(2,5-Dihydrofuran-3-yl)-2-hydroxymethyl-1-(2-thiophenecarbonyl)-2,3,4,7-
tetrahydro-1H-azepine (165) 
By general procedure D, the amine 133 (20 mg, 0.026 mmol), DMAP (16 mg, 0.13 mmol) 
and 2-thiophenecarbonyl chloride (11 µL, 0.10 mmol) gave (R,Z)-6-(2,5-dihydrofuran-3-
yl)-2-(((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl)-1-(2-thiophenecarbonyl)-2,3,4,7-tetrahydro-1H-azepine 145 (22 mg, 
98%, 60:40 mixture of rotamers, >90% purity by 500 MHz 1H NMR spectroscopy) as a 
colorless oil, δH (500 MHz, CDCl3) 7.58–7.08 (2H, m, thiophene 5-H and 3-H), 7.03–6.99 
(1H, m, thiophene 4-Hmin), 6.97–6.93 (1H, m, thiophene 4-Hmaj), 5.98–5.94 (1H, m, 
dihydrofuran 4-Hmin), 5.72–5.66(1H, m, 5-Hmaj), 5.51–5.45 (1H, m, 5-Hmin), 5.44–5.40 (1H, 
m, dihydrofuran 4-Hmaj), 4.92–3.79 (9H, m, 2-H, 2-CH2, 7-H2, dihydrofuran 2-H2 and 4-
H2), 2.50–1.91 (6H, m, 3-H2, 4-H2 and 2'-H2), 1.15–0.97 (14H, m, iPr), 0.95–0.81 (2H, m, 
1'-H2).  
By general procedure H, the silyl ether 145 (22 mg, 0.025 mmol) gave the amide 165 (7 
mg, 90%, 55:45 mixture of rotamers) as a colorless oil, Rf 0.09 (25:1 CH2Cl2–MeOH); 
νmax/cm-1 (neat) 3398, 2921, 2845, 1600, 1431, 1079; δH (500 MHz, CD3OD) 7.68–7.18 
(2H, m, thiophene 5-H and 3-H), 7.10 (1H, t, J 4.1, thiophene 4-Hmaj), 7.03 (1H, t, J 4.1, 
thiophene 4-Hmin), 6.00–5.52 (2H, m, 5-H and dihydrofuran 4-H), 4.82–3.67 (9H, m, 2-H, 
2-CH2, 7-H2, dihydrofuran 2-H2 and 5-H2), 2.54–1.71 (5H, m, 3-H2, 4-H2 and OH); m/z 
(ES+) (Found: MH+ 306.1147, C16H20O3S requires MH 306.1158).  
 
(R,Z)-6-(2,5-Dihydrofuran-3-yl)-2-hydroxymethyl-1-(5-isoxazolecarbonyl)-2,3,4,7-
tetrahydro-1H-azepine (166) 
By general procedure D, the amine 133 (20 mg, 0.026 mmol), DMAP (16 mg, 0.13 mmol) 
and 5-isoxazolecarbonyl chloride (13 µL, 0.10 mmol) gave (R,Z)-6-(2,5-dihydrofuran-3-
yl)-2-(((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl)-1-(5-isoxazolecarbonyl)-2,3,4,7-tetrahydro-1H-azepine 146 (20 mg, 
91%, 55:45 mixture of rotamers, >70% purity by 500 MHz 1H NMR spectroscopy) as a 
colorless oil, δH (500 MHz, CDCl3) 8.29 (1H, d, J 1.8, isoxazole 3-Hmaj), 8.25 (1H, d, J 
1.8, isoxazole 3-Hmin), 6.82 (1H, d, J 1.8, isoxazole 4-Hmaj), 6.58 (1H, d, J 1.8, isoxazole 4-
Natural-Product-Like Molecules 
172 
 
Hmin), 5.97–5.95 (1H, m, dihydrofuran 4-Hmaj), 5.56 (1H, d, J 7.5, 5-Hmaj), 5.52–5.50 (1H, 
m, dihydrofuran 4-Hmin), 5.49 (1H, d, J 7.5, 5-Hmin), 4.91–3.81 (9H, m, 2-H, 2-CH2, 7-H2, 
dihydrofuran 2-H2 and 5-H2), 2.51–1.97 (6H, m, 3-H2, 4-H2 and 2'-H2), 1.09–1.00 (14H, m, 
iPr), 0.91–0.83 (2H, m, 1'-H2). 
By general procedure H, the silyl ether 146 (20 mg, 0.024 mmol) gave the amide 166 (4 
mg, 57%, 55:45 mixture of rotamers) as a colorless oil, Rf 0.22 (20:1 CH2Cl2–MeOH); 
νmax/cm-1 (neat) 3418, 2919, 2853, 1633, 1424, 1076; δH (500 MHz, CD3OD) 8.49(1H, d, J 
1.9, isoxazole 3-Hmaj), 8.45 (1H, d, J 1.9, isoxazole 3-Hmin), 6.88 (1H, d, J 1.9, isoxazole 4-
Hmaj), 6.64 (1H, d, J 1.9, isoxazole 4-Hmin), 6.02–6.00 (1H, m, dihydrofuran 4-Hmaj), 5.68–
5.65 (1H, m, 5-Hmaj), 5.61–5.59 (1H, m, dihydrofuran 4-Hmin), 5.58–5.55 (1H, m, 5-Hmin), 
4.90 (1H, d, J 16.1, 7-Ha), 4.78–4.63 (4H, m, dihydrofuran 2-H2 and 5-H2), 4.43–4.40 (1H, 
m, 2-H), 4.11–4.06 (1H, m, 7-Hb), 3.78–3.65 (2H, m, 2-CH2), 2.51–1.81 (5H, m, 3-H2, 4-
H2 and OH); m/z (ES+) (Found: MNa+ 313.1158, C15H18N2O4 requires MNa 313.1159). 
 
(R,Z)-6-(2,5-Dihydrofuran-3-yl)-2-hydroxymethyl-1-(phenyl-aminecarbonyl)-2,3,4,7-
tetrahydro-1H-azepine (167) 
By general procedure E, the amine 133 (10 mg, 0.014 mmol) and phenyl isocyanate (6 µL, 
0.056 mmol) gave (R,Z)-6-(2,5-dihydrofuran-3-yl)-2-
(((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluoro-decyl)-diisopropyl-
silyloxy)-methyl)-1-(phenyl-aminecarbonyl)-2,3,4,7-tetrahydro-1H-azepine 147 (11 mg, 
92%, >50% purity by 500 MHz 1H NMR spectroscopy) as a colorless oil, δH (500 MHz, 
CDCl3) 7.33–7.29 (2H, m, phenyl 2-H), 7.26–7.22 (2H, m, phenyl 3-H), 6.98 (1H, t, J 7.3, 
phenyl 4-H), 5.94 (1H, m, dihydrofuran 4-H), 5.53–5.48 (1H, m, 5-H), 4.86–4.67 (5H, m, 
7-Ha, dihydrofuran 2-H2 and 5-H2), 4.26–4.14 (1H, m, 2-H), 3.87–3.82 (2H, m, 2-CH2a, 7-
Hb), 3.77–3.71 (1H, m, 2-CH2b), 2.49–2.32 (2H, m, 4-H2), 2.19–2.06 (3H, m, 3-Ha and 2'-
H2), 1.94–1.89 (1H, m, 3-Hb), 1.17–0.94 (14H, m, iPr), 0.90–0.82 (2H, m, 1'-H2). 
By general procedure H, the silyl ether 147 (11 mg, 0.013 mmol) gave the urea 167 (1 mg, 
25%) as a colorless amorphous solid, Rf 0.21 (20:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3308, 
2851, 1651, 1535, 1445, 1178, 1079; δH (500 MHz, CD3OD) 7.25–7.23 (4H, m, phenyl 2-
H and 3-H), 7.00–6.96 (1H, m, phenyl 3-H), 6.00–5.97 (1H, m, dihydrofuran 4-H), 5.57–
5.53 (1H, m, 5-H), 4.79–4.67 (4H, m, dihydrofuran 2-H2 and 5-H2), 4.54 (1H, d, J 16.8, 7-
Ha), 4.25–4.16 (1H, m, 2-H), 4.00–3.93 (1H, m, 7-Hb), 3.73–3.66 (2H, m, 2-CH2), 2.49–
2.41 (1H, m, 4-Ha), 2.37–2.29 (1H, m, 4-Hb), 1.97–1.92 (1H, m, 3-Ha), 1.91–1.87 (1H, m, 
3-Hb); m/z (ES+) (Found: MNa+ 337.1520, C18H22N2O3 requires MNa 337.1523). 
 
(R,Z)-6-(2,5-Dihydrofuran-3-yl)-2-hydroxymethyl-1-(benzyl-aminethiocarbonyl)-
2,3,4,7-tetrahydro-1H-azepine (168) 
By general procedure F, the amine 133 (20 mg, 0.026 mmol) and benzyl thioisocyanate (14 
µL, 0.10 mmol) gave (R,Z)-6-(2,5-dihydrofuran-3-yl)-2-
(((3',3',4',4',5',5',6',6',7',7',8',8',9',9', 10',10',10'-heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl)-1-(benzyl-aminethiocarbonyl)-2,3,4,7-tetrahydro-1H-azepine 148 (23 
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mg, 98%, >60% purity by 500 MHz 1H NMR spectroscopy) as a colorless oil, δH (500 
MHz, CDCl3) 7.34–7.26 (5H, m, benzyl 3-H, 4-H and 5-H), 5.56–5.48 (1H, m, 
dihydrofuran 4-H), 5.39–5.22 (1H, m, 5-H), 4.78–3.63 (11H, m, 2-H, 2-CH2, 7-H2, 
dihydrofuran 2-H2, 5-H2 and benzyl 1-H2), 2.54–2.22 (2H, m, 4-H2), 2.21–1.89 (4H, m, 3-
H2 and 2'-H2), 1.15–1.75 (16H, m, 1'-H2 and iPr). 
By general procedure H, the silyl ether 148 (23 mg, 0.025 mmol) gave the thiourea 168 (2 
mg, 22%) as a colorless oil, Rf 0.21 (25:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3337, 2853, 
1542, 1335, 1164, 1074; δH (500 MHz, CDCl3) 7.36–7.29 (4H, m, benzyl 3-H and 4-H), 
7.25–7.23 (1H, m, benzyl 5-H), 5.90–5.88 (1H, m, NH), 5.64–5.57 (1H, m, dihydrofuran 4-
H), 5.55–5.52 (1H, m, 5-H), 4.81–4.57 (7H, m, 7-Ha, dihydrofuran 2-H2, 5-H2 and benzyl 
1-H2), 4.23–4.17 (1H, m, 2-H), 4.14 (1H, d, J 18.8, 7-Hb), 3.63–3.59 (2H, m, 2-CH2a), 
2.51–2.43 (1H, m, 4-Ha), 2.39–2.33 (1H, m, 4-Hb), 2.02–1.94 (1H, m, 3-Ha), 1.81–1.76 
(1H, m, 3-Hb); m/z (ES+) (Found: MH+ 345.1628, C19H25N2O2S requires MH 345.1631). 
 
(R,Z)-6-(2,5-Dihydrofuran-3-yl)-2-hydroxymethyl-1-phenylsulfonyl-2,3,4,7-
tetrahydro-1H-azepine (169)  
By general procedure G, the amine 70 (20 mg, 0.026 mmol), DMAP (16 mg, 0.13 mmol) 
and benzenesulfonyl chloride (13 µL, 0.10 mmol) gave (R,Z)-6-(2,5-dihydrofuran-3-yl)-2-
(((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl)-1-phenylsulfonyl-2,3,4,7-tetrahydro-1H-azepine 149 (20 mg, 86%, >80% 
purity by 500 MHz 1H NMR spectroscopy) as a colorless oil, δH (500 MHz, CDCl3) 7.74 
(2H, d, J 7.5, phenyl 2-H), 7.51 (1H, t, J 7.5, phenyl 4-H), 7.40 (2H, d, J 7.5, phenyl 3-H), 
5.87–5.84 (1H, m, dihydrofuran 4-H), 5.04–5.00 (1H, m, 5-H), 4.84–4.72 (4H, m, 
dihydrofuran 2-H2 and 5-H2), 4.69 (1H, d, J 17.7, 7-Ha), 4.19–4.13 (1H, m, 7-Hb), 3.88–
3.83 (2H, m, 2-H and 2-CH2a), 3.79–3.74 (1H, m, 2-CH2b), 2.19–2.06 (3H, m, 4-Ha and 2'-
H2), 1.95–1.89 (2H, m, 3-H2), 1.49–1.40 (1H, m, 4-Hb), 1.10–1.01 (14H, m, iPr), 0.90–0.85 
(2H, m, 1'-H2). 
By general procedure H, the silyl ether 149 (20 mg, 0.022 mmol) gave the sulfonamide 169 
(6 mg, 81%) as a colorless oil, Rf 0.21 (20:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3424, 2924, 
2848, 1446, 1329, 1155; δH (500 MHz, CD3OD) 7.78–7.76 (2H, m, phenyl 2-H), 7.61–7.55 
(1H, m, phenyl 4-H), 7.50–7.46 (2H, m, phenyl 3-H), 5.94–5.92 (1H, m, dihydrofuran 4-
H), 5.10–5.07 (1H, m, 5-H), 4.81–4.68 (2H, m, dihydrofuran 2-H2), 4.64 (1H, dt, J 18.0 
and 1.0, 7-Ha), 4.59–4.49 (2H, m, dihydrofuran 5-H2), 4.21 (1H, dt, J 18.0 and 3.3, 7-Hb), 
3.94–3.88 (1H, m, 2-H), 3.68 (1H, dd, J 11.1 and 4.6, 2-CH2a), 3.62 (1H, dd, J 11.1 and 
6.3, 2-CH2b), 2.21–2.13 (1H, m, 4-Ha), 1.93–1.87 (2H, m, 3-H2), 1.56–1.48 (1H, m, 4-Hb); 
δC (75 MHz, CD3OD) 142.0, 140.1, 133.7, 131.5, 129.7 (2C), 128.4 (2C), 120.7, 77.6, 
75.8, 66.1, 61.2, 43.8, 28.9, 27.9 (the signal for one carbon atom is missing); m/z (ES+) 
(Found: MH+ 336.1257, C17H22NO4S requires MH 336.1264). 
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(R,Z)-6-(2,5-Dihydrofuran-3-yl)-2-hydroxymethyl-1-methylsulfonyl-2,3,4,7-
tetrahydro-1H-azepine (170)  
By general procedure G, the amine 133 (20 mg, 0.026 mmol), DMAP (16 mg, 0.013 
mmol) and methanesulfonyl chloride (8 µL, 0.10 mmol) gave (R,Z)-6-(2,5-dihydrofuran-3-
yl)-2-(((3',3',4',4',5',5',6',6',7',7',8',8',9',9',10',10',10'-heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl)-1-methylsulfonyl-2,3,4,7-tetrahydro-1H-azepine 150 (20 mg, 92%, >80% 
purity by 500 MHz 1H NMR spectroscopy) as a colorless oil, δH (500 MHz, CDCl3) 5.85–
5.83 (1H, m, dihydrofuran 4-H), 5.55–5.51 (1H, m, 5-H), 4.76–4.65 (4H, m, dihydrofuran 
2-H2 and 5-H2), 4.49 (1H, d, J 17.9, 7-Ha), 4.15–4.09 (1H, m, 7-Hb), 3.94–3.87 (1H, m, 2-
H), 3.81 (1H, dd, J 10.0 and 4.6, 2-CH2a), 3.73 (1H, dd, J 10.0 and 5.9, 2-CH2b), 2.84 (3H, 
s, CH3), 2.57–2.49 (1H, 4-Ha), 2.39–2.30 (1H, 4-Hb), 2.18–1.94 (4H, 3-H2 and 2'-H2), 
1.10–1.01 (14H, iPr), 0.90–0.85 (2H, 1'-H2). 
By general procedure H, the silyl ether 149 (20 mg, 0.024 mmol) gave the sulfonamide 170 
(4 mg, 61%) as a colorless oil, Rf 0.11 (25:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3412, 2927, 
2848, 1319, 1143; δH (500 MHz, CD3OD) 5.91–5.89 (1H, m, dihydrofuran 4-H), 5.61–5.58 
(1H, m, 5-H), 4.76–4.64 (4H, m, dihydrofuran 2-H2 and 4-H2), 4.43 (1H, d, J 17.8, 7-Ha), 
4.15–4.10 (1H, m, 7-Hb), 3.98–3.92 (1H, m, 2-H), 3.63 (1H, dd, J 11.4 and 6.2, 2-CH2a), 
3.59 (1H, dd, J 11.4 and 5.5, 2-CH2b), 2.95 (3H, s, CH3), 2.47–2.41 (2H, m, 4-H2), 2.04–
1.98 (1H, m, 3-Ha), 1.90–1.81 (1H, m, 3-Hb); δC (75 MHz, CD3OD) 139.7, 133.2, 131.2, 
120.8, 77.6, 75.9, 65.1, 61.1, 43.4, 40.2, 29.4, 27.5; m/z (ES+) (Found: MH+ 274.1097, 
C12H19NO4S requires MH 274.1108). 
 
(3aR,8aS)-8a-(Hydroxymethyl)-10-(2-thiophenecarbonyl)-6-phenyl-3,3a,8a,9,10,11-
hexahydrofuro[3,4-e]pyrrolo[3,4-c][1,2,4]triazolo[1,2-a]pyridazine-5,7(1H,6H)-dione 
((±)-171) 
By general procedure D including a elution with CH2Cl2 (3×3 mL) as part of the 
fluorophilic wash in the F-SPE, the amine (±)-134 (20 mg, 0.022 mmol), DMAP (13 mg, 
0.11 mmol) and 2-thiophenecarbonyl chloride (10 µL, 0.09 mmol) gave (3aR,8aS)-8a-
(((3’,3’,4’,4’,5’,5’,6’,6’,7’,7’,8’,8’, 9’,9’,10’,10’-heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl)-10-(2-thiophenecarbonyl)-6-phenyl-3,3a,8a,9,10,11-hexahydrofuro[3,4-
e]pyrrolo[3,4-c][1,2,4]triazolo[1,2-a]pyridazine-5,7(1H,6H)-dione (±)-151 (19 mg, 86%, 
>95% purity by 500 MHz 1H NMR spectroscopy) as a colorless amorphous solid, δH (500 
MHz, CDCl3) 7.56–7.45 (6H, m, phenyl 2-H, 3-H, 4-H and thiophene 5-H), 7.40–7.36 (1H, 
m, thiophene 3-H), 7.11–7.09 (1H, m, thiophene 4-H), 4.79 (1H, dd, J 9.0 and 7.2, 3-Ha), 
4.65–4.61 (1H, m, 9-Ha), 4.58–4.46 (4H, m, 1-H2, 3a-H and 11-Ha), 4.39–4.29 (2H, m, 8a-
CH2a and 11-Hb), 4.11–4.04 (1H, m, 9-Hb), 3.79 (1H, d, J 10.3, 8a-CH2b), 3.68 (1H, t, J 
9.0, 3-Hb), 2.08–1.96 (2H, m, 2'-H2), 1.03–0.95 (14H, m, iPr), 0.87–0,82 (2H, m, 1'-H2).  
By general procedure H, the silyl ether (±)-151 (19 mg, 0.019 mmol) gave the amide (±)-
171 (8 mg, 99%) as a colorless amorphous solid, Rf 0.21 (20:1 CH2Cl2–MeOH); νmax/cm-1 
(neat) 3417, 2936, 2869, 1764, 1704, 1598, 1429; δH (500 MHz, CDCl3) 7.55–7.45 (6H, m, 
phenyl 2-H, 3-H, 4-H and thiophene 5-H), 7.41–7.37 (1H, m, thiophene 3-H), 7.12–7.08 
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(1H, m, thiophene 4-H), 4.81–4.77 (1H, m, 3-Ha), 4.74 (1H, d, J 10.8, 9-Ha), 4.59–4.54 
(2H, m, 1-Ha and 3a-H), 4.52–4.44 (2H, m, 1-Hb and 11-Ha), 4.31–4.23 (1H, m, 11-Hb), 
4.19–4.14 (1H, m, 8a-CH2a), 3.93–3.88 (1H, m, 9-Hb), 3.78–3.70 (2H, m, 8a-CH2b and 3-
Hb), 3.20–3.13 (1H, m, OH); m/z (ES+) (Found: MH+ 453.1226, C22H21N4O5S requires 
MH 453.1227). 
 
(3aR,8aS)-8a-(Hydroxymethyl)-10-(5-isoxazolecarbonyl)-6-phenyl-3,3a,8a,9,10,11-
hexahydrofuro[3,4-e]pyrrolo[3,4-c][1,2,4]triazolo[1,2-a]pyridazine-5,7(1H,6H)-dione 
((±)-172) 
By general procedure D including a elution with CH2Cl2 (3×3 mL) as part of the 
fluorophilic wash in the F-SPE, the amine (±)-134 (20 mg, 0.022 mmol), DMAP (13 mg, 
0.11 mmol) and 5-isoxazolecarbonyl chloride (12 µL, 0.09 mmol) gave (3aR,8aS)-8a-
(((3’,3’,4’,4’,5’,5’,6’,6’,7’,7’, 8’,8’,9’,9’,10’,10’-heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl)-10-(5-isoxazolecarbonyl)-6-phenyl-3,3a,8a,9,10,11-hexahydrofuro[3,4-
e]pyrrolo[3,4-c][1,2,4]triazolo[1,2-a]pyridazine-5,7(1H,6H)-dione (±)-152 (15 mg, 68%, 
55:45 mixture of rotamers, >80% purity by 500 MHz 1H NMR spectroscopy) as a colorless 
amorphous solid, δH (500 MHz, CDCl3) 8.38 (1H, d, J 1.8, isoxazole 3-Hmin), 8.35 (1H, d, 
J 1.8, isoxazole 3-Hmaj), 7.52–7.45 (4H, m, phneyl 2-H and 3-H), 7.40–7.36 (1H, m, phenyl 
4-H), 7.04 (1H, d, J 1.8, isoxazole 4-Hmin), 6.96 (1H, d, J 1.8, isoxazole 4-Hmaj), 4.82–3.63 
(11H, m, 1-H2, 3-H2, 3a-H, 8a-CH2, 9-H2 and 11-H2), 2.08–1.96 (2H, m, 2'-H2), 1.03–0.97 
(14H, m, iPr), 0.88–0.83 (2H, m, 1'-H2). 
By general procedure H, the silyl ether (±)-152 (15 mg, 0.015 mmol) gave the amide (±)-
172 (6 mg, 92%, 60:40 mixture of rotamers) as a colorless amorphous solid, Rf 0.17 (20:1 
CH2Cl2–MeOH); νmax/cm-1 (neat) 3418, 2868, 1766, 1699, 1634, 1411, 1052; δH (500 
MHz, CDCl3) 8.38 (1H, d, J 1.8, isoxazole 3-Hmin), 8.34 (1H, d, J 1.8, isoxazole 3-Hmaj), 
7.53–7.46 (4H, m, phenyl 2-H and 3-H), 7.42–7.39 (1H, m, phenyl 4-H), 7.03 (1H, d, J 
1.8, isoxazole 4-Hmin), 6.96 (1H, d, J 1.8, isoxazole 4-Hmaj), 4.96–3.66 (11H, m, 1-H2, 3-
H2, 3a-H, 8a-CH2, 9-H2 and 11-H2), 3.26–3.20 (1H, m, OHmaj), 3.02–2.97 (1H, m, OHmin); 
m/z (ES+) (Found: MH+ 438.1409, C20H20N5O6 requires MH 438.1408). 
 
(3aR,8aS)-8a-(Hydroxymethyl)-10-(phenyl-aminecarbonyl)-6-phenyl-3,3a,8a,9,10,11-
hexahydrofuro[3,4-e]pyrrolo[3,4-c][1,2,4]triazolo[1,2-a]pyridazine-5,7(1H,6H)-dione 
((±)-173) 
By general procedure E, the amine (±)-134 (20 mg, 0.022 mmol) and phenyl isocyanate 
(10 µL, 0.09 mmol) gave (3aR,8aS)-8a-(((3’,3’,4’,4’,5’,5’,6’,6’,7’,7’,8’,8’,9’,9’,10’,10’-
heptadecafluorodecyl)-diisopropyl-silyloxy)-methyl)-10-(phenyl-aminecarbonyl)-6-phenyl-
3,3a,8a,9,10,11-hexahydrofuro[3,4-e]pyrrolo[3,4-c][1,2,4]triazolo[1,2-a]pyridazine-
5,7(1H,6H)-dione (±)-153 (19 mg, 84%, >95% purity by 500 MHz 1H NMR spectroscopy) 
as a colorless amorphous solid, δH (500 MHz, CDCl3) 7.51–7.44 (4H, m, 6-phenyl 2-H and 
3-H), 7.42–7.38 (3H, m, 6-phenyl 4-H and 10-phenyl 2-H), 7.33–7.29 (2H, m, 10-phenyl 
3-H), 7.07 (1H, t, J 7.4, 10-phenyl 4-H), 6.26 (1H, s, NH), 4.80–4.76 (1H, m, 3-Ha), 4.56–
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4.50 (2H, m, 1-Ha and 3a-H), 4.49–4.44 (1H, m, 1-Hb), 4.40 (1H, d, J 10.2, 9-Ha), 4.29–
4.24 (1H, m, 11-Ha), 4.24–4.22 (1H, m, 11-Hb), 4.21 (1H, d, J 10.1, 8a-CH2a), 3.84 (1H, d, 
J 10.2, 9-Hb), 3.76–3.73 (1H, m, 8a-CH2b), 3.66 (1H, t, J 9.1, 3-Hb), 2.10–1.98 (2H, m, 2'-
H2), 1.07–0.98 (14H, m, iPr), 0.89–0.84 (2H, m, 1'-H2). 
By general procedure H, the silyl ether (±)-153 (19 mg, 0.019 mmol) gave the urea (±)-173 
(4 mg, 45%) as a colorless amorphous solid, Rf 0.14 (20:1 CH2Cl2–MeOH); νmax/cm-1 
(neat) 3348, 2969, 1739, 1696, 1443, 1365; δH (500 MHz, CDCl3) 7.52–7.46 (4H, m, 6-
phenyl 2-H and 3-H), 7.42–7.37 (3H, m, 6-phenyl 4-H and 10-phenyl 2-H), 7.32–7.28 (2H, 
m, 10-phenyl 3-H), 7.07 (1H, t, J 7.3, 10-phenyl 4-H), 6.39 (1H, s, NH), 4.77 (1H, dd, J 8.9 
and 7.3, 3-Ha), 4.56–4.51 (2H, m, 1-Ha and 3a-H), 4.45–4.41 (1H, m, 1-Hb), 4.35 (1H, d, J 
9.8, 9-Ha), 4.25–4.16 (2H, m, 11-H2), 4.13 (1H, dd, J 11.6 and 7.1, 8a-CH2a), 3.75 (1H, dd, 
J 11.6 and 4.6, 8a-CH2b), 3.69 (1H, t, J 8.9, 3-Hb), 3.57 (1H, d, J 9.8, 9-Hb), 3.12–3.08 (1H, 
m, OH); m/z (ES+) (Found: MH+ 462.1753, C24H24N5O5 requires MH 462.1772). 
 
(3aR,8aS)-8a-(hydroxymethyl)-10-benzenesulfonyl-6-phenyl-3,3a,8a,9,10,11-
hexahydrofuro[3,4-e]pyrrolo[3,4-c][1,2,4]triazolo[1,2-a]pyridazine-5,7(1H,6H)-dione 
((±)-174) 
By general procedure G, the amine (±)-134 (20 mg, 0.022 mmol), DMAP (13 mg, 0.11 
mmol) and benzenesulfonyl chloride (12 µL, 0.09 mmol) gave (3aR,8aS)-8a-
(((3’,3’,4’,4’,5’,5’,6’,6’,7’,7’,8’,8’,9’,9’,10’,10’-heptadecafluorodecyl)-diisopropyl-
silyloxy)-methyl)-10-benzenesulfonyl-6-phenyl-3,3a,8a,9,10,11-hexahydrofuro[3,4-
e]pyrrolo[3,4-c][1,2,4]triazolo[1,2-a]pyridazine-5,7(1H,6H)-dione (±)-154 (21 mg, 91%, 
>95% purity by 500 MHz 1H NMR spectroscopy) as a colorless amorphous solid, δH (500 
MHz, CDCl3) 7.88–7.86 (2H, m, benzene 2-H), 7.69–7.65 (1H, m, benzene 4-H), 7.61–
7.57 (2H, m, benzene 3-H), 7.46–7.44 (4H, m, phenyl 2-H and 3-H), 7.39–7.34 (1H, m, 
phenyl 4-H), 4.70 (1H, dd, J 9.0 and 7.2, 3-Ha), 4.48–4.41 (2H, m, 1-Ha and 3a-H), 4.43 
(1H, d, J 14.5, 1-Hb), 4.24 (1H, d, J 10.4, 9-Ha), 4.16 (1H, d, J 10.8, 8a-CH2a), 4.08–4.03 
(1H, m, 11-Ha), 3.88 (1H, d, J 14.5, 11-Hb), 3.54 (1H, t, J 9.0, 3-Hb), 3.43 (1H, d, J 10.4, 9-
Ha), 3.35 (1H, d, J 10.8, 8a-CH2b), 2.05–1.91 (2H, m, 2'-H2), 0.98–0.93 (14H, m, iPr), 
0.79–0.74 (2H, m, 1'-H2). 
By general procedure H, the silyl ether (±)-154 (21 mg, 0.020 mmol) gave the sulfonamide 
(±)-174 (8 mg, 80%) as a colorless amorphous solid, Rf 0.23 (20:1 CH2Cl2–MeOH); 
νmax/cm-1 (neat) 3446, 2940, 2869, 1764, 1699, 1428, 1165; δH (500 MHz, CDCl3) 7.88–
7.85 (2H, m, benzene 2-H), 7.67 (1H, t, J 7.5, benzene 4-H), 7.59 (2H, t, J 7.5, benzene 3-
H), 7.48–7.44 (4H, m, phenyl 2-H and 3-H), 7.40–7.36 (1H, m, phenyl 4-H), 4.72–4.68 
(1H, m, 3-Ha), 4.52–4.45 (2H, m, 1-Ha and 3a-H), 4.30 (1H, d, J 13.9, 1-Hb), 4.28 (1H, d, J 
10.4, 9-Ha), 4.11–4.06 (1H, m, 11-Ha), 4.01 (1H, dd, J 11.6 and 6.2, 8a-CH2a), 3.84 (1H, d, 
J 13.8, 11-Hb), 3.59 (1H, t, J 9.0, 3-Hb), 3.59–3.55 (1H, m, 8a-CH2b), 3.27 (1H, d, J 10.4, 
9-Hb), 2.54 (1H, t, J 4.8, OH); δC (75 MHz, CDCl3) 150.3, 150.1, 136.3, 133.6, 133.2, 
131.0, 129.6 (2C), 129.3 (2C), 128.5, 127.7 (2C), 125.5 (2C), 125.2, 71.3, 67.4, 65.1, 63.8, 
54.5, 53.3, 47.4; m/z (ES+) (Found: MH+ 483.1344, C23H23N4O6S requires MH 483.1333). 
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(1S,3R,9R,10S) 5-Hydroxymethyl-7-(phenyl-aminecarbonyl)-2,12-dioxa-7-
azatricyclo[8.5.0.03,9]4,14-pentadecadiene (175) 
The sulfonamide 92 (11 mg, 0.011 mmol) and DBU (7 µL, 0.044 mmol) were dissolved in 
MeCN (0.5 mL) and PhSH (3 µL, 0.033 mmol) was added dropwise. The reaction mixture 
was stirred for 1.5 h at room temperature after which phenyl isocyanate (10 µL, 0.088 
mmol) was added and the reaction mixture was stirred for another 2 h, concentrated under 
a flow of N2 and purified by F–SPE, eluting with 160:40:1 MeOH–H2O–Et3N then 200:1 
MeOH–Et3N, to give (1S,3R,9R,10S)-5-(((3',3',4',4',5',5',6',6' ,7',7',8',8',9',9',10',10',10'-
heptadecafluorodecyl)-diisopropyl-silyloxy)-methyl) 7-(phenyl-aminecarbonyl)-2,12-
dioxa-7-azatricyclo[8.5.0.03,9]4,14-pentadecadiene 155 (10 mg, 100%, >75% purity by 
500 MHz 1H NMR spectroscopy) as a colorless oil, δH (500 MHz, CDCl3) 7.28–7.22 (4H, 
m, phenyl 2-H and 3-H), 7.07–7.03 (1H, m, phenyl 4-H), 6.85 (1H, m, NH), 6.08–6.04 
(2H, m, 4-H and 15-H), 5.72–5.67 (1H, m, 14-H), 4.62–4.58 (1H, m, 1-H ), 4.35 (1H, d, J 
7.8, 3-H), 4.23–4.11 (5H, m, 5-CH2, 6-Ha and 13-H2), 4.03 (1H, t, J 12.5, 8-Ha), 3.95–3.80 
(3H, m, 6-Hb and 11-H2), 3.40 (1H, dd, J 12.5 and 5.2, 8-Hb), 2.67–2.59 (2H, m, 9-H and 
10-H), 2.14–2.00 (2H, m, 2'-H2), 1.12–0.98 (14H, m, iPr), 0.93–0.87 (2H, m, 1'-H2). 
By general procedure H, the silyl ether 155 (10 mg, 0.011 mmol) gave the urea 175 (1.5 
mg, 38%) as a colorless oil, Rf 0.17 (20:1 CH2Cl2–MeOH); νmax/cm-1 (neat) 3306, 2928, 
2854, 1738, 1643, 1546, 1217; δH (500 MHz, CDCl3) 7.96 (1H, s, NH), 7.40 (2H, dd, J 8.6 
and 1.0, phenyl 2-H), 7.27–7.24 (2H, m, phenyl 3-H), 6.99 (1H, tt, J 7.5 and 1.0, phenyl 4-
H), 6.14–6.12 (1H, m, 4-H), 6.05 (1H, d, J 11.5, 15-H), 5.71–5.67 (1H, m, 14-H), 4.64–
4.60 (1H, m, 1-H ), 4.34 (1H, d, J 9.8, 3-H), 4.26–4.11 (4H, m, 5-CH2 and 13-H2), 4.05 
(1H, d, J 17.1, 6-Ha), 3.98 (1H, d, J 17.1, 6-Hb), 3.93–3.86 (1H, m, 8-Ha), 3.88 (1H, dd, J 
11.0 and 6.7, 11-Ha), 3.80 (1H, dd, J 11.9 and 11.0, 11-Hb), 3.67–3.58 (1H, m, 8-Hb), 2.72–
2.63 (1H, m, 10-H), 2.53–2.48 (1H, m, OH), 2.48–2.40 (1H, m, 9-H); m/z (ES+) (Found: 
MH+ 357.1796, C20H25N2O4 requires MH 357.1809). 
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Abbreviations 
ABD  7-amino-2-1,3-benzoxadiazol-4-yl 
ATRA  all-trans retinoic acid 
AUC  area under the concentration-time curve 
Boc  tert-butoxycarbonyl 
BOM  benzyloxy methyl 
Cbz  carboxybenzyl 
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC  dicyclohexylcarbodiimide 
DEAD  diethylazodicarboxylate 
DDQ  2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DHB  2,5-dihydroxybenzoic acid 
DHP  3,4-dihydropyran 
DIAD  diisopropyl azodicarboxylate;  
DIBAL-H  diisobutylaluminium hydride 
DIPEA  diisopropylethylamine 
DIPES  diisopropylethylsily 
DLS  dynamic light scattering 
DMAP  4-(N,N-dimethylamino)pyridine 
DMT  dimethoxytrityl 
DOPE  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine 
DOS  diversity oriented synthesis 
DPPC  1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DPPG  1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol 
DSC  differential scanning calorimetry 
DSPG  1,2-distearoyl-sn-glycero-3-phosphoglycerol 
1-O-DSPG   1-O-stearyl-2-stearoyl-sn-glycero-3-phosphoglycerol 
EDCI  1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride  
EPR  enhanced permeability and retention 
ESI  electrospray ionization 
Fmoc  9-fluorenylmethyl carbamate 
F-SPE  fluorous-solid phase extraction 
G I  Grubbs Catalyst, 1st generation 
HEPES  4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
HG II  Hoveyda-Grubbs Catalyst, 2nd generation 
HPLC  high pressure liquid chromatography 
IC50  half maximal inhibitory concentration    
Ki  inhibition constant 
Lyso-SPC  1-stearoyl-2-lyso-sn-glycero-3-phosphocholine  
MALDI-TOF matrix-assisted laser desorption/ionization time of flight  
mCPBA  m-chloroperoxybenzoic acid 
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MD  molecular dynamics;  
MLV  multilamellar vesicle 
MTT  3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide 
NBS  N-bromosuccinimide  
NBD-DPPE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[7-nitro-
2-1,3-benzoxadiazol-4-yl];  
NMR  nuclear magnetic resonance 
Ns  nosyl 
PC  phosphatidylcholine 
PdI  polydispersity index 
PE  phosphatidylethanolamine 
PEG  polyethyleneglycol 
Pg  protecting group 
PG  phosphatidylglycerol 
PMB  p-methoxybenzyl  
PMBTCA  p-methoxybenzyl trichloroacetimidate 
POPC  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine  
POPG  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol  
PPTS  pyridine p-toluenesulfonate 
PS  phosphatidylserine 
Px  9-(9-phenyl)xanthenyl, pixyl 
RAR  retinoic acid receptor  
RES  reticuloendothelial system 
RMSD  root mean square deviation 
RXR  retinoic X receptor  
S  substrate 
SAR  structure activity relationship 
SD  standard derivation 
sPLA2  secretory phospholipase A2  
TBAF  tetrabutylammonium fluoride 
TBDMS  tert-butyldimethylsilyl 
TBDPS  tert-butyldiphenylsilyl 
TES  triethylsilyl 
Tf  trifluoromethanesulfonyl 
TFA  trifluoroacetic acid 
THP  tetrahydropyranyl 
TIPS  triisopropylsilyl 
TLC  thin layer chromatography 
Tm  main phase transition temperature 
TMP  2,2,6,6-tetramethyl piperidine 
Tr  trityl 
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Ts  tosyl 
VDR  vitamin D receptor 
UV  unilamellar vesicle or ultraviolet 
 
Lipid nomenclature of phospholipids 
The phospholipids in this thesis have been named in accordance with the IUPAC-IUB 
Commission on Biochemical Nomenclature (Marsh, D. Handbook of Lipid Bilayers, 1990, 
CRC Press Inc, Florida). The system is based upon a semisystematic nomenclature, which 
allows trivial names and employs a fixed glycerol numbering, without considerations about 
the substituents. The carbon atoms of glycerol are numbered stereospecifically in order to 
assign the configuration of glycerol derivatives. The carbon atom at the top of a Fisher 
projection with the hydroxyl group in the C-2 position to the left is nominated C-1. The 
prefix “sn” (stereospecific numbering) is used to differentiate this numbering from 
conventional numbering without any steric information. 
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The synthesis and biophysical characterization of four prodrug ether phospholipid conjugates are described.
The lipids are prepared from the anticancer drug chlorambucil and have C16 and C18 ether chains with
phosphatidylcholine or phosphatidylglycerol headgroups. All four prodrugs have the ability to form unilamellar
liposomes (86-125 nm) and are hydrolyzed by phospholipase A2, resulting in chlorambucil release. Liposomal
formulations of prodrug lipids displayed cytotoxicity toward HT-29, MT-3, and ES-2 cancer cell lines in
the presence of phospholipase A2, with IC50 values in the 8-36 µM range.
Introduction
Ever since Gregoriadis et al.1 suggested liposomes as drug
carriers in 1974, serious efforts have been put into the
development of liposomes as efficient drug delivery systems
for the treatment of cancer. The discovery that liposomes
accumulate to a high degree in tumor tissue2 if their surface is
covered with poly(ethylene glycol) was a major improvement
over earlier formulations and made these nanoparticles ap-
plicable as drug carriers of chemotherapeutics to tumor tissue.
Such liposomal drug delivery systems based on the enhanced
permeation and retention (EPRa) effect were utilized in the
commercially successful liposomal formulation of doxorubicin.
However, it is now apparent that this formulation is not generally
useful for the majority of potentially interesting drug candidates
because of the lack of a controlled drug release.3 An optimal
drug delivery formulation should be able to retain and stabilize
the carried drug during blood circulation and effectively release
the drug in the target tissue.3 This calls for the utilization of
site specific release mechanisms, and several have been
investigated, e.g., enzymatic release4 and pH,5 light,6 and heat
sensitive liposomes.7
Liposomal drug delivery has mainly relied on the encapsula-
tion of hydrophilic drugs in the aqueous core3,8 or on trapping
hydrophobic molecules in the lipid bilayer.9 Although this
approach is successful, it does suffer from some limitations such
as the potential for leakage and the fact that the release of the
active drug is not directly coupled to the mechanism activating
the carrier. One strategy that addresses both these issues is the
formulation of a lipid-prodrug conjugate that is susceptible to
selective degradation by endogenous enzymes in the target
tissue, serving to simultaneously degrade the carrier and release
the drug.3 By covalent incorporation of the active chemothera-
peutic agent in the delivery system, the problem with premature
leakage is effectively circumvented. Herein, we describe the
synthesis and characterization of prodrugs (1 and 2, Figure 1)
that are suitable for liposomal delivery to cancerous tissue and
susceptible to secretory phospholipase A2 activation.
Secretory phospholipase A2 (sPLA2) is overexpressed in
cancer tissue,10 and has previously been exploited in liposomal
drug delivery.11 Subtype sPLA2 IIA has been identified in
several human tumors including breast,12 stomach,13 colorectal,14
pancreatic,15 prostate,10a,16 and liver cancer.17 The prodrugs are
based on covalently attaching an anticancer drug in the sn-2
position of sn-1 ether phospholipids. The principle is illustrated
in Figure 2: sPLA2 will hydrolyze the sn-2 ester bond, releasing
both the anticancer drug bound to the sn-2 position and an
anticancer ether lipid (AEL). Ether lipids were chosen because
of their higher stability and because of the cytotoxicity of the
lyso-lipids released upon sPLA2 hydrolysis.11 Furthermore, the
lyso-ether lipids have potential to attenuate the toxicity of
chlorambucil by increasing the cellular uptake of the drug,3 and
thus, the two molecules released by sPLA2 hydrolysis will work
in unison against cancer cells.
It is crucial for the prodrug strategy that suitable drug
candidates are available. Since the incorporated drug will be
part of the lipophilic membrane, a hydrophobic nature is an
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Figure 1. Four target chlorambucil prodrug ether lipids. Prodrugs 1a
and 1b have a phosphatidylcholine headgroup with a C16 and a C18
ether chain, respectively. Target compounds 2a and 2b have the
negatively charged phosphatidylglycerol headgroup.
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obvious requirement and, furthermore, a carboxylic acid moiety
is needed for the attachment of the drug to the AEL backbone.
We have identified a number of candidates such as chlorambucil
(3),18 all-trans retinoic acid,19 and prostaglandins.20 In the
present study prodrugs made from chlorambucil are investigated.
Chlorambucil (3) is a chemotherapeutic agent of the mustard
gas type,21 and it was originally synthesized by Everett et al. in
1953.18a It is used clinically for the treatment of lymphocytic
leukemia22 typically in combination with other drugs. Chloram-
bucil is orally administrated but undergoes rapid metabolism,
and as a result, the stability in aqueous environments is low
and 3 has an elimination half-life of 1.5 h.23 The prodrug
formulation could remedy this, since this system will shield
chlorambucil from degradation through the incorporation in the
lipophilic part of the liposomal membrane and deliver it directly
to the tumor, decreasing metabolism compared to the oral
administration route. To investigate the effect of sn-1 ether chain
length and headgroup charge on enzymatic activity, prodrugs 1
and 2 were prepared with both C16 and C18 ether chains and
a choline and a glycerol phosphate headgroup, respectively.
Biophysical and biological characterization of the synthesized
chlorambucil prodrugs (1, 2) is included, with focus on liposome
formulation, particle size determination, and in particular sPLA2
activity. Proof-of-principle of the strategy is demonstrated in
three cancer cell lines, providing the first successful example
of this prodrug approach to liposomal drug delivery.
Synthesis of Chlorambucil AEL Prodrugs
Anticancer ether lipids have previously been synthesized via
different routes, e.g., starting from D-mannitol24 or glycidols.25
Commercially available (R)-glycidyl tosylate (4) served as our
starting material, and the aliphatic ether chain was introduced
by ring-opening of the epoxide under Lewis acid catalysis,26
resulting in yields of 89% and 97% for 5a and 5b, respectively
(Scheme 1). The p-methoxybenzyl (PMB) group was chosen
for protection of the secondary alcohol27 and introduced by using
p-methoxybenzyl trichloroacetimidate with La(OTf)3 catalysis.28
The resulting tosylate was converted to the acetate with CsOAc
in a 9:1 mixture of DMSO and DMF and the ester hydrolyzed
with NaOMe in MeOH at 40 °C, yielding the primary alcohols
6a and 6b in overall yields of 70% and 78%, respectively, over
three steps. It was essential to carry out the hydrolysis at elevated
temperature in order to obtain homogeneous reaction mixtures
and achieve full conversion in the transformations.
The choline headgroup was attached to the primary alcohols
6a and 6b by reaction with phosphorus oxychloride and NEt3,
followed by addition of choline tosylate, pyridine, and finally
H2O (Scheme 2).11a,29 Excess choline tosylate was removed on
an MB-3 ion-exchange column, and after purification by flash
column chromatography the PMB-group was removed with 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in an 18:1 mix-
ture of CH2Cl2 and H2O,30 which resulted in full conversion
within 3 h with isolated yields of 99% and 79%. The final
attachment of chlorambucil to the lipid was achieved via a
Steglich esterification with DCC and a catalytic amount of
DMAP.31 When the acylation of 7a was performed in ethanol-
free chloroform at 20 °C or CH2Cl2 in the temperature range
from 0 °C to reflux, we did not observe any incorporation of
chlorambucil, but when the conditions were changed to reflux
in 1,2-dichloroethane, the acylation occurred in a 75% yield,
albeit only after adding 5 equiv of chlorambucil and DCC in
portions over 31 h. The acylation of 7b led to an isolated yield
of 76% in refluxing chloroform, and that was not improved by
using 1,2-dichlorethane as the solvent. Changing the coupling
reagents to EDCI and DMAP32 did not improve the conversion
of the AELs.
The phosphoramidite 11 needed for the installment of the
glycerol headgroup was synthesized in four steps from allyl
p-methoxybenzoate (8) (Scheme 3). The key step was a
Sharpless asymmetric dihydroxylation33 of 8, which occurred
with excellent enantioselectivity (97% ee, chiral HPLC, and
Mosher ester analysis; see Supporting Information). TBDMS
protection and reduction of the p-methoxybenzoate with DIBAL-H
at -78 °C afforded the TBDMS-protected glycerol 10. The
coupling between 10 and the commercially available phospho-
rylating agent (i-Pr)2NPClO(CH2)2CN resulted in the desired
phosphoramidite 11 in a very satisfactory yield, isolated as a
1:1 diastereomeric mixture as evident from 31P NMR.
The glycerol headgroup was attached to the lipid backbone
(6a and 6b) via reaction with 11 under activation of tetrazole
and successive oxidation with tBuOOH (Scheme 4). Deprotec-
tion of the PMB-group was achieved with DDQ in moist
CH2Cl2. Acylation with chlorambucil in CH2Cl2 followed by
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) mediated deprotec-
tion of the cyanoethylene group34 afforded the lipids 12a and
12b in good yields over five steps. Finally, removal of the
TBDMS protection groups was achieved by treatment with HF
in MeCN/H2O, providing 2a and 2b.
Biophysical and Biological Data
The chlorambucil AEL prodrugs (1, 2) were formulated as
liposomes by extrusion in HEPES buffer using the dry lipid
film technique.35 The lipid solutions were analyzed by dynamic
Figure 2. Schematic overview of the drug delivery concept. The AEL prodrugs are formulated as liposomes. Because of the EPR effect, the
liposomes will accumulate in cancer tissues and sPLA2, which is up-regulated in cancer tissue, will hydrolyze the AEL prodrug lipids, releasing
two anticancer drugs.
Scheme 1. Synthesis of Lipid Precursors 6a and 6ba
a Reagents: (a) C16H33OH or C18H37OH, BF3 ·OEt2, CH2Cl2; (b) (i)
PMBTCA, La(OTf)3, toluene; (ii) CsOAc, DMSO, DMF; (iii) NaOMe,
MeOH.
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light scattering (DLS) in order to investigate the particle size,
and DLS analysis revealed that 1 and 2 form particles in the
liposome size region (Table 1) and with a low polydispersity,
indicating formation of small unilaminar vesicles (SUVs). Initial
confirmation of enzymatic hydrolysis was obtained by treating
the liposome solutions with snake (Naja mossambica mossa-
mbica) venom sPLA2 for 24 h at 37 °C. Snake venom sPLA2 is
a convenient model enzyme, since it is not sensitive to the charge
of the interfacial region, unlike human sPLA2, but shows the
same substrate specificity.10d,36 DLS measurements of the
resulting solutions confirmed that the liposomes had been
degraded, as only particles with a diameter of less than 5 nm
were present. Incubation of the liposomes for 24 h without
enzyme did not result in a change in particle size as measured
by DLS (data not shown).
In order to investigate the hydrolysis on a molecular level,
we applied MALDI-TOF MS and HPLC. MALDI-TOF MS has
recently been exploited as a very fast and sensitive technique
for detection of lipids,37 and we decided to study the enzyme
activity with this method in order to verify that the lipids were
consumed and the anticancer drugs released. Figure 3 shows
the digestion of the chlorambucil AEL prodrugs 1a and 2a and
the release of AELs catalyzed by snake (Agkistrodon pisciVorus
pisciVorus) venom sPLA2. The spectra show the disappearance
over time of the prodrugs signals (M + H+ and M + Na+) and
the emergence of the expected AEL signals (M + H+ and M +
Na+). From the spectra it is also possible to get information
about the conversion rate, and whereas 2a is almost fully
consumed after 2 h, 1a needs more than 24 h for full digestion
by sPLA2. The MALDI-TOF MS analysis of 1b and 2b (see
Supporting Information) revealed that full degradation is
obtained in 2-6 h. These results were verified by HPLC (Figure
4 and Supporting Information). Neither HPLC nor MALDI-
TOF MS was capable of detecting the released chlorambucil,
but that was not surprising given the low stability of free
chlorambucil in an aqueous environment.23 Chatterji et al. report
15 min as the half-life of chlorambucil in a buffer like the
HEPES buffer at 37 °C.23b MALDI-TOF analysis (see Sup-
porting Information) of liposome solutions of 1b and 2b stored
for 6 weeks at 20 °C showed that the prodrug lipids were intact.
No significant hydrolysis of the chloroethyl groups of chloram-
bucil was detected, proving that the liposomal formulation
enhances chlorambucil stability significantly. These findings
were further supported by the 4-nitrobenzylpyridine alkylating
assay,38 which showed that alkylation by chlorambucil occurred
when liposomes of 1b and 2b were subjected to sPLA2, whereas
no alkylation of 1b and 2b was detected in the absence of sPLA2
(see Supporting Information).
To demonstrate the sPLA2-dependent cytotoxicity of the
chlorambucil AEL prodrugs, we investigated the activity of 1b
against HT-29 and MT-3 cancer cells for 24 h and 2b against
the same two cell lines in addition to ES-2 cells (Table 2). None
of these cells secrete sPLA2, which is an advantage in these
studies because it enables us to control the presence or ab-
sence of the enzyme in each experiment. Before addition of
snake (Agkistrodon pisciVorus pisciVorus) venom sPLA2, all
liposome formulations have IC50 values significantly higher than
that of free chlorambucil (entries 1-3), demonstrating that
cytotoxicity is associated with the prodrug activation by sPLA2.
Upon addition of the enzyme, both prodrugs display IC50 values
below that of chlorambucil itself for all three tested cell lines
(entries 4 and 5), suggesting a cooperative effect of the two
cytotoxic compounds released, chlorambucil and AELs. The
lyso-ether lipid 7b has activity in the same range as the prodrugs
with added sPLA2 (compare entries 4-5 and entry 6). Earlier
studies of sn-1 ether lipids with a fatty acid in the sn-2 position
have shown that AEL alone is more cytotoxic than the liposome
formulation,11a lending further support to our belief that the two
active components work in unison to kill the cancer cells.
Phospholipase A2 alone has no effect on cell viability (entry
7). Taken together, the data in Table 2 clearly show the potential
of this prodrug strategy for sPLA2 mediated degradation of
liposomes consisting of sn-1 ether lipids with an anticancer drug
covalently bound in the sn-2 position.
Conclusion
In the present study we have synthesized a series of novel
prodrugs and shown that they form small unilamellar vesicles
that are stable in size over time. It was found that sPLA2 can
hydrolyze all the prodrugs of this type, showing how diverse
sPLA2 substrates can be, which makes sPLA2 an excellent target
for future prodrug strategies. The approach described here is a
new application of prodrugs in liposomal formulations, and we
believe it has significant advantages over conventional liposomal
drug delivery system, where hydrophilic drugs are encapsulated.
Problems with leakage during circulation are circumvented
because of the covalent attachment of the active compound to
the phospholipids. Furthermore, since the drugs are contained
in the liposome membrane until activated by the enzyme, our
strategy opens up for the use of lipophilic compounds that would
otherwise be too toxic if employed systemically because of their
affinity for biological membranes. Lastly, the use of prodrug
strategies where the drug is protected in the membrane may
open new possibilities with respect to drugs with low stability
Scheme 2. Synthesis of Chlorambucil AEL Prodrugs 1a
a Reagents: (a) (i) POCl3, Et3N, CH2Cl2; (ii) choline tosylate, pyridine; (iii) H2O; (iv) DDQ, CH2Cl2, H2O; (b) 3, DCC, DMAP, CHCl3 or 1,2-dichloroethane.
Scheme 3. Synthesis of the Phosphoramidite 11a
a Reagents: (a) K2OsO4 ·2H2O, (DHQD)2PHAL, K3Fe(CN)6, K2CO3,
tBuOH, H2O; (b) (i) TBDMSOTf, DIPEA, CH2Cl2; (ii) DIBAL-H, CH2Cl2;
(c) 2-cyanoethyl N,N-diisopropylchlorophosphoramidite, DIPEA, CH2Cl2.
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in a biological environment, as evident from the stability of
chlorambucil in the liposomal formulation.
Experimental Section
General. Starting materials, reagents, and solvents were pur-
chased from Sigma-Aldrich Chemical Co. and used without further
purification. Reactions involving air or moisture sensitive reagents
were carried out under N2, and flasks were dried by flame heating
under reduced pressure. DMF, DMSO, MeCN, CH2Cl2, CHCl3, 1,2-
dichloroethane, and toluene were dried over 4 Å molecular sieves.
Pyridine and NEt3 were dried over KOH. Evaporation of solvents
was done under reduced pressure (in vacuo). TLC was performed
on Merck aluminum sheets precoated with silica gel 60 F254 plates.
Compounds were visualized by charring after dipping in a solution
of p-anisaldehyde (10 mL of H2SO4 and 10 mL of p-anisaldehyde
in 200 mL of 95% EtOH), KMnO4 (1.5 g of KMnO4, 10 g of
K2CO3, and 2.5 mL of 5% NaOH in 150 mL of H2O), or Cemol
(6.25 g of (NH4)6Mo7O24 and 1.5 g of Ce(SO4)2 in 250 mL of 10%
aqueous H2SO4). Flash column chromatography was performed
using Matrex 60 Å silica gel. Purity of all compounds was found
to be equal to or greater than 95% by elemental analysis or HPLC
(see below).
NMR spectra were recorded using a Varian Mercury 300 MHz
spectrometer or a Varian Unity Inova 500 MHz spectrometer.
Chemical shifts were measured in ppm and coupling constants in
Hz, and the field is indicated in each case. The solvent peaks from
CDCl3 (7.26 ppm in 1H NMR and 77.16 ppm in 13C NMR) or
acetone-d6 (2.05 ppm in 1H NMR) were used as standards.39 HPLC
was performed on a Waters Alliance HPLC equipped with a DAD,
using a LiChrospher Si 60 column and eluting with water/
isopropanol/heptane mixtures. Elemental analyses were obtained
from H. Kolbe, Mikroanalytisches Laboratorium, Mu¨lheim/Ruhr,
Germany. IR analysis was carried out on a Perkin-Elmer 1600 series
FTIR spectrometer, as KBr pills or neat between AgCl plates.
Melting points were measured by a Buch & Holm melting point
apparatus and given in degrees Celsius (°C) uncorrected. HRMS
was recorded on an Ionspec Ultima Fourier transform mass
spectrometer.
Liposome Preparation and Particle Size Determination. The
chlorambucil AEL prodrugs were dissolved in CHCl3 in a glass
tube, dried under a stream of N2, and then placed under vacuum
for 3-15 h to form a thin film. The film was solubilized by addition
of aqueous buffer (0.15 M NaCl, 2.5 mM HEPES, pH 7.4) and
vortexed periodically over 1 h at 20 °C. Subsequently, the solutions
were extruded through a 100 nm polycarbonate cutoff membrane
using a Hamilton syringe extruder (Avanti Polar Lipids, Birming-
ham, AL), yielding unilamellar vesicles with a diameter ranging
from 86 to 125 nm and with a low polydispersity as measured by
DLS. The DLS measurements were obtained using a BI-200SM
goniometer from Brookhaven Instruments (New York), applying a
fixed scattering angle of 90° with a 632.8 nm HeNe laser.
sPLA2 Activity Measurements Monitored by DLS. The
chlorambucil AEL prodrugs (2 mL, 0.05 mM), formulated in an
aqueous buffer (0.15 M NaCl, 5 mM CaCl2, 2.5 mM HEPES, pH
7.4), were incubated at 37 °C with snake venom sPLA2 from Naja
mossambica mossambica (1.93 nmol) for 24 h. The sPLA2 from
Naja mossambica mossambica was purchased from Sigma-Aldrich
Chemical Co. The resulting solutions were analyzed by DLS as
described above.
sPLA2 Activity Measurements Monitored by HPLC and
MALDI-TOF MS. The chlorambucil AEL prodrugs (2 mM) were
hydrated in an aqueous buffer (0.15 M KCl, 30 µM CaCl2, 10 µM
EDTA, 10 mM HEPES, pH 7.5) for 1 h at 60 °C and then sonicated
for 1 h at 60 °C, providing a clear solution. The formulated
chlorambucil AEL prodrugs (0.40 mL, 2 mM) were diluted in an
aqueous buffer (2.1 mL, 0.15 M KCl, 30 µM CaCl2, 10 µM EDTA,
10 µM HEPES, pH 7.5), and the mixture was stirred at 37 °C in a
container protected from light. The catalytic reaction was initiated
by addition of snake (Agkistrodon pisciVorus pisciVorus) venom
sPLA2 (20 µL, 42 µM). The purified snake venom sPLA2 was
donated by Dr. R. L. Biltonen (University of Virginia). Sampling
was done after 0, 2, 6, 8, 20, 24, and 90 h by collecting 100 µL of
the reaction mixture and rapidly mixing it with a solution of CHCl3/
MeOH/H2O/AcOH 4:8:1:1 (0.5 mL) in order to stop the reaction.
The mixture was washed with water (0.5 mL), and the organic phase
was isolated by extraction. For HPLC 30-75 µL of the organic
phase was injected on a 5 µm diol column and eluted with an
isocratic eluent (CHCl3/MeOH/H2O 730:230:30 for 1a and 2a;
CHCl3/MeOH/25% aqueous NH3 800:195:5 for 2a and 2b). An
evaporative light scattering detector was used for detection. For
the MALDI-TOF MS measurements 9 µL of the organic phase was
mixed with 3 µL of 2,5-dihydroxybenzoic acid (DHB) matrix (0.5
M DHB, 2 mM CF3COONa in MeOH), and 0.5 µL of this mixture
was used for the MS analysis.
Cytotoxicity. Colon cancer HT-29 and ovarian cancer ES-2 cells
were cultured in McCoy’s 5A medium in the presence of 10% FCS
and 1% Pen-Strep (InVitrogen). Breast cancer MT-3 cells were
cultured in RPMI medium. Cells were plated in 96-well plates at
a density of 1 × 104 cells per well 24 h prior to addition of the
tested compound. Chlorambucil (3) was solubilized in DMSO and
water (final DMSO concentration max of 0.5%). Liposomes were
diluted in PBS, and initial lipid concentration in the liposome
solutions was determined by phosphorus analysis.40 After 24 h of
incubation, the substances were removed and the cells were washed
and incubated in complete medium for another 48 h. Cytotoxic
activity was assessed using a standard 3-(4,5-dimethylthiazolyl)-
2,5-diphenyltetrazolium bromide (MTT) assay (Cell Proliferation
Kit I, Roche, Germany).41 Cell viability is expressed as percentage
reduction of incorporated MTT.
1-O-Hexadecyl-2-(4-(4-(bis-(2-chloroethyl)amino)phenyl)butanoyl)-
sn-glycero-3-phosphocholine (1a). Compound 7a (67 mg, 0.139
mmol) was dissolved in anhydrous 1,2-dichloroethane (3.5 mL),
and the mixture was heated to reflux under an atmosphere of N2.
DMAP (10 mg, 0.082 mmol), chlorambucil (3) (64 mg, 0.209
mmol), and DCC (1 M in CH2Cl2, 0.2 mL, 0.2 mmol) were added,
and after 5 and 19 h additional portions of chlorambucil (3) (64
mg, 0.209 mmol) and DCC (1 M in CH2Cl2, 0.2 mL, 0.2 mmol)
Scheme 4. Synthesis of Chlorambucil AEL Prodrugs 2a
a Reagents: (a) (i) 11, tetrazole, CH2Cl2, MeCN; (ii) tBuOOH; (iii) DDQ, CH2Cl2, H2O; (iv) 3, EDCI, DMAP, CH2Cl2; (v) DBU, CH2Cl2; (b) HF, MeCN,
H2O.
Table 1. DLS Analysis of Chlorambucil AEL Prodrugsa
before sPLA2 addition
prodrug diameter (nm) polydispersity
after sPLA2 addition,
diameter (nm)
1a 124 0.12 <5
1b 125 0.22 <5
2a 104 0.08 <5
2b 113 0.05 <5
a Determined before and after addition of snake venom (Naja mossambica
mossambica) sPLA2.
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were added. After 27 h the mixture was concentrated in vacuo and
purified by column chromatography (CH2Cl2/MeOH 4:1; then
CH2Cl2/MeOH/H2O 30:20:1) to give 80 mg (75%) of 1a as an oil.
Rf ) 0.18 (CH2Cl2/MeOH/H2O 30:20:1). 1H NMR (500 MHz, 4:1
CDCl3/CD3OD) δ 7.08 (d, J ) 8.6 Hz, 2H), 6.65 (d, J ) 8.6 Hz,
2H), 5.16 (p, J ) 5.9 Hz, 1H), 4.22 (s, 2H), 4.03-3.99 (m, 2H),
3.72 (t, J ) 7.1 Hz, 4H), 3.64 (t, J ) 7.1 Hz, 4H), 3.63-3.59 (m,
2H), 3.56 (s, 2H), 3.49-3.39 (m, 2H), 3.19 (s, 9H), 2.56 (t, J )
7.6 Hz, 2H), 2.36 (t, J ) 7.6 Hz, 2H), 1.90 (p, J ) 7.6 Hz, 2H),
1.54 (p, J ) 6.8 Hz, 2H), 1.32-1.26 (m, 26H), 0.88 (t, J ) 6.8
Hz, 3H). 13C NMR (75 MHz, 4:1 CDCl3/CD3OD) δ 174.1, 144.8,
130.8, 130.0 (2C), 112.6 (2C), 72.2 (d, J ) 8.2 Hz), 72.1, 69.6,
66.8, 64.4 (d, J ) 5.2 Hz), 59.2 (d, J ) 5.2 Hz), 54.5, 54.4, 54.4,
53.9 (2C), 40.9 (2C), 34.2, 34.0, 32.3, 30.1, 30.0, 29.9, 29.9, 29.7,
27.2, 26.4, 23.0, 14.3. IR (neat) 2923, 2852, 2366, 1734, 1091 cm-1.
m/z (M + H+) 767.43.
1-O-Octadecyl-2-(4-(4-(bis(2-chloroethyl)amino)phenyl)butanoyl)-
sn-glycero-3-phosphocholine (1b). Compound 7b (67 mg, 0.131
mmol) was dissolved in anhydrous CHCl3 (4 mL), and the mixture
was heated to reflux under an atmosphere of N2. DMAP (10 mg,
0.082 mmol), chlorambucil (3) (40 mg, 0.131 mmol), and DCC (1
M in CH2Cl2, 130 µL, 0.130 mmol) were added, and after 3, 6.5,
23.5, 26.5, and 31 h additional portions of chlorambucil (3) (40
mg, 0.131 mmol) and DCC (1 M in CH2Cl2, 130 µL, 0.130 mmol)
were added. After 48 h the mixture was concentrated in vacuo and
purified by column chromatography (CH2Cl2/MeOH 4:1, then
CH2Cl2/MeOH/H2O 30:20:1) to give 79 mg (76%) of 1b as an oil.
Rf ) 0.15 (CH2Cl2/MeOH/H2O 30:20:1). 1H NMR (500 MHz, 4:1
CDCl3/CD3OD) δ 7.07 (d, J ) 8.5 Hz, 2H), 6.65 (d, J ) 8.5 Hz,
2H), 5.16 (p, J ) 5.8 Hz, 1H), 4.22 (s, 2H), 4.06-3.94 (m, 2H),
3.72 (t, J ) 6.8 Hz, 4H), 3.64 (t, J ) 6.8 Hz, 4H), 3.63-3.59 (m,
2H), 3.56 (s, 2H), 3.48-3.40 (m, 2H), 3.20 (s, 9H), 2.56 (t, J )
Figure 3. MALDI-TOF MS monitoring of snake (Agkistrodon pisciVorus pisciVorus) venom sPLA2 activity on chlorambucil AEL prodrug 1a
(top) and 2a (bottom). The spectra demonstrate that the prodrugs (right) are consumed and the AELs (left) are released.
Figure 4. HPLC chromatogram for the snake (Agkistrodon pisciVorus pisciVorus) venom sPLA2 hydrolysis experiment on chlorambucil AEL
prodrug 1a showing the amount of prodrug (left) and AEL (right) before the addition of the enzyme and after 2, 4, 6, and 24 h.
Table 2. IC50 Values (µM) of Chlorambucil (3), a Lyso-Ether Lipid
(7b), and the Prodrugs 1b and 2b in the Presence and Absence of
sPLA2a
entry compd IC50 HT-29 IC50 MT-3 IC50 ES-2
1 3 70 ( 10 95 ( 21 34 ( 3
2 1b >200 >200 nd
3 2b >200 >200 97 ( 2
4 1b + sPLA2 32 ( 2 36 ( 4 nd
5 2b + sPLA2 10 ( 1 36 ( 4 8 ( 0,5
6 7b 18 ( 5 35 ( 1 30 ( 1
7 sPLA2 b b b
a Cytotoxicity was measured using the MTT assay as cell viability 48 h
after incubation with the indicated substances for 24 h and shown by mean
( SD (n ) 3); nd ) not determined. Snake (Agkistrodon pisciVorus
pisciVorus) venom sPLA2 was added to a final concentration of 5 nM. b No
change in cell viability was observed after 24 h.
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7.5 Hz, 2H), 2.36 (t, J ) 7.5 Hz, 2H), 1.90 (p, J ) 7.5 Hz, 2H),
1.54 (m, 2H), 1.32-1.26 (m, 30H), 0.88 (t, J ) 6.9 Hz, 3H). 13C
NMR (75 MHz, 4:1 CDCl3/CD3OD) δ 174.1, 144.9, 130.8, 130.1
(2C), 112.6 (2C), 72.3 (d, J ) 8.6 Hz), 72.1, 69.6, 66.9, 64.5 (d, J
) 5.2 Hz), 59.4 (d, J ) 5.2 Hz), 54.5, 54.4, 54.4, 53.9 (2C), 40.9
(2C), 34.3, 34.0, 32.3, 30.1, 30.0, 29.9, 29.9, 29.8, 27.3, 26.4, 23.1,
14.3. IR (neat) 2923, 2852, 2366, 1734, 1518, 1247, 1088, 750
cm-1. m/z (M + Na+) 817.44.
(S)-(2,3-Di-O-tert-butyldimethylsilyl)glyceryl 2-Cyanoethyl-N,N-
diisopropylphosphoramidite (11). Alcohol 10 (904 mg, 2.82 mmol)
and diisopropylethylamine (1.0 mL, 5.92 mmol) were dissolved in
anhydrous CH2Cl2 (10 mL) under an atmosphere of N2. 2-Cyano-
ethyl-N,N-diisopropylchlorophosphoramidite (1.0 g, 4.22 mmol) was
added dropwise, and the mixture was stirred at 20 °C for 1.5 h,
after which EtOAc (20 mL) and saturated NaHCO3 (50 mL) were
added and the organic layer was isolated by extraction with EtOAc
(2 × 50 mL). The combined organic phases were concentrated in
vacuo, and the residue was purified by column chromatography
(EtOAc) to give 1352 mg (92%) of 11 (two diastereoisomers, 1:1)
as a colorless oil. Rf ) 1.0 (EtOAc). 1H NMR (300 MHz, CDCl3):
δ 3.87-3.46 (m, 5H), 2.67-2.61 (m, 2H), 1.20-1.17 (m, 12H),
0.90 (s, 9H), 0.89 (s, 9H), 0.09-0.06 (m, 12H). 13C NMR (75 MHz,
CDCl3): δ 117.7, 73.3, 65.0, 58.6, 43.1 (2C), 26.1 (3C), 26.0 (3C),
24.7 (4C), 20.5, 18.5, 18.3, -4.4, -4.5, -5.2, -5.3. 31P NMR (202
MHz, CDCl3): δ 149.0, 148.5. IR (neat): 2958, 2929, 2883, 2857
cm-1. m/z (M + Na+) 543.32.
1-O-Hexadecyl-2-(4-(4-(bis-(2-chloroethyl)amino)phenyl)butanoyl)-
sn-glycero-3-(2-cyanoethylphospho)-(S)-2,3-di-O-tert-butyldimeth-
ylsilylglycerol (12a). To a solution of 6a (0.79 g, 1.8 mmol) and 11
(1.3 g, 2.5 mmol) in CH2Cl2 (10 mL) was added molecular sieves
(3 Å). After the mixture was stirred for 30 min, 1H-tetrazole in
acetonitrile (5.5 mL, 0.45 M, 2.5 mmol) was added and the mixture
stirred for another 30 min before 5.5 M tert-butyl hydroperoxide
in decane (0.50 mL, 2.8 mmol) was added and the mixture stirred
for 1 h before being concentrated in vacuo. The residue was purified
by column chromatography (EtOAc/heptane 1:1) to yield 1.63 g
of an oil. 31P NMR showed two signals at -0.66 and -0.82 in the
1:1 ratio set by the amidite. The product was subsequently treated
with DDQ (0.45 g, 2.2 mmol) in CH2Cl2 (10 mL) and water (0.6
mL) for 2 h before Na2SO3 was added and the mixture diluted with
CH2Cl2. The mixture was filtered and concentrated in vacuo before
purification by column chromatography (CH2Cl2, then EtOAc/
heptane 1:1) afforded 1.16 g. 31P NMR showed two signals at -0.10
and -0.18 ppm. The deprotected compound was dissolved in
CH2Cl2 (12 mL) together with chlorambucil (0.70 g, 2.3 mmol),
and EDCI (0.59 g, 3.1 mmol) and DMAP (0.38 g, 3.1 mmol) were
added. After being stirred for 2 h, the mixture was concentrated in
vacuo and purified by column chromatography (EtOAc/heptane 1:1)
and the resulting 1.36 g product dissolved in CH2Cl2 (10 mL) and
treated with DBU (0.20 mL, 1.3 mmol) for 30 min. The reaction
mixture was concentrated in vacuo and the residue was purified by
column chromatography (CH2Cl2/MeOH 9:1) to give the phospho-
lipid (0.96 g, 54%). Rf ) 0.73 (CH2Cl2/MeOH/H2O 65:25:4). 1H
NMR (500 MHz, CDCl3/CD3OD 3:1): δ 6.90 (d, J ) 8.5 Hz, 2H),
6.47 (d, J ) 8.5 Hz, 2H), 5.00 (q, J ) 5 Hz, 1H), 4.08 (m, 1H),
3.83-3.76 (m, 2H), 3.71-3.59 (m, 3H), 3.55-3.53 (m,
4H), 3.47-3.38 (m, 8H), 3.30-3.21(m, 2H), 2.38 (t, J ) 7.5 Hz,
2H), 2.19 (t, J ) 7.5 Hz, 2H), 1.73 (q, J ) 7.3 Hz, 2H), 1.36 (m,
2H), 1.09 (s, 26 H), 0.72 (s, 18H), -0.06 (s, 6H), -0.11 (s, 6H).
13C NMR (75 MHz, CDCl3/CD3OD 3:1): δ 173.1, 144.0, 130.0,
129.3, 111.8, 72.4 (d, J ) 9.5 Hz), 71.5, 71.4 (d, J ) 6.3 Hz),
68.8, 66.5 (d, J ) 5.6 Hz), 64.6, 63.5 (d, J ) 5.2 Hz), 53.2, 40.1,
33.5, 33.3, 31.5, 29.3, 29.3, 29.2, 29.1, 29.0, 26.4, 25.6, 25.5, 25.4,
22.3, 17.9, 17.7, 13.6, -5.1, -5.1, -5.8, -5.8. 31P NMR (202 MHz,
CDCl3/CD3OD 3:1): δ -1.82. IR (neat): 3450, 2922, 1732, 1616,
1519, 1463, 1360, 1252, 1102 cm-1. m/z (M + Na+) 1006.53.
1-O-Octadecyl-2-(4-(4-(bis-(2-chloroethyl)amino)phenyl)butanoyl)-
sn-glycero-3-(2-cyanoethylphospho)-(S)-2,3-di-O-tert-butyldimeth-
ylsilylglycerol (12b). The synthesis was performed as for 12a,
starting from 6b (650 mg, 1.40 mmol) and 11 (1.0 g, 1.9 mmol),
affording 810 mg (57%) of 12b as a colorless oil. Rf ) 0.73
(CH2Cl2/MeOH/H2O 65:25:4. 1H NMR (500 MHz, CDCl3/CD3OD
3:1): δ 6.96 (d, J ) 8.7 Hz, 2H), 6.53 (d, J ) 8.7 Hz, 2H), 5.08 (q,
J ) 5.4 Hz, 1H), 3.82-3.75 (m, 2H), 3.70-3.58 (m, 3H),
3.54-3.51 (m, 4H), 3.46-3.36 (m, 8H), 3.29-3.22 (m, 2H), 2.45
(t, J ) 7.7 Hz, 2H), 2.24 (J ) 7.7 Hz, 2H), 1.77 (q, J ) 7.4 Hz,
2H), 1.42 (m, 2H), 1.15 (s, 30H), 0.78 (s, 18H), -0.01 (s, 6H),
-0.05 (s, 6H). 13C NMR (75 MHz, CDCl3/CD3OD 3:1): δ 173.2,
144.1, 130.2, 129.4, 111.8, 72.4 (d, J ) 9.6 Hz), 71.5, 71.5 (d, J )
7.8 Hz), 68.8, 66.6 (d, J ) 5.5 Hz), 64.6, 63.6 (d, J ) 5.4 Hz),
53.3, 40.2, 33.6, 33.3, 31.6, 29.4, 29.4, 29.3, 29.2, 29.1, 26.5, 25.7,
25.6, 25.5, 22.4, 18.0, 17.8, 13.8, -4.9, -5.0, -5.7, -5.7. 31P NMR
(202 MHz, CDCl3/CD3OD 3:1): δ -2.00. IR (neat): 3448, 2926,
2854, 1735, 1617, 1519, 1464, 1360, 1252, 1108 cm-1. m/z (M +
Na+) 1034.57.
1-O-Hexadecyl-2-(4-(4-(bis(2-chloroethyl)amino)phenyl)butanoyl)-
sn-glycero-3-phospho-(S)-glycerol (2a). Compound 12a (0.42 g, 0.43
mmol) was dissolved in MeCN (9 mL) and cooled to 0 °C. Then
40% aqueous HF (1 mL) was added, and the mixture was allowed
to reach 20 °C while being stirred vigorously for 2 h. The reaction
mixture was then poured into saturated aqueous NaHCO3 (20 mL)
and extracted with CH2Cl2 (3 × 10 mL) and EtOAc (10 mL). The
combined organic extracts were dried over Na2SO4 and concentrated
in vacuo and the residue was purified by column chromatography
(CH2Cl2/MeOH/H2O 65:25:4) to afford 2a (0.19 g, 59%). Rf ) 0.56
(CH2Cl2/MeOH/H2O 65:25:4). 1H NMR (500 MHz, CDCl3:CD3OD
3:1): δ 6.88 (d, J ) 8.6 Hz, 2H), 6.45 (d, J ) 8.6 Hz, 2H), 4.98 (q,
J ) 5 Hz, 1H), 3.84-3.71 (m, 3H), 3.60 (q, J ) 5 Hz, 1H),
3.54-3.51 (m, 4H), 3.46-3.39 (m, 8H), 3.30-3.20 (m, 2H), 2.37
(t, J ) 7.5 Hz, 2H), 2.17 (t, J ) 7.6 Hz, 2H), 1.71 (q, J ) 7.3 Hz,
2H), 1.35 (t, J ) 6.6 Hz, 2H), 1.07 (s, 26H), 0.69 (t, J ) 6.8 Hz,
3H). 13C NMR (75 MHz, CDCl3/CD3OD 3:1): δ 173.2, 144.0,
129.9, 129.2, 111.7, 71.4 (d, J ) 5.4 Hz), 71.3, 70.4 (d, J ) 4.8
Hz), 68.7, 66.1 (d, J ) 4.9 Hz), 63.8 (d, J ) 4.8), 61.8, 53.1, 40.1,
33.5, 33.4, 33.2, 33.0, 31.5, 29.3, 29.2, 29.1, 29.1, 28.9, 26.4, 25.6,
22.2, 13.5. 31P NMR (202 MHz, CDCl3/CD3OD 3:1): δ -0.99. IR
(neat): 3345, 2923, 2853, 1732, 1616, 1519, 1466, 1356, 1248, 1115,
1002 cm-1. m/z (M + H+) 778.36.
1-O-Octadecyl-2-(4-(4-(bis(2-chloroethyl)amino)phenyl)butanoyl)-
sn-glycero-3-phospho-(S)-glycerol (2b). The synthesis was per-
formed as for 2a, starting from 12b (334 mg, 0.33 mmol) and
affording 2b (83 mg, 32%). Rf ) 0.56 (CH2Cl2/MeOH/H2O 65:
25:4). 1H NMR (500 MHz, CDCl3/CD3OD 3:1): δ 6.89 (d, J ) 8.5
Hz, 2H), 6.46 (d, J ) 8.2 Hz, 2H), 4.99 (q, J ) 5 Hz, 1H),
3.84-3.72 (m, 3H), 3.60 (q, J ) 5 Hz, 1H), 3.53 (m, 4H),
3.47-3.41 (m, 8H), 3.30-3.20 (m, 2H), 2.37 (t, J ) 7.5 Hz, 2H),
2.17 (t, J ) 7.5 Hz, 2H), 1.71 (q, J ) 7.5 Hz, 2H), 1.35 (t, J ) 6.5
Hz, 2H), 1.07 (s, 30H), 0.70 (t, J ) 6.8 Hz, 3H). 13C NMR (75
MHz, CDCl3/CD3OD 3:1): δ 173.3, 144.0, 130.0, 129.2, 111.8,
71.5, 71.4 (d, J ) 6.3 Hz), 70.5 (d, J ) 4.8 Hz), 68.7, 66.1, 63.8
(d, J ) 5.6 Hz), 61.9, 53.2, 40.1, 33.5, 33.2, 31.5, 29.3, 29.3, 29.2,
29.1, 29.0, 26.4, 25.6, 22.3, 13.6. 31P NMR (202 MHz, CDCl3/
CD3OD 3:1): δ -0.31. IR (neat): 3332, 2923, 2853, 1733, 1616,
1519, 1466, 1355, 1236, 1115, 1002 cm-1. m/z (M + Na+) 828.37.
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The design of retinoid phospholipid prodrugs is described based onmolecular dynamics simulations and
cytotoxicity studies of synthetic retinoid esters. The prodrugs are degradable by secretory phospholipase
A2 IIA and have potential in liposomal drug delivery targeting tumors. We have synthesized four
different retinoid phospholipid prodrugs and shown that they form particles in the liposome size region
with average diameters of 94-118 nm. Upon subjection to phospholipase A2, the lipid prodrugs were
hydrolyzed, releasing cytotoxic retinoids and lysolipids. The formulated lipid prodrugs displayed IC50
values in the range of 3-19 μM toward HT-29 and Colo205 colon cancer cells in the presence of
phospholipase A2, while no significant cell death was observed in the absence of the enzyme.
Introduction
Retinoids,1 suchas all-trans retinoic acid (ATRA,aFigure 1),
are known for their broad and diverse biological functions,
and various strategies have been explored to make retinoids
applicable as drugs in the treatment of diseases.2 One of the
biological functions of ATRA is its anticancer activity toward
a broad range of cancer types, like breast, prostate, and colon
cancer.3 For example, orally administrated ATRA is used
clinically in the treatment of leukemia.4 However, the oral
administration route is restricted by a relative low bioavail-
ability4c and a fast clearance from the bloodstream,5 and thus
alternative ways of administrating ATRA would be benefi-
cial. Intravenous administration is hampered by the lowwater
solubility of ATRA, but this can be circumvented by formu-
lating ATRA in liposome based drug delivery systems.6 Un-
fortunately, the liposomal formulation strategies have often
been plagued by problems with leakage, which have led to an
uncontrolled release of ATRA from the carrier system. Re-
cently, we have introduced new liposomal drug delivery
systems7 that address the formulation challenges of relatively
hydrophobic drugs. The drug delivery systems consist of
secretory phospholipase A2 (sPLA2) IIA sensitive phospholi-
pids and are constructed of drug-lipid prodrugs, in which the
lipophilic anticancer drugs are covalently attached to the
phospholipids. Despite successful incorporation of the well-
known anticancer drug chlorambucil in the sn-2 position,7a it
was later experienced that the desired delivery of free ATRA
was not feasible due to lack of sPLA2 activity on substrates
like 1 (Figure 1).7b ATRA is a rigid molecule and contains a
methyl substituent in close proximity to the carboxylic acid
moiety. These features contrast with naturally occurring fatty
acids, which are predominantly saturated and flexible mole-
culeswithoutbranching.Knowing that some esters andamides
of ATRA retain their activity,8 we decided to incorporate an
aliphatic C6-linker between ATRA and the lipid backbone
(Figure 2). To gain further insight into the substrate specificity
of the sPLA2 enzyme, hydrolysis of the lipid prodrugs was
investigated by molecular dynamics (MD) simulation, which
has earlier been demonstrated as a valuable tool for assessing
sPLA2 activity toward a range of substrates.
9
One major drawback in applying ATRA as a drug is its
nonselective activation of retinoic acid receptor (RAR) sub-
types (RARs,R, β, γ), retinoic X receptor subtypes (RXRs,R,
Figure 1. Structure of the cytotoxic compounds ATRA and 2 and the
ATRA phospholipid prodrug (1) that is not hydrolyzed by sPLA2.
7b.
*To whom correspondence should be addressed. Phone: þ45
45252131. Fax: þ45 45933968. E-mail: mhc@kemi.dtu.dk.
aAbbrevations: ATRA, all-trans retinoic acid; sPLA2, secretory
phospholipase A2; MD, molecular dynamics; RAR, retinoic acid recep-
tor; RXR, retinoic X receptor; rmsd, root-mean-square deviation; S,
substrate; PMB, p-methoxybenzyl; DDQ, 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; DIAD, diiso-
propyl azodicarboxylate; NBS, N-bromosuccinimide; DLS, dynamic
light scattering; DPPG, 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol;
DSPG, 1,2-distearoyl-sn-glycero-3-phosphoglycerol; 1-O-DSPG, 1-O-
stearyl-2-stearoyl-sn-glycero-3-phosphoglycerol; POPG, 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoglycerol; NBD-DPPE, 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-[7-nitro-2-1,3-benzoxadiazol-4-yl];
MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight;
DHB, 2,5-dihydroxybenzoic acid; MTT, 3-(4,5-dimethylthiazolyl)-2,5-
diphenyltetrazolium bromide.
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β, γ), and/or the subtype RAR isoforms, R1, R2, β1-β5, γ1,
and γ2.3a,10 The lack of selectivity is believed to be responsible
for the severe side effects that have been observed during
chronic administration of ATRA,10 and therefore there is
much interest in discovering more selective RAR agonists.11
Targeting of RARβ2 has been found to have a suppressive
effect on human tumors,12 and recently 4-(4-octylphenyl)-
benzoic acid (2, Figure 1) was identified as a selective RARβ2
agonist.13 The lipophilicity of 2 makes it is a good candidate
for incorporation into a liposomal drug delivery system
through covalent attachment to the lipid backbone.However,
since Bonsen et al. have demonstrated that benzoic acid is not
released from the sn-2-position by sPLA2,
14 direct attachment
of 2 to the phospholipidswas ruled out. Instead, we decided to
investigate how attachment of an aliphatic C6-linker would
influence the cytotoxicity of 2 and the sPLA2 activity toward
the corresponding prodrug.
The retinoid-lipid prodrugs are designed to include the
phosphatidylglycerol headgroup because human sPLA2 IIA
has strong affinity for negatively charged phospholipids.15
The lipid backbone of the prodrugs contains either an sn-1-
ester or an sn-1-ether functionality.Uponactivationof sPLA2,
the prodrugswill be converted into the free drug and lysolipids
(Figure 2) andwhile sn-1-ether lysolipids have goodmetabolic
stability and are cytotoxic against many cell lines,16 sn-1-ester
lysolipids are rapidly metabolized (by e.g., lysophospholi-
pases) and have been dismissed as suitable lysolipid drug
candidates.16a Information about the cytotoxicityof sn-1-ester
lysolipids is limited and covers only lysophosphatidylcholine
lipids,17 but these lipids have shown to be slightly better
substrates for sPLA2 than sn-1-ether lipids.
18 Therefore, we
found it interesting to synthesize both types of prodrugs in
order to study their relative hydrolysis rate and cytotoxicity.
Molecular Dynamics Simulations
Molecular dynamics (MD) simulations were performed to
understand why 1 is not hydrolyzed by sPLA2
7b and which
structural modification(s) of the prodrug would regain enzy-
matic hydrolysis. Simulations were carried out for sPLA2-
DPPG, sPLA2-1, and as discussed below also for sPLA2-3
and sPLA2-5. Simulations for each complex were repeated
five times to estimate the statistical uncertainties in the
calculated quantities. The stability of the simulations of the
different sPLA2 complexes were checked by computing the
time evolution of the root-mean-square deviation (rmsd) of
the CR atoms with respect to the protein structure obtained
afterminimization. Stable rmsddatawereobtainedafter 1-2ns
for the sPLA2-DPPG, sPLA2-3 and sPLA2-5 complexes
reaching a plateau of∼1.4 A˚ (Supporting Information). rmsd
data for the sPLA2-1 complex were not stable, increasing to
∼2.5 A˚ after ∼6.5 ns (Supporting Information).
A prerequisite for successful hydrolysis is that a stable
Michaelis-Menten complex is obtained and that a water
molecule acting as a nucleophile can enter the catalytic cleft.
To monitor the stability of the Michaelis-Menten complex,
we have chosen distances according to their importance in
the calcium-dependent enzymatic reaction.19 The catalytic
mechanism has been identified by X-ray crystallography,
revealing that the catalytic device of sPLA2 is essentially
characterized by an aspartic acid-histidine dyad, a calcium-
binding site, and a water molecule acting as the nucleophile.
A schematic representation of the catalytic mechanism is
shown in Figure 3, indicating that the calcium ion (cofactor)
is coordinated to the D48 carboxylate groups (atoms: OD1
and OD2), the G29 carbonyl (O), the carbonyl (O22) in the
substrate (S), and the phosphate (O4) in S. Atom types given
in parentheses refer to the Protein Data Bank nomenclature.
Furthermore, the catalytic residue, H47, is stabilized by D91,
Figure 2. The sPLA2degradablephospholipidprodrugs3-6, withanaliphaticC6-linker incorporatedbetween the drug,R0COOH(ATRAor2),
and the lipid backbone.
Figure 3. Representation of the active site in sPLA2 with hydrogen
bonds and ionic interactions indicated with dashed bonds. Key
protein residues are drawn in blue, the substrate in red, and the
calcium ion and the water molecule both in brown. The two gray
circles indicate the H-S region, where the overlap in dark gray
represents the water count region. Labels are shown in black, and
atom types indicated in parentheses refer to the Protein Data Bank
nomenclature.
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which forms hydrogen bonds with Y51 and Y66. The water
molecule acting as the nucleophile enters the region between
H47ND1 and SC21. This region will be referred to as theH-S
region (Figure 3).
We have checked the stability of the Michaelis-Menten
complexes by monitoring the following distances during the
simulations: Ca2þ-G29O, Ca2þ-D48OD1, Ca2þ-SO22, SO22-
G29HN, H47HE2-D91OD1, H47ND1-SC21, D91OD2-Y66HH,
andD91OD1-Y51HH. The time evolution of these distances is
provided in the Supporting Information, and 2D scatter plots
are shown in Figure 4.
For prodrug1, no stableMichaelis-Menten complex could
be observed, and hence in accordance with experimental data,
nohydrolysis canoccur.The rigid nature of theATRAester at
the sn-2-position of the prodrug causes distortion of several
distances involved in theMichaelis-Mentencomplex (Figure4).
For instance, distances Ca2þ-SO22 and G29HN-SO22 are signi-
ficantly larger for sPLA2-1 than sPLA2-DPPG(Figure4).The
distortion is also highlighted by the images taken at the begin-
ning and upon completion of an sPLA2-1 simulation, respec-
tively (Figure 4). Introduction of a C6-linker between the
phospholipid backbone and 1was sufficient to confer stability
of theMichaelis-Menten complex in sPLA2-3 and sPLA2-5.
Although a stable Michaelis-Menten complex could be
obtained by introducing a C6-linker, the question remained if
water can reach the H-S region (Figure 3) in sPLA2 com-
plexed with 3 or 5. To quantify the probability that water
molecules enter the H-S region, we counted the number of
water molecules within certain distances (d = 3 A˚ - 6 A˚;
Δd=0.5 A˚) frombothH47ND1 and SC21, and the counts were
normalized by dividing the respective water counts by the
water count determined at 6 A˚ (Figure 4). Averages and
standard deviations of normalized water counts were calcu-
lated from the five simulations of each complex. The relative
water counts extracted from sPLA2-3 and -5 simulations
were similar to those extracted from sPLA2-DPPG simula-
tions (Figure 4). Contrarily, the relative water counts ex-
tracted from sPLA2-1 were very low when compared to the
other complexes. Because complexes of DPPG, 3, and 5 show
similar relative water counts and their Michaelis-Menten
complexes are stable, these results predict that 3 and 5 will be
hydrolyzed by sPLA2.
Synthesis of Retinoid Esters
The linkermoiety tert-butyl 6-hydroxyhexanoate (11)20was
coupled with ATRA by a Mitsunobu reaction (Scheme 1),21
which we previously have demonstrated as a reliable method
for forming esters of ATRA.7b The following tert-butyl
deprotection led to degradation of the ATRA skeleton under
acidic conditions (5% TFA or ZnBr2
22 in CH2Cl2 or HF in
MeCN), but using 2,6-lutidine and TMSOTf in CH2Cl2
23
afforded the carboxylic acid 9 in a good yield (Scheme 1). The
ATRA ester 9 was isolated as yellow crystals and was stable
when stored at-20 Cunder an inert atmosphere, whereas the
oily tert-butyl ester of 9decomposes upon less thanonemonth
of storage. This highlights the importance of storing ATRA-
analogues as solids in order to avoid decomposition. The
corresponding linker-molecule of 224 was synthesized by a
Steglich coupling25 with 11 followed by a deprotection of the
tert-butyl esterwithTFA inCH2Cl2 (Scheme 1). In contrast to
the ATRA-analogues, we never observed any decomposition
of the synthetic derivatives of 2 neither as oils nor solids. The
cytotoxicity of ATRA, 2, 9, and 10were evaluated in three cell
lines, and the retinoid esters had activities comparable to the
acids (vide infra).
Synthesis of Lipid Prodrugs
The cytotoxicity of the esters 9 and 10 and the results from
theMDsimulations promptedus to proceedwith the synthesis
Figure 4. (A) ATRA induced structural perturbation of the Michaelis-Menten complex. Images taken at the beginning (top) and at the end
(bottom) of an sPLA2-1 simulation revealed thatATRA induced conformational changes (as evident from theG29
(O)-Ca2þ-S(O22) distances
indicated by the triangles) leading to the distortion of theMichaelis-Menten complex. (B) 2D scatter plots of distances between selected residue
pairs important for stabilizing the Michaelis-Menten complex. (C) Histograms of relative water counts as a function of distance from both
H47ND1 and SC21 (H-S region; Figure 3).
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of the corresponding sn-1-ether and sn-1-ester lipid prodrugs
3-6. The backbone of the sn-1-ether prodrugs was con-
structed by a tetrazole mediated coupling of alcohol 12 and
phosphoramidite 13, followed by an oxidation of the phos-
phite to the phosphate with tBuOOH (Scheme 2).7a Deprotec-
tion of the p-methoxybenzyl (PMB) group in moist CH2Cl2
with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) af-
forded the secondary alcohol, which was reacted with 6-(4-
methoxybenzyloxy)-1-hexanoic acid (14) to give an ester. The
newly introduced PMB-group was then removed, affording
alcohol 15 in an overall yield of 51% (Scheme 2). Secondary
alcohol 16, synthesized from2,3-O-isopropylidene-sn-glycerol
according to the procedures by Gaffney et al26 and Burgos
et al.,27 served as the starting material for the sn-1-ester pro-
drugs (Scheme 2). Diester 17 was obtained by coupling of 14
and 16, and the following TBDMS deprotection was best
achieved using N-bromosuccinimide (NBS) in a mixture of
DMSO, THF, and H2O (Scheme 2),
27,28 while alternative
conditions like Bu4NF and imidazole in THF
29 or HF in
MeCN led to a significant degree of acyl migration. Mosher
ester analysis30 of 17 showed that the enantiomeric purity was
>95%. The phosphate headgroup was attached in the same
way as for the sn-1-ether lipids, and PMB deprotection gave
the primary alcohol 18 (Scheme 2). Phospholipids 15 and 18
were converted to the desired prodrugs of ATRA and 2
(Scheme 3). The ATRA moiety was introduced either by the
Mitsunobu reaction or the Steglich coupling, and the final
prodrugs 3 and 4 were obtained after removal of the cyano-
ethyl group with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)
andTBDMS-deprotectionmediatedbyHF inMeCN/CH2Cl2/
H2O. Prodrugs 5 and 6 were accessed by coupling between 2
and the primary alcohols 15 and 18, after which the remaining
chemistrywas similar to the synthesis of 3 and 4 (Scheme3). 31P
NMR of the synthesized prodrugs showed one signal resonat-
ing between -1 ppm and 2 ppm, demonstrating high diaster-
eomeric and regioisomeric purity (>95%).
Biophysical Characterization
The lipid prodrugs (3-6) were formulated as liposomes by
extrusion inHEPESbuffer using thedry lipid film technique,31
yielding clear solutions. The particle size of the formulated
Scheme 1. Synthesis of the Retinoid Estersa
aReagents: (a) (i) diisopropyl azodicarboxylate (DIAD), PPh3, THF; (ii) TMSOTf, 2,6-lutidine, CH2Cl2; (b) (i) dicyclohexylcarbodiimide (DCC),
DMAP, CH2Cl2; (ii) TFA, triisopropylsilane, CH2Cl2.
Scheme 2. Synthesis of the Lipid Precursors 15 and 18a
aReagents: (a) (i) tetrazole,CH2Cl2,MeCN; (ii)
tBuOOH; (iii)DDQ,H2O,CH2Cl2; (iv) 14, DCC,DMAP,CH2Cl2; (v)DDQ,H2O,CH2Cl2; (b) (i) 14,
EDCI, DMAP, CH2Cl2; (ii) NBS, DMSO, THF, H2O; (c) (i) 13, tetrazole, CH2Cl2, MeCN; (ii)
tBuOOH; (iii) DDQ, H2O, CH2Cl2.
Scheme 3. Synthesis of the sn-1-Ether and sn-1-Ester prodrugs 3, 4, 5, and 6a
aReagents: (a) (i) 15, ATRA,DIAD,PPh3, THFor 18, ATRA,DCC,DMAP,Et3N, Et2O; (ii)DBU,CH2Cl2; (iii)HF,H2O,CH2Cl2,MeCN; (b) (i) 2,
DCC, DMAP, CH2Cl2; (ii) DBU, CH2Cl2; (iii) HF, H2O, CH2Cl2, MeCN.
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lipids was measured by dynamic light scattering (DLS). The
DLS analysis revealed that all of the lipids were able to form
particles with a diameter around 100 nm (Table 1 and Sup-
porting Information) andwith a lowpolydispersity, indicating
the formation of unilamellar vesicles. The formation of a uni-
lamellar bilayer is further supported by the fluorometric
procedure described by McIntyre et al.,32 which was used to
study the permeability. Vesicles formed from prodrug 5 was
compared to vesicles of 1,2-dipalmitoyl-sn-glycero-3-phos-
phoglycerol (DPPG) and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoglycerol (POPG). The lipids were formulated with
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[7-ni-
tro-2-1,3-benzoxadiazol-4-yl] (NBD-DPPE, 0.15mol%).The
fluorescence of the NBD group was monitored over time
before and after the addition of dithionite (S2O4
-2), which
functions as a quenching agent. At the end of the experiment,
the detergent Triton X-100 was added to solubilize the lipid
vesicles and cause 100% quenching (see Figure 5). As evident
from the figure, the decrease in the fluorescence of the NBD-
labeled gel-state DPPG occurs in two distinct steps, an
immediate and fast one completed after 20 min followed by
much slower decay of fluorescence. We anticipate that the
quick drop in fluorescence signal corresponds to quenching of
the dye in the outer leaflet and is dependent on the fraction of
lipids exposed to the surrounding, i.e., vesicle size and lamel-
larity. The slower second step is due to quenching of the dye in
the inner leaflet, which is controlled by membrane permeabil-
ity to dithionite. In the case of the fluid POPG vesicles, the
quenching of both leaflets occurs simultaneously, resulting
effectively in a single exponential-like decay in the NBD
fluorescence. A comparable behavior for gel-state and fluid
membranes has been reported previously.32,33 The quenching
of the NBD-labeled vesicles for prodrug 5 resembles that of
DPPG, demonstrating that 5 forms a bilayer membrane,
however seemingly more permeable to dithionite than the
vesicles of DPPG.
Differential scanning calorimetry scans (15-65 C) of the
lipid solutions of 3 and 5 displayed no gel-to-liquid crystalline
or any other thermotropic phase transition in the tested
temperature range (data not shown), indicating that the lipid
bilayers are in a fluid state. This was not surprising taking into
account the bulky and stiff nature of the substituents in the
sn-2-position, which hampers well-ordered chain packing.
The ability of sPLA2 to hydrolyze the formulated lipids at
37 C was investigated with matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) MS. MALDI-TOF
MS is a fast and sensitive technique which has been shown to
be a reliable tool for detection of lipids.34 In Figure 6, the
obtained MS data for the sn-1-ether prodrug 3 subjected to
purified sPLA2 from snake (Agkistrodon piscivorus piscivorus)
venom is shown.Gratifyingly, and as evident from the spectra
(Figure 6), the prodrug (MþHþ) is consumed by the enzyme
and the desired constituents, lysolipid 7 (MþHþ) andATRA
ester 9 (M þ Naþ), are released. The MALDI-TOF MS
analysis of the sn-1-ether prodrugs 3 and 5 and the sn-1-ester
prodrugs 4 and 6 revealed that all of the prodrugs were
degraded by the enzyme (Table 2) and the desired molecules
were released (see Supporting Information). The observation
that the sn-1-ether prodrugs were consumed by sPLA2 to the
same extent as the sn-1-ester prodrugs illustrate and confirm
that sn-1-ether phospholipids are excellent substrates for
sPLA2. On the basis of the MALDI-TOF MS analysis of
the sPLA2 activity on the various prodrugs, we can conclude
that the incorporation of an aliphatic C6-linker between
ATRA and the lipid backbone resolved the issue of sPLA2
activity on ATRA-lipid prodrugs. The experimental observa-
tions are in agreement with the outcome from the MD
simulations, illustrating the power and potential of using
MD simulations in the design of sPLA2 degradable lipid
prodrugs. To rule out that the degradation of the prodrugs
was caused by nonenzymatic hydrolysis, a sample of each
prodrug was subjected to the reaction conditions in the
absence of sPLA2. As evident from the spectra in Figure 6
(and in Supporting Information), no degradation of the
prodrugs was observed within 48 h and none of the release
products were detectable. Finally, we compared the enzyme
activity of the purified sPLA2 from snake (Agkistrodon pisci-
vorus piscivorus) venom with the commercially available
sPLA2 from snake (Naja mossambica mossambica) venom,
and as can be seen in Table 2, the two enzymes perform
equally well on all substrates.
Fawzy et al.35 and Hope et al.36 have demonstrated two
decades ago that ATRA is an inhibitor for sPLA2, reporting
IC50 values of<50 and10μMrespectively.However,we have
later shown that DPPG is fully hydrolyzed by sPLA2 in the
presenceof 0.1 and1.0 equiv ofATRA,7bproving that the lack
of hydrolysis for the ATRA-lipid prodrug 1 is not a conse-
quence of inhibition by ATRA. These observations are
further supported by the present work, in which it was found
that 9 (IC50=8μM,Ki=6 μM, see Supporting Information)
inhibits sPLA2 at the same level as ATRA (IC50 = 15 μM,
Ki = 11 μM), and whereas the ATRA-lipid prodrug 1 is not
consumed by the enzyme, the prodrugs 3 and 4 are fully
degraded. This demonstrates that under the conditions used,
the released ATRA ester 9 does not inhibit sPLA2, and the
difference in degradation of the prodrugs therefore solely
relies on the ability of sPLA2 to hydrolyze the different
prodrugs. Additionally, Cunningham et al. have reported Ki
values <100 nM37 for potent sPLA2 inhibitors, illustrating
that ATRA and 9 are weak inhibitors.
Table 1. Measurement of Particle Size with DLS
particle size
prodrug diameter (nm) polydispersity index
3 94 0.08
4 97 0.13
5 118 0.16
6 118 0.05
Figure 5. Time-dependent fluorescence from NBD labeled lipids
quenched by dithionite.
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Cytotoxicity
The cytotoxicity of ATRA, 2, 9, and 10 were evaluated in
MT-3 breast carcinoma, HT-29 colon carcinoma, and
Colo205 colon adenocarcinoma cell lines (Table 3). Interest-
ingly, the retinoid esters were either more active than ATRA
and 2 or equal in potency in the tested cell lines. A possible
explanation for the enhancedactivityof thesemolecules is that
the derivatization increases the lipophilicity of the drugs,
augmenting transport over the cell membrane. RARβ2 ago-
nists 2 and 10 showed very little activity against HT-29 cells,
and presumably this is because growth inhibition in this cell
line is induced byRARR agonists38 and 2has a lowaffinity for
that receptor.13 The result is also a strong indication that the
cytotoxicity of 10 in MT-3 and Colo205 originate from
RARβ2 activation.
The cytotoxicity of the prodrugs 3-6 was investigated in
HT-29 colon carcinoma and Colo205 colon adenocarcinoma
cells. HT-29 colon carcinoma cells do not secrete sPLA2,
which allowed us to test the activity in the presence and
absence of sPLA2. As evident from Table 4 and the dose-
response curve for 3 and 5 (Figure 7), none of the prodrugs
were able to induce significant cell death in the absence of
sPLA2, whereas upon sPLA2 addition, all of the prodrugs
displayed IC50 values below10μMinHT-29 cells and complete
cell death was obtained when higher concentrations were
applied (see Figure 7). Evidently, the cytotoxicity is induced
by sPLA2 triggeredbreakdownof the prodrugs into 9or 10 and
the lysolipids. Interestingly, we observed that the sn-1-ester
prodrug 6 in the presence of sPLA2 displayed almost the same
cytotoxicity towardHT-29 cells as the corresponding sn-1-ether
prodrug 5, and taking the low activity of 10 in HT-29 cells
Figure 6. MALDI-TOF MS monitoring of snake (Agkistrodon piscivorus piscivorus) venom sPLA2 activity on the sn-1-ether prodrug 3. The
spectra demonstrate that the prodrug 3 (top left) is consumed and that the lysolipid 7 (top right) and the ATRA ester 9 (bottom) are released.
Table 2. Measurement of sPLA2 Activity on the Prodrugs byMALDI-
TOF MS
hydrolysis by sPLA2
a
prodrug
Agkistrodon piscivorus
piscivorus
Naja mossambica
mossambica
3 þ nd
4 þ þ
5 þb þb
6 þ þ
aDetermined by MALDI-TOF MS after 48 h incubation at 37 C
with purified sPLA2 from snake (Agkistrodon piscivorus piscivorus or
Naja mossambica mossambica) venom. bAfter 48 h, a small signal for
prodrug 5 remains; nd = not determined.
Table 3. IC50 (μM)Values for theRetinoids in Three CancerCell Lines
a
compd
MT-3
IC50 (μM)
HT-29
IC50 (μM)
Colo205
IC50 (μM)
ATRA 30( 4 4.3 ( 0.2 37 ( 1
9 17( 1 3.6 ( 1.8 17 ( 2
2 51( 3 >200 >200
10 14( 1 >200 127 ( 18
aCytotoxicitywasmeasured using theMTTassay as cell viability 48 h
after incubation with the indicated substances for 24 h and shown by
mean ( SD (n= 3).
Table 4. IC50 (μM)Values for the Prodrugs 3-6, the Lysolipids 7 and 8,
DSPG, and 1-O-DSPG in HT-29 and Colo205 Cancer Cell Linesa
compd
HT-29
IC50 (μM)
HT-29 þ sPLA2b
IC50 (μM)
Colo205
IC50 (μM)
3 >200 7 ( 2 16 ( 4
4 >200 6 ( 1 12 ( 3
5 >200 3 ( 1 7 ( 6
6 >200 8 ( 1 19 ( 4
7 11 ( 6 nd 25 ( 2
8 7 ( 1 nd 22 ( 3
DSPG >200 25 ( 11 54 ( 7
1-O-DSPG >200 9 ( 2 33 ( 4
C17H35COOH >200 nd >200
sPLA2 c c c
aCytotoxicitywasmeasured using theMTTassay as cell viability 48 h
after incubation with the indicated substances for 24 h and shown by
mean( SD (ng 3); nd=not determined. bSnake (Agkistrodon piscivorus
piscivorus) venomsPLA2was added to a final concentrationof 5 nM.
cNo
change in cell viability was observed after 24 h.
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(Table 3) into account, these results indicate that sn-1-ester
lysolipids (8) contribute with the same degree of potency as sn-
1-ether lysolipids (7). These findingswere verifiedwhen the free
lysolipids 7 (see Supporting Information) and 8 were tested
against HT-29 cells. Both lysolipids displayed IC50 values close
to 10μM,and similar resultswere obtained forDSPGand1-O-
stearyl-2-stearoyl-sn-glycero-3-phosphoglycerol (1-O-DSPG, see
Supporting Information) in the presence of sPLA2 (Table 4).We
conclude that even though sn-1-ester lysolipids generally are
rapidly metabolized, under these in vitro conditions, there is no
significant metabolism of the lipid backbone and therefore we
observe an equal potency of the two lysolipids. With the control
experiments in hand, it is possible to determine the origin of the
cytotoxicity of the prodrugs in HT-29 cells, and as evident from
Tables 3 and 4, the majority of the activity arises from the
lysolipids in prodrug 5 and 6while for the prodrugs 3 and 4 there
appear to be an equal contribution from the lysolipids
(7 and 8) and the ATRA ester 9. Colo205 cells express sPLA2,
and encouragingly, the four prodrugs induce cell deathwith IC50
values below 20 μM (Table 4) and complete cell death was
obtainedwhenhigher concentrationswereapplied (seeFigure8),
indicating that the secreted sPLA2 in Colo205 cells provides the
desired hydrolysis and release of the anticancer agents. Addi-
tionally, the prodrugs 3 and 4 displayed IC50 values below the
free lysolipids but similar to 9, indicating that themajority of the
cytotoxicity can be ascribed to the released ATRA ester 9. For
prodrugs 5 and 6, the IC50 values indicate a cumulative effect
because these prodrugs aremorepotent thanbothof the released
cytotoxic compounds by themselves, demonstrating the advan-
tage of the prodrug formulation.
Conclusion
In the present study we have successfully synthesized lipid
prodrugs of retinoids and demonstrated that they can be
formulated as liposomes that are degraded by sPLA2. On
the basis of MD simulations, we incorporated a C6-linker
between the glycerol backbone of the lipids and the retinoids
to overcome the lack of enzymatic activity stemming from the
rigid nature ofATRAand 2. The resulting prodrugs 3-6were
hydrolyzed completely by sPLA2 within 24 h and were
demonstrated to be cytotoxic to cancer cells in the presence
of the enzyme.
The liposomal formulation is very well suited for active
substances with low water solubility, and the novel prodrugs
present a solution to formulation of retinoids for applications
in cancer therapy. Furthermore, our findings underpin the
overall strategy of covalently linking cytotoxic compounds to
lipids and widen the scope of the approach because even very
sterically hindered substrates can now be effectively incorpo-
rated into liposomesand released throughanenzyme-triggered
degradation.
Experimental Section
General. Starting materials, reagents, and solvents were pur-
chased from Sigma-Aldrich and used without further purifica-
tion. POPG,DPPG,DSPG, 1-stearoyl-2-hydroxy-sn-glycero-3-
phospho-(10-rac-glycerol) (8), and NBD-DPPE were purchased
from Avanti Polar Lipids (Alabaster, AL). The purified snake
venom sPLA2 from Agkistrodon piscivorus piscivorus was do-
nated byDr. R. L. Biltonen (University of Virginia), and sPLA2
fromNaja mossambica mossambicawas purchased from Sigma-
Aldrich. CH2Cl2 was dried over 4 A˚ molecular sieves, and
THF was dried over sodium/benzophenone and distilled before
use. Evaporation of solvents was done under reduced pressure
(in vacuo). TLC was performed on Merck aluminum sheets
precoated with silica gel 60 F254. Compounds were visualized by
charring after dipping in a solution of Ce(IV) (6.25 g of (NH4)6-
Mo7O24 and 1.5 g of Ce(SO4)2 in 250 mL of 10% aq H2SO4) or
an ethanolic solution of phosphomolybdenic acid (48 g/L).
Flash column chromatography was performed using Matrex
60 A˚ silica gel. The purity of all tested compounds was found to
be >95% by HPLC (see Supporting Information). HPLC was
performed on a Waters Alliance HPLC equipped with a DAD,
using a LiChrospher Si 60 column and eluting with water/
isopropanol/hexane mixtures.39 NMR spectra were recorded using
a Bruker AC 200 MHz spectrometer, a Varian Mercury 300 MHz
spectrometer, or a Varian Unity Inova 500 MHz spectrometer.
Chemical shifts were measured in ppm and coupling constants in
Hz,and the field is indicated ineachcase. IRanalysiswas carriedout
on a Bruker Alpha FT-IR spectrometer, and optical rotations were
measured with a Perkin-Elmer 341 polarimeter. HRMS was re-
cordedonan IonspecUltimaFourier transformmass spectrometer.
Molecular Dynamics Simulations. The crystal structures of
bee venom (Apis Mellifera) phospholipase A2 complexed with
the transition-state analogue, L-1-O-octyl-2-heptylphosphonyl-
sn-glycero-3-phosphoethanolamine (diC8(2Ph)PE),19 resolved
to 2.0 A˚, and human phospholipase A2 IIA complexed with 6-
phenyl-4(R)-(7-phenyl-heptanoylamino)-hexanoic acid,40 resol-
ved to 2.1 A˚, were obtained from the ProteinData Bank41 (entry
codes: 1poc and 1kqu, respectively). The initial modeling step
Figure 7. Dose-response curves for the treatment of HT-29 cells
with the sn-1-ether prodrugs 3 (b), 3 þ sPLA2 (9), 5 ([), and 5 þ
sPLA2 (2).
Figure 8. Dose-response curves for the treatment of Colo205 cells
with sn-1-ester prodrugs 4 (9) and 6 (2).
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involved placing diC8(2Ph)PE into the binding cleft of human
phospholipase A2 IIA, as described previously.
18 A previously
assembled sPLA2-substrate complex18was used as the template
to place lipid prodrugs into the active site. The optimized lipid
prodrugs were manually overlapped with the pre-existing sub-
strate, which was subsequently deleted. NAMD software42 with
the Charmm27 all-atom parameter set and TIP3 water model
was used for all simulations.43 The lipid prodrugs were first
energy-minimized for 1000 steps before using them in simula-
tions. Missing force field parameters for the prodrug molecules
were taken from similar atom types in the CHARMM27 force
field. The sPLA2-lipid complexes were solvated using the
program SOLVATE.44 Eighteen water molecules were ran-
domly replaced with chloride ions to neutralize the systems.
Ultimately, the system contained ∼4900 water molecules in a
simulation cell of dimensions 52.7  51.7  67.3 A˚3. An initial
energy minimization of the complex was carried out for 1000
steps, and the system was further minimized for 100, 200, 300,
400, and 500 steps to generate different starting structures.
Periodic boundary conditions were applied in x, y, and z
directions. Initial MD simulations were conducted for ∼100
ps in which each systemwas slowly heated to 300K. Simulations
were carried out for 10 ns in the NPT ensemble, i.e., at constant
number of atoms (N), pressure (P), and temperature (T). A time
step of 1 fs and an isotropic pressure of 1 atm using the Langevin
piston method45 were employed. Electrostatic forces were cal-
culated using the particle mesh Ewald method with a uniform
grid spacing of ∼1 A˚.46 A 12 A˚ cutoff was used for terminating
the van der Waals interactions in combination with a switching
function starting at 10 A˚. Analysis of the trajectories were per-
formed using the Visualization Molecular Dynamics software
suite.47
Liposome Preparation and Particle Size Determination. The
lipid prodrugs 3-6 were dissolved in CHCl3 in a glass tube
and dried under vacuum for 15 h to form a thin film. The lipid
prodrugs (2mM)were solubilized by addition of aqueous buffer
(0.15MKCl, 30 μMCaCl2, 10 μMEDTA, 10 mMHEPES, pH
7.5) and vortexed periodically over 1 h at 20 C. Subsequently,
the solutions were extruded through a 100 nm polycarbonate
cutoff membrane (20-30 repetitions) using a Hamilton syringe
extruder (Avanti Polar Lipids, Birmingham, AL). The particle
size distribution of the formulated lipids was measured by
DLS. The DLSmeasurements were obtained using a Zetasizer
nano particle analyzer (ZS ZEN3600, Malvern Instrument,
Westborough, MA).
Permeability Assay. The permeability of the lipid vesicles was
examined using the procedure described by McIntyre et al.32
The lipid vesicles were labeled with NBD-DPPE (0.15 mol %)
and prepared in an aqueous buffer (10mMHEPES, 1M sucrose,
150mMNaCl, pH7.4) by sonication for 30min at 45 Cand then
extrusion through a 100 nm filter at 45 C. Sucrose was added
to minimize the osmolarity difference between the external solu-
tion and the vesicle interior that will arise after the addition of
dithionite.48 The experiments were performed in duplicates or
moreusingFLUOstarOmegamicroplate reader (BMGLABTECH)
in a 96-well microplate at 20 C (150 μL). The lipid samples
(100 μM) were allowed to equilibrate at 20 C before the
addition of sodium dithionite (Na2S2O4) solution (33 mM),
which was used as a quenching agent. Because of the high
instability of dithionite,49 the dithionite solution was freshly
prepared prior to use. The NBD fluorescence was observed at
520 nm (ex 485 nm). After 85 min, Triton X-100 was added to
the medium (0.3 wt %).
sPLA2 Activity Measurements Monitored by MALDI-TOF
MS. The formulated lipid prodrugs (0.40 mL, 2 mM) were
diluted in an aqueous buffer (2.1mL, 0.15MKCl, 30 μMCaCl2,
10 μM EDTA, 10 mM HEPES, pH 7.5), and the mixture was
stirred at 37 C in a container protected from light. The catalytic
reaction was initiated by addition of snake (Agkistrodon pisci-
vorus piscivorus (20 μL, 42 μM) orNaja mossambica mossambica
(12 μL, 71 μM)) venom sPLA2. Sampling was done after 0, 2, 24,
and 48 h by collecting 100 μLof the reactionmixture and rapidly
mixing it with a solution of CHCl3/MeOH/H2O/AcOH 4:8:1:1
(0.5 mL) in order to stop the reaction. The mixture was washed
with water (0.5 mL), and the organic phase (80 μL) was isolated
by extraction and then concentrated in vacuo. The extract was
mixed with 9 μL of 2,5-dihydroxybenzoic acid (DHB) matrix
(0.5 M DHB, 2 mM CF3COONa, 1 mg/mL DPPG in MeOH),
and 0.5 μL of this mixture was used for the MS analysis.
Cytotoxicity. Colon cancer HT-29 cells were cultured in
McCoy’s 5A medium in the presence of 10% fetal calf serum
and 1% Pen-Strep (InVitrogen). Breast cancer MT-3 and colon
cancer Colo205 cells were cultured in RPMI 1640 supplemented
with 10% fetal calf serum and 1% Pen-Strep in a humidified
atmosphere containing 5% CO2. Colo205 cells secrete sPLA2-
IIa, however as the cytotoxicity assay was made with low cell
density and for a short incubation period, inadequate concen-
trations were reached in the medium, which is why conditioned
medium was used. Conditioned medium was made as follows:
Colo205 cells were grown to confluency for 72 h, at which point
the cells were pelleted and themedium,which contained approx-
imately 100 ng/mL sPLA2 IIA, was collected and used for the
assay. Cells were plated in 96-well plates at a density of 1  104
cells per well for HT-29 andMT-3 cells and 2 104 cells per well
for Colo205 cells, 24 h prior to addition of the tested compound.
The retinoids (ATRA, 2, 9, 10, and stearic acid) were solubilized
in DMSO and water (final DMSO concentration e0.5%).
Liposomes were diluted in PBS, and initial lipid concentrations
in the liposome solutions were determined by phosphorus
analysis.50 After 24 h of incubation, the substances were removed
and the cells were washed and incubated in complete medium for
another 48 h. Cytotoxic activity was assessed using a standard
3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazoliumbromide (MTT)
assay (Cell ProliferationKit I, Roche, Germany).51 Cell viability is
expressed as percentage reduction of incorporated MTT.
1-O-Octadecyl-2-(6-(all-trans-retinoyloxy)-hexanoyl)-sn-glycero-
3-phospho-(S)-glycerol (3).Alcohol15 (13mg, 0.014mmol),ATRA
(6mg, 0.019mmol), and PPh3 (9 mg, 0.043mmol) were dissolved
in THF (1.0mL).DIAD (11 μL, 0.043mmol) was added, and the
reaction mixture was stirred at 20 C for 1 h and then concen-
trated in vacuo and purified by flash column chromatography
(heptane/EtOAc 2:1 then heptane/EtOAc 1:2) to give 13 mg that
was dissolved in CH2Cl2 (1.0 mL) and DBU (2 μL, 0.012 mmol)
was added. The reaction mixture was stirred for 30 min at 20 C
and then purified directly by flash column chromatography
(heptane/EtOAc 1:1 then CH2Cl2/MeOH 9:1) to afford 8 mg
that was dissolved in MeCN (0.9 mL) and CH2Cl2 (0.3 mL) and
cooled to 0 C. Aqueous HF (40%, 30 μL) was added dropwise,
and the reaction mixture was allowed to reach 20 C. After 3.5 h,
the reaction was quenched by dropwise addition of MeOSiMe3
(0.3 mL) and the mixture was stirred for 30 min, after which
NaHCO3 (6 mg, 0.07 mmol) was added and the mixture was
concentrated in vacuo and purified by flash column chromato-
graphy (CH2Cl2/MeOH 10:1 then CH2Cl2/MeOH 4:1) to afford
4 mg (31% over 3 step) of 3 as a yellow amorphous solid. Rf =
0.44 (CH2Cl2/MeOH 4:1).
1H NMR (500MHz, CDCl3/CD3OD
4:1): δ 7.02 (dd, J=15.0, 11.4 Hz, 1H), 6.32-6.27 (m, 2H), 6.15
(d, J = 11.4 Hz, 1H), 6.14 (d, J = 16.2 Hz, 1H), 5.77 (s, 1H),
5.18-5.13 (m, 1H), 4.11 (t, J=6.6 Hz, 2H), 4.03-3.94 (m, 2H),
3.94-3.90 (m, 2H), 3.82-3.77 (m, 1H), 3.62 (t, J=5.2 Hz, 2H),
3.60-3.57 (m, 2H), 3.49-3.39 (m, 2H), 2.39-2.33 (m, 5H),
2.05-2.00 (m, 5H), 1.72 (s, 3H), 1.71-1.60 (m, 6H), 1.57-1.51
(m, 2H), 1.50-1.45 (m, 2H), 1.45-1.40 (m, 2H), 1.31-1.23 (m,
30H), 1.03 (s, 6H), 0.88 (t, J=6.9 Hz, 3H). 13C NMR (50MHz,
CDCl3/CD3OD 4:1): δ 174.0, 168.0, 153.7, 140.0, 138.0, 137.7,
135.3, 131.7, 130.3, 129.8, 129.2, 118.5, 72.2 (2C), 71.2, 69.4, 66.7,
64.5, 64.1, 62.7, 40.0, 34.5 (2C), 33.4, 32.3, 30.1, 29.7 (12C), 29.2
(2C), 28.7, 26.4, 25.9, 24.9, 23.0, 22.0, 19.6, 14.3, 14.1, 13.3. IR
(neat) 3325, 2923, 2853, 1733, 1709, 1609, 1584, 1457, 1259, 1064,
798 cm-1; m/z (M þ Hþ) 917.58.
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1-Octadecanoyl-2-(6-(all-trans-retinoyloxy)-hexanoyl)-sn-glycero-
3-phospho-(S)-glycerol (4).Alcohol 18 (47mg, 0.052mmol), ATRA
(31 mg, 0.104 mmol), DMAP (13 mg, 0.104 mmol), and Et3N
(72μL, 0.52mmol)were dissolved inEt2O (1.2mL).DCC (27mg,
0.13 mmol) was added, and the reaction mixture was stirred at
20 C for 22 h and then concentrated in vacuo and purified by
flash column chromatography (toluene then toluene/EtOAc 5:1)
to give 32 mg that was dissolved in CH2Cl2 (2.2 mL) and DBU
(4.2μL, 0.028mmol) was added. The reactionmixturewas stirred
for 30 min at 20 C and then purified directly by flash column
chromatography (heptane/EtOAc 1:1 then CH2Cl2/MeOH 9:1)
to afford 21mg thatwas dissolved inMeCN(1.5mL) andCH2Cl2
(0.5 mL) and cooled to 0 C. Aqueous HF (40%, 90 μL) was
added dropwise, and the reaction mixture was allowed to reach
20 C. After 3.5 h, the reaction was quenched by dropwise
addition of MeOSiMe3 (0.3 mL) and the mixture was stirred
for 30 min, after which NaHCO3 (6 mg, 0.07 mmol) was added
and the mixture was concentrated in vacuo and purified by flash
column chromatography (CH2Cl2/MeOH 10:1 then CH2Cl2/
MeOH 4:1 then CH2Cl2/MeOH/H2O 65:25:1) to afford 15 mg
(31% over 3 step) of 4 as a yellow amorphous solid. Rf = 0.56
(CH2Cl2/MeOH 5:1).
1HNMR (500MHz, CDCl3/CD3OD 4:1):
δ 7.02 (dd, J= 15.0, 11.4 Hz, 1H), 6.32-6.27 (m, 2H), 6.15 (d,
J = 11.4 Hz, 1H), 6.15 (d, J = 16.2 Hz, 1H), 5.77 (s, 1H),
5.25-5.20 (m, 1H), 4.39 (dd, J=12.0, 3.3Hz, 1H), 4.16 (dd, J=
12.0, 6.6 Hz, 1H), 4.11 (t, J= 6.6 Hz, 2H), 3.99-3.91 (m, 4H),
3.83-3.78 (m, 1H), 3.63 (t, J=5.1 Hz, 2H), 2.36 (t, J=7.5 Hz,
2H), 2.34 (s, 3H), 2.31 (t, J = 7.6 Hz, 2H), 2.05-2.00 (m, 5H),
1.71 (s, 3H), 1.71-1.65 (m, 4H), 1.65-1.57 (m, 4H), 1.50-1.45
(m, 2H), 1.45-1.41 (m, 2H), 1.34-1.21 (m, 28H), 1.03 (s, 6H),
0.88 (t, J = 7.0 Hz, 3H). 13C NMR (50 MHz, CDCl3/CD3OD
4:1): δ 174.2, 173.5, 168.0, 153.6, 140.1, 138.0, 137.6, 135.3, 131.6,
130.3, 129.7, 129.1, 118.5, 71.2, 70.7, 66.8, 64.0 (2C), 62.6 (2C),
39.9, 34.3 (3C), 33.4, 32.2, 29.9 (12C), 29.2 (2C), 28.7, 25.8, 25.1,
24.8, 23.0, 21.9, 19.5, 14.3, 14.1, 13.1. 31P NMR (202 MHz,
CDCl3/CD3OD 4:1): δ -0.08. IR (neat): 3390, 2924, 2853,
1734, 1709, 1661, 1458, 1260, 1237, 1153, 1050, 805 cm-1;m/z (M
þ Hþ) 931.57.
1-O-Octadecyl-2-(6-(40-octyl-4-phenylbenzoyloxy)-hexanoyl)-sn-
glycero-3-phospho-(S)-glycerol (5). Alcohol 15 (62 mg, 0.068
mmol), carboxylic acid 2 (43mg, 0.14mmol), andDMAP(25mg,
0.20mmol) were dissolved inCH2Cl2 (4.5mL).DCC (42mg, 0.20
mmol) was added, and the reaction mixture was stirred at 20 C
for 18 h. The mixture was concentrated in vacuo and purified by
flash column chromatography (toluene then toluene/EtOAc 5:1)
to give 65 mg that was dissolved in CH2Cl2 (5.0 mL) and DBU
(9 μL, 0.06 mmol) was added. The reaction mixture was stirred
for 35 min at 20 C and then purified directly by flash column
chromatography (heptane/EtOAc 1:1 then CH2Cl2/MeOH 10:1)
to afford58mg thatwas dissolved in amixtureofMeCN(4.2mL)
and CH2Cl2 (1.4 mL) and cooled to 0 C. Aqueous HF (40%,
250μL)was addeddropwise, and the reactionmixturewas allowed
to reach 20 C. After 3.5 h, the reaction was quenched by drop-
wise addition of MeOSiMe3 (0.93 mL), and the mixture was
stirred for 30 min, after which NaHCO3 (8 mg, 0.095 mmol) was
added and themixturewas concentrated in vacuo and purified by
flash columnchromatography (CH2Cl2/MeOH10:1 thenCH2Cl2/
MeOH 4:1) to afford 24 mg (38% over 3 step) of 5 as a color-
less amorphous solid.Rf = 0.23 (CH2Cl2/MeOH 4:1).
1H NMR
(300MHz, CDCl3/CD3OD 4:1): δ 8.08 (d, J=8.3 Hz, 2H), 7.67
(d, J=8.3Hz, 2H), 7.55 (d, J=8.1Hz, 2H), 7.29 (d, J=8.1Hz,
2H), 5.19-5.14 (m, 1H), 4.34 (t, J= 6.6 Hz, 2H), 4.06-3.93 (m,
4H), 3.85-3.80 (m, 1H), 3.66-3.61 (m, 2H), 3.60-3.56 (m, 2H),
3.48-3.38 (m, 2H), 2.66 (t, J=7.7 Hz, 2H), 2.40 (t, J=7.5 Hz,
2H), 1.86-1.79 (m, 2H), 1.76-1.70 (m, 2H), 1.69-1.62 (m, 2H),
1.56-1.49 (m, 4H), 1.39-1.19 (m, 40H), 0.89 (t, J=6.8Hz, 3H),
0.88 (t, J = 6.9 Hz, 3H). 13C NMR (50 MHz, CDCl3/CD3OD
4:1): δ 173.9, 167.3, 146.1, 143.6, 137.5, 130.3 (2C), 129.3 (2C),
128.9, 127.4 (2C), 127.1 (2C), 72.1 (2C), 71.3, 69.3, 66.7, 65.2,
64.6, 62.6, 35.9, 34.5, 32.1 (2C), 31.8, 30.0, 29.7 (15C), 28.8, 26.3,
25.8, 24.9, 23.0 (2C), 14.3 (2C). 31P NMR (202 MHz, CDCl3/
CD3OD 4:1): δ -1.02. IR (neat): 3320, 2920, 2851, 1717, 1276,
1102, 1069 cm-1; m/z (M þ Hþ) 927.58.
1-Octadecanoyl-2-(6-(40-octyl-4-phenylbenzoyloxy)-hexanoyl)-
sn-glycero-3-phospho-(S)-glycerol (6).The synthesiswasperformed
as for 5, starting from alcohol 18 (70 mg, 0.077 mmol) and afford-
ing 51 mg (70% over 3 step) of 6 as a colorless amorphous solid.
Rf = 0.54 (CH2Cl2/MeOH 5:1).
1H NMR (500 MHz, CDCl3/
CD3OD4:1): δ 8.08 (d, J=8.3Hz, 2H), 7.67 (d, J=8.3Hz, 2H),
7.56 (d, J=8.1 Hz, 2H), 7.29 (d, J=8.1 Hz, 2H), 5.27-5.22 (m,
1H), 4.39 (dd, J=12.0, 3.2Hz, 1H), 4.34 (d, J=6.6Hz, 2H), 4.17
(dd, J=12.0, 6.6Hz, 1H), 4.05-4.00 (m, 2H), 3.98-3.91 (m, 2H),
3.85-3.80 (m, 1H), 3.65-3.61 (m, 2H), 2.66 (t, J= 7.7 Hz, 2H),
2.40 (t, J= 7.5 Hz, 2H), 2.31 (t, J= 7.6 Hz, 2H), 1.86-1.78 (m,
2H), 1.76-1.69 (m, 2H), 1.68-1.62 (m, 2H), 1.62-1.56 (m, 2H),
1.55-1.49 (m, 2H), 1.39-1.20 (m, 38H), 0.89 (t, J=6.7 Hz, 3H),
0.88 (t, J=6.8Hz, 3H). 13CNMR(50MHz,CDCl3/CD3OD4:1):
δ 174.4, 173.6, 167.4, 146.3, 143.7, 137.6, 130.4 (2C), 129.4 (2C),
129.0, 127.5 (2C), 127.2 (2C), 71.2, 70.8, 67.1, 65.2, 64.4, 62.7 (2C),
36.0, 34.4 (2C), 32.3 (2C), 31.8, 29.9 (15C), 28.8, 25.9, 25.2, 24.9,
23.0 (2C), 14.3 (2C). 31P NMR (202MHz, CDCl3/CD3OD 4:1): δ
-1.30. IR (neat): 3314, 2921, 2851, 1737, 1467, 1277, 1103 cm-1;
m/z (M þ Hþ) 941.55.
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